<SEC-DOCUMENT>0000896262-19-000014.txt : 20191030
<SEC-HEADER>0000896262-19-000014.hdr.sgml : 20191030
<ACCEPTANCE-DATETIME>20191030082431
ACCESSION NUMBER:		0000896262-19-000014
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191030
DATE AS OF CHANGE:		20191030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		191177927

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20193009x10xq.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:e015752617cd4377bbc9458eca43c499,x:241315e6e5914ccdb3f53b1c91172884-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:amed="http://www.amedisys.com/20190930" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember" name="amed:ConsolidatedLeverageRatio" id="Fact-DDCD2484F4385067A726DD0D81500DBF-wk-Fact-DDCD2484F4385067A726DD0D81500DBF">0.75</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" name="amed:ConsolidatedLeverageRatio" id="Fact-A45DD2F0100A5A6CA452DEC04CB49B8E-wk-Fact-A45DD2F0100A5A6CA452DEC04CB49B8E">2.00</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" name="amed:ConsolidatedLeverageRatio" id="Fact-E0A5744A95515F089C93660FAB3BDB48-wk-Fact-E0A5744A95515F089C93660FAB3BDB48">3.00</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember" name="amed:ConsolidatedLeverageRatio" id="Fact-ABBA60EE3EF453B28FFB1267C7CE80AE-wk-Fact-ABBA60EE3EF453B28FFB1267C7CE80AE">3.00</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" name="amed:ConsolidatedLeverageRatio" id="Fact-913FAE28065354A09A60DB9CCE6D0013-wk-Fact-913FAE28065354A09A60DB9CCE6D0013">0.75</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" name="amed:ConsolidatedLeverageRatio" id="Fact-028D16549C8D562EBEBF7C85BEE31100-wk-Fact-028D16549C8D562EBEBF7C85BEE31100">2.00</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" name="amed:DebtInstrumentInterestRateatPeriodEnd" id="Fact-C9322829F79F54C892E2C634A7F69751-wk-Fact-C9322829F79F54C892E2C634A7F69751">0.035</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" name="amed:DebtInstrumentInterestRateatPeriodEnd" id="Fact-05E0E941706B514EB54EBDE9DE3D9436-wk-Fact-05E0E941706B514EB54EBDE9DE3D9436">0.036</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:EpisodeOfCareAsEpisodicBasedRevenueDuration" id="Fact-7A0BA1D8225B5D73A1D7D245E62F86A0-wk-Fact-7A0BA1D8225B5D73A1D7D245E62F86A0">P60D</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="visit" contextRef="FD2019Q3YTD" name="amed:FirstThresholdOfTherapyServicesRequired" id="Fact-FBED4D611B9353F3BAB26FA12D36590D-wk-Fact-FBED4D611B9353F3BAB26FA12D36590D">6</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="Fact-77DFBEB67AFB50FE865AC53A52781914-wk-Fact-77DFBEB67AFB50FE865AC53A52781914">P60D</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="visit" contextRef="FD2019Q3YTD" name="amed:SecondThresholdOfServicesRequired" id="Fact-546815BA86A155AE8DE269B0759B4AFB-wk-Fact-546815BA86A155AE8DE269B0759B4AFB">14</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="visit" contextRef="FD2019Q3YTD" name="amed:ThirdThresholdOfTherapyServicesRequired" id="Fact-EE56F77C1C2D58D5BDBC8B1E42BD2ADA-wk-Fact-EE56F77C1C2D58D5BDBC8B1E42BD2ADA">20</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:AmendmentFlag" id="Fact-864D560A133C5515AED6E21CED8BEC76-wk-Fact-864D560A133C5515AED6E21CED8BEC76" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-81533095FC6A53D7A951AB005EC9E7CF-wk-Fact-81533095FC6A53D7A951AB005EC9E7CF">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-C17310B7AFF15D5698563D449F075BCD-wk-Fact-C17310B7AFF15D5698563D449F075BCD">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-4D7985236F4B54F1B40BB9B2DD034400-wk-Fact-4D7985236F4B54F1B40BB9B2DD034400">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-BE8CB1FD722E55A29D02910F4220F84B-wk-Fact-BE8CB1FD722E55A29D02910F4220F84B">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:EntityRegistrantName" id="Fact-6DB194118F165514B141208568002FC3-wk-Fact-6DB194118F165514B141208568002FC3">AMEDISYS INC</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-263CC87A9FE155C3BAD223B15A338513-wk-Fact-263CC87A9FE155C3BAD223B15A338513">95472000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-B6607FED019B5DC4A91F9E5E406FA258-wk-Fact-B6607FED019B5DC4A91F9E5E406FA258">101446000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-7FB3E0AB369A56D5BC8861BC472C1AAD-wk-Fact-7FB3E0AB369A56D5BC8861BC472C1AAD">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-3D0B0FEB5DBA527AB5F6342026E6845D-wk-Fact-3D0B0FEB5DBA527AB5F6342026E6845D">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-69F7A80E327D56BBABC49591749FAE6F-wk-Fact-69F7A80E327D56BBABC49591749FAE6F">60000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesAuthorized" id="Fact-74AF3D59D6DE5E7E9B2EAD7A3A233BD6-wk-Fact-74AF3D59D6DE5E7E9B2EAD7A3A233BD6">60000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-19D8AB3F78225349BA72BCBCA5FD8DA1-wk-Fact-19D8AB3F78225349BA72BCBCA5FD8DA1">36252280</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesIssued" id="Fact-64E5C174B84C5E8B983ADA590F48822C-wk-Fact-64E5C174B84C5E8B983ADA590F48822C">36599273</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-BB70B4F683D35F74BEA0E13E6C081852-wk-Fact-BB70B4F683D35F74BEA0E13E6C081852">31973505</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesOutstanding" id="Fact-0F88BB33E8425E799DBEDD0809A0B697-wk-Fact-0F88BB33E8425E799DBEDD0809A0B697">32246575</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" name="us-gaap:ConcentrationRiskPercentage1" id="Fact-D9CB007691535640BD547C4BE1AE43B6-wk-Fact-D9CB007691535640BD547C4BE1AE43B6">0.74</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="Fact-E51D6BDF340C5D3FA31635BA37CAB168-wk-Fact-E51D6BDF340C5D3FA31635BA37CAB168">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum. </ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="Fact-B060C1406E425165910B38330B9E53E8-wk-Fact-B060C1406E425165910B38330B9E53E8"> Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months </ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" name="us-gaap:DebtInstrumentFaceAmount" id="Fact-39EDA7F85B92559889B4F25C3B96B3E9-wk-Fact-39EDA7F85B92559889B4F25C3B96B3E9">550000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" name="us-gaap:DebtInstrumentFaceAmount" id="Fact-F0C14B1EBA4859D588757B9C687533C9-wk-Fact-F0C14B1EBA4859D588757B9C687533C9">175000000</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" name="us-gaap:DebtInstrumentMaturityDate" id="Fact-F00923F4825F549483B71F35034608B8-wk-Fact-F00923F4825F549483B71F35034608B8">2024-02-04</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" name="us-gaap:DebtInstrumentMaturityDate" id="Fact-3BD8298B75B358A6A8AD5AE11F689714-wk-Fact-3BD8298B75B358A6A8AD5AE11F689714">2024-02-04</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact-7F2EAE2D04655C5DA4052110E7063206-wk-Fact-7F2EAE2D04655C5DA4052110E7063206">33050000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact-3490C8BDBBE853CC8FC3DFCF14B78BFA-wk-Fact-3490C8BDBBE853CC8FC3DFCF14B78BFA">36799000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3YTD" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" id="Fact-989B9E39B94D6AF7549DEEE8037F3315-wk-Fact-989B9E39B94D6AF7549DEEE8037F3315">1455000000</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="Fact-1C2BD8E7793D548AB1B378D95E811971-wk-Fact-1C2BD8E7793D548AB1B378D95E811971">Option for early termination of lease after three years</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="Fact-5559187B984059028FB2ECAA30DA5759-wk-Fact-5559187B984059028FB2ECAA30DA5759">Option for early termination of lease after one year</ix:nonNumeric><ix:nonNumeric contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-6BB9AE7599FB5004860D333B71E381D7-wk-Fact-6BB9AE7599FB5004860D333B71E381D7">P1Y</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" name="us-gaap:OperatingIncomeLoss" id="Fact-2F63574A903E54A3B84821DDAA05E9B1-wk-Fact-2F63574A903E54A3B84821DDAA05E9B1">900000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" name="us-gaap:OperatingIncomeLoss" id="Fact-47CA2AB2CCE85C9881A05B25A989CA5B-wk-Fact-47CA2AB2CCE85C9881A05B25A989CA5B" sign="-">4200000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact-98564944728E53839B3CA9D4E6106F2B-wk-Fact-98564944728E53839B3CA9D4E6106F2B">80000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" name="us-gaap:PaymentsOfFinancingCosts" id="Fact-4E69C15E4DFD5B66B97619A2396177B7-wk-Fact-4E69C15E4DFD5B66B97619A2396177B7">800000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-E0FC5AD8A85E5E8EAF001A422327D96D-wk-Fact-E0FC5AD8A85E5E8EAF001A422327D96D">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-58CAF82E3EDD5C5C8D5E163FF73EDB8F-wk-Fact-58CAF82E3EDD5C5C8D5E163FF73EDB8F">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-6CCFCB7D50455903BCF200A17305336D-wk-Fact-6CCFCB7D50455903BCF200A17305336D">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-C3480840CD1B5BD789A6D3A43340FF73-wk-Fact-C3480840CD1B5BD789A6D3A43340FF73">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-C60A4BA0535E5CCB8ED96CF6F88AB648-wk-Fact-C60A4BA0535E5CCB8ED96CF6F88AB648">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesIssued" id="Fact-9ECF508E107C576AB43596B09B495CE4-wk-Fact-9ECF508E107C576AB43596B09B495CE4">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-B888A840EC095F8CA177DC37C1B8EB13-wk-Fact-B888A840EC095F8CA177DC37C1B8EB13">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-A4114A567ED552D99E6211BB45BE14F4-wk-Fact-A4114A567ED552D99E6211BB45BE14F4">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:TreasuryStockShares" id="Fact-4B86BB953F385AA78EC953B82E0334E4-wk-Fact-4B86BB953F385AA78EC953B82E0334E4">4278775</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:TreasuryStockShares" id="Fact-8B86565AC4DE5CF58120E2DCC246CA8A-wk-Fact-8B86565AC4DE5CF58120E2DCC246CA8A">4352698</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="amed-20190930.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Oct252019">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr042019_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_amed_FleetLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">amed:FleetLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb04_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-04</xbrli:startDate>
			<xbrli:endDate>2019-02-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb04">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb042019-Mar312020_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-04</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb04_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-04</xbrli:startDate>
			<xbrli:endDate>2019-02-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2023Q1Apr012020-Mar312023_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2023-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2024Q2Apr012023-Feb042024_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2023-04-01</xbrli:startDate>
			<xbrli:endDate>2024-02-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Feb0419-Sep3019_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-04</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q1Jan01-Mar31_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-01-01</xbrli:startDate>
			<xbrli:endDate>2010-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-18</xbrli:startDate>
			<xbrli:endDate>2016-01-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2Jun27_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_ParkersburgWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-27</xbrli:startDate>
			<xbrli:endDate>2016-06-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1Jan302015_srt_LitigationCaseAxis_amed_CompassionateCareHospiceCIAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-30</xbrli:startDate>
			<xbrli:endDate>2015-01-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-06-06</xbrli:startDate>
			<xbrli:endDate>2011-06-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q2Apr23_srt_LitigationCaseAxis_amed_AmedisysCIAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-23</xbrli:startDate>
			<xbrli:endDate>2014-04-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Nov03_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_MorgantownWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-03</xbrli:startDate>
			<xbrli:endDate>2015-11-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q2May21_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_stpr_MA_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-05-21</xbrli:startDate>
			<xbrli:endDate>2015-05-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-04</xbrli:startDate>
			<xbrli:endDate>2018-06-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb252019">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-25</xbrli:startDate>
			<xbrli:endDate>2019-02-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb252019">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="visit">
		<xbrli:measure>amed:visit</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>amed:day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="beneficiary">
		<xbrli:measure>amed:beneficiary</xbrli:measure>
	</xbrli:unit><xbrli:unit id="state">
		<xbrli:measure>amed:state</xbrli:measure>
	</xbrli:unit><xbrli:unit id="care_center">
		<xbrli:measure>amed:care_center</xbrli:measure>
	</xbrli:unit><xbrli:unit id="patient">
		<xbrli:measure>amed:patient</xbrli:measure>
	</xbrli:unit><xbrli:unit id="claim">
		<xbrli:measure>amed:claim</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Segments">
		<xbrli:measure>amed:Segments</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s5C6E6B913B495B7CAE3835B686F42109"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington D.C. 20549</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d131209688e386-wk-Fact-1DA953ECECE8505197BBA27114306A65" name="dei:DocumentType" contextRef="FD2019Q3YTD"><span style="font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d131209688e419-wk-Fact-9984C909F95550819F990001A719FA51" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d131209688e431-wk-Fact-EB2545D7E628543691AF2875BF4B563A" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q3YTD" format="ixt:datemonthdayyearen">September 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">or</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131209688e451-wk-Fact-58967381CFC25F80A7430918C40C649A" name="dei:DocumentTransitionReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> to </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d131209688e470-wk-Fact-1B92ECDADA4F533C95BFCD4E1F97E564" name="dei:EntityFileNumber" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">0-24260</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="image0.jpg" alt="image0.jpg" style="height:82px;width:160px;"></img></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span style="font-family:inherit;font-size:24pt;font-weight:bold;">AMEDISYS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d131209688e540-wk-Fact-1EAB8829366655A6856A94604C9D130F" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q3YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d131209688e550-wk-Fact-5BD21805BA205CCDA9EC0EF3FB8F63D8" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q3YTD">11-3131700</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d131209688e575-wk-Fact-C8CDFF4F582D5240A5662EC0EED2BED4" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">3854 American Way</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d131209688e580-wk-Fact-7C5DF9BA877E530BB967855D24F0EC07" name="dei:EntityAddressAddressLine2" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">Suite A</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d131209688e585-wk-Fact-5127A12615D35D62B6D738807E23FF5D" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">Baton Rouge</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d131209688e590-wk-Fact-C07045EAD5285A3999BCAE9A9D49426A" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">LA</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d131209688e595-wk-Fact-6AEC0E21B44D5D8D9CA762C22AD7BE68" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">70816</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices, including zip code)</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d131209688e607-wk-Fact-33A251E1A30A5A21B96D5627D7ADC3B4" name="dei:CityAreaCode" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">225</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d131209688e612-wk-Fact-9011A73A39E0566DB306F86A91E0BBEF" name="dei:LocalPhoneNumber" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">292-2031</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or (800)&#160;467-2662</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d131209688e681-wk-Fact-57245F3DDB4551C1907581DB9B6BCB09" name="dei:Security12bTitle" contextRef="FD2019Q3YTD">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d131209688e691-wk-Fact-D5BDDEDB30C956C4BB2B7810328C97B4" name="dei:TradingSymbol" contextRef="FD2019Q3YTD">AMED</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d131209688e701-wk-Fact-8E57F552BA875AF18BEAB1D659C94CCF" name="dei:SecurityExchangeName" contextRef="FD2019Q3YTD" format="ixt-sec:exchnameen">The NASDAQ Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131209688e708-wk-Fact-E12196EF02415FCC9682586000887142" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q3YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131209688e719-wk-Fact-1BC80983689B5075B8A38E76593DB485" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q3YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:18%;"></td><td style="width:3%;"></td><td style="width:51%;"></td><td style="width:3%;"></td><td style="width:19%;"></td><td style="width:3%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131209688e787-wk-Fact-4084756887AE5AF391BBD8321A183C73" name="dei:EntityFilerCategory" contextRef="FD2019Q3YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;padding-left:4px;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d131209688e889-wk-Fact-BC3F0E5C02645D33A8A2301E9E47D3C3" name="dei:EntitySmallBusiness" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging&#160;growth&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;padding-left:4px;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d131209688e941-wk-Fact-62DECFCFAC2158EAA4826298B17963CB" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131209688e971-wk-Fact-AD21957E86FD54A2B6856F0B28BCBB14" name="dei:EntityShellCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131209688e980-wk-Fact-99155C72A70A563A9965364A2215301D" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q4Oct252019" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">32,255,257</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares outstanding as of </span><span style="font-family:inherit;font-size:10pt;">October&#160;25, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s427D5FD6132D5F2592031CE952D9617B"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:87%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE34CC9C3441054CD8C942F2767294895"><span style="font-family:inherit;font-size:10pt;">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE34CC9C3441054CD8C942F2767294895">1</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">;;;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PART I. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s113E63CD440052DD996C487A2AC29A20"><span style="font-family:inherit;font-size:10pt;">FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB9885A303EF955E7AF6A46587A96912B"><span style="font-family:inherit;font-size:10pt;">FINANCIAL STATEMENTS:</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76BCEC2327A5596995841FC68C55F736"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2019 (UNAUDITED) AND DECEMBER&#160;31, 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s76BCEC2327A5596995841FC68C55F736">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB2C75DE490655876A0D3C5F4237A4F73"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2019 AND 2018 (UNAUDITED)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB2C75DE490655876A0D3C5F4237A4F73">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06E340FD16C757F6901DA33EFEE4D062"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2019 AND 2018 (UNAUDITED)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s06E340FD16C757F6901DA33EFEE4D062">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC1679DC72E8A57DF9231F2453DB0A7A8"><span style="font-family:inherit;font-size:10pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2019 AND 2018 (UNAUDITED)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sC1679DC72E8A57DF9231F2453DB0A7A8">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sACD708EB178C5009968DC325774C3B09"><span style="font-family:inherit;font-size:10pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sACD708EB178C5009968DC325774C3B09">24</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM 3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s75DF7347B93E539CBDF1AD4BA4E53714"><span style="font-family:inherit;font-size:10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s75DF7347B93E539CBDF1AD4BA4E53714">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE6BFECD395F5FC58BAB4C128796F75C"><span style="font-family:inherit;font-size:10pt;">CONTROLS AND PROCEDURES</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAE6BFECD395F5FC58BAB4C128796F75C">40</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA60DEA89D0E75A7ABCF0D55DCF10E299"><span style="font-family:inherit;font-size:10pt;">PART II. OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E48C95805C351ABA769EC598BB7ED58"><span style="font-family:inherit;font-size:10pt;">LEGAL PROCEEDINGS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3E48C95805C351ABA769EC598BB7ED58">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s55B11869E4A95FA680B602C10603EF06"><span style="font-family:inherit;font-size:10pt;">RISK FACTORS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s55B11869E4A95FA680B602C10603EF06">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s43967CFDEBFD50B6A13DA80A943283BC"><span style="font-family:inherit;font-size:10pt;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s43967CFDEBFD50B6A13DA80A943283BC">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s818BCBF025255B998D0D0E97A860ADCA"><span style="font-family:inherit;font-size:10pt;">DEFAULTS UPON SENIOR SECURITIES</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s818BCBF025255B998D0D0E97A860ADCA">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA90EFD5548735FDCA88CF4D2F967ECB9"><span style="font-family:inherit;font-size:10pt;">MINE SAFETY DISCLOSURES</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA90EFD5548735FDCA88CF4D2F967ECB9">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s383F25C80C395F8ABB060AD154CA78FD"><span style="font-family:inherit;font-size:10pt;">OTHER INFORMATION</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s383F25C80C395F8ABB060AD154CA78FD">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8D5A31DB0C05755A04C42AC1B4C1E1C"><span style="font-family:inherit;font-size:10pt;">EXHIBITS</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB8D5A31DB0C05755A04C42AC1B4C1E1C">43</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE7461C62352C53A4AABE2CE24FEBFCA9"><span style="font-family:inherit;font-size:10pt;">SIGNATURES</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE7461C62352C53A4AABE2CE24FEBFCA9">44</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sE34CC9C3441054CD8C942F2767294895"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of the acquisition of Compassionate Care Hospice ("CCH"), our ability to comply with requirements stipulated in the CCH corporate integrity agreement, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, filed with the SEC on February 28, 2019, particularly, Part I, Item&#160;1A - Risk Factors therein, which are incorporated herein by reference and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="s113E63CD440052DD996C487A2AC29A20"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div><a id="sB9885A303EF955E7AF6A46587A96912B"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. FINANCIAL STATEMENTS</span></div><div><a id="s76BCEC2327A5596995841FC68C55F736"></a></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share data)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019<br/>(unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e507-wk-Fact-5B458D36A5AF5DC1A4CC7C8988414378" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e526-wk-Fact-4CA6620396B25DD49702768F70290CC9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e541-wk-Fact-89FB6A1DAB385D1F96F8D169B6D046FD" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">254,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e560-wk-Fact-0EB7D4D08B98588D8A9B0F68362E8879" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e580-wk-Fact-530AAE3ED0DC54DFB35ED9933979E3C2" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e599-wk-Fact-77199500CEAD5D2CAF0D34053879CDE9" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e619-wk-Fact-45B2B22FB5FA567DB02615B600F75B19" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e638-wk-Fact-3B5E069EFCAC57908287A8AEE91B7A91" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e658-wk-Fact-AB0E1539A4D45F16B848E0DC397B1908" name="us-gaap:AssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299,519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e677-wk-Fact-BCA90CE3BE7D5AAA8F4DDF28F93C15F1" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation of $101,446 and $95,472</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e697-wk-Fact-E0D797DEE6C957E2AD2225EEEEDE9963" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e716-wk-Fact-EEBE44144C3E5334AE3EB0298D13AA5D" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e736-wk-Fact-2BB4F990345C55C3AD37EFC37FBEC454" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e755-wk-Fact-666B1D1124BC53D3957DF5BD2F15512B" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e775-wk-Fact-96A2653F94B95B0DA174757754DB5BC4" name="us-gaap:Goodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">660,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e794-wk-Fact-FDB954BCBB7852DF98A73A5C9D827C1C" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets, net of accumulated amortization of $36,799 and $33,050</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e815-wk-Fact-661A1B09FD42506EAE9250F814DD21D3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e834-wk-Fact-E5CD11FA9EB15EF09A729AF3BC2C0F7A" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e854-wk-Fact-2646B2EA69885D169184F4499D59B480" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e873-wk-Fact-CCB5316F47A059AFA8736BF75B401246" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,794</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e893-wk-Fact-53B7DE63BFA75C548881C02B4164B88C" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e912-wk-Fact-F8A653F6B8A356C0BE214B560AFB6E56" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e937-wk-Fact-62B16D113C9F58F497CC6A35C5B488C1" name="us-gaap:Assets" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,212,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e956-wk-Fact-5C8CC2D0F82E59AEAF0F42B90A068276" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">717,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1058-wk-Fact-EB7C0EEC0A545B2EBD4904EBBF510D02" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1077-wk-Fact-761A58ACCF6758F6B55E4A29E5BD29AC" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1092-wk-Fact-494156663B0550F392F54E545FED878D" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,899</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1111-wk-Fact-04ED939407A45AC2B1A3EED0B2904005" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1131-wk-Fact-E5B9C3BD048F5A479DEF3FB9A17B4143" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1150-wk-Fact-8E86396853E55FC49E8F0523FB702667" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1170-wk-Fact-7A0D36B0106B55F686437A0005719B89" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,959</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1189-wk-Fact-38FDB57FD51C547799F45112DF0426D0" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1209-wk-Fact-FD0596A08350546D87A563A8A2F930A7" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1228-wk-Fact-BE26BC9FDEF758E1B598F27E63D68663" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1249-wk-Fact-72A462AD2BC35AC0BA4A410D9BD2AA80" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1268-wk-Fact-618121DD40235D68A070034F3CCB5815" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">222,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term obligations, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1288-wk-Fact-3C3D1BD2ADCF573BAB804233A8AEDD28" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1307-wk-Fact-D05496C5F3515024A913F39B5B1C3829" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1327-wk-Fact-E09C75818D985539B519941692286E4B" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1346-wk-Fact-38124F982EB15EB99A3F02930E96C5D5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1366-wk-Fact-AE8B5A8D4F8052879264984E8409F7C1" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1385-wk-Fact-A49E94DE13645FA7817088AE78C7EE8B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1405-wk-Fact-343F693CE58B5BC2B9FC1B035E2AE75F" name="us-gaap:Liabilities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">608,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1424-wk-Fact-10CE796BC1B15419BF7C5F9924FD4968" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and Contingencies&#8212;Note 6</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1444-wk-Fact-47C74217BB0A50D99F3655CEC892FC17" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q3" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1525-wk-Fact-E34A2ABE12A0503FBF83297311163F8D" name="us-gaap:PreferredStockValueOutstanding" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1544-wk-Fact-A34C0DED1E0A5E9390F5819858750441" name="us-gaap:PreferredStockValueOutstanding" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value, 60,000,000 shares authorized; 36,599,273 and 36,252,280 shares issued; and 32,246,575 and 31,973,505 shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1564-wk-Fact-16E3E76D0E895531BDAEC8C37102DB7D" name="us-gaap:CommonStockValueOutstanding" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1583-wk-Fact-CFE448C129305997A1FC61B5E95FE6EF" name="us-gaap:CommonStockValueOutstanding" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1603-wk-Fact-72D7B971C5345A1BA41CB0FB1F5F8944" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">634,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1622-wk-Fact-93364A8E68DC58388954F65261431797" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Treasury stock, at cost 4,352,698 and 4,278,775 shares of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131233436e1642-wk-Fact-5B2C897849E159E1A444BFEF53384667" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">251,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131233436e1662-wk-Fact-3E3E9D9DEDF95AD4A8E4C2D9BA0D499D" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">241,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1684-wk-Fact-2D821D6E3D3053DCB7EE5A4F28E221BE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1703-wk-Fact-C7D3F23582765A8495F7ADE91B73882F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1723-wk-Fact-EADC611865D959B598F979852B1BC76E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1742-wk-Fact-85040A2F41715A98B6962949575984D1" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Amedisys, Inc. stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1762-wk-Fact-4E1E8B632FCC5B828244E43D5FEA7E4F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">602,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1781-wk-Fact-D85C6A08037A5FF2BF4C56D283F4F0AF" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">481,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1801-wk-Fact-E5E80DFD2D2256AC90A49752A8D6FB74" name="us-gaap:MinorityInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1820-wk-Fact-36678F9429A154EABEA15A10E17F6584" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1840-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1859-wk-Fact-3A4847BF8CC05471AB47677C18ED37FD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">482,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1884-wk-Fact-5DDE1FD78AEB514696E8880455E818CD" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,212,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131233436e1903-wk-Fact-8B67C43A1B8059E99C6CB122D34B4D2D" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">717,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB2C75DE490655876A0D3C5F4237A4F73"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except per share data)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;September 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For&#160;the&#160;Nine-Month&#160;<br/>Periods&#160;Ended&#160;September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e561-wk-Fact-598A6E82F5C05E998D91640F1D12B716" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">494,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e580-wk-Fact-D0A40BF54DF752D5B5E15F8BACD71F03" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">417,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e599-wk-Fact-9B5CA803ECC55EA0906AF00E9A8AAA7B" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,454,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e619-wk-Fact-63DD06D0AD8256AF824DECA986BD42F7" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,228,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e634-wk-Fact-11DBFECCB503527EAB7C0891CCB0497F" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">288,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e653-wk-Fact-7EBF34EE228255F4B141A9EDA98CA166" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e672-wk-Fact-CAEBF4F1BB385739B4BEAD938A23B3B1" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">854,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e692-wk-Fact-916310D77D4D5F289271C2E9076A645B" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Salaries and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e794-wk-Fact-ACEE864C3D9F51DDBAD1988C3F3883B8" name="us-gaap:LaborAndRelatedExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e813-wk-Fact-29BA6CBFEF885A6EA04C27DFAA907B8E" name="us-gaap:LaborAndRelatedExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e832-wk-Fact-675F62BB38AB51F88C15650E2FACF205" name="us-gaap:LaborAndRelatedExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e852-wk-Fact-2E22961F197950499EAD94647996CFC7" name="us-gaap:LaborAndRelatedExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">232,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e872-wk-Fact-757100BD57955B9990B7BF68EE5B9561" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e891-wk-Fact-FCA027B3D1655D67AEF6FA76A3F2E6C1" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e910-wk-Fact-4341C80739FA5B1D8BEF530041F3D12F" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e930-wk-Fact-D74B12412EAE58B6B28311DA1812C160" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e950-wk-Fact-64D602D245185FBF91782FBCB9E830A4" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e969-wk-Fact-163406C243DA5B87914A0A946CC2B20B" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e988-wk-Fact-CE7A83A7752951CEB120C1387B11A6D9" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1008-wk-Fact-979DE5C5D2035F81992A18CB385C73F0" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1028-wk-Fact-C59913AFDE885E6AB087F12FEA1D3842" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1047-wk-Fact-ABBE40ECAE495CA1B2F6343D611E695F" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1066-wk-Fact-0F22A7FE8BE252B78F0258F658FB350D" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1086-wk-Fact-6BFE83D49A595882BD4AAC1F7D8CB0FA" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1106-wk-Fact-7846832CF8515DBCA965A276FA125D3B" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">447,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1125-wk-Fact-617FD2D74E555237AF1B77516AF41B3B" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1144-wk-Fact-4444C6577EBD5D66A3AFD79C2934C7B3" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,319,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1164-wk-Fact-807B7ABB6FFA51FABF0FDFA74DDB0849" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,109,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1184-wk-Fact-6689DE4324DA5A95ACF7D188864A5408" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1203-wk-Fact-1A228D07E3565FBCB20D3ADC5C147346" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1222-wk-Fact-A9362601345E55358683B32A8482FA59" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1242-wk-Fact-0063F0C430815495ADC32F01AA8D846D" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1345-wk-Fact-2F98DF574C12581AA30C374A406A9AA2" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1364-wk-Fact-3C1490626FC55179AE04605729A9504F" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1383-wk-Fact-FC1F5E3272875034A2CD1D575E16EA55" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1403-wk-Fact-E942ACAF18C651C6ADDABB7B0E3142B6" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1423-wk-Fact-E81E1F18CA1053BAA6717BDEAF6B63DE" name="us-gaap:InterestExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,778</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1443-wk-Fact-9FF276785AA5546394D3AD65AB22E984" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1463-wk-Fact-D7769975C2E35636AD97A7FC11BDA12E" name="us-gaap:InterestExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1484-wk-Fact-57FDE185A0565E5CA4450DA8D384B7BF" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,834</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in (losses) earnings from equity method investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1505-wk-Fact-A13F190DFFC251F3BAA62200F9D0F451" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1525-wk-Fact-40B8D0E2A8145CEAA748BE14B6D0B859" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1544-wk-Fact-639E153B9FD15FE29A870E935A51BF90" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1564-wk-Fact-041416182B46531998B9E6782D465AC9" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Miscellaneous, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1584-wk-Fact-A34C1B7ADF5D5894B178E582576EC5EC" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1603-wk-Fact-188D8FD063BE5BE493C984B75D889486" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1622-wk-Fact-E0AC9AFA275355E6AC1AD48EC1AF2731" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1642-wk-Fact-C6673A4F64D6510186426F47A15E270E" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other (expense) income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1662-wk-Fact-8FA1EDC4E1A5571FA9F21321F9845AC7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1682-wk-Fact-67141299A3C0565096E2BDA7A3985258" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1701-wk-Fact-DB8B9DE3C3E75DFC83F70E8D1C5591AC" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1722-wk-Fact-3440895D092955A4A2D0A6F6F19489A7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1742-wk-Fact-798DEDFD1DD55A6BA9F2C188C9A47FE7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1761-wk-Fact-4E5CEB259F2B589991257B14D567D328" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1780-wk-Fact-BF7183FABB315F06A2F67D9DBA551336" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">131,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1800-wk-Fact-7DBA8130386E5C599AF3DBABEBCF22E6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1820-wk-Fact-90E550D1CDA159C59C53AB35C0941FA4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1840-wk-Fact-CA831D59D0AA522CB1CA826FE6CA7DB8" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1860-wk-Fact-FB64EDB3A41653D8B0A640F0FA8AB1C8" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1881-wk-Fact-014CAB37BE1B5981923841BBD3B696D6" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1902-wk-Fact-3C758350A806512D9A9AA28BFF0CD296" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1921-wk-Fact-0DD2105951DB5013A2B9E0EFA59AEF67" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1940-wk-Fact-E182736C69245E579EAB5E886D6344BD" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e1960-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e1980-wk-Fact-FA91E367E7C75A409B7ED260D8CCB5B6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e2000-wk-Fact-3B50B1D5B02155BDA43A8DC5A61D66E9" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e2020-wk-Fact-CAE197BFFA2F5336A233673A50F3E0C4" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131212750e2041-wk-Fact-5D942C3DEDCA5EC593CDDC5BCD13C268" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2067-wk-Fact-3052EC66FCF05D57A3ADB91ABD397752" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2086-wk-Fact-1597EF7ACA3C59B597CC39DCD7FA77AE" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2105-wk-Fact-2CF272BA3AD6545E9038A10BD728391B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2125-wk-Fact-F2F85C88C2FC5D8CA2948693E64CB90E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2228-wk-Fact-4E72A175B1485D1993706CEE0B4BDE19" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2247-wk-Fact-623617FB568559C797B02DAEFAE0E917" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2266-wk-Fact-DFDD1795853A50B1A6F45A060280615B" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2286-wk-Fact-D846E5878AFE5E7FAE24F24FE5E6FC10" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2301-wk-Fact-CD11DC571B9851778D9F4ABC891E8923" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2320-wk-Fact-93B2D8D871FA5DDFA6739CE528068113" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">31,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2339-wk-Fact-89F85BF475A95C96A5BBDBF1DB638438" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2359-wk-Fact-6C2CAE056DF9575186ED2BE686165C73" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc. common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2466-wk-Fact-275F916EA3545BF0B3BF3C76E65C07E4" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2485-wk-Fact-7E20A5070B3E52D8B493FC8CCA8C436E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2504-wk-Fact-D3F9A136E8FC5437A78C6637976984A9" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2524-wk-Fact-38085835207C5A6F825994A933CF3F33" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2539-wk-Fact-28CF598E0CB95194B9F5F379A14254DD" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2558-wk-Fact-85B676CCD8CD502C93833B814DEDEB3C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2577-wk-Fact-FE6C4CE2C1BE5BC79A55744349AD541D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131212750e2597-wk-Fact-5655AC2AEFFB5F57B1BE932580F9E145" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s06E340FD16C757F6901DA33EFEE4D062"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except common stock shares)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="30" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Months Ended September 30, 2019</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Income</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings </span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interests</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e906-wk-Fact-205C3B9E36D8504099A6C7E5751C9979" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">562,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e920-wk-Fact-43B43743B08156E59B51ECAA1CE48FC8" name="us-gaap:SharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,445,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e939-wk-Fact-5E2B7D6E36A65CF7B24A50F0331076E3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e959-wk-Fact-C16CDD9FF9595CD6A3EEEDFA5FDD0FCC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">623,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e978-wk-Fact-87740D865AA5583590FDB69D511DFA28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">246,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e998-wk-Fact-5FFC4FABE90659B69A95ED011734AD25" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1018-wk-Fact-5A121754E0B35C67A33F46274D813D77" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1037-wk-Fact-8A1E8B8044325E68A93412B01D055C06" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1052-wk-Fact-7098743CF6AD5DCB9CD3A84605B3F2CD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1071-wk-Fact-731D4F4AA8B55EBDAB3B90DA9801CAF3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1105-wk-Fact-95218B7595B2569FA2D6A2C816EC0275" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; 401(k) plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1202-wk-Fact-0B0B7726AD0651D2A3E8DD478D220ED4" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1221-wk-Fact-43F2F663D6D3561C8A99BE6F6EBFECE0" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">19,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1255-wk-Fact-848710950E245568BAC6FB6E0A77A089" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance/(cancellation) of non-vested stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1352-wk-Fact-9D0B8D08C3B953D78F3B5D4ED81CEE71" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1371-wk-Fact-7615C67D512C5F8997B17111AB6B24F9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">88,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1385-wk-Fact-ED2A983ED3F44244B52EEBCE20B01F7D" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e1405-wk-Fact-F38CE69F7DC95C61B7A76F07BC71986A" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1503-wk-Fact-5E9D839B10685225BA9C49CE2F45E7D7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1522-wk-Fact-0B5515AEFFC455DB9B60B984C4EEF94D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">37,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1556-wk-Fact-9BE4B78E18A752C5AC87EBEFA822DE2A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1653-wk-Fact-FEC4B23F33215E78AC93B12B8A437761" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e1706-wk-Fact-C11AF203E09C5CA99B20243C25F01558" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Surrendered shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e1803-wk-Fact-EB8AA6102CEA520FA3EDDE2D52E94807" name="amed:SurrenderedShares" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e1876-wk-Fact-BC3C03E151C05C20B4D50D5CE3AA9FE5" name="amed:SurrenderedShares" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interest distribution</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e1955-wk-Fact-5324FA014A135B5BB7F4A6627486D258" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e2086-wk-Fact-77AEA78BCFB75212A79FFC9FFB16FCBF" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2108-wk-Fact-3C758350A806512D9A9AA28BFF0CD296" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2219-wk-Fact-8D867608644355449F046ECE4CDC19CC" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2238-wk-Fact-2E8A37502B075F7DA5316C75B256BCDC" name="us-gaap:ProfitLoss" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2263-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2277-wk-Fact-720EEAFDFB275616868BF4AAECE2F904" name="us-gaap:SharesOutstanding" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,599,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2296-wk-Fact-B7BF2DC31E2C5246B114096AA9A3635A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2315-wk-Fact-E4A2BF2C6B415C16B9547F2C4F7697CA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">634,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e2334-wk-Fact-D2FCBBAE888451F6972C2E7758FC4E84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">251,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2354-wk-Fact-A7A697394B575449BAA41877B890DB17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2374-wk-Fact-0E802A87000355839C413996A73AF994" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e2393-wk-Fact-1058523278555BA790C34BDBBC18C2E9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="30" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Income</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings </span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interests</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3064-wk-Fact-0EA241F713A05A5E9A188669C9449DE9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">409,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3078-wk-Fact-88266939999D5FED9BD5493423FDE769" name="us-gaap:SharesOutstanding" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,044,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3097-wk-Fact-D1F9CE689550522B8A2D054F8E51E9DF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3117-wk-Fact-1782A5370F80578780C027E7B8DCD5CE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">585,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e3136-wk-Fact-6214BA7373E5504180B7994F9FA69265" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">237,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3156-wk-Fact-91C370F320405C1493559F32C23C5DAE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3176-wk-Fact-0B1971EDA43A5FF695C4CD1AAC9BD79E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3195-wk-Fact-99D089390A25532C8E453F0480A6834E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3210-wk-Fact-F718ADF5EEC05AA09B8FE5860DF2ABC7" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3229-wk-Fact-12C74857584E51F995A64CD731B43DB6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3263-wk-Fact-2DB37B710304507BBF00F26698BEF115" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; 401(k) plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3360-wk-Fact-BDCAB6401E325621AF624225ED6E3D85" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3379-wk-Fact-B2866FCB7DBB5DC39D5FCF5BD1BC9D9A" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">28,123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3413-wk-Fact-55A0B0302518568D867BADD2FCFF188E" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance/(cancellation) of non-vested stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3510-wk-Fact-EAF7EF928B6A5F9AA5D8B5E5B78B3136" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3529-wk-Fact-198D4DBF81055CAF95996C9101FCAD43" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">63,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3543-wk-Fact-A472D04AB4BB5C7E9267113C31F9CAEE" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3563-wk-Fact-EDE2387504EC5E60B0966ED5AC901AF2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3660-wk-Fact-9D4D72EFF1075D77A0999F97F7CD22C9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3679-wk-Fact-6CBF35F7F8A95069A6037EE2FBAF8702" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3713-wk-Fact-5ACDF133581A52A1893423DD435AA90D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3811-wk-Fact-C71FB8B3C09F5876A685B5EE8F10AD49" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e3864-wk-Fact-B01AD87718665D7C9C34EC54117E3CE5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Surrendered shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e3961-wk-Fact-7C5103F7B4BA5181B31A077ED51490E5" name="amed:SurrenderedShares" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4034-wk-Fact-B3BDEF67A88D523AAD34A05DB14E5E79" name="amed:SurrenderedShares" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interest distribution</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4113-wk-Fact-716225786DFB5A26A8402BD760200654" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4244-wk-Fact-77E21BB7B91B58F6AB0E56501F5B612C" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Repurchase of noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4265-wk-Fact-849BBEC67D29E9504302EE96DA2518F2" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4319-wk-Fact-A4B582646B33BBBB6083EE9734AE254B" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4397-wk-Fact-AB89222A68EE1450CEEAEE97D74035C3" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4417-wk-Fact-0DD2105951DB5013A2B9E0EFA59AEF67" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4528-wk-Fact-76BB92DDF2635226890392555E11624A" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4547-wk-Fact-0D4AE645E4E05E2C9DF4F939195F8ABD" name="us-gaap:ProfitLoss" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4572-wk-Fact-18C1C855DD705C73BF021B045678C942" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">445,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4586-wk-Fact-E6B5AF128DB751DDA8F4654EAAB5609E" name="us-gaap:SharesOutstanding" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,146,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4605-wk-Fact-1CB212C0AC115A7CBF7F7C1326604AE5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4625-wk-Fact-049CC4660519535FBC8083C2FAD260EC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">592,539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e4644-wk-Fact-B9B0790FF6FF5AB0A2823ACD7B7E3BFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">240,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4664-wk-Fact-6A7C0F9CA6055F8F94619E9CC0018994" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4684-wk-Fact-0F4E56BD75DF53B0BDB4F8042330CBB0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e4703-wk-Fact-03AA0B1C5545585C9B3D25624CDD1385" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="30" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Income</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings </span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interests</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5374-wk-Fact-3A4847BF8CC05471AB47677C18ED37FD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">482,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5388-wk-Fact-C975FB1181EA508B99C702A2E9EB7298" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,252,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5407-wk-Fact-C8DF3D7CE457509393498F44D92DD97C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5427-wk-Fact-7AAB1D678B69529C8DA1E0620FF00636" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e5446-wk-Fact-6CCB23F1B4855A1081AB7A68F2D044F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">241,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5466-wk-Fact-6C87214BD39D5A0D8CDE7965E3C9D7E5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5486-wk-Fact-2C3DCDD23C4B54808D3856A18244AF2D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5505-wk-Fact-68E22870DA18588D8D3A39BABAF45C17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5521-wk-Fact-2885E2C0E32E5F239530B60CA4893539" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5540-wk-Fact-A8EA412063DC5837A9D80839055FC312" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">23,267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5574-wk-Fact-F78D575155A55D40B5D8D874F9400B16" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; 401(k) plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5671-wk-Fact-8EFECC12D5685B8EA59843461BBF2A08" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5690-wk-Fact-F13457DC993654ABA7CF510431A7C01D" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">57,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5724-wk-Fact-77E1DEB7225B55349B66BE19CE509CEC" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance/(cancellation) of non-vested stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5821-wk-Fact-31D4E17E089A5992B41BAB77E10FFFF8" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5840-wk-Fact-8378013ECA54507094FFBD8C0657B5C6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">185,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5854-wk-Fact-99F54C2FA6A1B4D3D9E0EBCF5914FA71" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e5874-wk-Fact-239E90F8C18554B88E77CC16E18DF8C9" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5972-wk-Fact-ED8E829D09D750FE998ABF91B8C5416B" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e5991-wk-Fact-A5E7490898CA55A1B022CFA53D89BD0A" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">80,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6025-wk-Fact-AE251DBF019651E9BA338ECD55D314D5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6122-wk-Fact-A574E6D5726B58F987507C59C63F9B55" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6175-wk-Fact-887AFC16FB3F576FA5463B259E8134A6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Surrendered shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e6272-wk-Fact-D2BEC671149D54B3BB9DBA1E409474CF" name="amed:SurrenderedShares" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e6345-wk-Fact-000F5B3EF25955878AC93C072B2112C2" name="amed:SurrenderedShares" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interest distribution</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e6424-wk-Fact-E882B852046851D7888222D08542C3BA" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e6555-wk-Fact-7B29F4E8AE975FA99ECE36D2505A45BF" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6576-wk-Fact-E182736C69245E579EAB5E886D6344BD" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6687-wk-Fact-0D5C75DD182E596085B7458E4601B597" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6706-wk-Fact-16957CA6764952E393397F36D904B6FA" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6731-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">603,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6745-wk-Fact-720EEAFDFB275616868BF4AAECE2F904" name="us-gaap:SharesOutstanding" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,599,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6764-wk-Fact-B7BF2DC31E2C5246B114096AA9A3635A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6783-wk-Fact-E4A2BF2C6B415C16B9547F2C4F7697CA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">634,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e6802-wk-Fact-D2FCBBAE888451F6972C2E7758FC4E84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">251,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6822-wk-Fact-A7A697394B575449BAA41877B890DB17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6842-wk-Fact-0E802A87000355839C413996A73AF994" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e6861-wk-Fact-1058523278555BA790C34BDBBC18C2E9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="30" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Income</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings </span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interests</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7533-wk-Fact-AB8FD3F7DB9353A4ADD9BD01E9C5D213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">516,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7547-wk-Fact-5D86963196E151EEAE23DA0C71CF614A" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">35,747,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7566-wk-Fact-CDEF8D2AEFC15B34BCDD1D9113B1F881" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7586-wk-Fact-1B61660144AD5B0DAFB840C1B342CD6B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">568,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e7605-wk-Fact-673050B9566F5D218D25D7FA1952E2CD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">53,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7625-wk-Fact-6C48C65366695D81B1E650B6C8CB1B90" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7645-wk-Fact-BCD2D33C90DC5D749B5EC8EC4EF5F721" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7664-wk-Fact-A2B9FAEC4F9753BB99F363226B6C76E9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7679-wk-Fact-6477091DE2E55782B02B8E68FBDAE79C" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7698-wk-Fact-3F48DE8BC0BD56239CF485DD2BB1D6A0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">32,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7732-wk-Fact-E72C1E53AD68573C8CE9C9836205DB29" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of stock &#8211; 401(k) plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7829-wk-Fact-D98F0FAB43485407B6B4CEC8D21AF4F4" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7848-wk-Fact-AA5BF39CE08157ECB8424844AAB7FE41" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">113,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7882-wk-Fact-1774DB5964B955B58BBC76826208E331" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance/(cancellation) of non-vested stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7979-wk-Fact-5038FCA8F0855E2680B8ADDDE03CBF99" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e7998-wk-Fact-44532C8FDA01562EBAC837C7EC5A9FF6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">169,811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8012-wk-Fact-356D9AEAC81B5305825906239C57C231" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8032-wk-Fact-775466C1C1AC551BB0539D87190ACDC5" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8130-wk-Fact-DB69769BEEF95578B1CC92ADAD70576E" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8149-wk-Fact-F8F033B8C9785E8CA4EEE2232981EC4D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">83,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8183-wk-Fact-691EE2164D2B53468EDD21631EDFD9EF" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8280-wk-Fact-2D4F047F63D450438883A3ECA2A6E265" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e8333-wk-Fact-380ED50CD6425E878F0403DD28C9D402" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Surrendered shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8430-wk-Fact-D741CD868C5D5443BCA727F18C277479" name="amed:SurrenderedShares" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8503-wk-Fact-B88CAF9782C5536F8E6E42F8DAFDF887" name="amed:SurrenderedShares" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares repurchased</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8582-wk-Fact-A4D2C1E3808958B4AE579895A369EB67" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8655-wk-Fact-E66DA40CADC656D2BD9C81DEE8EAA733" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Noncontrolling interest distribution</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8734-wk-Fact-9EEB3F691FC35DE89DA1E5BEC7D18A15" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8865-wk-Fact-A1546ECD05345DB1877CD4ACA9C93B03" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Repurchase of noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8887-wk-Fact-9B3E2C99460DC4420707EE98A11A8041" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e8941-wk-Fact-DD2573CD22BFB4C150D3EE98A54C4E71" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9019-wk-Fact-D4948D74DDF8FFFA9DFCEE98AB2A7923" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9039-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9150-wk-Fact-2165655D74355BFA85FE86400D36C431" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9169-wk-Fact-361D174FE4AF50A790B36CCF54022663" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9194-wk-Fact-18C1C855DD705C73BF021B045678C942" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">445,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9208-wk-Fact-E6B5AF128DB751DDA8F4654EAAB5609E" name="us-gaap:SharesOutstanding" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,146,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9227-wk-Fact-1CB212C0AC115A7CBF7F7C1326604AE5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9247-wk-Fact-049CC4660519535FBC8083C2FAD260EC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">592,539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d131227501e9266-wk-Fact-B9B0790FF6FF5AB0A2823ACD7B7E3BFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">240,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9286-wk-Fact-6A7C0F9CA6055F8F94619E9CC0018994" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9306-wk-Fact-0F4E56BD75DF53B0BDB4F8042330CBB0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d131227501e9325-wk-Fact-03AA0B1C5545585C9B3D25624CDD1385" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC1679DC72E8A57DF9231F2453DB0A7A8"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For&#160;the&#160;Nine-Month&#160;<br/>Periods&#160;Ended September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e508-wk-Fact-E182736C69245E579EAB5E886D6344BD" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e527-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e583-wk-Fact-48E7D98293975891AFADB3ADC04E2515" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e602-wk-Fact-EE6080AF0F7E5B56A340B663FB7B84D5" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e622-wk-Fact-4341C80739FA5B1D8BEF530041F3D12F" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e641-wk-Fact-D74B12412EAE58B6B28311DA1812C160" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">401(k) employer match</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e661-wk-Fact-3E9A598B98A950BFA9FB7BB310CE7F87" name="us-gaap:PensionExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e680-wk-Fact-46503FDACA2C58ADB834675475EF8E26" name="us-gaap:PensionExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization and impairment of operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e700-wk-Fact-7AA2BC955D6B56D2B52DD88793F363F3" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e719-wk-Fact-27731EAE13605255A8EE60F999E830BF" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on disposal of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e739-wk-Fact-F0ABF54DE11E5A2FBD52C6EB5FA290FF" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e758-wk-Fact-4D5F423B1F0C5CD98A05F80C9CEBA3AA" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e778-wk-Fact-9DB5E202FDB65AA5A0EB1C74216189E7" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,798</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e797-wk-Fact-24BA7C619FC151978EDCEAA9DB00E1FB" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity in earnings from equity method investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e818-wk-Fact-639E153B9FD15FE29A870E935A51BF90" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e838-wk-Fact-041416182B46531998B9E6782D465AC9" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of deferred debt issuance costs/debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e859-wk-Fact-F74BD6D7258054708E3C3ACF118E41D8" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e878-wk-Fact-4347109F210858269E7CD9B53BF0F559" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Return on equity investment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e898-wk-Fact-91C96D25FACB52A9924F4CA5FDF36936" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e917-wk-Fact-234B471AF58A56619C314DCC3000A913" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities, net of impact of acquisitions:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e978-wk-Fact-63F03CFF28FC5BD3918812490FF2F5C4" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e998-wk-Fact-7F398646E5FF5CC2BA56527D5398B6F1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1018-wk-Fact-8C0055D614DC54DD816E5557D0C3C826" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1038-wk-Fact-FA98F0828E3D50FEAD962F7AB133F7BC" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1059-wk-Fact-E7706B2F270E543E8963B9FD426BB7AE" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1078-wk-Fact-B8E6BAD2239B5591A866715F706FAE5D" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1098-wk-Fact-D116C6D5BB1D5299803EF016605FB6B5" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1118-wk-Fact-2E2DF3D074315C7298BF6851088E1193" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1139-wk-Fact-98A5FD90944355EF9E2621C684675CDE" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1158-wk-Fact-23BD85D443875190977BBE8A658DFD63" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1178-wk-Fact-BF078DEEE3DD51CAA41FE169C3A3CCA0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1198-wk-Fact-E612250DAC04542FB37CCCCF5BB3C638" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1218-wk-Fact-730D5B781A0950AF9C2201BA10228527" name="amed:IncreaseDecreaseInOperatingLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1238-wk-Fact-D2AD26A72752581396ED13143FF165CD" name="amed:IncreaseDecreaseInOperatingLeaseLiability" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1259-wk-Fact-02A3C5E094925C4699F980451136F8DB" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,622</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1279-wk-Fact-238B603B617E5040B3A382449A0566EE" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1299-wk-Fact-E6DCDCA835B653E5A08FC1B9010C47B7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1318-wk-Fact-5F9542F128EF5B00BFE682462B65912A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Investing Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from sale of deferred compensation plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1379-wk-Fact-3AB790327D6B5C28B261DBC91BABF813" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1398-wk-Fact-B4C37633A31C5D0599E127034BB9E52A" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from the sale of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1418-wk-Fact-7CD139248687524F8ADDA73C89A323B7" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1437-wk-Fact-CE1D417D4BDF5E9C924161F2AFC9A509" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments in equity method investees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1457-wk-Fact-FE7F0A414AF35054A308564A4DC56132" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1477-wk-Fact-B3C0EFB6D2EE58698C9A212DF1E35B6F" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1498-wk-Fact-1260A36DA2BA55F99002E0FAD4DD2F2E" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1518-wk-Fact-DA52EF503A1054308A7AE5B8CC59C829" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions of businesses, net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1539-wk-Fact-89B428D6ED775A2E9139F8F9F99478C6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">345,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1559-wk-Fact-4F939374EB915535814F70B6F45A91E9" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1580-wk-Fact-4AC8DFB727765072BAA7F59278CC3560" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">351,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1600-wk-Fact-45D1983FDAA15140A3A65E40B4FABAF8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows from Financing Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of stock upon exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1662-wk-Fact-F9FD188D9B8F59168017EB86CFAA5387" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1681-wk-Fact-A37525F67D545B26B2397D70F9A47E36" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of stock to employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1702-wk-Fact-0AAB40A144705AD99D2E67B1E10B8F74" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1721-wk-Fact-D9E6D9A8498D5BA9AF71BD3A70B6FF77" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares withheld upon stock vesting</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1741-wk-Fact-EE2ED0FF511F58C8B88B87959177A884" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1761-wk-Fact-7190352750AB50FAB6CB95FC0C7734FF" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncontrolling interest distribution</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1782-wk-Fact-919791E97C385470AA07AB00A0D52ED5" name="amed:CashDistributionToNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1802-wk-Fact-87415B2C40CE5837AB0A1727CD8BC7FF" name="amed:CashDistributionToNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from borrowings under term loan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1823-wk-Fact-BFBF1DF9A78E5AE7AA0A3EBCD36788BA" name="amed:ProceedsFromBorrowingsUnderTermLoan" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">175,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1842-wk-Fact-E78901ED93C0535F9F423779EBD3FD5B" name="amed:ProceedsFromBorrowingsUnderTermLoan" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from borrowings under revolving line of credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1862-wk-Fact-CAB6B159DD665634A7EFCEB715A04FA3" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e1881-wk-Fact-EAD43FCBEAA95B75A396D47B4ADF863B" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repayments of borrowings under revolving line of credit </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1901-wk-Fact-8E27EA96C4795C51A543A79E779F9FCD" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">133,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1921-wk-Fact-06ED20AF4AA853FA9A1C57D565B4AA79" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal payments of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1942-wk-Fact-9B918460AD5A513293E33FDE3BC578D3" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1962-wk-Fact-A07C10896E565579B76F340DCB51C826" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e1983-wk-Fact-543F7F8234DA57DEA889B707534EDE31" name="us-gaap:PaymentsOfFinancingCosts" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e2003-wk-Fact-D77ABF4B79F45856A2F3946C8217F890" name="us-gaap:PaymentsOfFinancingCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase of company stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2024-wk-Fact-A78D52875E6851289ADB95F61FDB5E09" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e2043-wk-Fact-305804EB1A615F7AA21F44622777A755" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2064-wk-Fact-08BF5251B25CC82E7C50EE99D034CA6F" name="amed:PaymentsForRepurchaseOfNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e2083-wk-Fact-8DF05E33A44ACA17DA0EEE9A030BFE1D" name="amed:PaymentsForRepurchaseOfNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2104-wk-Fact-C0DD1034D47E5863B84C8CA7AE826B04" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e2123-wk-Fact-C579988DA07F56E58EFE81E633321BC0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">219,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2145-wk-Fact-8A5183083A2C5C90A598EB019CBA78C4" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131217219e2164-wk-Fact-660B9D2A5754510F8B3DA079A9B01E42" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2185-wk-Fact-4CA6620396B25DD49702768F70290CC9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2204-wk-Fact-F1F082EE8F595EAFBE34DC4E8B7CB65C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2229-wk-Fact-5B458D36A5AF5DC1A4CC7C8988414378" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2248-wk-Fact-9C5C0DA6BBA45232A716DD616C8C7FFC" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosures of Cash Flow Information:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2309-wk-Fact-8367724E75F453EAA862FA9DC4771AAF" name="us-gaap:InterestPaidNet" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2328-wk-Fact-B0A5AEDEF18455F9981CED39C6CD10B6" name="us-gaap:InterestPaidNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for income taxes, net of refunds received</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2348-wk-Fact-F002D082D8315E70A90E1C2C36F66D78" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131217219e2367-wk-Fact-51752773533D5DB2950C8D9BA2C3073F" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s073087F259BF5CB399523A6FBAC64D8D"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sCAEF4678FC2F5EB5ABE08CC6D64A83A6"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-A842DB817E335812A5DA86B4FA857BFD-0-wk-Fact-C5C9BB0FEDCC51FFBDA4D8E7EC622073" continuedAt="TextSelection-A842DB817E335812A5DA86B4FA857BFD-1" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A842DB817E335812A5DA86B4FA857BFD-1" continuedAt="TextSelection-A842DB817E335812A5DA86B4FA857BFD-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e357-wk-Fact-3C6E291B447857B3936D0F1F88262283" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">74</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our revenue derived from Medicare for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e369-wk-Fact-829FC6725DC1203FB633EBD2F624E871" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">73</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e373-wk-Fact-39BDCD1925757C832BE6EBD370D7C03B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">74</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our revenue derived from Medicare for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we owned and operated </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e386-wk-Fact-A1A40A933F64539889CBB106A52D990B" name="amed:OperatingCareCenters" contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="care_center" decimals="INF" scale="0" format="ixt:numdotdecimal">321</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified home health care centers, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e390-wk-Fact-8DA5A36620225AAC825789DFC15AED68" name="amed:OperatingCareCenters" contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="care_center" decimals="INF" scale="0" format="ixt:numdotdecimal">137</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified hospice care centers and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e394-wk-Fact-2D1F9194073152E690E078B168C1D14F" name="amed:OperatingCareCenters" contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="care_center" decimals="INF" scale="0" format="ixt:numdotdecimal">12</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> personal-care care centers in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e398-wk-Fact-7122BEBCC4265326A7E8D437A4A12EFC" name="us-gaap:NumberOfStatesInWhichEntityOperates" contextRef="FI2019Q3" unitRef="state" decimals="INF" scale="0" format="ixt:numdotdecimal">38</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> states within the United States and the District of Columbia.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-708276F12951595BB60A7DEC6C787AB5-0-wk-Fact-06C19239CB235643B8B1702F7DDB46F4" continuedAt="TextSelection-708276F12951595BB60A7DEC6C787AB5-1" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-708276F12951595BB60A7DEC6C787AB5-1" continuedAt="TextSelection-708276F12951595BB60A7DEC6C787AB5-2"><span style="font-family:inherit;font-size:10pt;">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-708276F12951595BB60A7DEC6C787AB5-2">, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2019 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-2F250E4D4C195D98A93F2A1F80C34762-0-wk-Fact-251782FA89D6516D9D220C6AB9552077" continuedAt="TextSelection-2F250E4D4C195D98A93F2A1F80C34762-1" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842);</span><span style="font-family:inherit;font-size:10pt;"> ASU 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">; ASU 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:inherit;font-size:10pt;">; and ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "Topic 842") using a modified retrospective transition approach, which requires the new standards to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are using the standards' effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides several optional practical expedients that can be adopted at transition. We have elected the "package of practical expedients" which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231509e460-wk-Fact-9EBD1B8346D65B50BA2F1C19D031E9B3" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.  </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-2F250E4D4C195D98A93F2A1F80C34762-1">The new standard also provides practical expedients for an entity's ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. We are applying the short-term lease recognition exemption to certain information technology leases; therefore, we did not recognize ROU assets and lease liabilities for these leases.</ix:continuation> </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:UseOfEstimates" id="TextSelection-6866F0396A9752B981BEAE97AE7D2DC3-0-wk-Fact-798EBAD501D15A048F6985FBC00F2ADF" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-A842DB817E335812A5DA86B4FA857BFD-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-926E07992CF45BB0BFF4456BAD64880A-0-wk-Fact-03D94774134A54C1B6D383D5536A1E96" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:EquityAndCostMethodInvestmentsPolicy" id="TextSelection-808EE9F1028353C4B12C23D4E6EE3669-0-wk-Fact-149307E2EC0055D980E0060E344CE38C" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e515-wk-Fact-48B868AE06CA577E94499104D3240E1D" name="amed:MinimumPercentOwnershipForControllingInterestPercent" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e522-wk-Fact-7EA380A6477152ACBB848104103BF61F" name="amed:MaximumPercentOwnershipForEquityMethodPercent" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231509e526-wk-Fact-3248FF2AA68456B2BAF96F495A692A91" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231509e530-wk-Fact-725955E70BCD57169649890C1D0E88E0" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have less than a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231509e545-wk-Fact-2A68B019987E5F2CA50D640D0BC5C1B7" name="amed:MaximumPercentOwnershipForCostMethodPercent" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee.</span></div></ix:nonNumeric></ix:continuation><div><a id="sC9723715350F500ABD2851256262264F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-9BB63133510E52F1BEB14065BF855720-0-wk-Fact-DA45AE110E5D5B6B8BACF6E659BFF53F" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-0-wk-Fact-D5EFA67D05555AB6AD3832715AC48CED" continuedAt="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-1" escape="true"><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-1" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> and ASU 2015-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The implicit price concession represents </span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-1" continuedAt="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-2"><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-2" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e406-wk-Fact-3C6E291B447857B3936D0F1F88262283" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">74</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's consolidated net service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e414-wk-Fact-829FC6725DC1203FB633EBD2F624E871" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">73</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e418-wk-Fact-39BDCD1925757C832BE6EBD370D7C03B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">74</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our consolidated net service revenue for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for price concessions related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts we estimate to be realizable for services provided.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine our estimates for implicit price concessions related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e436-wk-Fact-72A7494C32D0510F85ADC4BDA0F2CC8B" name="amed:HistoricalCollectionRateFromMedicare" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="TextSelection-FFCBA3E0D6E1579F94EBB7C80C197BB3-0-wk-Fact-166D8F9460235DAC87DCBE25D591D61E" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Periods Ended September 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Periods Ended September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Home Health:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e663-wk-Fact-D59E82B81F7F569B8FFB9F06E47693E3" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e678-wk-Fact-1DD311278A175E409F0D11999E13E339" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e693-wk-Fact-CB3E1A3EB3C854578EC60640BE72F36D" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e708-wk-Fact-0AC2B99AB0905FF082F678A5A914FF59" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e725-wk-Fact-942AC1E6295752DFA7755D892243EC81" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e740-wk-Fact-B12EADE2EBD95B8FB86E4DCA967ABB1A" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e755-wk-Fact-68BA94A08733583080B9DC2D7D0B9796" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e770-wk-Fact-2BC419573D9E5CD2BDDC32B998F9A9B9" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e787-wk-Fact-D355BF8B9D235C8D8667DF84D463B521" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e802-wk-Fact-581FFCCFC84854A082F271C40138609C" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e817-wk-Fact-91834E5B1CD8583DA9A1359C88D8F816" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e832-wk-Fact-21CBF57071F354CF9E9EEA5E19CB5B9D" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice (1):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e911-wk-Fact-23566AD0DC59503B8C9F66946942813B" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e926-wk-Fact-853918F2B4705484AA97BD94F8DDAFE6" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e941-wk-Fact-65A989562E0F5F57A5567C6BACF0F201" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e956-wk-Fact-A531E5988AE55833B3226EEDBCA778DC" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e973-wk-Fact-C13D9E3A813752298BF0633E5B96A23B" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e988-wk-Fact-F68E96D3EB785DA09814D7D96FC5329B" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1003-wk-Fact-656DBDC98F4C5CAC89CF7EB5CE133EAB" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1018-wk-Fact-2C85B9F074A1505A8D8335559252566E" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1035-wk-Fact-AA6BF04279A95947959BACA9E776A539" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1050-wk-Fact-ED9F20519BDE577C8104AEEB9E057AE3" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1065-wk-Fact-4163BE914194562C870F1BF63A152FCB" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1080-wk-Fact-9FB28468FA455CAEBECDDA9061C91760" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1097-wk-Fact-F0CD9E091FDE5D18B6C9DFDB72A46E31" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1112-wk-Fact-9B74E505319E57368458418DA2ED8164" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1127-wk-Fact-5C42A7084F7456929CFB2B4698549AF3" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1142-wk-Fact-DC170A4B13385D8C97E59734CCF150E0" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" contextRef="FD2018Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Home Health Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on an established Federal Medicare  home health episode payment rate, that is subject to adjustment based on certain variables, including, but not limited to (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1228-wk-Fact-90374F847C9B57B3A4C3126F79D2867D" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" contextRef="FD2019Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1232-wk-Fact-4A08E5EBD0F55FA6923C2E310EA85D2D" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" contextRef="FD2019Q3YTD" unitRef="visit" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> or fewer; (c)&#160;a partial payment if a patient transferred to another provider or we admitted a patient transferring from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the </span><span style="font-family:inherit;font-size:10pt;">sixth</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">fourteenth</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">twentieth</span><span style="font-family:inherit;font-size:10pt;"> visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#160;changes in the base episode payments established by the Medicare Program; and (g)&#160;adjustments to the base episode payments for case mix and geographic wages. Medicare rates are based on the severity of the patient's condition, service needs and goals, and other factors relating to the cost of providing services and supplies, bundled into an episode of care, not to exceed </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct </span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-2" continuedAt="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-3"><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-3" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-4"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Expected Medicare revenue per episode is recognized based on a pro-rated service output method, utilizing our historical average length of episode prior to discharge.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1262-wk-Fact-1D11ADC6D17859F7BDD5E3DBFC50DAA6" name="amed:HistoricalCollectionRateFromMedicare" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record this estimate during the period in which services are rendered as an estimated price concession and a corresponding reduction to patient accounts receivable. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the company's average percentage of days complete on episodes as of the end of the year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Episodic-based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms which generally range from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1281-wk-Fact-23C97B9529BB5144A427234AAEFD0656" name="amed:NonMedicareRevenueTermRates" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1285-wk-Fact-161C563A6B465F3699FEF267F0ED1B61" name="amed:NonMedicareRevenueTermRates" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of Medicare rates.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-episodic based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make adjustments to non-episodic revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hospice Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1304-wk-Fact-75237BBF332157D88CDC860C9554234B" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" contextRef="FD2019Q3QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1308-wk-Fact-A6EAC9AE67A252B7A3CBB47D7C2A0D8A" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1316-wk-Fact-3CD8E6559652518CB982FE2F59A1E5B9" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" contextRef="FD2018Q3QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1320-wk-Fact-0DFE0FD813982F1CD288EBDFF352AE33" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" contextRef="FD2018Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">97</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. There are two separate payment rates for routine care: payments for the first </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days of care and care beyond </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make adjustments to Medicare revenue for implicit price concessions, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1347-wk-Fact-F4D88F2F3BE558518917A5127A27589C" name="amed:HistoricalCollectionRateFromMedicare" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record it during the period services are rendered.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance </span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-4" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-5"><ix:continuation id="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-3"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report and pay their estimated cap liability by February 28</span><span style="font-family:inherit;font-size:9pt;">th</span><span style="font-family:inherit;font-size:10pt;"> of the following year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1365-wk-Fact-70B1970E88CA5451BC976CEC068AE315" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" contextRef="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in accrued expenses for estimated amounts due back to Medicare for the Federal cap years ended October&#160;31, 2013 through September 30, 2019; approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1369-wk-Fact-CD6FD2CA457F5FD9A6F92E3E075562C7" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" contextRef="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of this amount is related to the cap liability acquired as part of the Compassionate Care Hospice ("CCH") acquisition. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1378-wk-Fact-C336F88A0AA454628F8C5E203274D12F" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" contextRef="FI2018Q4_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make adjustments to non-Medicare revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Care Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for price concessions. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). </span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="TextSelection-F2764A373B0453368BB62FF4A14F1EA2-0-wk-Fact-9A7C87DB0CC45BBFB317DA887548BA06" continuedAt="TextSelection-F2764A373B0453368BB62FF4A14F1EA2-1" escape="true"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patient Accounts Receivable</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We report accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there is no single payor, other than Medicare, that accounts for more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1418-wk-Fact-7F217A0DAC065150AF8DF70AA60EF85A" name="amed:PercentageOfPatientReceivablesOutstanding" contextRef="FD2019Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1422-wk-Fact-434B8185CB865BACB4DF19D1481BB7B3" name="amed:AccountsReceivablePortionDerivedFromMedicare" contextRef="FI2019Q3" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">59</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1426-wk-Fact-7C9EFDDDFE31597EA621E2386A0D4555" name="amed:AccountsReceivablePortionDerivedFromMedicare" contextRef="FI2018Q4" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">56</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our patient accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, is limited due to our historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1439-wk-Fact-72A7494C32D0510F85ADC4BDA0F2CC8B" name="amed:HistoricalCollectionRateFromMedicare" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Home Health</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1452-wk-Fact-A4363600314D5D16BB54D27E0066BEFB" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our estimated payment for the initial episode at the start of care or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1456-wk-Fact-8D0271494D785FC893B479D608B85AE3" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" contextRef="FD2019Q3YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1460-wk-Fact-E542D24AC029550F8D91FF2BF8E3A4BB" name="amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode" contextRef="FD2019Q3YTD" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">120</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> days from the start of the episode, or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1464-wk-Fact-7670435167B15C539BB3204ED96BC105" name="amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" contextRef="FD2019Q3YTD" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">60</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-5" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-6"><ix:continuation id="TextSelection-F2764A373B0453368BB62FF4A14F1EA2-1"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Hospice</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:DebtIssuanceCostsPolicyPolicyTextBlock" id="TextSelection-EE6A38CB8E7851989EDB730C481352B4-0-wk-Fact-64661A1AC73A554AB0AD60FD4114A6C3" escape="true"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Issuance Costs</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the nine-month period ended September 30, 2019, we recorded </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our condensed consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 5 - Long-Term Obligations). As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018, we had unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1501-wk-Fact-E20CC861121E500C959BF84DAF457F87" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1505-wk-Fact-8467D6AF6E9C50669CFFCC02D1D16221" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, recorded as long-term obligations, less current portion in our condensed consolidated balance sheet. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1509-wk-Fact-B2F517F5704452AAB0E884E768FD9187" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1514-wk-Fact-2D9EAB083A005877AEB57D6D5CA44AB4" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance during the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131214993e1522-wk-Fact-E20CC861121E500C959BF84DAF457F87" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> will be amortized over a weighted-average amortization period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131214993e1526-wk-Fact-0335FB81AF3154C3B63409AC96210F31" name="amed:UnamortizedDebtIssuanceCostAmortizationPeriod" contextRef="FD2019Q3YTD" format="ixt-sec:duryear">4.3</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-8CA8E3D3E4B15B3192E9AB98A16D8630-0-wk-Fact-82A383A32E7056059304CD7E87A9356C" continuedAt="TextSelection-8CA8E3D3E4B15B3192E9AB98A16D8630-1" escape="true"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:FinancialInstrumentDetailsTableTextBlock" id="TextSelection-DEF75CF2A1F85AB7AE8572BE3448D484-0-wk-Fact-1F4149D7B847523F8F98AB8286ADDBA0" escape="true"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Financial Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value as of<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1779-wk-Fact-655A6156CACD59B0BECD82C962C2D218" name="amed:DebtInstrumentCarryingAmountExcludingCapitalLeases" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1798-wk-Fact-42AE5B714ADD5FEB86380CE4D4D35960" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="1" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1817-wk-Fact-A581F7DC34FD54F7AF53AD5EF6EDBA72" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e1837-wk-Fact-6F4928329B4551BF8D2FC11BEA8B644A" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="1" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></td></tr></table></ix:nonNumeric><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-8CA8E3D3E4B15B3192E9AB98A16D8630-1">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-6" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-7"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-12EBBA161834579BAC62DA85BC382142-0-wk-Fact-97AC8AD49687557287EB58A23B521D97" continuedAt="TextSelection-12EBBA161834579BAC62DA85BC382142-1" escape="true"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted-Average Shares Outstanding</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-12EBBA161834579BAC62DA85BC382142-1">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="TextSelection-9E3B17785EE35D44B882D36C1FF5619D-0-wk-Fact-7A49A2B4D39A571DB247D37992945744" continuedAt="TextSelection-9E3B17785EE35D44B882D36C1FF5619D-1" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9E3B17785EE35D44B882D36C1FF5619D-1"><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:52%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2064-wk-Fact-CD11DC571B9851778D9F4ABC891E8923" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2078-wk-Fact-93B2D8D871FA5DDFA6739CE528068113" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">31,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2092-wk-Fact-89F85BF475A95C96A5BBDBF1DB638438" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2106-wk-Fact-6C2CAE056DF9575186ED2BE686165C73" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2184-wk-Fact-B101B5F595315592B6F4282E93179A89" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2198-wk-Fact-14BA2FFDEDE455DA8F3B5CA574288F1E" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2212-wk-Fact-4A22D7B51FAC50D4B1BF565ECA1698F1" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2226-wk-Fact-54FEA63AAF4259E196743CA96E887026" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested stock and stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2242-wk-Fact-5A8271CD48D750CA89EF9187D6D2929F" name="amed:NonVestedStockAndStockUnits" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2256-wk-Fact-419570FF74975D2EB4052B0566868630" name="amed:NonVestedStockAndStockUnits" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2270-wk-Fact-5E785FBDEF175339B7C829D9F3592182" name="amed:NonVestedStockAndStockUnits" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2284-wk-Fact-069B1D088FA150D79E494E0E74FC0E60" name="amed:NonVestedStockAndStockUnits" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2300-wk-Fact-28CF598E0CB95194B9F5F379A14254DD" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2314-wk-Fact-85B676CCD8CD502C93833B814DEDEB3C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2328-wk-Fact-FE6C4CE2C1BE5BC79A55744349AD541D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">32,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2342-wk-Fact-5655AC2AEFFB5F57B1BE932580F9E145" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2358-wk-Fact-5FDC2368708153D7B1A6ED004F52EF10" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2372-wk-Fact-2DDC8ECDB66A55A0B5241C26DEB47611" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2386-wk-Fact-388728C9425752768CC3E3D40FF37F5A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131214993e2400-wk-Fact-C40CF847B16F51FE9AE581ADF67D7377" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-CC8F3EBDC7955E77923A1015E112214F-0-wk-Fact-D29A1BCEAFA6551C90809F703A633386" continuedAt="TextSelection-CC8F3EBDC7955E77923A1015E112214F-1" escape="true"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-CC8F3EBDC7955E77923A1015E112214F-1" continuedAt="TextSelection-CC8F3EBDC7955E77923A1015E112214F-2"><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-7" continuedAt="TextSelection-9BB63133510E52F1BEB14065BF855720-8"><span style="font-family:inherit;font-size:10pt;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-CC8F3EBDC7955E77923A1015E112214F-2"><ix:continuation id="TextSelection-9BB63133510E52F1BEB14065BF855720-8">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</ix:continuation></ix:continuation> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div><a id="s0D52A2BC0CF35825AF65B59D499704E3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-0-wk-Fact-B7D9B9FCC7CC5E84A8028833868B7DAF" continuedAt="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-1" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-1" continuedAt="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, we acquired Compassionate Care Hospice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e361-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">327.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e365-wk-Fact-11067BD03D6C5A85A4E2B985B909481D" name="us-gaap:CashAcquiredFromAcquisition" contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="TextSelection-EE49EEA4C6935E44B49A79FC279B19BC-0-wk-Fact-E736E0896AD351C6892947FB012D78F4" continuedAt="TextSelection-EE49EEA4C6935E44B49A79FC279B19BC-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. During the three-month period ended September 30, 2019, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e374-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">327.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-2" continuedAt="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-3"><ix:continuation id="TextSelection-EE49EEA4C6935E44B49A79FC279B19BC-1"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e424-wk-Fact-5C605A124F455A11B4D7E54430DC034D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e439-wk-Fact-C61542A62CD6577F9B50DB206915268C" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e459-wk-Fact-461267C2A88550F3BB26826153D9F995" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e479-wk-Fact-6A2353EA575050CAA690D016FE04D29F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e499-wk-Fact-27952BAFC0B95B779EEA7EEC94FC9C61" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e519-wk-Fact-D97A76BEE2C1EFF9BA73EEB213AB2066" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e539-wk-Fact-0616E8343A06555B9D088AE3799E870C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e559-wk-Fact-2C4C20DCF77D5565AD821C95B237954B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e580-wk-Fact-3A496B17C37059609C730D32D152F5A1" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e601-wk-Fact-09FAADB9B4F058EEB19D0AED26D36A8A" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e623-wk-Fact-65BF8E8BF06D56DDAEA1858F8B56968F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e644-wk-Fact-D564565497541A1B9762EEB550B534A3" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131234774e665-wk-Fact-965223E05C655109A4E639E4A2A4D37D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e686-wk-Fact-D9384B590C465F7BA10547C28133CED8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e706-wk-Fact-53A674204CC9546E9AC02E78F48943FA" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">315.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total estimated consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e731-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">327.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired include Medicare licenses, certificates of need, trade names and non-compete agreements. The trade names and non-compete agreements will be amortized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131234774e743-wk-Fact-43CB1204B9A05D5DA2DC4D3887806827" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" format="ixt-sec:duryear">2.0</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131234774e747-wk-Fact-EFC0471194B952BE98B271E4C9C3F159" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" format="ixt-sec:duryear">2.3</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CCH contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e755-wk-Fact-B539F17F63C15A03BFED94288D3DD0FA" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and operating income of </span><span style="font-family:inherit;font-size:10pt;">$0.9 million</span><span style="font-family:inherit;font-size:10pt;"> (inclusive of acquisition and integration costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e763-wk-Fact-4180CFEF77BB5C3A8377BC300C85B1FA" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">) during the three-month period ended September 30, 2019 and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e767-wk-Fact-056FE771379958EBA20C8F2D16F8C5BE" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">123.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and an operating loss of </span><span style="font-family:inherit;font-size:10pt;">$4.2 million</span><span style="font-family:inherit;font-size:10pt;"> (inclusive of acquisition and integration costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e776-wk-Fact-618D96A545E354EDB965D739477BCDE0" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">) during the nine-month period ended September 30, 2019. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="TextSelection-D705A365248554E597436889E71D74A5-0-wk-Fact-32F7D9656BB75F00A2FE1C99AD48BEC5" escape="true"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table contains unaudited pro forma condensed consolidated statement of operations information for the three and nine-month periods ended September 30, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-<br/>Month Periods<br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e990-wk-Fact-523160FFB8A3516D8F74A5426E18884E" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">494.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1009-wk-Fact-E138CCF602CD578FBC1DF4790C633C30" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">467.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1028-wk-Fact-8CCB815CA1585AA8A4764F2A53582540" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,471.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1048-wk-Fact-5C3072210825536E9AB7DD799910CE8B" name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,373.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1063-wk-Fact-5D664B8BC24853369C026C26226250C4" name="amed:Businessacquisitionproformaoperatingincomeloss" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1082-wk-Fact-3A4E6348BE1D544FBE82940E8CEB7CB0" name="amed:Businessacquisitionproformaoperatingincomeloss" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1101-wk-Fact-BEC7C0F4AC295F12A53C16F8BBE232AC" name="amed:Businessacquisitionproformaoperatingincomeloss" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">142.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1121-wk-Fact-6A2D641554535CB38E5C435BC102D961" name="amed:Businessacquisitionproformaoperatingincomeloss" contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1141-wk-Fact-E651D7CA6227555189E7F9479DA46D3A" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1160-wk-Fact-51AEEF4DC1ED5427BBD72CA17D4C1CBB" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1179-wk-Fact-751E3110FA525C02A7ECD8780EAA9984" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1199-wk-Fact-B4C6C19D46945EB68F7A8F02C8651ECE" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1219-wk-Fact-B16D4704524C5DD8987E47E97ACE36F2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1238-wk-Fact-92A60DECEBBA5374B0A4956315996949" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1257-wk-Fact-7FE608906AD4545686914EAA1063A681" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1277-wk-Fact-F64FFAA3675055CB8EF537EC7FE45A48" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1302-wk-Fact-9E610C437D985775B9942B0405AAEC20" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1321-wk-Fact-B758F882A8425ED78292425EF20381CF" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1340-wk-Fact-B4C5BEEA148853D8A6937195D59AECB0" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131234774e1360-wk-Fact-E8BEEFCF3EBB5DE6BDEAA401A59FD959" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-3"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1375-wk-Fact-5B369437C79D5F80858CE94A69FCF28E" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q2Apr042019_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1379-wk-Fact-E31E9AFB7BD0512C98C3DCEE74714932" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and other intangibles including non-compete agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1383-wk-Fact-57F0CEC243F8511BA73F67CC2EF68BC5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and tradenames of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1387-wk-Fact-D57FCAD17E58524A9245673DE7C339B3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the three-month period ended June 30, 2019. The non-compete agreement will be amortized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131234774e1391-wk-Fact-616F364E356D5428A1A26ECD1382CB46" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" format="ixt-sec:duryear">2.8</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. RoseRock contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1396-wk-Fact-E7A9007958F3553DB192383F16C9CA3E" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1400-wk-Fact-85A4DC2B64D55F589FCE886939D4B286" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating income during the three-month period ended September 30, 2019 and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1404-wk-Fact-E73D9064E44EEE0333C6EBED7615C9FE" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131234774e1408-wk-Fact-16B90C5A7B610749070DEBEE159B70B7" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating income during the nine-month period ended September 30, 2019.</span></div></ix:continuation><div><a id="sCF567D7E90025C9E9D854A41F09BD348"></a></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-DCB1F45C2EF254748839C30EFC860505-0-wk-Fact-92DC4774CB7452E090813AC1DA3D729A" continuedAt="TextSelection-DCB1F45C2EF254748839C30EFC860505-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DCB1F45C2EF254748839C30EFC860505-1" continuedAt="TextSelection-DCB1F45C2EF254748839C30EFC860505-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e355-wk-Fact-4DB203B3751C52E182EF899564E5C9A7" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. We also have finance leases covering certain office equipment that expire at various dates over the next </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e359-wk-Fact-259536B06B5B5715999420695419EB6A" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="FI2019Q3" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. Our leases do not contain any restrictive covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our office leases generally contain renewal options for periods ranging from one to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e368-wk-Fact-380307E80E585E2DBBD62E336A217410" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our fleet leases include a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e377-wk-Fact-BD77750525B8B1485AF7036B9EFE5FB6" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_amed_FleetLeasesMember" format="ixt-sec:durday">367</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-2826537A8FBD5552B1F53A053A10180F-0-wk-Fact-ACA10ADB0CE25380B217EDA8B82EB358" continuedAt="TextSelection-2826537A8FBD5552B1F53A053A10180F-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for the three and nine-month periods ended September 30, 2019 are as follows (amounts in millions):</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-DCB1F45C2EF254748839C30EFC860505-2" continuedAt="TextSelection-DCB1F45C2EF254748839C30EFC860505-3"><ix:continuation id="TextSelection-2826537A8FBD5552B1F53A053A10180F-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.78752436647173%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three-Month Period Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e516-wk-Fact-13D20104BE6252A39D4324C6E9644F4C" name="us-gaap:OperatingLeaseExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e535-wk-Fact-2B2ADB4A80525B42A6C4B97F87D2733A" name="us-gaap:OperatingLeaseExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e550-wk-Fact-060350A830EA5CF2803C136419523A7B" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e569-wk-Fact-203AA32A6BF55098BAAEF250773FF480" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e589-wk-Fact-F86AB4AA11CC5D69B7D793745BFEA3D7" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e608-wk-Fact-983092A5EF7F54CF85848EACAE3B4680" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e710-wk-Fact-F3381F7D53BA50AF820536957FB4BBD3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e729-wk-Fact-29098B1F2C885F58AEF44609C8461EF9" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e749-wk-Fact-15B919CC73515D8F95DD9A74C4413E51" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e768-wk-Fact-1C612101680556369F8CB74AE6E9D66F" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e788-wk-Fact-F8A9A7107CE8549F8BDB205234F4B00C" name="amed:FinanceLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e807-wk-Fact-EF2D9CC57A395425BDF0D27EC6443F24" name="amed:FinanceLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e869-wk-Fact-BBB5FC411A9B52D1A5558143006FD49D" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e888-wk-Fact-F7795E44F91B52DDA1A82228967DE6BA" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e908-wk-Fact-EC0BDB2551E351C99A038A8759F1857B" name="us-gaap:ShortTermLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e927-wk-Fact-F8E4C08EC4DA535FA3EB9176F2A434FF" name="us-gaap:ShortTermLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e993-wk-Fact-356E7D8ED6665C00BFDD525C57DEB0E1" name="us-gaap:LeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1012-wk-Fact-21EA3E6AB16D5CD1803D770A90E3F33B" name="us-gaap:LeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:OperatingleasesTableTextBlock" id="TextSelection-65E394E3C6545191A2B791A75034B947-0-wk-Fact-08DE99A1578057FD94F16B29DF368080" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1074-wk-Fact-A09E255371915BC0A94C68E56FD0A372" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1110-wk-Fact-3A5AA0D149DD512FBE4DD8D751E1AF8F" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1130-wk-Fact-5BA1C23C134C554B96EAAF3BE282D809" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1155-wk-Fact-AEF641B80376572E9D3D96FBE9798E14" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:FinanceleasesTableTextBlock" id="TextSelection-807F0E85547D5E21AD5EC6B0FAF9B29E-0-wk-Fact-67953B4177F55F3DA0CBC364C074A97D" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our condensed consolidated balance sheet. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our condensed consolidated balance sheet.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1217-wk-Fact-E085FD729F845BFBBECDA20AD2D00344" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e1232-wk-Fact-CE7FDD12E83950D18D79BC4A4C535805" name="amed:LesseeFinanceleasesAccumulatedAmortization" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1253-wk-Fact-4FB22436860250F1A38E6006E05C4BD6" name="amed:FinanceleaseRightofUseAssetNet" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current installments of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1294-wk-Fact-565EA7B8788C52669C23B1B843F77076" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1314-wk-Fact-9909ECC4CF7B50FDA530E26766698696" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1339-wk-Fact-DD96E1C7B3A459DDBBA91BE2FCBB945F" name="us-gaap:FinanceLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-DCB1F45C2EF254748839C30EFC860505-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock" id="TextSelection-EC0D50A3BE9854089D3EAB31253593F8-0-wk-Fact-39DA7210E41859BE9E2CCCC530AF6761" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.73489278752436%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flow from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e1425-wk-Fact-F375D7FB74505CF0B1E6AD9BDDF3C7AE" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flow from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e1441-wk-Fact-8710F998BC79541E9E693B329EE072BC" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1504-wk-Fact-64EBA052049F596A895D004BE46BCDA0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1524-wk-Fact-D162FE79BE15586D99044C88C24DECB5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions to ROU assets resulting from reductions to lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e1586-wk-Fact-8477E15CB75F52639D054400412CD629" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1608-wk-Fact-78CD79EC9DB352DFAB53F7CD3FE8C869" name="amed:LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:WeightedaverageremainingleasetermanddiscountrateTableTextBlock" id="TextSelection-A3E530CD21D8520799A8269546B1B96C-0-wk-Fact-970FF943AEBC55CA9F366D88586805F0" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease terms and discount rates for our leases as of September 30, 2019 are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:77%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e1686-wk-Fact-51AE795A46DA5A03860AF45F759493A6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q3" format="ixt-sec:duryear">4.0</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230659e1701-wk-Fact-BE4A8F9F4E74556B8114F7C9FD1CFA58" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q3" format="ixt-sec:duryear">2.3</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1748-wk-Fact-E682E3B4136353938845D921A99F4651" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q3" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1764-wk-Fact-BDCB8331A7AF5F3F9D5D878A24B048CA" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q3" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="amed:LeaseLiabilityMaturityTableTextBlock" id="TextSelection-5A0FA7B1EFB75DE29E863FDBCE609550-0-wk-Fact-6FE90204170A5F26A1D52EBD5009F64D" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities as of September 30, 2019 are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1857-wk-Fact-7C8191AD2CCF569E8AB00E791F3BA785" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1876-wk-Fact-71D901D961045FCA9D3B4D3BBC0DBA5B" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1891-wk-Fact-BBCBCABB25F35D2188296C4C361F8214" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1910-wk-Fact-353F5A59B4675EEC834CEB575B326F92" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1930-wk-Fact-3F570761672C5432BB9722259151CB74" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1949-wk-Fact-CD0A9BCD23655380A6E244308C6FA773" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1969-wk-Fact-45A9D0CCE90550CFB81D0A7BE36F8367" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e1988-wk-Fact-B615F799203F599EADC18A169394D908" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2008-wk-Fact-9C3CF86AEE365FDFAE2EAAD488D2AA87" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2027-wk-Fact-FE8C49CE6A1E52DC910EA342BAC6A2E8" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2047-wk-Fact-CB9817337F1356FABBBC3F2C3BBB8D45" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2066-wk-Fact-58C957633BBF55F9AD41735C9EF6B483" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2086-wk-Fact-1FF005F7CFEB5C94910C8CFBA9A9972B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">90.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2105-wk-Fact-0C661BF00B285CE2BD6AD4B508DF59FE" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e2125-wk-Fact-C9574D2BB9B15251AC0F7D7B06544C48" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230659e2145-wk-Fact-95C9B8402F005BDD9A13974CAA8E2D36" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2171-wk-Fact-AEF641B80376572E9D3D96FBE9798E14" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230659e2190-wk-Fact-DD96E1C7B3A459DDBBA91BE2FCBB945F" name="us-gaap:FinanceLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:126px;text-indent:-78px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Excludes the nine-month period ended September 30, 2019.</span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD952A9ECBEDB5F5382110B875227FCF5"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-0-wk-Fact-AB6F01B712EC51E69FB21C59427E2CB6" continuedAt="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-1" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-1" continuedAt="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="TextSelection-173DA99A06A15D35A6961C0EDCD6957F-0-wk-Fact-ADBDFD8990D65500B0C0F9963EEC5BF6" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.81286549707602%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e432-wk-Fact-8F5ECD47278B563C807C358EA2AAA24C" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">172.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e451-wk-Fact-EAE3DD35960E56ACA5B1DC71C67DD2AD" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e466-wk-Fact-D5A39AB87F0A56A9A5DDF777B6395DBE" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e485-wk-Fact-0C8878B6DFF556FA8CBE3885C04F5C4E" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promissory notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e505-wk-Fact-263C3A1C41EC534AB5BA7807A794A4CE" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e524-wk-Fact-5D86455C22245F01ADEE149F7D82B63A" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e544-wk-Fact-96370ADB744A593EBEDC304BCFFC994D" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e563-wk-Fact-C1DFCF5B53A25D91A2F97865C160C08F" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e583-wk-Fact-ED53AA76226A5AD4B8DEADC8DF8EB92E" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e602-wk-Fact-F46D4F22FBA75289857607F05AE06532" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230578e622-wk-Fact-5C1CC49866D05348B2A703E2C08DD872" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230578e642-wk-Fact-F67F7A9E5FE25FCFBA679ABAF6D3F547" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e663-wk-Fact-5F7F17A675CA547D9EEFDF3C061A8762" name="us-gaap:LongTermDebt" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e682-wk-Fact-9662723D13D653E48498E667FD6B3B6C" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230578e702-wk-Fact-2BC6C1E3C401528AB8DA80E3B2F375CE" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131230578e722-wk-Fact-3AA4362682075C5A99CF6CA79627BA22" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e748-wk-Fact-28638BF0548252B0867BA7F68796F2BF" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">231.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e767-wk-Fact-72E6C1A2AF705B57AFDE277E9C11719F" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e788-wk-Fact-621F87680B50564EBF957B5EE9D5BAD8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2019Q1Feb04" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">725.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e792-wk-Fact-5FE5992888DE5204A8A49B1B0BABBED9" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">550.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e796-wk-Fact-CF65B158826F5739B032CADDFB2F8D2E" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">175.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e810-wk-Fact-76CF38EE2A9E5141B151227C7861B9D7" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e814-wk-Fact-0F49BE71FB1B5516A6BCD6B4CB45BC65" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Applicable Rate is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e822-wk-Fact-34E3154144C45F98A7725D9DE2F7239E" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum for Base Rate loans and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e826-wk-Fact-2B8B6B3CB51C5372A9F6132222257DE5" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum for Eurodollar Rate loans. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="TextSelection-3BB83B06CA5158AE8A7AD0BA9E4CF5AB-0-wk-Fact-DD68E00FCA9657E58B7D31E40AF34AFD" continuedAt="TextSelection-3BB83B06CA5158AE8A7AD0BA9E4CF5AB-1" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3BB83B06CA5158AE8A7AD0BA9E4CF5AB-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.39766081871345%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:11%;"></td><td style="width:27%;"></td><td style="width:18%;"></td><td style="width:13%;"></td><td style="width:18%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pricing Tier</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitment Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Letter of Credit Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eurodollar Rate Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Base Rate Loans</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">I</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8805; 3.00 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e895-wk-Fact-CAD118BD2E0650FB8EEB7669E002600D" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.35</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e900-wk-Fact-D46B9D18943557C69671139147451B26" name="amed:LetterOfCreditFee" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e905-wk-Fact-5FD815B2ADBC5ACC9F1598144739FC25" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.00</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e910-wk-Fact-575376D014EB5EA9A27150C7C38A40C9" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e926-wk-Fact-C5A7C8423B3D51C0975A38DA3E85D06D" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.30</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e931-wk-Fact-99FCE19AA8D25F7DA28D399D3C6857A2" name="amed:LetterOfCreditFee" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.50</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e936-wk-Fact-C4C4F92AF4935C77827AD07C88CBC29D" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e941-wk-Fact-48F6AC0385BA560380F88AECDE9DCF09" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.75</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">III</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e957-wk-Fact-246D290B6F055490AEEDC13431653C2F" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e962-wk-Fact-C18CA013CC0B5F0A9AAD0B311E213ACC" name="amed:LetterOfCreditFee" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e967-wk-Fact-72041134F1CB5374B1E81100EC0CB28A" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.50</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e972-wk-Fact-140813D2AA1F5C17A3CED216371386E5" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e988-wk-Fact-3FA784FC17595819987B8B00D4201EB4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.20</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e993-wk-Fact-E77B0F1DFFD155C7A2193F3EB3424FAA" name="amed:LetterOfCreditFee" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e998-wk-Fact-495D7E9D1F93596CAA7F2BF15CAB3AA5" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1003-wk-Fact-C85283B6847A5F04AA282BCE0230CAE1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The final maturity date of the Credit Facility is </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d131230578e1014-wk-Fact-16076887F2175867A98C77735071867D" name="us-gaap:DebtInstrumentMaturityDate" contextRef="D2019Q1Feb04_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" format="ixt:datemonthdayyearen">February 4, 2024</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;">. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1018-wk-Fact-2294352741AA559BBC7361F63F7BA67C" name="amed:DebtInstrumentPeriodicPaymentPercentage" contextRef="D2020Q1Feb042019-Mar312020_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.625</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1022-wk-Fact-5ACCC1001B225B00B9D2ADFA42E8BF18" name="amed:DebtInstrumentPeriodicPaymentPercentage" contextRef="D2023Q1Apr012020-Mar312023_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.250</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1026-wk-Fact-A52CD87945255A4FA6F079DE141165F1" name="amed:DebtInstrumentPeriodicPaymentPercentage" contextRef="D2024Q2Apr012023-Feb042024_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.875</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on April 1, 2023 and </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1033-wk-Fact-256024227A7E588593A5E046F69ABCE4" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" contextRef="D2019Q1Feb04_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the nine-month period ended September 30, 2019.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1051-wk-Fact-39AB70D0B046539E80A9931C3F12B47C" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">95</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1055-wk-Fact-F317830706E95DFEACA6FEBFBA5310C5" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our weighted average interest rate for borrowings under our </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1064-wk-Fact-0FC425A394ED535F95B1EB11AEC5A761" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">550.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1068-wk-Fact-76E257A18D96573D99747C6B68DB0008" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" contextRef="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.8</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1072-wk-Fact-E2BB5EC984D9387EE379EC1FBC70D714" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.9</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our weighted average interest rate for borrowings under our </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1080-wk-Fact-C399BD88F96A5B239AEDD4545FBCB6CF" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">175.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> Term Loan Facility was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1085-wk-Fact-F6603246AC515F65BB46E15B165B8194" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" contextRef="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.8</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1089-wk-Fact-EDDE5655AD1793FF1FD5EC215D34D067" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" contextRef="D2019Q3Feb0419-Sep3019_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.9</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the period February 4, 2019 to </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our consolidated leverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1109-wk-Fact-D13EA4E437DA5B8EB5F709502B99BC45" name="amed:TotalLeverageRatio" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, our consolidated interest coverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230578e1113-wk-Fact-4544B6785B515BB293F411DE07690550" name="amed:ConsolidatedInterestCoverageRatio" contextRef="FI2019Q3" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">19.5</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our availability under our </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1125-wk-Fact-C016A99C81D15A58847E1E2D626577DE" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">550.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1129-wk-Fact-D5EFDFCABA9258E78F3B4E945C097B5F" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as we have </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1133-wk-Fact-D5A39AB87F0A56A9A5DDF777B6395DBE" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding in borrowings and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230578e1137-wk-Fact-099AA4E6B78D5AAB89005E1653937E7F" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding in letters of credit.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joinder Agreement</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.</span></div></ix:continuation><div><a id="s985E7036914C5477A53909C9E9385618"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-3E28ABB7F5885038B358D484039A24F1-0-wk-Fact-B1E4338A11625F9099805FD451A36EF3" continuedAt="TextSelection-3E28ABB7F5885038B358D484039A24F1-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3E28ABB7F5885038B358D484039A24F1-1" continuedAt="TextSelection-3E28ABB7F5885038B358D484039A24F1-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in the following legal actions:</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e369-wk-Fact-22F8ECE2E9EA5FF0B8D8EE133BA49F79" name="amed:Numberofpatients" contextRef="D2015Q2May21_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_stpr_MA_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="patient" decimals="INF" scale="0" format="ixt:numdotdecimal">53</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e376-wk-Fact-FCAD0A5E2BF95A6DB3CA448E0CF604A0" name="amed:Numberofpatients" contextRef="D2015Q4Nov03_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_MorgantownWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="patient" decimals="INF" scale="0" format="ixt:numdotdecimal">66</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e386-wk-Fact-86AA8E24225C5253A974498BC8A24D47" name="amed:Numberofpatients" contextRef="D2016Q2Jun27_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_ParkersburgWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="patient" decimals="INF" scale="0" format="ixt:numdotdecimal">68</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e393-wk-Fact-23FD2D8E0E5A52CDBDC2BD503E5217E8" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to accrued expenses in our condensed consolidated balance sheet related to this matter as of September 30, 2019.&#160; Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Investigative Matters - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Corporate Integrity Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#8220;CIA&#8221;) with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA required that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230865e413-wk-Fact-5D6137D879E95301826154DB469A2B2D" name="amed:CorporateIntegrityAgreementTerm" contextRef="D2014Q2Apr23_srt_LitigationCaseAxis_amed_AmedisysCIAMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> that ended on April 21, 2019. We filed our final annual report on July 19, 2019.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-3E28ABB7F5885038B358D484039A24F1-2" continuedAt="TextSelection-3E28ABB7F5885038B358D484039A24F1-3"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 30, 2015, Compassionate Care Hospice (&#8220;CCH&#8221;) entered into a CIA with the OIG. The CIA requires that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization (IRO) to complete claims review for hospice services rendered in New York. The OIG has waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA requires that CCH report substantial overpayments that CCH discovers it has received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The CIA has a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d131230865e423-wk-Fact-23B7F9D6A9A45604833F05D9520C2B25" name="amed:CorporateIntegrityAgreementTerm" contextRef="D2015Q1Jan302015_srt_LitigationCaseAxis_amed_CompassionateCareHospiceCIAMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> that will end on January 30, 2020. </span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Party Audits - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;) and Medicaid Integrity Contributors (&#8220;MICs&#8221;) in which third party firms engaged by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e436-wk-Fact-18731E511B5F59A584FBF4C4C2FBB203" name="amed:NumberOfBeneficiaries" contextRef="D2008Q1Jan01-Mar31_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="beneficiary" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e440-wk-Fact-0ED52F781FFC50189DD3BC5EE7C610CD" name="amed:NumberOfBeneficiaries" contextRef="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="beneficiary" decimals="INF" scale="0" format="ixt:numdotdecimal">16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e444-wk-Fact-CB921A265BFA5BB8BF20F2A3ABE95E07" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> with a balance owed of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e448-wk-Fact-903513F79C53599F8FCEDB3191908919" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" contextRef="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, including interest, based on </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e452-wk-Fact-26AB57F36AA9573E94C51C9F09EAA588" name="amed:NumberOfClaimsSubmittedBySubsidiary" contextRef="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="claim" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> disputed claims (originally </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e457-wk-Fact-0ED52F781FFC50189DD3BC5EE7C610CD" name="amed:NumberOfBeneficiaries" contextRef="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="beneficiary" decimals="INF" scale="0" format="ixt:numdotdecimal">16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">). We filed an appeal to the Medicare Appeals Council on the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e461-wk-Fact-26AB57F36AA9573E94C51C9F09EAA588" name="amed:NumberOfClaimsSubmittedBySubsidiary" contextRef="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="claim" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Medicare has withheld payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e469-wk-Fact-A72C695BEF76542696F0EEB4AA7C08B4" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e473-wk-Fact-FDCC1D78CF7B5C6A9B3522C43B0E6FBE" name="amed:IndemnificationAmount" contextRef="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Accordingly, the Company reduced its indemnity receivable from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e477-wk-Fact-55D66D450738501985E5087A5378F87D" name="us-gaap:LossContingencyReceivableNoncurrent" contextRef="FI2018Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e482-wk-Fact-A40A31F75D135FECA69468B87DE6465A" name="us-gaap:LossContingencyReceivableNoncurrent" contextRef="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e486-wk-Fact-EA7A5BCBA9FE5D68BAE477464EC7177C" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="FD2018Q4QTD_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> impact was recorded to general and administrative expenses, other within our consolidated statements of operations during the three-month period ended December 31, 2018. As of  </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have an indemnity receivable of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e494-wk-Fact-BCCF928DA2A15C4CA9D83E498A4BAC82" name="amed:LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the amount withheld related to the period prior to August&#160;1, 2009.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e501-wk-Fact-0C70A69B051656D5A2D82022BC3EED83" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Lakeland Care Centers on a universe of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e505-wk-Fact-F787B8A2531850C3B2360D067B821AE3" name="amed:NumberOfClaimsSubmittedBySubsidiary" contextRef="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="claim" decimals="INF" scale="0" format="ixt:numdotdecimal">72</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Medicare claims totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e509-wk-Fact-D21F34451E8B528FAB1052D42EDF7EDB" name="amed:ActualClaimsPayment" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in actual claims payments using a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e513-wk-Fact-681BA50C712453779F935DF26C15C1A8" name="amed:ErrorRatePercentage" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> error rate and an overpayment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e517-wk-Fact-0240B49DB9B45C08A77EF5C976825CFD" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Clearwater Care Center on a universe of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e522-wk-Fact-0A1B344664E054ECA53ED6F35959223A" name="amed:NumberOfClaimsSubmittedBySubsidiary" contextRef="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="claim" decimals="INF" scale="0" format="ixt:numdotdecimal">70</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Medicare claims totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e526-wk-Fact-FAF48FA7C8D85FEF9ACC5120CE9AE345" name="amed:ActualClaimsPayment" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in actual claims payments using a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131230865e530-wk-Fact-61B577D602285520A711D7C33469B8DE" name="amed:ErrorRatePercentage" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> error rate.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-3E28ABB7F5885038B358D484039A24F1-3"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e537-wk-Fact-43ADEC7565EA5C13B8A5C8834683E3C6" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and the alleged overpayment for the Clearwater Care Center has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e541-wk-Fact-4EF67B4C7A4A5A50935AEE7E69B24326" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e545-wk-Fact-993F8C64C1175D898F9E2A93703D8C99" name="amed:IndemnificationAmount" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e553-wk-Fact-0F13561B1BB659CEAEE83B42103D65B8" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e557-wk-Fact-79BCE801625359D4A5BCF9C7AA3AD84F" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e561-wk-Fact-993F8C64C1175D898F9E2A93703D8C99" name="amed:IndemnificationAmount" contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is subject to indemnification by the prior owners) to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e565-wk-Fact-C3EB60D808C7589DAC0D95D3402EAAD8" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have an accrued liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e576-wk-Fact-0DFE9DB7ACC4525CB209573A951DE457" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this matter. We expect to be indemnified by the prior owners for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e580-wk-Fact-FA6A69BD1249568BBD371E23352A1F4F" name="us-gaap:LossContingencyReceivableNoncurrent" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the total </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e584-wk-Fact-A03E490F438751259EF59866FAF6878C" name="amed:IndemnificationAmount" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The net of these two amounts, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e593-wk-Fact-65E49CBC1C795A8593CD8561D41A9651" name="amed:FloridaZpicRevenueReduction" contextRef="FD2017Q3QTD_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, was recorded as a reduction in revenue in our condensed consolidated statements of operations during the three-month period ended September 30, 2017. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e601-wk-Fact-D74E073951B25579835D2B4F8BD695AC" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of receivables have been impacted by this payment suspension.</span></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insurance</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our health insurance has an exposure limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e614-wk-Fact-A224D68B7A8B58339862FDAC7D6C220C" name="amed:HealthInsuranceRetentionLimit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e618-wk-Fact-9DA7EDB408F75AAB91DA609ED22972CF" name="amed:WorkersCompensationInsuranceRetentionLimit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> per incident and our professional liability insurance has a retention limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131230865e622-wk-Fact-EF22D2BAA4845D129DC52C4545854E0C" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> per incident.</span></div></ix:continuation><div><a id="s5FD17D2E23095B5DBB366C9096ED7B8B"></a></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-0-wk-Fact-75E4C0E43D6559128250EC308FBA8634" continuedAt="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-1" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-1" continuedAt="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-2"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations involve servicing patients through our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e358-wk-Fact-3DCD0C4E10D857879386C793CD19F2C2" name="us-gaap:NumberOfReportableSegments" contextRef="FD2019Q3YTD" unitRef="Segments" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-2"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="TextSelection-9B05BFCDC6705C528A5A0E75271CDE19-0-wk-Fact-9F1F6D8902855ABA9DFE9D2DBC33CDA0" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e620-wk-Fact-E70BCAD04CCB56FDBAF187C726AB4DE2" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">311.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e639-wk-Fact-D7C09AAF43D35444A70F94B9152BA0E0" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e658-wk-Fact-34B64EA55D265622AEC430BC9932CAC5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e678-wk-Fact-EAC8873237CF5F1D905677DC16B7253C" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e697-wk-Fact-E6ADFC5ED04D5FF9A35A97580773B7DB" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">494.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e712-wk-Fact-76C3229443035568AE6A18FFF715BE5D" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">188.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e731-wk-Fact-27FBA3B435AA5FA1A50B775E550EA813" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e750-wk-Fact-A5786BEDD3925C67AEFF943C1EF0153E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e770-wk-Fact-DE6C439C1EE5510E9716A9572F555363" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e789-wk-Fact-3D1B783CCF53FC064D5DEC2BDF12524E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">288.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e809-wk-Fact-BCBC5AF239BA55B3AA4D91A3779C496F" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e828-wk-Fact-1A6C831D76935D09BAD83FDD30EB6FD3" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e847-wk-Fact-380A49373F43551597CFBE8B70BD0DC2" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e867-wk-Fact-DA060BAD5F9353F2BD9F51FB060610BB" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e886-wk-Fact-9925906F52585C8EAE09B2FC61DC4DB4" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">154.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e906-wk-Fact-2E383E6CA8675704BFF1382537E90EE0" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e925-wk-Fact-881F8850163A5EC5AF0AF8F8BD75EBD6" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e944-wk-Fact-2A2C3A2B675657B1866A1330D0D85589" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e964-wk-Fact-DAFBFA623D19515E9A1BED9BEF404504" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e983-wk-Fact-FB9CCFAECEE0F5F04FBBEFA39819F6BC" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1003-wk-Fact-39B721350131513EA08080DD3DB2BF07" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">265.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1022-wk-Fact-378DF17992F25132B58E22BFAE477525" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1041-wk-Fact-5DF59E3069105B85BF6ABAD066710A19" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1061-wk-Fact-DBB239B26FE154798D30620E76982A92" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1080-wk-Fact-19A2D23B31705254BAC74CE0376D01C4" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">447.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1105-wk-Fact-1E9A61671139550983FBFA415A6234A8" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1124-wk-Fact-14FD8A6AC05C5BA0998258059E247A7D" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1143-wk-Fact-A92FBC966C365AEC8B29622C1291EA76" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131253740e1163-wk-Fact-BF3980137BF559E6945E9F155CA9C9D4" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1183-wk-Fact-6E3CE31EE6BC576EA7BDF8580AA791B1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1515-wk-Fact-FB96413548135846B721B8F87301FBBA" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">294.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1534-wk-Fact-CF5487BDF6CA5604823A45D99673439D" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1553-wk-Fact-3504B25067D95D479120EAEE3C3E6147" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1573-wk-Fact-5824530F84755C419A0BDED5D8E79E0C" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1592-wk-Fact-F31DB09FE1905F959FCAED82FDBB8392" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">417.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1607-wk-Fact-71B9C23161BE5C24BE0A2639636B6260" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1626-wk-Fact-BE7407F2F58E59168AA51EA828953C4C" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1645-wk-Fact-67DFB18A1EB655638D7A081EE2F26FDE" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1665-wk-Fact-A269E05DFBEA521C8823E1C219EF0A74" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1684-wk-Fact-48DCD6DB78FE5C9BBCBD610533E97EB6" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">249.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1704-wk-Fact-57371C30206C55B3BB5E020EB7844FFF" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1723-wk-Fact-35BD65C7CD4254A39DFF1E46658D2818" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1742-wk-Fact-AD77F28EABC951788C87D3FAD57CDD26" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1762-wk-Fact-49982FDAD5E25796816809BF2099B51B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1781-wk-Fact-499811EDEECA543C81E4031D0E3C70DF" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1801-wk-Fact-4F036D10B5965C3DAEFFAB6D36E5C741" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1820-wk-Fact-4EF14D70610B5C179B4F2449839C2999" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1839-wk-Fact-51A2B15ECE5454D4AE346A2DB2E6C86F" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1859-wk-Fact-ED420F59525758EC8FB0E514460A49A3" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1878-wk-Fact-54C7856B43F457D1BFFFBBD310C092B9" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1898-wk-Fact-7B0718050B085F6E9CF810C2D1A7322B" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">251.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1917-wk-Fact-674DD4E032C55EE2A90D001F88AD188D" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1936-wk-Fact-B62BD3939F1556FF9E56BD9D29FCB4FB" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1956-wk-Fact-0BBC94A9169053D995B2C8D41E8F995A" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e1975-wk-Fact-F42F5A447239531089364C6CCAC5DFBD" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2000-wk-Fact-EADC5903FB955FB3A7B3E660BFD12885" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2019-wk-Fact-7370FBDF78E859259904173551848F1C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2038-wk-Fact-C1C47F9C9D5C5325A9373216FE0E1435" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131253740e2058-wk-Fact-7060AB431BEE52DC8CF5A6221EAD7845" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2078-wk-Fact-BBEB55B080E654F7A7D014C10B55F828" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2409-wk-Fact-4703C5E5C31A54278D5F14D494E3E8BD" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">940.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2428-wk-Fact-05E86A79B7155538A0059C00AC79C449" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2447-wk-Fact-EA13E10BEE8B52BCBCD91684DB8C67AD" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2467-wk-Fact-DA375D692F095A59AA43504D8459139A" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,454.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2501-wk-Fact-6E0B8974CBEF5A5F87327733FBD33349" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">562.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2520-wk-Fact-E8BD2377064A54C4B13E4194E286C4F2" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">245.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2539-wk-Fact-8377FF0D517753C1AF5016E1EB8B98CC" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2559-wk-Fact-E815A33CA3CC544BBE56B9FCA91F9DE2" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2578-wk-Fact-8BB832B9151A57DDB454918EDC3CAFAA" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">854.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2599-wk-Fact-2487AA15F73D5634B5E9986BEF271F91" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2618-wk-Fact-F52C34596992554FAC2C6D23F32EFB6A" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2637-wk-Fact-B6C03EC49E53507886D8F90635011D84" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2657-wk-Fact-3401CB564AD95D5695F95A667047338B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2676-wk-Fact-C29477259B205417B00084FF4A025C73" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">451.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2696-wk-Fact-8336C6AFB3FE55FC9F3CDB56A5A53303" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2715-wk-Fact-2DA712FEA6755E558C58EFA7B721658F" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2734-wk-Fact-AD95752D4B99507093071C47B7B26450" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2754-wk-Fact-A61E62B2F3CF5D14B4906DF03DD813E5" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2773-wk-Fact-4D252E62C7F8517AA6E6F9F9E6D0E330" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2793-wk-Fact-58F2F056077F567280639D03FAE023A9" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">786.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2812-wk-Fact-F2A14943405454DDA3CB36AC9F788FED" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2831-wk-Fact-EBE74144ED8F5791941A9104F996DF77" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2851-wk-Fact-C92A6CADDE265288852F5D13BE371157" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2870-wk-Fact-5D59517E47345EF6818472AAA2B6CD2D" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,319.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2895-wk-Fact-C47A0F3329F35F54ADB86892097D75C3" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">153.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2914-wk-Fact-EE1BC792D5B153429DD7D3709DE1647E" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2933-wk-Fact-133890600C325A76B6F5B185A0EF97A1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131253740e2953-wk-Fact-264A4994442F5B4EA458C91253A6D69A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">129.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e2973-wk-Fact-92D035DF46585DB9AF651D51809EBF6C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3304-wk-Fact-80C3204A058E5A768ADDF0D764804BC3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">870.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3323-wk-Fact-C0DE73DEB8805FE9BF0589ECCF54C425" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">302.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3342-wk-Fact-BDD38481D10D5401BAE5FFFDF2109A52" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3362-wk-Fact-35A6A9FEA4EC54968BEA6E24CCFEDB26" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3381-wk-Fact-C2B348E9D7DB5A27B809E4422CAD95B6" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,228.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3396-wk-Fact-BCCB54E6959F557DA0ABDC392EF52261" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">532.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3415-wk-Fact-B3677C40F6F358F687253334891C8203" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3434-wk-Fact-58F6B5810EEC51ED826234D42CADE760" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3454-wk-Fact-3ED38EA90F2C5C658B1FB3B6126E37F1" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3473-wk-Fact-090BEFE753CE5FBDBEE23D29397ED2E4" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">730.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3493-wk-Fact-B976A56D2F485D12946649DABFED0DB7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3512-wk-Fact-534A86706E3559159A696A3C8CB1B42B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3531-wk-Fact-10F9541E0BFA56F59E50AC0A97FBA6EB" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3551-wk-Fact-15C3777DCBA0521FB2F70C5F5925D336" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3570-wk-Fact-F5A2383EC2055618B0D8F034092D62FC" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">369.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3590-wk-Fact-B7068E2D2F215AE9AB1A80C774BD639A" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3609-wk-Fact-E17FFF03F295519D834A1F8796A0894E" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3628-wk-Fact-668304A95BC450DF85009E2F7C756177" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3648-wk-Fact-8948B554018D576388307B4A4C45BEBA" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3667-wk-Fact-E1C86F14BCC857578DA3F6A752A4E94D" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3688-wk-Fact-F1216BEBAFA55BC3BB97790A0B2B5E6E" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">740.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3707-wk-Fact-E68EA3061BEC55A0AAC5DF0DD077F9F1" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">217.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3726-wk-Fact-98F5C10C2F84569EAD67D945FBE0ACC5" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3746-wk-Fact-D1BC84099E075559BD9191F3414D9DF5" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3765-wk-Fact-E43B1B3C0F0756120573EC2C3FB099B3" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,109.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3790-wk-Fact-433692E50BFC5997B2F47ADF0CB92834" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3809-wk-Fact-5AF0AD6AF0DE556B8C3D028B65D4C5B7" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3828-wk-Fact-028BD406EEAB542F84D6A9BC9B1EC8C1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d131253740e3848-wk-Fact-A8A8ABE8B55657D59C4B7E6F1ED0264C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">99.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131253740e3868-wk-Fact-D22C5ECEC44758068D0EFFA48BCF5678" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="s597828AF06E150E0831755C7E18AE2D6"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:TreasuryStockTextBlock" id="TextSelection-7C2E26EA1D655199AEFA469F62284D7F-0-wk-Fact-DF9C8B3E04015D8B847DD4E81FF5E1FA" continuedAt="TextSelection-7C2E26EA1D655199AEFA469F62284D7F-1" escape="true">SHARE REPURCHASE </ix:nonNumeric></span></div><ix:continuation id="TextSelection-7C2E26EA1D655199AEFA469F62284D7F-1"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019 Stock Repurchase Program</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231163e359-wk-Fact-6B8DBE78D25E57EFAC04D1A254AE2BE5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2019Q1Feb252019" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of our outstanding common stock through </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d131231163e363-wk-Fact-33714902318E563FAB42B5B7215C7F74" name="us-gaap:StockRepurchaseProgramExpirationDate" contextRef="D2019Q1Feb252019" format="ixt:datemonthdayyearen">March 1, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the program, we are allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We are allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not repurchase any shares pursuant to this stock repurchase program during the three or nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Share Repurchase</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 4, 2018, we purchased </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231163e383-wk-Fact-3F6BACF27FD25507B35527928C9903BB" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,418,304</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then-current holdings in the Company and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231163e387-wk-Fact-25997DAE7A1554E3A309004393924901" name="amed:PercentageofSharesOutstanding" contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate outstanding shares of the Company's common stock for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231163e391-wk-Fact-ABBE44153D7E5D21B1B9B4DF2E857403" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> including related direct costs. The Company repurchased the shares at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231163e395-wk-Fact-DB833EE0A8065052A867474CF7930D2D" name="amed:Discountedclosingstockprice" contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">73.96</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> which represents </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d131231163e399-wk-Fact-F242028A9FED524C99B5B56D6F6C239B" name="amed:Percentageofclosingstockprice" contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">96</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div></ix:continuation><div><a id="sc6a5148bb7854872b3b7175ded0cbf59"></a></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-8DE6E60C7E19B8FB20CE03F8E1501AA6-0-wk-Fact-052E7662332423B0B32F03FA1A0E8FD6" escape="true"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. RELATED PARTY TRANSACTIONS</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, we made a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231273e353-wk-Fact-DD6AB2B4AF11039B73DB04E9B64FF77A" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three and nine-month periods ended September 30, 2019, we incurred costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231273e357-wk-Fact-7F75F4F58E4127C7951104ED6B4F1F8B" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d131231273e361-wk-Fact-768760A53A24EDFBA5AF04EEB3E3161A" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in connection with the usage of Medalogix's analytics platforms.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><a id="sACD708EB178C5009968DC325774C3B09"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2019 (the &#8220;Form 10-K&#8221;), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately </span><span style="font-family:inherit;font-size:10pt;">74%</span><span style="font-family:inherit;font-size:10pt;"> of our revenue derived from Medicare for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately 73% and 74% of our revenue derived from Medicare for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we owned and operated </span><span style="font-family:inherit;font-size:10pt;">321</span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified home health care centers, </span><span style="font-family:inherit;font-size:10pt;">137</span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified hospice care centers and </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> personal-care care centers in </span><span style="font-family:inherit;font-size:10pt;">38</span><span style="font-family:inherit;font-size:10pt;"> states within the United States and the District of Columbia.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">323</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions/Startups</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Closed/Consolidated</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">321</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">137</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding our corporate integrity agreements and for a discussion of and updates regarding other legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Payment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 31, 2019, the Centers for Medicare and Medicaid Services ("CMS") issued a final rule to update hospice payment rates and the wage index for fiscal year 2020. The rule includes a rebasing of continuous home care, inpatient respite care and general inpatient care to better reflect the costs of care. This rebasing will be offset by a reduction in routine home care payments of 2.7% to achieve budget neutrality.&#160; In addition, CMS eliminated the one-year &#8220;lag&#8221; in the use of the hospital wage index in an effort to align with the Inpatient Prospective Payment System ("IPPS") and other payment systems. CMS estimates hospices serving Medicare beneficiaries would see an estimated 2.6% increase in payments. This increase is the result of a 3.0% market basket adjustment less a 0.4% productivity adjustment. We have estimated the impact of the final rule on us to be an increase in revenue of approximately 0.5%; however, we are expecting the impact on gross margin percentage to be a reduction of approximately 0.6% as the majority of the revenue increase will be passed through to the general inpatient and respite facilities. These estimates are subject to change as our mix of work changes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, CMS issued the Calendar Year 2019 Home Health Final Rule, which provided for the first payment rate increase for home health providers since 2010. CMS estimated that the net impact of the payment provisions of the final rule </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">would result in an increase of 2.2% in reimbursement to home health providers. The increase is the result of a 3.0% market basket increase less a 0.8% productivity adjustment. We have estimated the impact of the final rule on us to be an increase in revenue of 1.2%. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the 2019 rule, CMS also issued proposed payment changes for Medicare home health providers for 2020. These proposed changes included changes to the Home Health Prospective Payment System ("HHPPS") case-mix adjustment methodology through the use of a new Patient-Driven Groupings Model ("PDGM") for home health payments, a change in the unit of payment from a 60-day payment period to a 30-day payment period and the elimination of the use of therapy visits in the determination of payments. While the proposed changes are to be implemented in a budget neutral manner to the industry, the ultimate impact will vary by provider based on factors including patient mix and admission source. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In July 2019, CMS issued a proposed rule for 2020 which reaffirmed the 2020 changes included in the 2019 rule including implementation of PDGM and a change in the unit of payment from 60-day episodes of care to 30-day periods of care. Additionally, in an effort to eliminate fraud risks, CMS proposed to phase out requests for anticipated payment ("RAPs") over 2020 with the full elimination of RAPs in 2021. CMS estimates that the proposed rule will result in a 1.3% increase in payments to home health providers. The increase is the result of a 1.5% market basket increase reduced by 0.2% for the rural add-on. CMS is also assuming that the industry will make certain behavioral changes resulting in a decrease in reimbursement of 8.01%. We have estimated the impact of the proposed rule on us to be a reduction in revenue of 6.8%. Our current view is that we can offset approximately 50% of the impact via behavioral changes, while mitigating the remainder of the impact via a mix of cost levers, including optimizing clinical mix and utilization. We will continue to refine our estimate and will reassess upon the release of the final rule.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, we acquired Compassionate Care Hospice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of $327.9 million, net of cash acquired. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019, we acquired the assets of RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider for a purchase price of $17.5 million.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we continue to focus on inorganic expansion in all three segments, we anticipate incurring acquisition and integration costs throughout 2019. During the three and nine-month periods ended September 30, 2019, we incurred approximately $4 million and $14 million, respectively, in costs related to various acquisitions and the integration of CCH. Our total acquisition and integration costs related to CCH for 2019 are expected to be approximately $15 million to $16 million.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Partnerships</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, we signed an agreement with ClearCare, Inc. ("ClearCare"), the personal care industry&#8217;s leading software platform, representing 4,000 personal care agencies in every zip code in the United States. Our agreement with ClearCare creates an opportunity to establish a network partnership between Amedisys and personal care agencies using ClearCare in order to better coordinate patient care. Long term, this allows us to build a nation-wide network of personal care agencies and furthers our efforts to provide patients with a true care continuum in the home. This relationship will also help us as we continue to have innovative payment conversations with Medicare Advantage plans who have begun to recognize the value that combined home health, hospice and personal care services brings to their members and care delivery infrastructure.&#160; </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three-Month Period Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Compared to the Three-Month Period Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consolidated</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                    Three-Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">494.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">417.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">205.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">167.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">% of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">41.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">40.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">124.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">% of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">31.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">29.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other (expense) income, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Effective income tax rate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">22.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">23.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $7&#160;million on a revenue increase of $77&#160;million. Our results for the three-month period ended September 30, 2019 include the acquisitions of CCH on February 1, 2019 and RoseRock on April 1, 2019. For the quarter, CCH and RoseRock contributed approximately $48 million in revenue and approximately $1 million in operating income which is inclusive of $3 million in acquisition and integration costs and $1 million in intangibles amortization.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our quarterly performance reflects growth and operating improvement within all three segments of our legacy operations. Our gross margin was positively impacted by 2019 changes in reimbursement for both home health and hospice totaling $5 million, increases in the acuity level of our patients and improved utilization within our home health segment. Our other operating expenses as a percentage of revenue increased 1.5% compared to prior year; this increase is inclusive of approximately $4 million in acquisition and integration costs. Excluding the acquisition and integration costs, our other operating expenses as a percentage of revenue increased less than 1% compared to prior year despite planned wage increases that became effective during the three-month period ended September 30, 2019.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Home Health Segment</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our home health segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                     Three-Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">211.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">208.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">311.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">294.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">188.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">181.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">113.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Same Store Growth (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic admissions (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic volume (4)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (5):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48,295</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46,371</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recertifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,662</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,551</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75,957</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74,922</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Completed episodes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74,355</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73,114</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,281,380</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,301,090</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average revenue per completed episode (6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,909</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,855</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits per completed episode (7)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Medicare:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,642</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,325</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recertifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,678</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,539</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,320</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43,864</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">775,804</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">698,181</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total (5):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visiting Clinician Cost per Visit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83.68</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82.78</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical Manager Cost per Visit</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8.09</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8.18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Cost per Visit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91.77</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90.96</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,057,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,999,271</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Same store information represents the percent change in our Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume includes all admissions and recertifications.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic admissions includes admissions for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic volume includes admissions and recertifications for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions and denovos.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(7)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $3 million on a $17 million increase in net service revenue. Our gross margin as a percentage of revenue was positively impacted by growth in volumes, an increase in the acuity level of our patients and improved utilization. The impact of the 2019 change in reimbursement resulted in an increase in net service revenue and gross margin of approximately $3 million. These items were partially offset by planned wage increases that became effective during the three-month period ended September 30, 2019 and an increase in revenue price concessions. In addition, our operating expenses increased due to the addition of resources to support volume growth.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Net Service Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenue increased $17 million on a 6% increase in total volume and a 2% increase in Medicare revenue per episode, partially offset by an increase in our revenue price concessions. The volume growth was driven by a 9% increase in admissions. The increase in Medicare revenue per episode is the result of a 1.2% increase in reimbursement with the remainder due to an increase in the acuity level of our patients. Additionally, our non-Medicare (per visit and episodic) rates increased approximately 2% which is a combination of increases in rate and the acuity level of our patients. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Our cost of service increased 4% on a 3% increase in total visits which was driven by a 6% growth in volumes. Our total cost per visit increased less than 1% as an improvement in clinician utilization and optimization of discipline mix partially offset planned wage increases that became effective during the three-month period ended September 30, 2019. Additionally, changes in our home health care center staffing resulted in a shift of some office staff from cost of service to other operating expenses totaling approximately $2 million.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Operating Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses increased approximately $7 million primarily due to an increase in salaries and benefits expense as a result of the addition of resources to support volume growth, planned wage increases that became effective during the three-month period ended September 30, 2019 and a shift of some of our home health office staff from cost of service to other operating expenses.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Hospice Segment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our hospice segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                    Three-Month Periods <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">153.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">162.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Same Store Growth (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hospice admissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average daily census</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (2):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hospice admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,914</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,765</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average daily census</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,565</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,768</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per day, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">152.67</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">144.71</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service per day</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79.51</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74.72</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average discharge length of stay</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions and denovos.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, we acquired CCH, which owned and operated 53 hospice care centers. On April 1, 2019, we acquired RoseRock Healthcare, which owned and operated one hospice care center. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2019 and 2018 are not fully comparable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $13 million on a $59&#160;million increase in net service revenue. Our operating results for the quarter were positively impacted by the 2019 change in reimbursement, which resulted in an increase in net service revenue and gross margin of approximately $2 million, by continued growth and by our acquisitions. Our acquisitions contributed approximately $48 million in revenue and $7 million in operating income to our hospice segment's results for the three-month period ended September 30, 2019. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Net Service Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our hospice revenue increased $59&#160;million, approximately $48 million of which is attributable to our acquisition activity. The remaining $11 million increase is the result of a 5% increase in our average daily census, a 1.6% increase in reimbursement effective for services provided from October 1, 2018 and a reduction in our revenue price concessions.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our hospice cost of service increased $31&#160;million, approximately $29 million of which is attributable to our acquisition activity. The remaining $2 million increase is primarily due to a 5% increase in average daily census and the impact of planned wage increases that became effective during the three-month period ended September 30, 2019. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Operating Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses increased $15&#160;million; approximately $12 million of the increase is related to our acquisition activity. The remaining $3 million increase is due to increases in other care center related expenses, primarily salaries and benefits due to the addition of resources to support census growth and planned wage increases that became effective during the three-month period ended September 30, 2019. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Personal Care Segment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our personal care segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                    Three-Month Periods <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Billable hours</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">824,251</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">810,427</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clients served</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,687</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,380</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shifts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">370,451</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">357,382</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per hour</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25.12</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.40</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per shift</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55.90</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.06</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hours per shift</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:42px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018, we acquired the assets of Bring Care Home which serviced the state of Massachusetts. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our personal care operating results for 2019 and 2018 are not fully comparable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income related to our personal care segment increased approximately $1 million on a $2 million increase in net service revenue offset by a $1 million increase in cost of service; other operating expenses remained flat.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Corporate</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our corporate results of operations:</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                    Three-Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate expenses consist of costs relating to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three-month period ended September 30, 2019, corporate operating expenses increased $10 million; approximately $6 million of which is attributable to the CCH acquisition: $2 million relates to CCH corporate and administrative support functions, $1 million relates to CCH intangibles amortization and approximately $3 million relates to CCH acquisition and integration costs. Excluding the impact of the CCH acquisition, other operating expenses increased $4 million which represents 5% of our $77 million increase in revenue. The increase is due to increases in salaries and benefits expense, information technology expense and rent expense which were partially offset by a decrease in professional fees. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nine-Month Period Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Compared to the Nine-Month Period Ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consolidated</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                      Nine-Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,454.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,228.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">600.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">497.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">% of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">41.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">40.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">451.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">369.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">% of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">31.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">30.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">135.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">118.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other (expense) income, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(31.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(30.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Effective income tax rate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">23.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">24.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $17&#160;million on a revenue increase of $227 million. Our results for the nine-month period ended September 30, 2019 include the acquisitions of CCH and RoseRock. CCH and RoseRock contributed approximately $129 million in revenue and an operating loss of approximately $3 million which is inclusive of $13 million in acquisition and integration costs and $3 million in intangibles amortization.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our operating income was negatively impacted by a $7 million accrual related to settlement discussions with the U.S. Department of Justice (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information).</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our year-to-date performance reflects growth and operating improvement in all three segments of our legacy operations. Our gross margin was positively impacted by 2019 changes in reimbursement totaling $15 million. We also continue to remain focused on costs as our other operating expenses as a percentage of revenue increased only 1.1% compared to prior year; this increase is inclusive of approximately $14 million in acquisition and integration costs. Excluding the acquisition and integration costs, our other operating expenses as a percentage of revenue remained flat compared to prior year despite planned wage increases and the addition of resources to support growth. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Home Health Segment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our home health segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                      Nine-Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions)</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">644.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">619.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">296.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">251.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">940.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">870.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">562.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">532.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">377.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">337.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">224.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">207.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">153.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130.2</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Same Store Growth (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic admissions (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic volume (4)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (5):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">147,485</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">142,884</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recertifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82,551</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84,218</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">230,036</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">227,102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Completed episodes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">224,635</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">220,726</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,935,182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,933,290</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average revenue per completed episode (6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,922</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,841</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits per completed episode (7)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Medicare:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88,485</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recertifications</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45,945</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,862</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">146,129</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129,347</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,303,576</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,049,662</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total (5):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visiting Clinician Cost per Visit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82.23</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.06</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical Manager Cost per Visit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7.91</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7.98</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total Cost per Visit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90.14</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89.04</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Visits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,238,758</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,982,952</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Same store information represents the percent change in our Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total volume includes all admissions and recertifications.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic admissions includes admissions for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Episodic volume includes admissions and recertifications for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions and denovos.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(7)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $24 million on a $70 million increase in net service revenue. Our gross margin as a percentage of revenue was positively impacted by the 2019 changes in reimbursement, growth in volumes, the acuity level of our patients and improved utilization. The impact of the 2019 change in reimbursement was an increase in net service revenue and gross margin of approximately $9 million. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Net Service Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenue increased $70 million (8%) on a 6% increase in total volume and a 3% increase in Medicare revenue per episode. The volume growth was driven by a 7% increase in admissions. The increase in Medicare revenue per episode is the result of a 1.2% increase in reimbursement with the remainder due to an increase in the acuity level of our patients. Additionally, our non-Medicare (per visit and episodic) rates increased approximately 3% which is a combination of rate increases and increases in the acuity level of our patients. The increase in revenue for the nine-month period ended September 30, 2019 was also positively impacted by a reduction in our revenue price concessions.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who maintain the overall delivery of care. Our cost of service increased 6% on a 4% increase in total visits. Our total cost per visit increased approximately 1% as improvements in clinician utilization and optimization of discipline mix partially offset planned wage increases. Additionally, changes in our home health care center staffing resulted in a shift of some office staff from cost of service to other operating expenses totaling approximately $3 million.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Operating Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses increased approximately $16 million primarily due to an increase in salaries and benefits expense as a result of the addition of resources to support volume growth, planned wage increases and the home health staffing shifts referenced above.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Hospice Segment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our hospice segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                       Nine-Month Periods <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">430.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">286.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">452.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">302.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">245.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">155.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">206.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">146.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Same Store Growth (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hospice admissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average daily census</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (2):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hospice admissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,055</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,444</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average daily census</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,997</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,514</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per day, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">150.77</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">147.28</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service per day</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.92</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75.65</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average discharge length of stay</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions and denovos.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our 2019 acquisitions, our hospice segment operating results for 2019 and 2018 are not fully comparable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overall, our operating income increased $21 million on a $150&#160;million increase in net service revenue. Our operating income was negatively impacted by a $7 million reduction to revenue and gross margin related to settlement discussions with the U.S. Department of Justice (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information). Our operating results for the nine-month period ended September 30, 2019 were positively impacted by the 2019 change in reimbursement, which resulted in an increase in net service revenue and gross margin of approximately $6 million, by continued growth and by our acquisitions which contributed approximately $128 million in revenue and $18 million in operating income to our hospice segment's results for the nine-month period ended September 30, 2019. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Net Service Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our hospice revenue increased $150&#160;million; approximately $128 million of which is attributable to our acquisition activities. The remaining $22 million increase is the result of a 6% increase in our average daily census and a 1.6% increase in reimbursement effective for services provided from October 1, 2018, partially offset by an increase in our revenue price concessions, which include a $7 million reduction to revenue and gross margin related to the U.S. Department of Justice matter noted above.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our hospice cost of service increased $91&#160;million, approximately $80 million of which is attributable to our acquisition activity. The remaining $11 million increase is primarily due to a 6% increase in average daily census and planned wage increases. The increase in cost of service per day of 8% is driven by our acquisitions as our same store cost of service per day increased less than 1%. We expect our acquisitions' cost of service per day to approximate our legacy metric as we fully integrate them during 2020.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Operating Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses increased $38&#160;million; approximately $30 million of the increase is related to our acquisition activity. The remaining $8 million increase is due to increases in other care center related expenses, primarily salaries and benefits due to the addition of resources to support census growth and planned wage increases and travel and training expense.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Personal Care Segment</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our personal care segment results of operations:</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                       Nine-Month Periods <br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Key Statistical Data - Total (1):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Billable hours</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,506,113</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,357,608</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clients served</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,134</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,731</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shifts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,128,920</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,062,422</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per hour</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24.77</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.57</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue per shift</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55.00</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.30</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hours per shift</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:42px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total includes acquisitions.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Results</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income related to our personal care segment increased $3 million on a $7 million increase in net service revenue. Cost of service increased approximately $4 million; other operating expenses remained relatively flat. These results are inclusive of the acquisitions of East Tennessee Personal Care Services on May 1, 2018 and Bring Care Home on October 1, 2018. As a result, our personal care operating results for 2019 and 2018 are not fully comparable.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Corporate</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our corporate results of operations:</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                       Nine-Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in millions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the nine-month period ended September 30, 2019, corporate operating expenses increased $31 million; approximately $21 million of which is attributable to the CCH acquisition: $5 million relates to CCH corporate and administrative support functions, $3 million relates to CCH intangibles amortization and approximately $13 million relates to CCH acquisition and integration costs. Excluding the impact of the CCH acquisition, other operating expenses increased $10 million which represents 4% of our $227 million increase in revenue. The remaining increase is primarily due to increases in salaries and benefits expense and information technology expense which were partially offset by decreases in professional fees, depreciation and gains on the sale of fleet vehicles. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the                                       Nine-Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">126.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">159.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(351.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by (used in) financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">225.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(219.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(72.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by operating activities decreased $32.6&#160;million during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to the payment of acquisition and integration costs, a decrease in our cash collections and an increase in the payment of acquired liabilities related to our acquisition activity. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash used in investing activities increased $338.9&#160;million during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as a result of our acquisitions of CCH and RoseRock.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by financing activities increased $444.5&#160;million during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to our borrowings under our Amended Credit Agreement to fund acquisitions.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we spent </span><span style="font-family:inherit;font-size:10pt;">$6.3 million</span><span style="font-family:inherit;font-size:10pt;"> in capital expenditures as compared to </span><span style="font-family:inherit;font-size:10pt;">$5.7 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Our capital expenditures for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are expected to be approximately $8.0 million to $10.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had $20.8 million in cash and cash equivalents and </span><span style="font-family:inherit;font-size:10pt;">$452.8 million</span><span style="font-family:inherit;font-size:10pt;"> in availability under our $550.0&#160;million Revolving Credit Facility. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Patient Accounts Receivable</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our patient accounts receivable increased $65.7&#160;million from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">; $44.6 million of the increase is related to CCH. Our cash collection as a percentage of revenue was 102% and </span><span style="font-family:inherit;font-size:10pt;">104%</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our days revenue outstanding at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">44.5</span><span style="font-family:inherit;font-size:10pt;"> days which is an increase of 6.5 days from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and an increase of 3.4 days from June 30, 2019. As anticipated, our acquisition activity has negatively impacted our days revenue outstanding. The estimated impact is 4.3 days. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">0-90</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">91-180</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">181-365</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Over&#160;365</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">At September&#160;30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare patient accounts receivable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">125.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">149.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other patient accounts receivable:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total patient accounts receivable</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">254.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Days revenue outstanding (1)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">0-90</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">91-180</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">181-365</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Over 365</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">At December&#160;31, 2018:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare patient accounts receivable</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other patient accounts receivable:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total patient accounts receivable</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">189.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Days revenue outstanding (1)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> by our average daily patient revenue for the three-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indebtedness</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We borrowed the entire principal amount of the Term Loan Facility on February 4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our weighted average interest rate for borrowings under our </span><span style="font-family:inherit;font-size:10pt;">$550.0 million</span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;">3.8%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">3.9%</span><span style="font-family:inherit;font-size:10pt;"> for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our weighted average interest rate for our borrowings under our $175.0 million Term Loan Facility was </span><span style="font-family:inherit;font-size:10pt;">3.8%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">3.9%</span><span style="font-family:inherit;font-size:10pt;"> for the three-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the period February 4, 2019 to </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our consolidated leverage ratio was </span><span style="font-family:inherit;font-size:10pt;">1.0</span><span style="font-family:inherit;font-size:10pt;">, our consolidated interest coverage ratio was </span><span style="font-family:inherit;font-size:10pt;">19.5</span><span style="font-family:inherit;font-size:10pt;"> and we are in compliance with our covenants under the Amended Credit Agreement.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our availability under our $550.0&#160;million Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;">$452.8 million</span><span style="font-family:inherit;font-size:10pt;"> as we have </span><span style="font-family:inherit;font-size:10pt;">$67.0 million</span><span style="font-family:inherit;font-size:10pt;"> outstanding in borrowings and </span><span style="font-family:inherit;font-size:10pt;">$30.2 million</span><span style="font-family:inherit;font-size:10pt;"> outstanding in letters of credit.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 5 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Repurchase</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019 Stock Repurchase Program</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the program, we are allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We are allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not repurchase any shares pursuant to this stock repurchase program during the three or nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Share Repurchase</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then-current holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not believe inflation has significantly impacted our results of operations.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K except for the changes related to the adoption of Accounting Standards Updates 2016-02, 2018-01, 2018-10 and 2018-11 as disclosed in Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements.</span></div><div><a id="s75DF7347B93E539CBDF1AD4BA4E53714"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility carries a floating interest rate which is tied to the Eurodollar rate (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</span><span style="font-family:inherit;font-size:10pt;"> LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total amount of outstanding debt subject to interest rate fluctuations was $239.8 million. A 1.0% interest rate change would cause interest expense to change by approximately $2.4&#160;million annually, assuming the Company makes no principal repayments.</span></div><div><a id="sAE6BFECD395F5FC58BAB4C128796F75C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#8217;s rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the preparation of this Quarterly Report on Form 10-Q, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the end of the period covered by this Quarterly Report.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Controls</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inherent Limitations on Effectiveness of Controls</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the end of the period covered by this Quarterly Report.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA60DEA89D0E75A7ABCF0D55DCF10E299"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="s3E48C95805C351ABA769EC598BB7ED58"></a></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 6 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div><a id="s55B11869E4A95FA680B602C10603EF06"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors included in Part I, Item 1A. &#8211; Risk Factors of our Annual Report on Form 10-K. These risk factors could materially impact our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely impact our business, financial condition and/or operating results.</span></div><div><a id="s43967CFDEBFD50B6A13DA80A943283BC"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:33%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(a)&#160;Total&#160;Number</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">of&#160;Shares&#160;(or&#160;Units)</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(b)&#160;Average&#160;Price</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Paid&#160;per&#160;Share&#160;(or</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Unit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(c)&#160;Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares (or Units)</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Purchased&#160;as&#160;Part&#160;of</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Publicly Announced</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Plans or Programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">(d)&#160;Maximum&#160;Number&#160;(or</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Approximate Dollar</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Value) of Shares (or</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Units) That May Yet Be</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Purchased Under the</span></div><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Plans or Programs</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 1, 2019&#160;to&#160;July 31,&#160;2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37,291</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">131.27</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 1,&#160;2019&#160;to&#160;August 31,&#160;2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 1, 2019 to September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37,291</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">131.27</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div></td></tr></table><div><a id="s818BCBF025255B998D0D0E97A860ADCA"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="sA90EFD5548735FDCA88CF4D2F967ECB9"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="s383F25C80C395F8ABB060AD154CA78FD"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5. OTHER INFORMATION</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB8D5A31DB0C05755A04C42AC1B4C1E1C"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6. EXHIBITS</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:9%;"></td><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Document Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Report or Registration Statement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">SEC File or</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Registration</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">or Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reference</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm"><span style="font-family:inherit;font-size:10pt;">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0-24260</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;3.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx32.htm"><span style="font-family:inherit;font-size:10pt;">Composite of By-Laws of the Company inclusive of all amendments through October 17, 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx101.htm"><span style="font-family:inherit;font-size:10pt;">Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers (inclusive of all amendments through July 25, 2019)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;31.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx311.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;31.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx312.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;&#8224;32.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx321.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;&#8224;32.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="amed-20193009xexx322.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.INS</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.SCH</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.CAL</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.LAB</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8224;101.PRE</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE7461C62352C53A4AABE2CE24FEBFCA9"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:273px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56px;"></td><td style="width:20px;"></td><td style="width:197px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A</span><span style="font-family:inherit;font-size:8pt;">MEDISYS</span><span style="font-family:inherit;font-size:10pt;">, I</span><span style="font-family:inherit;font-size:8pt;">NC</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ SCOTT G. GINN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Scott G. Ginn,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Financial Officer and</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Duly Authorized Officer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: </span><span style="font-family:inherit;font-size:10pt;">October&#160;30, 2019</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>amed-20193009xexx32.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3514F6FBEA549FF27BFBF9D04D09E3D5"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Exhibit 3.2</font></div><div style="line-height:105%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">COMPOSITE BY-LAWS</font></div><div style="line-height:105%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">OF</font></div><div style="line-height:105%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">AMEDISYS, INC.</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Incorporated under the Laws of the State of Delaware <br>(Inclusive of Amendments Dated October 17, 2019)</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE I.</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">OFFICES AND RECORDS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 1.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Delaware Office</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The principal office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 1.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Other Offices</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Corporation may have such other offices, either within or without the State of Delaware, as the Board of Directors may designate or as the business of the Corporation may from time to time require.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 1.3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Books and Records</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The books and records of the Corporation may be kept outside the State of Delaware at such place or places as may from time to time be designated by the Board of Directors.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE II.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">STOCKHOLDER MEETINGS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Annual Meeting</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The annual meeting of the stockholders of the Corporation shall be held on such date and at such place and time as may be fixed by resolution of the Board of Directors.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Special Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Subject to the rights, if any, of the holders of any series of stock having a preference over the Common Stock of the Corporation as to dividends or upon liquidation (&#8220;Preferred Stock&#8221;) with respect to such series of Preferred Stock, special meetings of the stockholders may be called only by the Chairman of the Board or by the President or by the Board of Directors or a Committee thereof, or by the holders of at least 30% of all the shares entitled to vote at the proposed special meeting. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto). Notice of any special meeting shall be delivered by the Corporation pursuant to Section 2.5 of these By-Laws. The holders of the requisite percentage of voting power may request a special meeting by submitting a written notice of demand to the Secretary of the Corporation at the Corporation&#8217;s principal executive offices stating the purpose or purposes </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">of the meeting. Such written notice of demand shall be signed by the stockholder or stockholders holding the requisite percentage of the voting power to demand a special meeting and shall also set forth the information required by Section 2.8(c) of these By-Laws.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Business at Annual and Special Stockholder Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">No business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors) may be transacted at an annual meeting of the Corporation&#8217;s stockholders other than business that is:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">specified in a notice of meeting (or any supplement thereto) given by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">otherwise brought before the meeting by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">otherwise brought before the meeting:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">by a stockholder who was a stockholder of record at the time of giving notice provided in Section 2.8 and at the time of the meeting and who is entitled to vote at the meeting on such business (including electing or re-electing persons to the Corporation&#8217;s Board of Directors) (a &#8220;Record Holder&#8221;); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">who complies with the notice procedures set forth in Section 2.8 (any such Record Holder being hereafter referred to as a &#8220;Noticing Stockholder&#8221;).</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">For the avoidance of doubt, clause (a)(iii) of this Section 2.3 shall be the exclusive means for a stockholder to nominate persons to be elected or re-elected to the Corporation&#8217;s Board of Directors at an annual meeting of stockholders or to bring or submit other business before an annual meeting of stockholders (other than proposals properly brought pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and included in the Corporation&#8217;s notice of and proxy materials submitted in connection with such meeting). Nothing in this Section 2.3(a) shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto). Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting only:</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">provided that the Board of Directors has determined that directors are to be elected at such special meeting, by a Noticing Stockholder who complies with the notice procedures set forth in Section 2.8.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">For the avoidance of doubt, clause (b)(ii) of this Section 2.3 shall be the exclusive means for a stockholder to nominate persons to be elected or re-elected to the Corporation&#8217;s Board of Directors at a special meeting of stockholders. Nothing in this Section 2.3(b) shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Place of Meeting</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Board of Directors, the Chairman of the Board, or President, as the case may be, may designate the place of meeting for any annual meeting or for any special meeting of the stockholders called by the Board of Directors, the Chairman of the Board or President. If no designation is so made, the place of meeting shall be the principal office of the Corporation.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Notice of Meeting</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Written or printed notice, stating the place, day and hour of the meeting and the purpose or purposes for which the meeting is called, shall be delivered by the Corporation not less than 10 days nor more than 60 days before the date of the meeting, either personally or by mail, to each stockholder of record entitled to notice of such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail with postage thereon prepaid, addressed to the stockholder at his address as it appears on the stock transfer books of the Corporation. Such further notice shall be given as may be required by law. Meetings may be held without notice if all stockholders entitled to vote are present, or if notice is waived by those not present in accordance with Section 6.4 of these By-Laws. Any previously scheduled meeting of the stockholders may be postponed, and (unless the Certificate of Incorporation otherwise provides) any special meeting of the stockholders (other than a special meeting called at the request of holders of at least 30% of all the shares entitled to vote at the proposed special meeting) may be cancelled, by resolution of the Board of Directors upon public notice given prior to the date previously scheduled for such meeting of stockholders.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Quorum and Adjournment</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Except as otherwise provided by law or by the Certificate of Incorporation, the holders of a majority of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors (the &#8220;Voting Stock&#8221;), represented in person or by proxy, shall constitute a quorum at a meeting of stockholders, except that when specified business is to be voted on separately by a class or series of stock voting as a class, the holders of a majority of the shares of such class or series shall constitute a quorum of such class or series for the transaction of such business. The Chairman of the meeting or a majority of the shares so represented may adjourn the meeting from time to time, whether or not there is such a quorum. No notice of the time and place of adjourned meetings need be given except as required </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">by law. The stockholders present at a duly called meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Proxies</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. At all meetings of stockholders, a stockholder may vote by proxy executed in writing (or in such manner prescribed by the General Corporation Law of the State of Delaware) by the stockholder, or by his duly authorized attorney in fact.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.8.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Notice of Stockholder Business to be Conducted at a Meeting of Stockholders</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. In order for a Noticing Stockholder to (i) properly bring any item of business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors) before an annual meeting of stockholders in accordance with Section 2.3(a) or (ii) nominate persons for election to the Board of Directors at a special meeting of stockholders (at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting) in accordance with Section 2.3(b), the Noticing Stockholder must have given timely notice of that business in proper form in writing to the Secretary of the Corporation in compliance with the requirements of this Section 2.8 and such business must otherwise be a proper matter for stockholder action under relevant law. This Section 2.8 shall constitute an &#8220;advance notice provision&#8221; for annual meetings of stockholders for purposes of Rule 14a-4(c)(1) under the Exchange Act. Certain capitalized terms used in this Section 2.8 are defined in subsection (d), below.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">To be timely, a Noticing Stockholder&#8217;s notice required by these By-Laws must be delivered to the Secretary at the Corporation&#8217;s principal executive offices in proper written form:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Annual Meeting Deadlines. In connection with business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors) to be properly brought at an annual meeting of stockholders in accordance with Section 2.3(a), not earlier than the close of business on the one hundred twentieth (120th) day and not later than the close of business on the ninetieth (90th) day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however, that in the event the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day prior to the date of such annual meeting and not later than the close of business on the later of: (A) the ninetieth (90th) day prior to the date of such annual meeting or, (B) if the first Public Announcement of the date of such annual meeting is less than one hundred (100) days prior to the date of such annual meeting, the tenth (10th) day following the day on which Public Announcement of the date of such annual meeting is first made by the Corporation; and</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Special Meeting Deadlines. In connection with the nomination of persons for election to the Board of Directors at a special meeting of stockholders (at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting) in accordance with Section 2.3(b), not earlier than the close of business on the one-hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of: (A) the ninetieth (90th) day prior to such special meeting, or (B) the tenth (10th) day following the day on which Public Announcement of the date of the special meeting is first made by the Corporation.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In no event shall any adjournment, deferral or postponement of an annual or special meeting of stockholders, or the announcement thereof, commence a new time period for the giving of a stockholder&#8217;s notice as described above.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Notwithstanding anything in Section 2.8(a) to the contrary, if the number of persons to be elected to the Corporation&#8217;s Board of Directors is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board of Directors at least 100 days prior to the first anniversary of the preceding year&#8217;s annual meeting, a Noticing Stockholder&#8217;s notice required by these By-Laws shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it is delivered to the Secretary at the Corporation&#8217;s principal executive offices not later than the close of business on the tenth (10th) day following the day on which the Public Announcement naming all nominees or specifying the size of the increased Board of Directors is first made by the Corporation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">To be in proper form, whether in regard to nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors or any other business, a Noticing Stockholder&#8217;s written notice required by these By-Laws must completely and accurately:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Set forth, as to each Noticing Stockholder and, if a Noticing Stockholder holds for the benefit of another, the beneficial owner on whose behalf the nomination or proposal is made (any Noticing Stockholder or such beneficial owner a &#8220;Holder&#8221; and, collectively, &#8220;Holders&#8221;), the following information together with a representation as to the completeness and accuracy of the information:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i) the name and address of the Noticing Stockholder as they appear on the Corporation&#8217;s books and the residence address (if different from the Corporation&#8217;s books) of the Noticing Stockholder, (ii) if the Noticing Stockholder holds for the benefit of another, the name and </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:192px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">address of such beneficial owner and (iii) the name and address of any Holder Associated Person covered by this Section 2.8(c)(i);</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">the class or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially or of record by each Holder and each Holder Associated Person covered by this Section 2.8(c)(i), and the date such ownership was acquired;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">a description of any Derivative Instrument that is directly or indirectly owned beneficially by any Holder or Holder Associated Person and any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares or other securities of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any proxy, contract, arrangement, understanding, or relationship pursuant to which any Holder or Holder Associated Person has a right to vote or has granted a right to vote any securities (including the shares of common stock) of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(E)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">a description of any Hedging Transaction entered into by or on behalf of any Holder or Holder Associated Person;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(F)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any rights to dividends or other distributions on the shares or other securities of the Corporation owned beneficially by any Holder or Holder Associated Person that are separated or separable from the underlying shares or other securities of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(G)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any proportionate interest in shares or other securities of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership or limited liability company or other entity in which any Holder or Holder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, is the manager, managing member or directly or indirectly beneficially owns an interest in the manager or managing member of a limited liability company or similar entity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(H)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any performance-related fees (other than an asset-based fee) that any Holder or Holder Associated Person is entitled to based on any increase or decrease in the value of shares or other securities of the Corporation or Derivative Instruments, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(I)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">a representation that the Noticing Stockholder intends to appear in person or by proxy at the meeting to nominate the persons named or </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:192px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">propose the business specified in the notice, together with a statement whether the Noticing Stockholder intends to deliver a proxy &#160;&#160;&#160;&#160;statement or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding shares required to approve the nomination or the business proposed or otherwise to solicit proxies from Corporation&#8217;s stockholders in support of the nomination or the business proposed; and</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(J)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any other information relating to the Holder and any Holder Associated Person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal or for the election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations thereunder (even if an election contest or proxy solicitation is not involved), or is otherwise required pursuant to Section 14 of the Exchange Act.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">If a Noticing Stockholder&#8217;s notice required by these By-Laws relates to any business other than the nomination of one or more persons to be elected or re-elected to the Corporation&#8217;s Board of Directors that is proposed to be brought before the meeting, the notice also must set forth:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">a brief description of the business desired to be brought before the meeting (including the specific text of any resolutions or actions proposed for consideration and if such business includes the proposal to amend the Corporation&#8217;s Certificate of Incorporation or By-Laws, the specific language of the proposed amendment) and the reasons for conducting such business at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">a description of all direct and indirect agreements, arrangements or understandings between the Holder, any Holder Associated Person and any other Person (including their names) in connection with the proposal of such business by the Holder and any material direct or indirect interest of the Holder, any Holder Associated Person or any such other Person in such business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">If a Noticing Stockholder&#8217;s notice required by these By-Laws relates to the nomination of a person (each such person a &#8220;Nominee&#8221; and collectively, &#8220;Nominees&#8221;) to be elected or re-elected to the Corporation&#8217;s Board of Directors, the written notice, as to each Nominee, also must:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">set forth the Nominee&#8217;s name, age, business and residence address and principal occupation or employment and the class or series and </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:192px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">number of shares of common stock or other securities of the Corporation that are directly or indirectly owned beneficially or of record by the Nominee and all such other information that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election (even if an election contest or proxy solicitation is not involved), or is otherwise required, pursuant to Section 14 of the Exchange Act and the rules and regulations thereunder (including the Nominee&#8217;s written consent to being named in the proxy statement as a nominee, if applicable, and to serving as a director if elected);</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">set forth a description (including party names) of any agreements, arrangements or understandings (including financial transactions) between or among the Holder, any Holder Associated Person or any Nominee, on the one hand, and any other Persons (including any Holder Associated Person and any Nominee), on the other hand, in connection with the Nominee&#8217;s nomination; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">set forth a description of all direct and indirect compensation and any other material monetary agreements, arrangements or understandings during the past three years, and any other material relationships, between or among the Holder, any Holder Associated Person and their respective Affiliates and Associates, or other Persons acting in concert therewith, on the one hand, and each Nominee, and his or her respective Affiliates and Associates, or other Persons acting in concert therewith, on the other hand.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Any notice submitted pursuant to this Section 2.8(c) shall be updated and supplemented by the Holder in writing and delivered to the Secretary at the Corporation&#8217;s principal executive offices not later than 10 days after the record date for the meeting, if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In addition to the other terms that are defined in these By-Laws, for purposes of these By-Laws, the following terms shall have the respective meanings ascribed thereto:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Affiliate&#8221; means a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, another specified Person.</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Associate&#8221; means, with respect to a specified Person:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any corporation or organization of which that Person is an officer or partner or of which that Person is, directly or indirectly, the beneficial owner of ten percent (10%) or more of any class of equity securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any trust or other estate in which that Person has a substantial beneficial interest or as to which such Person serves as trustee or in a similar fiduciary capacity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">any Immediate Family Member of that Person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Control&#8221; means the possession, direct or indirect, of the power to direct or cause the direction of the management policies of a person, whether through the ownership of voting securities, by contract, or otherwise.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Derivative Instrument&#8221; means any derivative positions including, without limitation, any option, warrant, convertible security, stock appreciation right, profits interest or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares or other securities of the Corporation or with a value derived in whole or in part from the value of any class or series of shares or other securities of the Corporation, whether or not the instrument or right shall be subject to settlement in the underlying class or series of shares or other securities of the Corporation or otherwise and any performance-related fees to which such Holder or Holder Associated Person is entitled based, directly or indirectly, on any increase or decrease in the value of shares or other securities of the Corporation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Hedging Transaction&#8221; means, any hedging or other transaction (such as borrowed or loaned shares) or series of transactions, or any other agreement, arrangement or understanding, the effect or intent of which is to increase or decrease the voting power or economic or pecuniary interest of a Holder or Holder Associated Person with respect to the Corporation&#8217;s securities, including, without limitation, a short interest in any securities (including the shares of common stock) of the Corporation (for purposes of these By-Laws a person shall be deemed to have a short interest in a security if a Holder or Holder Associated Person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value or price of the subject security).</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Holder Associated Person&#8221; means, with respect to any Holder, (A) any person acting in concert with such Holder, (B) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such Holder (other than a stockholder that is a depositary) and (C) any Person, directly or indirectly, controlling, controlled by or under common control with any Holder, or any Holder Associated Person identified in clauses (A) or (B) above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Immediate Family Member&#8221; means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of a specified person, and any person (other than a tenant or employee) sharing the household of such specified person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Person&#8221; means an individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Public Announcement&#8221; means disclosure by the Corporation in a press release reported by the Dow Jones News Service, Associated Press, Business Wire, PR Newswire or comparable national news service or in a document publicly filed with or furnished by the Corporation to the Securities and Exchange Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act and the rules and regulations thereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Only those persons who are nominated in accordance with the procedures set forth in these By-Laws shall be eligible to serve as directors. Only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in these By-Laws. Except as otherwise provided by law, the Certificate of Incorporation, or these By-Laws, the Chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in compliance with the procedures set forth in these By-Laws and, if any nomination or proposed business is not in compliance with these By-Laws, to declare that such nomination or proposed business is defective, in which case it shall be disregarded.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In addition to the foregoing provisions of these By-Laws, a Holder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in these By-Laws; provided, however, that any references in these By-Laws to the Exchange Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">nominations or proposals as to any other business to be considered pursuant to Section 2.3 or Section 2.8.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Nothing in these By-Laws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act. In addition, nothing in these By-Laws shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.9.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Procedure for Election of Directors; Required Vote</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Election of directors at all meetings of the stockholders at which directors are to be elected shall be by ballot unless the presiding officer at the meeting determines that written ballots are unnecessary, and subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, a plurality of the votes cast thereat shall elect directors. Except as otherwise provided by law, the Certificate of Incorporation, or these By-Laws, in all matters other than the election of directors, the affirmative vote of the holders of a majority of the voting power represented by the shares present in person or represented by proxy at the meeting and entitled to vote on the matter shall be the act of the stockholders.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.10.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Inspectors of Elections; Opening and Closing the Polls</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Board of Directors by resolution may appoint one or more inspectors, which inspector or inspectors may include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives, to act at the meetings of stockholders and make a written report thereof. One or more persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to act or is able to act at a meeting of stockholders, the Chairman of the meeting may appoint one or more inspectors to act at the meeting. Each inspector, before discharging such inspector&#8217;s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability. The inspectors shall have the duties prescribed by law.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Chairman of the meeting shall fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.11.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Record Date for Action by Written Consent</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary (which written notice must set forth the information required by Section 2.8(c) of these By-Laws and include a copy of the proposed written consent), request the Board of Directors to fix a record date. The </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Board of Directors shall promptly, but in all events within 10 days after the date on which such a request is received, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within 10 days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business or to any officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&#8217;s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.12.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Inspectors of Written Consent</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. In the event of the delivery, in the manner provided by Section 2.11, to the Corporation of the requisite written consent or consents to take corporate action and/or any related revocation or revocations, the Corporation shall engage nationally recognized independent inspectors of elections for the purpose of promptly performing a ministerial review of the validity of the consents and revocations. For the purpose of permitting the inspectors to perform such review, no action by written consent without a meeting shall be effective until such date as the independent inspectors certify to the Corporation that the consents delivered to the Corporation in accordance with Section 2.11 represent at least the minimum number of votes that would be necessary to take the corporate action. Nothing contained in this paragraph shall in any way be construed to suggest or imply that the Board of Directors or any stockholder shall not be entitled to contest the validity of any consent or revocation thereof, whether before or after such certification by the independent inspectors, or to take any other action (including, without limitation, the commencement, prosecution or defense of any litigation with respect thereto, and the seeking of injunctive relief in such litigation).</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 2.13.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Effectiveness of Written Consent</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated written consent received in accordance with Section 2.11, a written consent or consents signed by a sufficient number of holders to take such action are delivered to the Corporation in the manner prescribed in Section 2.11.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE III.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;"><br>BOARD OF DIRECTORS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">General Powers</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The business and affairs of the Corporation shall be managed under the direction of the Board of Directors. In addition to the powers and authorities by </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">these By-Laws expressly conferred upon them, the Board of Directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these By-Laws required to be exercised or done by the stockholders.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Number and Tenure</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, the business and affairs of the Corporation shall be managed by the Board of Directors of not less than three nor more than 15 persons, the exact number thereof to be determined from time to time by resolution of the Board of Directors. Each director shall serve for a term expiring at the next annual meeting of stockholders and until his successor shall have been duly elected and qualified. Directors need not be stockholders.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Chairman of the Board</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Chairman of the Board shall be chosen from among the Directors. The Chairman of the Board shall preside at all meetings of the stockholders and of the Board of Directors. The Chairman of the Board shall perform all duties incidental to his office which may be required by law and all such other duties as are properly required of him by the Board of Directors. In the event the Board has elected Co-Chairmen of the Board, each Co-Chairman shall have the authority to act as a Chairman of the Board as provided in these By-laws.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Lead Director</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Whenever the Chairman of the Board is an executive officer of the Corporation, the independent directors, within the meaning of then effective NASDAQ Marketplace Rules, shall appoint one of the independent directors as Lead Director of the Corporation to lead the Board in fulfilling its duties effectively, efficiently and independent of management. The Lead Director&#8217;s responsibilities will be set forth in the Company&#8217;s Corporate Governance Guidelines, as amended from time to time.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Regular Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Regular meetings of the Board of Directors shall be held without notice at such time and at such place as shall from time to time be determined by the Board.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Special Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Special meetings of the Board of Directors shall be called at the request of the Chairman of the Board or a majority of the Board of Directors then in office. The person or persons authorized to call special meetings of the Board of Directors may fix the place and time of the meetings.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Notice of Board Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Notice of any special meeting of directors shall be given to each director at the director&#8217;s business or residence in writing by hand delivery, first-class or overnight mail or courier service or by telegram or facsimile transmission, by electronic transmission or orally by telephone. If mailed by first-class mail, such notice shall be deemed adequately delivered when deposited in the United States mails so addressed, with postage thereon prepaid, at least five days before such meeting. If by telegram, overnight mail or courier service, such notice shall be deemed adequately delivered when the telegram is delivered to the telegraph company or the notice is delivered to the overnight mail or courier service company at least 24 </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">hours before such meeting. If by facsimile transmission or by electronic transmission, such notice shall be deemed adequately delivered when the notice is transmitted at least 12 hours before such meeting. If by telephone or by hand delivery, the notice shall be given at least 12 hours prior to the time set for the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice of such meeting, except for amendments to these By-Laws, as provided under Section 8.1. A meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Section 6.4 of these By-Laws.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.8.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Action by Consent of Board of Directors</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.9.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Conference Telephone Meetings</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at such meeting.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.10.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Quorum</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Subject to Section 3.9, a whole number of directors equal to at least a majority of the total number of directors which the Corporation would have if there were no vacancies (&#8220;Whole Board&#8221;) shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there shall be less than a quorum present, a majority of the directors present may adjourn the meeting from time to time without further notice. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. The directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough directors to leave less than a quorum.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.11.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Vacancies</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Subject to applicable law and the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock, and unless the Board of Directors otherwise determines, vacancies resulting from death, resignation, retirement, disqualification, removal from office or other cause, and newly created directorships resulting from any increase in the authorized number of directors, may be filled only by the affirmative vote of a majority of the remaining directors, though less than a quorum of the Board of Directors, and directors so chosen shall hold office for a term expiring at the next annual meeting of stockholders and until such director&#8217;s successor shall have been duly elected and qualified. No decrease in the number of authorized directors constituting the Whole Board shall shorten the term of any incumbent director.</font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.12.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Executive and Other Committees</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Board of Directors may, by resolution adopted by a majority of the Whole Board, designate an Executive Committee to exercise, subject to and to the full extent of applicable provisions of law, all the powers of the Board in the management of the business and affairs of the Corporation when the Board is not in session and may, by resolution similarly adopted, designate one or more other committees. The Executive Committee may not, however (i) approve or adopt, or recommend to the stockholders of the Corporation, any action or matter expressly required by the General Corporation Law of the State of Delaware to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any By-Law of the Corporation. The Executive Committee and each such other committee shall consist of two or more directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, other than the Executive Committee (the powers of which are expressly provided for herein), may to the extent permitted by law exercise such powers and shall have such responsibilities as shall be specified in the designating resolution. In the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not constituting a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Each committee shall keep written minutes of its proceedings and shall report such proceedings to the Board when required.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">A majority of any committee may determine its action and fix the time and place of its meetings, unless the Board shall otherwise provide. Notice of such meetings shall be given to each member of the committee in any such manner as the committee may determine from time to time. A majority of the Whole Board shall have power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee. Nothing herein shall be deemed to prevent the Board from appointing one or more committees consisting in whole or in part of persons who are not directors of the Corporation; provided, however, that no such committee shall have or may exercise any authority of the Board.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.13.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Subject to the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock, any director, or the entire Board of Directors, may be removed from office at any time, either with or without cause, by the affirmative vote of holders of a majority of the voting power of shares of Voting Stock.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 3.14.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Records</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Board of Directors shall cause to be kept a record containing the minutes of the proceedings of the meetings of the Board and of the stockholders, appropriate stock books and registers and such books of records and accounts as may be necessary for the proper conduct of the business of the Corporation.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE IV.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">OFFICERS</font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Elected Officers</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The elected officers of the Corporation shall be a Chief Executive Officer, a President, a Secretary, a Treasurer, and such other officers (including, without limitation, a Chief Financial Officer) as the Board of Directors from time to time may deem proper. All officers elected by the Board of Directors shall each have such powers and duties as generally pertain to their respective offices, subject to the specific provisions of this Article IV. Such officers shall also have such powers and duties as from time to time may be conferred by the Board of Directors or by any committee thereof. The Board or any committee thereof may from time to time elect, or the Chief Executive Officer may appoint, such other officers (including one or more Assistant Vice Presidents, Assistant Secretaries, Assistant Treasurers, and Assistant Controllers) and such agents, as may be necessary or desirable for the conduct of the business of the Corporation. Such other officers and agents shall have such duties and shall hold their offices for such terms as shall be provided in these By-Laws or as may be prescribed by the Board or such committee or by the Chief Executive Officer, as the case may be.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Election and Term of Office</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The elected officers of the Corporation shall be elected annually by the Board of Directors at the regular meeting of the Board of Directors held after the annual meeting of the stockholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as convenient. Each officer shall hold office until his successor shall have been duly elected and shall have been qualified or until his death, resignation or removal.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Chief Executive Officer</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Chief Executive Officer shall be responsible for the general management of the affairs of the Corporation and shall perform all duties incidental to this office which may be required by law and all such other duties as are properly required of this officer by the Board of Directors. The Chief Executive Officer shall make reports to the Board of Directors and the stockholders, and shall see that all orders and resolutions of the Board of Directors and of any committee thereof are carried into effect. The Chief Executive Officer may also serve as President, if so elected by the Board.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">President</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The President shall act in a general executive capacity and shall assist the Chief Executive Officer in the administration and operation of the Corporation&#8217;s business and general supervision of its policies and affairs. The President shall, in the absence of or because of the inability to act of the Chief Executive Officer, perform all duties of the Chief Executive Officer.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Vice-Presidents</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Each Vice President shall have such powers and shall perform such duties as shall be assigned to him by the Board of Directors or the Chief Executive Officer.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Chief Financial Officer</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Chief Financial Officer (if any) shall be a Vice President and act in an executive financial capacity. He shall assist the Chief Executive Officer and the President in the general supervision of the Corporation&#8217;s financial policies and affairs.</font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Treasurer</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Treasurer shall exercise general supervision over the receipt, custody and disbursement of corporate funds. The Treasurer shall cause the funds of the Corporation to be deposited in such banks as may be authorized by the Board of Directors, or in such banks as maybe designated as depositaries in the manner provided by resolution of the Board of Directors. He shall have such further powers and duties and shall be subject to such directions as may be granted or imposed upon him from time to time by the Board of Directors or the Chief Executive Officer.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.8.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Secretary</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Secretary shall keep or cause to be kept in one or more books provided for that purpose, the minutes of all meetings of the Board, the committees of the Board and the stockholders; he shall see that all notices are duly given in accordance with the provisions of these By-Laws and as required by law; he shall be custodian of the records and the seal of the Corporation and affix and attest the seal to all stock certificates of the Corporation (unless the seal of the Corporation on such certificates shall be a facsimile, as hereinafter provided) and affix and attest the seal to all other documents to be executed on behalf of the Corporation under its seal; and he shall see that the books, reports, statements, certificates and other documents and records required by law to be kept and filed are properly kept and filed; and in general, he shall perform all the duties incident to the office of Secretary and such other duties as from time to time may be assigned to him by the Board or the Chief Executive Officer.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.9.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Any officer or agent may be removed at any time by the affirmative vote of a majority of the Whole Board or, except in the case of an officer or agent elected by the Board, by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights, if any, of the person so removed. No elected officer shall have any contractual rights against the Corporation for compensation by virtue of such election beyond the date of the election of his successor, his death, his resignation or his removal, whichever event shall first occur, except as otherwise provided in an employment contract or under an employee deferred compensation plan.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 4.10.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Vacancies</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. A newly created elected office and a vacancy in any elected office because of death, resignation, or removal may be filled by the Board of Directors for the unexpired portion of the term at any meeting of the Board of Directors. Any vacancy in an office appointed by the Chief Executive Officer because of death, resignation, or removal may be filled by the Chief Executive Officer.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE V.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">STOCK CERTIFICATES AND TRANSFERS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 5.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Stock Certificates and Transfers</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock in such form as the appropriate officers of the Corporation may from time to time prescribe; provided that the Board of Directors may provide by </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">resolution or resolutions that some or all of any or all classes or series of the stock of the Corporation shall be represented by uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The shares of stock represented by certificates shall be signed, countersigned and registered in such manner as the Board of Directors may by resolution prescribe, which resolutions may permit all or any of the signatures on such certificates (if any) to be by facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The shares of the stock of the Corporation represented by certificates shall be transferred on the books of the Corporation by the holder thereof in person or by his attorney, upon surrender for cancellation of certificates for at least the same number of shares, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, with such proof of the authenticity of the signature as the Corporation or its agents may reasonably require. Upon receipt of proper transfer instructions from the registered owner of uncertificated shares, such uncertificated shares shall be canceled and issuance of new equivalent uncertificated shares or certificated shares (if authorized) shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the Corporation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to the General Corporation Law of the State of Delaware or, unless otherwise provided by the General Corporation Law of the State of Delaware, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 5.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Lost, Stolen or Destroyed Certificates</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. No certificate for shares of stock nor uncertificated shares of stock in the Corporation shall be issued in place of any certificate alleged to have been lost, destroyed or stolen, except on production of such evidence of such loss, destruction or theft and on delivery to the Corporation of a bond of indemnity in such amount, upon </font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">18</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">such terms and secured by such surety, as the Board of Directors or any financial officer may in its or his discretion require.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE VI.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">MISCELLANEOUS PROVISIONS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Fiscal Year</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The fiscal year of the Corporation shall begin on the first day of January and end on the 31st day of December of each year.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Dividends</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and the Certificate of Incorporation.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Seal</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The Corporation need not have a corporate seal, but if it does the corporate seal shall have inscribed thereon the words &#8220;Corporate Seal&#8221;, the year of incorporation and around the margin thereof the words &#8220;Amedisys, Inc. &#8211; Delaware&#8221;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Waiver of Notice</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Whenever any notice is required to be given to any stockholder or director of the Corporation under the provisions of the General Corporation Law of the State of Delaware or these By-Laws, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders or the Board of Directors or committee thereof need be specified in any waiver of notice of such meeting.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Audits</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. The accounts, books and records of the Corporation shall be audited upon the conclusion of each fiscal year by an independent certified public accountant selected by the Board of Directors, and it shall be the duty of the Board of Directors to cause such audit to be done annually.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Resignations</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Any director or any officer, whether elected or appointed, may resign at any time by giving written notice of such resignation to the Chief Executive Officer, the President, or the Secretary, and such resignation shall be deemed to be effective as of the close of business on the date said notice is received by the Chief Executive Officer, the President, or the Secretary, or at such later time as is specified therein. No formal action shall be required of the Board of Directors or the stockholders to make any such resignation effective.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 6.7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Indemnification and Insurance</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. In addition to the indemnification rights provided in the Certificate of Incorporation:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;proceeding&#8221;), by reason of the fact that such person </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">or a person of whom such person is the legal representative is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans maintained or sponsored by the Corporation, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended(but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement)reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators; provided, however, that except as provided in paragraph (c) of this By-Law, the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors. The right to indemnification conferred in this By-Law shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition, such advances to be paid by the Corporation within 20 days after the receipt by the Corporation of a statement or statements from the claimant requesting such advance or advances from time to time; provided, however, that if the General Corporation Law of the State of Delaware requires, the payment of such expenses incurred by a director or officer in such persons capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this By-Law or otherwise.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">To obtain indemnification under this By-Law, a claimant shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification pursuant to the first sentence of this paragraph (b), a determination, if required by applicable law, with respect to </font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">the claimant&#8217;s entitlement thereto shall be made as follows: (i) by the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (ii) if a quorum of the Board of Directors consisting of Disinterested Directors is not obtainable or, even if obtainable, such quorum of Disinterested Directors so directs, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the claimant, or (iii) if a quorum of Disinterested Directors so directs, by the stockholders of the Corporation. If it is so determined that the claimant is entitled to indemnification, payment to the claimant shall be made within 10 days after such determination.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">If a claim under paragraph (a) of this By-Law is not paid in full by the Corporation within 30 days after a written claim pursuant to paragraph (b) of this By-Law has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standard of conduct which makes it permissible under the General Corporation Law of the State of Delaware for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, Independent Counselor stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because such claimant has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, Independent Counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">If a determination shall have been made pursuant to paragraph (b) of this By-Law that the claimant is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to paragraph (c) of this By-Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to paragraph (C) of this By-Law that the procedures and presumptions of this By-Law are not valid, binding and enforceable and shall stipulate in such proceeding that the Corporation is bound by all the provisions of this By-Law.</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this By-Law shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, By-Laws, agreement, vote of stockholders or Disinterested Directors or otherwise. No repeal or modification of this By-Law shall in anyway diminish or adversely affect the rights of any director, officer, employee or agent of the Corporation hereunder in respect of any occurrence or matter arising prior to any such repeal or modification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware. To the extent that the Corporation maintains any policy or policies providing such insurance, each such director or officer, and each such agent or employee to which rights to indemnification have been granted as provided in paragraph (h) of this By-Law, shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage thereunder for any such director, officer, employee or agent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:17px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification, and rights to be paid by the Corporation the expenses incurred in defending any proceeding in advance of its final disposition, to any employee or agent of the Corporation to the fullest extent of the provisions of this By-Law with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">If any provision or provisions of this By-Law shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (1) the validity, legality and enforceability of the remaining provisions of this By-Law (including, without limitation, each portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in anyway be affected or impaired thereby; and (2) to the fullest extent possible, the provisions of this By-Law (including, without limitation, each such portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">For purposes of this By-Law:</font></div></td></tr></table><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Disinterested Director&#8221; means a director of the Corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;Independent Counsel&#8221; means a law firm, a member of a law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the Corporation or the claimant in an action to determine the claimant&#8217;s rights under this By-Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Any notice, request or other communication required or permitted to be given to the Corporation under this By-Law shall be in writing and either delivered in person or sent by telecopy, telex, telegram, overnight mail or courier service, or certified or registered mail, postage prepaid, return receipt requested, to the Secretary of the Corporation and shall be effective only upon receipt by the Secretary.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE VII.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">CONTRACTS, PROXIES, ETC.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 7.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Contracts</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Except as otherwise required by law, the Certificate of Incorporation or these By-Laws, any contracts or other instruments may be executed and delivered in the name and on the behalf of the Corporation by such officer or officers of the Corporation as the Board of Directors may from time to time direct. Such authority may be general or confined to specific instances as the Board may determine. The Chief Executive Officer, the President or any Vice President may execute bonds, contracts, deeds, leases and other instruments to be made or executed for or on behalf of the Corporation. Subject to any restrictions imposed by the Board of Directors or the Chief Executive Officer, the President or any Vice President of the Corporation may delegate contractual powers to others under his jurisdiction, it being understood, however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated power.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 7.2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Proxies</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Unless otherwise provided by resolution adopted by the Board of Directors, the Chief Executive Officer, the President or any Vice President may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation, or to consent in writing, in the name of the Corporation as such holder, to any action by such other corporation, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consent, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such written proxies or other instruments as he may deem necessary or proper in the premises.</font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:center;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">ARTICLE VIII.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">AMENDMENTS</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">SECTION 8.1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Amendments</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">. Except as expressly provided otherwise by the Delaware General Corporation Law, the Certificate of Incorporation of the Corporation, or other provisions of these By-Laws, these By-Laws may be altered, amended or repealed and new By-Laws adopted at any regular or special meeting of the Board of Directors by an affirmative vote of a majority of the Whole Board.</font></div><div><br></div><div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>amed-20193009xexx101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s62FFDB3ED3314598A9F70472B1D006FF"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMEDISYS HOLDING, L.L.C.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMENDED AND RESTATED SEVERANCE PLAN FOR EXECUTIVE OFFICERS </font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JULY 25, 2019</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1. &#160;&#160;&#160;&#160;Purpose</font><font style="font-family:inherit;font-size:12pt;">. The purpose of this Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers (this &#8220;Plan&#8221;) is to provide a fair framework in the event of the termination of employment in certain circumstances of certain executive officers of the Company. This document supersedes any prior plan, program or arrangement that provides severance benefits to a Covered Executive (as defined below) eligible for benefits under this Plan. This document is intended to serve both as the official plan document and the summary plan description for this Plan.  The Plan is sponsored by Amedisys Holding, L.L.C. (&#8220;Company&#8221;).  The Company is the Plan Administrator.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2. &#160;&#160;&#160;&#160;Covered Executives</font><font style="font-family:inherit;font-size:12pt;">. To be eligible for benefits under this Plan an executive must (1) be employed by the Company in the position of an executive officer of the Company as appointed by the Board of Directors (the &#8220;Board&#8221;) of Amedisys, Inc.; or  have been designated in writing by the Board of Directors (the &#8220;Board&#8221;) of Amedisys, Inc. or the Compensation Committee of the Board (the &#8220;Committee&#8221;), as appropriate, as being covered by this Plan; and (2) have executed and delivered to the Company (and not have revoked or attempted to revoke) the Company&#8217;s Executive Protective Covenants Agreement (&#8220;EPCA&#8221; or other similarly named agreement) (a &#8220;Covered Executive&#8221;). </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Plan shall not be applicable to any employee who is a party to a separate employment agreement with the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3. &#160;&#160;&#160;&#160;Definitions</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Cause</font><font style="font-family:inherit;font-size:12pt;">. &#8220;Cause,&#8221; as it applies to the determination by the Company to terminate the employment of a Covered Executive, shall mean any one or more of the following: (i)&#160;Covered Executive&#8217;s default or breach of any of the provisions of any agreement that the Covered Executive may have with the Company or any affiliate or subsidiary; (ii)&#160;Covered Executive engages in an act or series of acts constituting fraud, abuse, dishonesty, embezzlement, destruction or theft of Company property, or breach of the duty of loyalty owed by Covered Executive to the Company; (iii) Covered Executive&#8217;s violation of any applicable laws, rules or regulations (including, without limitation, all Medicare and other health care laws, rules and regulations pertaining to the provision of home health care, hospice or any other services provided by the Company); (iv) Covered Executive&#8217;s furnishing materially false, inaccurate, misleading or incomplete information to the Company; (v) Covered Executive engages in an act or series of acts constituting a material breach of the Company&#8217;s Code of Ethical Business Conduct, the Company&#8217;s employee handbook or any other Company policy; (vi) Covered Executive&#8217;s willful failure to follow reasonable and lawful directives of Covered Executive&#8217;s supervisor, or any of the Company&#8217;s senior executive officers, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">which are consistent with Covered Executive&#8217;s job responsibilities and performance; or (vii) Covered Executive&#8217;s failure to satisfy the requirements of Covered Executive&#8217;s job, regardless whether or not such failure is willful, including the failure to satisfy the objectives of any action plan or performance improvement plan that Covered Executive may be under. In the event of a termination by the Company for Cause, Covered Executive shall have no right to any severance benefits under this Plan.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Code. </font><font style="font-family:inherit;font-size:12pt;">&#8220;Code&#8221; shall mean the United States Internal Revenue Code of 1986, as amended, or any successor provision of law, and the regulations promulgated thereunder.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">. &#8220;Good Reason,&#8221; as it applies to the determination by a Covered Executive to terminate Covered Executive&#8217;s employment with the Company at his or her initiative shall mean the occurrence of any of the following events without Covered Executive&#8217;s written consent: (i)&#160;Covered Executive suffers a material diminution in authority, responsibilities, or duties; or (ii)&#160;Covered Executive suffers a material reduction in base salary other than in connection with a proportionate reduction in the base salaries of all similarly situated senior officer-level employees. Good Reason shall not be deemed to have occurred unless (i) Covered Executive provides the Company with notice of one of the conditions described above within 90 days of the existence of the condition, (ii) the Company is provided at least 30 days to cure the condition and fails to cure same within such 30 day period and (iii) Covered Executive terminates employment within at least 150 days of the existence of the condition.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Employment Termination</font><font style="font-family:inherit;font-size:12pt;">. &#8220;Employment Termination&#8221; shall mean a Covered Executive no longer being an employee of the Company as a result of a termination by the Company without Cause or by Covered Executive with Good Reason.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Change in Control. </font><font style="font-family:inherit;font-size:12pt;">A &#8220;Change in Control&#8221; shall be deemed to have occurred if: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a.&#160;&#160;&#160;&#160;any person or entity, including a &#8220;group&#8221; as defined in Section 13(d)(3) of the Exchange Act or in Section 409A of the Code, other than the Company or a wholly-owned Subsidiary, or any employee benefit plan of the Company or any Subsidiary, becomes the beneficial owner of the Company&#8217;s securities having 50% or more of the combined voting power of the then outstanding securities of the Company that may be cast for the election of directors of the Company (other than as a result of an issuance of securities initiated by the Company in the ordinary course of business); or</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">b.&#160;&#160;&#160;&#160;as the result of, or in connection with, any cash tender or exchange offer, merger or other business combination, sales of assets or contested election, or any combination of the foregoing transactions, after the transaction less than a majority of the combined voting power of the then outstanding securities of the Company, or any successor corporation or cooperative or entity, entitled to vote generally in the election of the directors of the Company, or other successor corporation or other entity, are held in the aggregate by the holders of the Company&#8217;s securities who immediately prior to the transaction had been entitled to vote generally in the election of directors of the Company; or</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c.&#160;&#160;&#160;&#160;during any period of 12 consecutive months, individuals who at the beginning of the period constitute the Board cease for any reason to constitute at least a majority of the Board, unless the election, or the nomination for election by the Company&#8217;s stockholders, of each director of the Company first elected during the relevant 12 month period was approved by a vote of at least 2/3 of the directors of the Company then still in office who were directors of the Company at the beginning of that period.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4. &#160;&#160;&#160;&#160;Result of Termination by the Company without Cause or by Covered Executive with Good Reason Prior to a Change in Control</font><font style="font-family:inherit;font-size:12pt;">. The following provisions shall apply should the Company terminate a Covered Executive&#8217;s employment without Cause or should a Covered Executive terminate Covered Executive&#8217;s employment with Good Reason:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Salary and Bonus</font><font style="font-family:inherit;font-size:12pt;">. The Company shall pay to Covered Executive an amount equal to one (1) times the sum of (A) the Covered Executive&#8217;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and (B) the greater of (x) an amount equal to the cash bonus earned by the Covered Executive for the previous fiscal year or (y) an amount equal to the Covered Executive&#8217;s short-term incentive bonus target percentage for the fiscal year of the Employment Termination times the Covered Executive&#8217;s base salary, as in effect on the date of the Employment Termination (or, in the event a reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in substantially equal monthly installments in accordance with the Company&#8217;s normal payroll practices for a period of 12 months and which payments shall commence in accordance with the provisions of Section 6, herein (unless otherwise required to be paid in accordance with Section 7 below). </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Stock Vesting. </font><font style="font-family:inherit;font-size:12pt;">Any unvested equity awards issued in the name of Covered Executive as of the date of termination, will vest in accordance with the terms contained in the applicable Award Agreement for such awards.  </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5. &#160;&#160;&#160;&#160;Termination by the Company without Cause or Termination by Covered Executive with Good Reason Following a Change in Control. </font><font style="font-family:inherit;font-size:12pt;">The following provisions shall apply should the Company terminate a Covered Executive&#8217;s employment without Cause or should a Covered Executive terminate Covered Executive&#8217;s employment with Good Reason, in either case within  two years following a Change in Control (as defined above):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;Salary and Bonus.</font><font style="font-family:inherit;font-size:12pt;">&#32;The Company shall pay to Covered Executive (i) an amount equal to two (2) times the sum of (A) the Covered Executive&#8217;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and (B) the greater of (x) an amount equal to the cash bonus earned by the Covered Executive for the previous fiscal year or (y) an amount equal to the Covered Executive&#8217;s short-term incentive bonus target percentage for the fiscal year of the Employment Termination times the Covered Executive&#8217;s base salary, as in effect on the date of the Employment Termination  (or, in the event a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in a lump sum on the date or dates specified in Section 6, herein (unless otherwise required to be paid in accordance with Section 7 below).</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#160;&#160;&#160;&#160;Stock Vesting. </font><font style="font-family:inherit;font-size:12pt;">Any unvested equity awards issued in the name of Covered Executive as of the occurrence of a Change in Control will vest in accordance with the provisions of the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, as the same may be amended from time to time, or any successor plan thereto.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6. &#160;&#160;&#160;&#160;Release of Claims</font><font style="font-family:inherit;font-size:12pt;">. The Company&#8217;s obligations under this Plan are contingent upon Covered Executive&#8217;s executing (and not revoking during any applicable revocation period) a valid, enforceable, full and unconditional release of all claims Covered Executive may have against the Company, Amedisys, Inc. and their respective directors, officers, employees, subsidiaries, stockholders, successors, assigns, agents, representatives subsidiaries and affiliates (whether known or unknown) as of the date of Employment Termination in such form as provided by the Company no later than 60 days after the date of Employment Termination. If the foregoing release is executed and delivered and no longer subject to revocation within 60 days after the date of Employment Termination, then the following shall apply:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;To the extent any payments due to Covered Executive under this Plan are not &#8220;deferred compensation&#8221; for purposes of Section&#160;409A of the Code then such payments shall commence upon the first regularly-scheduled payment date immediately following the date the release is executed and no longer subject to revocation (the &#8220;Release Effective Date&#8221;). The first such cash payment shall include payment of all amounts that otherwise would have been due prior to the Release Effective Date under the terms of this Plan had such payments commenced after the date of Employment Termination, and any payments to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had such payments commenced after the date of Employment Termination.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;To the extent any payments due to Covered Executive under this Plan above are &#8220;deferred compensation&#8221; for purposes of Section&#160;409A, then such payments shall commence upon the 60th day following the date of Employment Termination. The first such cash payment shall include payment of all amounts that otherwise would have been due prior thereto under the terms of this Plan had such payments commenced after the date of Employment Termination, and any payments to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had such payments commenced immediately following the date of Employment Termination.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7. &#160;&#160;&#160;&#160;Section 409A</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding any provisions in this Plan to the contrary, if at the time of the Employment Termination the Covered Executive is a &#8220;specified employee&#8221; as defined in Section 409A and the deferral of the commencement of any payments or benefits otherwise payable as a result of such Employment Termination is necessary to avoid the additional tax under Section 409A, the Company will defer the payment or commencement of the payment of any such payments or benefits (without any reduction in such payments or benefits ultimately paid or provided </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to Covered Executive) until one day after the day which is six months from the date of Employment Termination. Any monthly payment amounts deferred will be accumulated and paid to Covered Executive (without interest) six months after the date of Employment Termination in a lump sum, and the balance of payments due to Covered Executive will be paid as otherwise provided in this Plan. Each monthly payment described in this Plan is designated as a &#8220;separate payment&#8221; for purposes of Section&#160;409A and, subject to the six-month delay, if applicable, and the first monthly payment shall commence on the payroll date as in effect on termination following the termination. For purposes of this Plan, a termination of employment means a separation from service as defined in Section&#160;409A. No reimbursement payable to Covered Executive pursuant to any provisions of this Plan or pursuant to any plan or arrangement of the Company shall be paid later than the last day of the calendar year following the calendar year in which the related expense was incurred, and no such reimbursement during any calendar year shall affect the amounts eligible for reimbursement in any other calendar year, except, in each case, to the extent that the right to reimbursement does not provide for a &#8220;deferral of compensation&#8221; within the meaning of Section&#160;409A. This Plan will be interpreted, administered and operated in accordance with Section&#160;409A, although nothing herein will be construed as an entitlement to or guarantee of any particular tax treatment to Covered Executive.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Claims Procedure</font><font style="font-family:inherit;font-size:12pt;">. If a Covered Executive does not receive a benefit to which the Covered Executive believes he or she is entitled under the Plan, or if the Covered Executive believes that the Covered Executive is entitled to a greater benefit than was approved, the Covered Executive must, within 60 days following the date of Employment Termination, file a written claim with the Plan Administrator. The Plan Administrator will investigate the claim and will send the Covered Executive a written decision within 60 days from the date upon which it receives the claim. If the claim is denied, the written decision will specify the reasons for the denial (including the pertinent Plan provisions upon which the denial is based), as well as an explanation of how the Covered Executive may obtain a further review by the Plan Administrator. If special circumstances require an extension of time for the Plan Administrator to render a decision, the Plan Administrator will send the Covered Executive a written notice of the extension prior to the commencement of the extension and will explain the reasons for the delay. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the Covered Executive disagrees with the Plan Administrator's decision, in whole or in part, the Covered Executive has 60 days following receipt of written notice from the Plan Administrator to request a review in writing. The request must describe the reasons why the Covered Executive believes the denial was wrong and whatever evidence the Covered Executive believes supports his or her position. If the Covered Executive wishes to examine any Company documents, he or she must request an examination and specify the documents requested.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within 60 days following a request for review, the Plan Administrator will send the Covered Executive its written decision specifying the reasons for the decision, including the pertinent Plan provisions upon which it is based. This decision shall be final and binding.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If special circumstances require an extension of time for the Plan Administrator to render a decision, the Plan Administrator will send the Covered Executive a written notice of the extension prior to the commencement of the extension and will explain the reasons for the delay.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company, as Plan Administrator, has the exclusive discretionary authority to construe and interpret the Plan, to decide all questions of eligibility for severance benefits under the Plan and to determine the amount of any such severance benefits, and its decisions on such matters are final and conclusive. Any interpretations or determinations made pursuant to such discretionary authority will be upheld on judicial review, unless it is shown that the interpretation or determination was an abuse of discretion (i.e., arbitrary and capricious).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Your Rights Under ERISA</font><font style="font-family:inherit;font-size:12pt;">. As a participant in the Plan, a Covered Executive is entitled to certain rights and protection under the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). ERISA provides that all Plan participants shall be entitled to:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Examine, without charge, at the Plan Administrator's office and at other specified locations, such as worksites, all documents governing the Plan, including a copy of the latest annual report (Form 5500 Series) filed by the Plan with the U.S. Department of Labor.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including a copy of the latest annual report (Form 5500 Series) and updated summary plan description. The Administrator may make a reasonable charge for the copies.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Receive a summary of the Plan's annual financial report. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called "fiduciaries" of the Plan, have a duty to do so prudently and in the interest of the Covered Executive and other Plan participants and beneficiaries. No one, including the employer, or any other person, may fire the Covered Executive or otherwise discriminate against the Covered Executive in any way to prevent the Covered Executive from obtaining a welfare benefit or exercising his or her rights under ERISA. If the Covered Executive&#8217;s claim for a welfare benefit is denied, in whole or in part, he or she must receive a written explanation of the reason for the denial. The Covered Executive has the right to have the Plan review and reconsider his or her claim.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under ERISA, there are steps a Covered Executive can take to enforce the above rights. For instance, if the Covered Executive requests materials from the Plan and does not receive them within 30 days, he or she may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay the Covered Executive up to $110 a day until he or she receives the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the Covered Executive has a claim for benefits which is denied or ignored, in whole or in part, the Covered Executive may file suit in a state or Federal court. In addition, if the Covered Executive disagrees with the Plan's decision or lack thereof concerning the qualified status of a medical child support order, he or she may file suit in Federal court. If it should happen that Plan fiduciaries misuse the Plan's money, or if the Covered Executive is discriminated against for asserting </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">his or her rights, the Covered Executive may seek assistance from the U.S. Department of Labor, or may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If the Covered Executive is successful, the court may order the person the Covered Executive has sued to pay these costs and fees. If the Covered Executive loses, the court may order him or her to pay these costs and fees &#8212; for example, if the court finds the Covered Executive&#8217;s claim is frivolous.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the Covered Executive has any questions about the Plan, he or she should contact the Plan Administrator. If the Covered Executive has any questions about this statement or about his or her rights under ERISA, the Covered Executive should contact the nearest office of the Pension and Welfare Benefits Administration, U.S. Department of Labor, listed in the telephone directory or the Division of Technical Assistance and Inquiries, Pension and Welfare Benefits Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Additional Important Information</font><font style="font-family:inherit;font-size:12pt;">.  The name of the Plan is the Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The sponsor of the Plan is Amedisys Holding, L.L.C. and its employer identification number is 36-4576454. The sponsor's address and telephone number is 3854 American Way, Suite A, Baton Rouge, LA 70816, (888) 777-4312.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amedisys Holding, L.L.C. also serves as the Plan Administrator under ERISA for the Plan, and can be contacted at 3854 American Way, Suite A, Baton Rouge, LA 70816, (888) 777-4312.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The agent for service of process for the Plan is Secretary, Amedisys Holding, L.L.C., 209 10</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Avenue South, Suite 512, Nashville, TN 37203.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Plan is an employee welfare benefit plan providing severance pay and benefits as described in this Plan document under the Amedisys Employees' Health and Welfare Benefit Plan (the BenefitPlan&#8221;). All Severance Benefits under the Benefit Plan shall be paid directly by the Company from its general assets, and the rights of an eligible employee to any benefits hereunder shall not be superior to those of an unsecured general creditor of the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Benefit Plan&#8217;s plan year is the calendar year and the Plan Number is 502.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severance benefits under the Plan may not be assigned, transferred or pledged to a third party.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;At-Will Employment.</font><font style="font-family:inherit;font-size:12pt;">&#32;No provision of the Plan is intended to provide any Covered Executive with any right to continue as an employee or in any other capacity with the Company, for any specific period of time, or otherwise affect the right of the Company to terminate the employment or service of any individual at any time for any reason with or without cause.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;Amendment and Termination</font><font style="font-family:inherit;font-size:12pt;">. The Company reserves the right in its discretion to terminate the Plan and to amend the Plan in any manner at any time, subject to the prior approval </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of the Board and/or the Committee, as applicable. Any such action will be in writing and signed by the Chief Executive Officer or the Chief Human Resources Officer of the Company or such other persons as he or she shall designate. Oral or other informal communications made by the Company or its representatives shall not give rise to any rights or benefits other than those contained in the Plan described herein, and such communications will not diminish the Company's rights to amend or terminate the Plan in any manner.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This document is executed as of this 25th day of July 2019. </font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMEDISYS HOLDING, L.L.C.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:  AMEDISYS, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its Sole Member and Manager</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/S/ Sharon Brunecz</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sharon Brunecz</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chief Human Resources Officer</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>amed-20193009xexx311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9A232163C0E35607A7526E1AF2409098"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Paul B. Kusserow, certify that:</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, of Amedisys, Inc.;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:32.8125%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ Paul B. Kusserow</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Paul B. Kusserow</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>amed-20193009xexx312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBC641408E85855108A19DD7D21C3B711"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Scott G. Ginn, certify that:</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, of Amedisys, Inc.;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:25%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ Scott G. Ginn</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scott G. Ginn</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>amed-20193009xexx321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5CC10EEBCA025171B47FFD1CDC5B8795"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;), I, Paul B. Kusserow, President and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:224px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:224px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ Paul B. Kusserow</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Paul B. Kusserow</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>amed-20193009xexx322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s42DD9FBDF41D5F84B9CF257F7040322D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;), I, Scott G. Ginn, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:8px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:171px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:170px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ Scott G. Ginn</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scott G. Ginn</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>amed-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20190930" xmlns:amed="http://www.amedisys.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://www.amedisys.com/role/Acquisitions">
        <link:definition>2103100 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.amedisys.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2403402 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaDetails" roleURI="http://www.amedisys.com/role/AcquisitionsProFormaDetails">
        <link:definition>2403403 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.amedisys.com/role/AcquisitionsTables">
        <link:definition>2303301 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.amedisys.com/role/CommitmentsAndContingencies">
        <link:definition>2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityStatement" roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0001000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.amedisys.com/role/LeasesDetails">
        <link:definition>2404402 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFinanceLeaseDetails" roleURI="http://www.amedisys.com/role/LeasesFinanceLeaseDetails">
        <link:definition>2404405 - Disclosure - LEASES Finance lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.amedisys.com/role/LeasesLeaseCostDetails">
        <link:definition>2404403 - Disclosure - LEASES Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeases" roleURI="http://www.amedisys.com/role/LeasesLeases">
        <link:definition>2104100 - Disclosure - LEASES LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesDetails" roleURI="http://www.amedisys.com/role/LeasesMaturitiesDetails">
        <link:definition>2404408 - Disclosure - LEASES Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseDetails" roleURI="http://www.amedisys.com/role/LeasesOperatingLeaseDetails">
        <link:definition>2404404 - Disclosure - LEASES Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2404406 - Disclosure - LEASES Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amedisys.com/role/LeasesTables">
        <link:definition>2304301 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageRemainingTermAndDiscountRateDetails" roleURI="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails">
        <link:definition>2404407 - Disclosure - LEASES Weighted Average Remaining Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligations" roleURI="http://www.amedisys.com/role/LongTermObligations">
        <link:definition>2105100 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails">
        <link:definition>2405404 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsLongTermObligationsTables" roleURI="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables">
        <link:definition>2305301 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsNarrativeDetails" roleURI="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails">
        <link:definition>2405405 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails">
        <link:definition>2405403 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsScheduleOfLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails">
        <link:definition>2405402 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsScheduleOfLongTermDebtDetailsCalc2" roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2">
        <link:definition>2405402 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements">
        <link:definition>2101100 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails">
        <link:definition>2401401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2410401 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsRelatedPartyTransactions" roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions">
        <link:definition>2110100 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.amedisys.com/role/SegmentInformation">
        <link:definition>2107100 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.amedisys.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2407402 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationOperatingIncomeOfReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails">
        <link:definition>2407403 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.amedisys.com/role/SegmentInformationTables">
        <link:definition>2307301 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchaseNarrativeDetails" roleURI="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails">
        <link:definition>2408401 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchaseShareRepurchase" roleURI="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase">
        <link:definition>2108100 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.amedisys.com/role/SubsequentEvent">
        <link:definition>2109100 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventNarrativeDetails" roleURI="http://www.amedisys.com/role/SubsequentEventNarrativeDetails">
        <link:definition>2409401 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails">
        <link:definition>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails">
        <link:definition>2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails">
        <link:definition>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails">
        <link:definition>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails">
        <link:definition>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails">
        <link:definition>2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amed_AccountsReceivablePortionDerivedFromMedicare" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_ActualClaimsPayment" name="ActualClaimsPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_AmedisysCIAMember" name="AmedisysCIAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_AmendedCreditAgreementMember" name="AmendedCreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_Businessacquisitionproformaoperatingincomeloss" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CapYearAxis" name="CapYearAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CapYearDomain" name="CapYearDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" name="CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_CashDistributionToNoncontrollingInterest" name="CashDistributionToNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ChristianCareatHomeMember" name="ChristianCareatHomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ClearwaterFloridaMember" name="ClearwaterFloridaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CompanysinsurancecarriersMember" name="CompanysinsurancecarriersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CompassionateCareHospiceCIAMember" name="CompassionateCareHospiceCIAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_CompassionateCareHospiceMember" name="CompassionateCareHospiceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_ConsolidatedInterestCoverageRatio" name="ConsolidatedInterestCoverageRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_ConsolidatedLeverageRatio" name="ConsolidatedLeverageRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_CorporateIntegrityAgreementTerm" name="CorporateIntegrityAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_DebtInstrumentByLeverageRatioTrancheFourMember" name="DebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_DebtInstrumentByLeverageRatioTrancheOneMember" name="DebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_DebtInstrumentByLeverageRatioTrancheThreeMember" name="DebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_DebtInstrumentByLeverageRatioTrancheTwoMember" name="DebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_DebtInstrumentCarryingAmountExcludingCapitalLeases" name="DebtInstrumentCarryingAmountExcludingCapitalLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_DebtInstrumentInterestRateatPeriodEnd" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_DebtInstrumentPeriodicPaymentPercentage" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_DebtIssuanceCostsPolicyPolicyTextBlock" name="DebtIssuanceCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_Discountedclosingstockprice" name="Discountedclosingstockprice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_EastTennesseePersonalCareServicesMember" name="EastTennesseePersonalCareServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_ErrorRatePercentage" name="ErrorRatePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_ExtrapolatedMember" name="ExtrapolatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_FinanceleaseRightofUseAssetNet" name="FinanceleaseRightofUseAssetNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_FinanceleasesTableTextBlock" name="FinanceleasesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_FinancialInstrumentDetailsTableTextBlock" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_FirstThresholdOfTherapyServicesRequired" name="FirstThresholdOfTherapyServicesRequired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_FleetLeasesMember" name="FleetLeasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_FloridaZpicRevenueReduction" name="FloridaZpicRevenueReduction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_HealthInsuranceRetentionLimit" name="HealthInsuranceRetentionLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HealthcareanalyticscompanyMember" name="HealthcareanalyticscompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_HistoricalCollectionRateFromMedicare" name="HistoricalCollectionRateFromMedicare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HomeHealthMedicareMember" name="HomeHealthMedicareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HomeHealthMember" name="HomeHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HomeHealthNonMedicareEpisodicBasedMember" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HospiceMedicareMember" name="HospiceMedicareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HospiceMember" name="HospiceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_HospiceNonMedicareMember" name="HospiceNonMedicareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_IndemnificationAmount" name="IndemnificationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_InfinityHomeCareMember" name="InfinityHomeCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_InternalAuditComplianceReviewMember" name="InternalAuditComplianceReviewMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_KKRShareRepurchaseMember" name="KKRShareRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_LakelandFloridaMember" name="LakelandFloridaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_LeaseLiabilityMaturityTableTextBlock" name="LeaseLiabilityMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations" name="LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="amed_LesseeFinanceleasesAccumulatedAmortization" name="LesseeFinanceleasesAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="amed_LetterOfCreditFee" name="LetterOfCreditFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_MajorSinglePayorCustomerMember" name="MajorSinglePayorCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" name="MaximumDaysToSubmitFinalBillFromStartOfEpisode" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_MaximumPercentOwnershipForCostMethodPercent" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_MedalogixMember" name="MedalogixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_MedicareRevenueMember" name="MedicareRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_MorgantownWestVirginiaMember" name="MorgantownWestVirginiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_NonMedicareRevenueTermRates" name="NonMedicareRevenueTermRates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_NonVestedStockAndStockUnits" name="NonVestedStockAndStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_NumberOfBeneficiaries" name="NumberOfBeneficiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_NumberOfClaimsSubmittedBySubsidiary" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_Numberofpatients" name="Numberofpatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_OneHundredMillionTermLoanMember" name="OneHundredMillionTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_OperatingCareCenters" name="OperatingCareCenters" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="amed_OperatingleasesTableTextBlock" name="OperatingleasesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ParkersburgWestVirginiaMember" name="ParkersburgWestVirginiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PaymentsForRepurchaseOfNoncontrollingInterest" name="PaymentsForRepurchaseOfNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="amed_Paymentsrelatedtotaxassetandworkingcapital" name="Paymentsrelatedtotaxassetandworkingcapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PayorClassAxis" name="PayorClassAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PayorClassDomain" name="PayorClassDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PayorsAxis" name="PayorsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PayorsDomain" name="PayorsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PercentageOfPatientReceivablesOutstanding" name="PercentageOfPatientReceivablesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_PercentageofSharesOutstanding" name="PercentageofSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_Percentageofclosingstockprice" name="Percentageofclosingstockprice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PersonalCareMember" name="PersonalCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PriorCreditAgreementMember" name="PriorCreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_ProceedsFromBorrowingsUnderTermLoan" name="ProceedsFromBorrowingsUnderTermLoan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_PromissoryNotesMember" name="PromissoryNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="amed_RevenueAdjustmentToMedicareRevenue" name="RevenueAdjustmentToMedicareRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_RevolvingCreditFacilityTotal" name="RevolvingCreditFacilityTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_RoseRockHealthcareMember" name="RoseRockHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_SafeguardZoneProgramIntegrityContractorMember" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_SecondThresholdOfServicesRequired" name="SecondThresholdOfServicesRequired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_SecuritiesClassActionLawsuitMember" name="SecuritiesClassActionLawsuitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_SecuritiesClassActionLawsuitsettlement" name="SecuritiesClassActionLawsuitsettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ShareRepurchaseAxis" name="ShareRepurchaseAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ShareRepurchaseDomain" name="ShareRepurchaseDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ShareRepurchaseLineItems" name="ShareRepurchaseLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_ShareRepurchaseTable" name="ShareRepurchaseTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock" name="SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_SurrenderedShares" name="SurrenderedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_SwingLineLoanMember" name="SwingLineLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_ThirdThresholdOfTherapyServicesRequired" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_TotalLeverageRatio" name="TotalLeverageRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="amed_TwoHundredMillionRevolvingCreditFacilityMember" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_TypeofEquityMethodInvestmentAxis" name="TypeofEquityMethodInvestmentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_TypeofEquityMethodInvestmentDomain" name="TypeofEquityMethodInvestmentDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_UnamortizedDebtIssuanceCostAmortizationPeriod" name="UnamortizedDebtIssuanceCostAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_UnfavorableMember" name="UnfavorableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="amed_UsDepartmentOfJusticeMember" name="UsDepartmentOfJusticeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock" name="WeightedaverageremainingleasetermanddiscountrateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="amed_WorkersCompensationInsuranceRetentionLimit" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>amed-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amedisys.com/role/Acquisitions" xlink:href="amed-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:href="amed-20190930.xsd#AcquisitionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:href="amed-20190930.xsd#AcquisitionsProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsTables" xlink:href="amed-20190930.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:href="amed-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="amed-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:href="amed-20190930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesDetails" xlink:href="amed-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:href="amed-20190930.xsd#LeasesFinanceLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:href="amed-20190930.xsd#LeasesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeases" xlink:href="amed-20190930.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:href="amed-20190930.xsd#LeasesMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:href="amed-20190930.xsd#LeasesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="amed-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesTables" xlink:href="amed-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="amed-20190930.xsd#LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligations" xlink:href="amed-20190930.xsd#LongTermObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:href="amed-20190930.xsd#LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:href="amed-20190930.xsd#LongTermObligationsLongTermObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:href="amed-20190930.xsd#LongTermObligationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformation" xlink:href="amed-20190930.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:href="amed-20190930.xsd#SegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:href="amed-20190930.xsd#SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationTables" xlink:href="amed-20190930.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:href="amed-20190930.xsd#ShareRepurchaseNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:href="amed-20190930.xsd#ShareRepurchaseShareRepurchase" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEvent" xlink:href="amed-20190930.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:href="amed-20190930.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_265f3d44-db40-2656-dee4-40c75e9bde2a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_265f3d44-db40-2656-dee4-40c75e9bde2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_872beecf-7614-c912-a2d2-2937513b9a4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_872beecf-7614-c912-a2d2-2937513b9a4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_84969fe3-08fd-b500-b7ad-ebd7bf4d768b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_84969fe3-08fd-b500-b7ad-ebd7bf4d768b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValueOutstanding_55fda19b-3ba6-61b5-220d-6f7ed397180a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_0dc12af8-2c59-5eab-e79c-1e4893d6b706" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PensionExpense_0dc12af8-2c59-5eab-e79c-1e4893d6b706" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_43579010-063b-0564-01de-d4868fc5f7d2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_43579010-063b-0564-01de-d4868fc5f7d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3efa67a8-b5d1-d104-f06b-ebff325bad28" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3efa67a8-b5d1-d104-f06b-ebff325bad28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_fc492244-7d5a-7cd0-89f2-ebfd74c617eb" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_fc492244-7d5a-7cd0-89f2-ebfd74c617eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_50c58eff-6efc-4473-1e7a-d4868fc52241" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_50c58eff-6efc-4473-1e7a-d4868fc52241" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7ad014bc-a788-2653-a9c6-d4868f96b60b" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7ad014bc-a788-2653-a9c6-d4868f96b60b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1880f4b5-a1fc-d439-2f25-edf870e93934" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1880f4b5-a1fc-d439-2f25-edf870e93934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_94ef4f28-36c0-ebcc-c252-3b37968b424e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_94ef4f28-36c0-ebcc-c252-3b37968b424e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_80abba07-181c-6ed2-349d-9d7dfc078eab" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_80abba07-181c-6ed2-349d-9d7dfc078eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_ca784f69-4cdc-d7af-9559-d4868eef5dcc" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_ca784f69-4cdc-d7af-9559-d4868eef5dcc" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsFromBorrowingsUnderTermLoan" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_89287dc9-0b81-2170-ec94-d4868f675fdf" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_89287dc9-0b81-2170-ec94-d4868f675fdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_3968b97a-e384-0792-f18c-90471315207a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_3968b97a-e384-0792-f18c-90471315207a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_60d40a9e-f0e0-6260-467c-4ae1cdffac25" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_60d40a9e-f0e0-6260-467c-4ae1cdffac25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8bd1a974-560d-3f84-e984-727058b1874b" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8bd1a974-560d-3f84-e984-727058b1874b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_9847f108-2c2b-1d1b-2fe7-d4868f2fa6ee" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_9847f108-2c2b-1d1b-2fe7-d4868f2fa6ee" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4b7dccc4-e948-a221-4406-b9b8fb2b58e6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4b7dccc4-e948-a221-4406-b9b8fb2b58e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_1283cb92-0ae2-bdeb-f803-6d5e502ce8d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_LaborAndRelatedExpense_1283cb92-0ae2-bdeb-f803-6d5e502ce8d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b0900f4c-cf87-dac5-5867-06d700305f08" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b0900f4c-cf87-dac5-5867-06d700305f08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_7267cf96-41e4-1138-f484-44ab662a687e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_7267cf96-41e4-1138-f484-44ab662a687e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesLeases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_CED24D77833E56CE82E43907DABAD0F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_AA4116DB92E5540A90D2FA8CAA2676A2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_CED24D77833E56CE82E43907DABAD0F6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_AA4116DB92E5540A90D2FA8CAA2676A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_2514A7FF708C52FFA0E79333F7EBAFB9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_CED24D77833E56CE82E43907DABAD0F6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_2514A7FF708C52FFA0E79333F7EBAFB9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_70C76D4F0BC11DBB1B1AD4A132A13F6E_CED24D77833E56CE82E43907DABAD0F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_70C76D4F0BC11DBB1B1AD4A132A13F6E_9D461C73BC6654BE9A2B91EE69AE337D" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_70C76D4F0BC11DBB1B1AD4A132A13F6E_CED24D77833E56CE82E43907DABAD0F6" xlink:to="loc_us-gaap_LongTermDebtCurrent_70C76D4F0BC11DBB1B1AD4A132A13F6E_9D461C73BC6654BE9A2B91EE69AE337D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_70C76D4F0BC11DBB1B1AD4A132A13F6E_AD22FAF5B50F5AB59D03BF67B2E7BAFB" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_70C76D4F0BC11DBB1B1AD4A132A13F6E_CED24D77833E56CE82E43907DABAD0F6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_70C76D4F0BC11DBB1B1AD4A132A13F6E_AD22FAF5B50F5AB59D03BF67B2E7BAFB" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SubsequentEvent" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5D84E9ED90CB5E51AD5488885A40F07F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4406E836D0E45A468BBCC6964A9BDDEA" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5D84E9ED90CB5E51AD5488885A40F07F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4406E836D0E45A468BBCC6964A9BDDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FDFF775211351908D594D2C69DC7AE6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5D84E9ED90CB5E51AD5488885A40F07F" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0FDFF775211351908D594D2C69DC7AE6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NonVestedStockAndStockUnits" xlink:label="loc_amed_NonVestedStockAndStockUnits_BA42ADCFDA5657DE9BB6F9BF8AE2FFEA" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5D84E9ED90CB5E51AD5488885A40F07F" xlink:to="loc_amed_NonVestedStockAndStockUnits_BA42ADCFDA5657DE9BB6F9BF8AE2FFEA" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>amed-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amedisys.com/role/Acquisitions" xlink:href="amed-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:href="amed-20190930.xsd#AcquisitionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:href="amed-20190930.xsd#AcquisitionsProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsTables" xlink:href="amed-20190930.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:href="amed-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="amed-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:href="amed-20190930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesDetails" xlink:href="amed-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:href="amed-20190930.xsd#LeasesFinanceLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:href="amed-20190930.xsd#LeasesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeases" xlink:href="amed-20190930.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:href="amed-20190930.xsd#LeasesMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:href="amed-20190930.xsd#LeasesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="amed-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesTables" xlink:href="amed-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="amed-20190930.xsd#LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligations" xlink:href="amed-20190930.xsd#LongTermObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:href="amed-20190930.xsd#LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:href="amed-20190930.xsd#LongTermObligationsLongTermObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:href="amed-20190930.xsd#LongTermObligationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformation" xlink:href="amed-20190930.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:href="amed-20190930.xsd#SegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:href="amed-20190930.xsd#SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationTables" xlink:href="amed-20190930.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:href="amed-20190930.xsd#ShareRepurchaseNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:href="amed-20190930.xsd#ShareRepurchaseShareRepurchase" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEvent" xlink:href="amed-20190930.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:href="amed-20190930.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:to="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:to="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:to="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN" xlink:label="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:to="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:to="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:to="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_88DD1B5EB811D9B3E938034F0A5350DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:to="loc_amed_HospiceMember_88DD1B5EB811D9B3E938034F0A5350DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_6657FC1F34B7B4380C1C034F0A54F35B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_CompassionateCareHospiceMember_6657FC1F34B7B4380C1C034F0A54F35B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ChristianCareatHomeMember" xlink:label="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EastTennesseePersonalCareServicesMember" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RoseRockHealthcareMember" xlink:label="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageofSharesOutstanding" xlink:label="loc_amed_PercentageofSharesOutstanding_D111EA2EB84B1DDD97B3034F0A5558CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_PercentageofSharesOutstanding_D111EA2EB84B1DDD97B3034F0A5558CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A51D702C4015405FCFDC034F0A56709D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A51D702C4015405FCFDC034F0A56709D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_7D82972137FA66E559620A7DFADF662D_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:to="loc_us-gaap_SegmentDomain_7D82972137FA66E559620A7DFADF662D_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:to="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_4956FB79F8D45725AFD983C1B0BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:to="loc_amed_HospiceMember_4956FB79F8D45725AFD983C1B0BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12C4B8E991D49061500E0A7DFAE020C6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12C4B8E991D49061500E0A7DFAE020C6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:to="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_258EE9BE2790BFA51A3F0A7DFAE072E6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_258EE9BE2790BFA51A3F0A7DFAE072E6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_36758EE73E8C20FFD0820A7DFAE17C57_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:to="loc_srt_OwnershipDomain_36758EE73E8C20FFD0820A7DFAE17C57_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:to="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_64FA462401E2ACCBEC0C0A7DFAE15267_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:to="loc_us-gaap_ClassOfStockDomain_64FA462401E2ACCBEC0C0A7DFAE15267_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:to="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsAxis" xlink:label="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsDomain" xlink:label="loc_amed_PayorsDomain_8D477478C4255DD165622EAE0A0AF371_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:to="loc_amed_PayorsDomain_8D477478C4255DD165622EAE0A0AF371_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsDomain" xlink:label="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:to="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompanysinsurancecarriersMember" xlink:label="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:to="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_92AF642706E533BBC0B72EAE0A0BB39B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:to="loc_srt_LitigationCaseTypeDomain_92AF642706E533BBC0B72EAE0A0BB39B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:to="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmedisysCIAMember" xlink:label="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceCIAMember" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_InternalAuditComplianceReviewMember" xlink:label="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_37E97212CCBE9CF9EE322EAE0A0C04F8_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:to="loc_srt_SegmentGeographicalDomain_37E97212CCBE9CF9EE322EAE0A0C04F8_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:to="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:label="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MorgantownWestVirginiaMember" xlink:label="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC" xlink:label="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL" xlink:label="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LakelandFloridaMember" xlink:label="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:to="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ClearwaterFloridaMember" xlink:label="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:to="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_68DD378FDA823669F9A82EAE0A0E5668_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:to="loc_us-gaap_SegmentDomain_68DD378FDA823669F9A82EAE0A0E5668_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:to="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_858B27FBBBEC569C93D32CF0F57433C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:to="loc_amed_HospiceMember_858B27FBBBEC569C93D32CF0F57433C1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_36D35558DD275DE0842F1CCAA191655F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:to="loc_amed_HomeHealthMember_36D35558DD275DE0842F1CCAA191655F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_554334509000719B73F62EAE0A0F5A64_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_554334509000719B73F62EAE0A0F5A64_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_InfinityHomeCareMember" xlink:label="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:to="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_F1E2BCA00C34D73120102EAE0A104B6F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_F1E2BCA00C34D73120102EAE0A104B6F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ExtrapolatedMember" xlink:label="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:to="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UnfavorableMember" xlink:label="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:to="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_948AF740A5DAC93B47C92EAE0A103243_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:to="loc_srt_RangeMember_948AF740A5DAC93B47C92EAE0A103243_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:to="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8F2A0FD799D25F4F95248AC3AD5B38C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:to="loc_srt_MinimumMember_8F2A0FD799D25F4F95248AC3AD5B38C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2E54270A8B94507C978971F5B7F397BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:to="loc_srt_MaximumMember_2E54270A8B94507C978971F5B7F397BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Numberofpatients" xlink:label="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableCurrent" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitsettlement" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_ADBFE573699958BA924D13EFBD14B8E9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_ADBFE573699958BA924D13EFBD14B8E9" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfBeneficiaries" xlink:label="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ActualClaimsPayment" xlink:label="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ErrorRatePercentage" xlink:label="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IndemnificationAmount" xlink:label="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FloridaZpicRevenueReduction" xlink:label="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_F02DAC64CC265578823C47992414E49D" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_F02DAC64CC265578823C47992414E49D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:to="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:to="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SurrenderedShares" xlink:label="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4D1E4DCFE2F1D8F9E15EF3F1E2640599" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_ProfitLoss_4D1E4DCFE2F1D8F9E15EF3F1E2640599" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FleetLeasesMember" xlink:label="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:to="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:to="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:to="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E65884A92010627C418104F1313A4CEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:to="loc_srt_MinimumMember_E65884A92010627C418104F1313A4CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:to="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesLeases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B4530C8298872A07D10DD4A132727F6F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:to="loc_srt_RangeMember_B4530C8298872A07D10DD4A132727F6F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:to="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_32C373E8661F5EA6859F9D341238A03F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:to="loc_srt_MinimumMember_32C373E8661F5EA6859F9D341238A03F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4DA4696B5C4C5AEAA03B332E3AC11B3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:to="loc_srt_MaximumMember_4DA4696B5C4C5AEAA03B332E3AC11B3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9D63D79F666DB90F3E3ED4A1328291B6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9D63D79F666DB90F3E3ED4A1328291B6_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_A1CAEE55FBBCD9FFF39ED4A13282137A_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:to="loc_us-gaap_VariableRateDomain_A1CAEE55FBBCD9FFF39ED4A13282137A_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:to="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_E227E067ADC35A4582FB5156F2C0A80F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:to="loc_us-gaap_EurodollarMember_E227E067ADC35A4582FB5156F2C0A80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_F632F64A53E05F80A0063C66F06AC95C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:to="loc_us-gaap_BaseRateMember_F632F64A53E05F80A0063C66F06AC95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_045676D75368D8175461D4A132829479_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_045676D75368D8175461D4A132829479_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_D772F83650C1232CC2B4D4A1328258EB_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:to="loc_us-gaap_CreditFacilityDomain_D772F83650C1232CC2B4D4A1328258EB_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:to="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedLeverageRatio" xlink:label="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LetterOfCreditFee" xlink:label="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D906B752E7D65E7D9F11EADD25D3E6D8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D906B752E7D65E7D9F11EADD25D3E6D8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:to="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:to="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:to="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:to="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:to="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:to="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:to="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:to="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SwingLineLoanMember" xlink:label="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_896542C3271CB5454497199498F68366" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LoansPayableMember_896542C3271CB5454497199498F68366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_32BDA13EC5CE0101939A199498F65DAC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_32BDA13EC5CE0101939A199498F65DAC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PriorCreditAgreementMember" xlink:label="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmendedCreditAgreementMember" xlink:label="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmendedCreditAgreementMember" xlink:label="loc_amed_AmendedCreditAgreementMember_C17A5D6AACBD6FD74919199498F791B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_AmendedCreditAgreementMember_C17A5D6AACBD6FD74919199498F791B3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="loc_amed_OneHundredMillionTermLoanMember_04417B370EC61766AAEB199498F8810F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_OneHundredMillionTermLoanMember_04417B370EC61766AAEB199498F8810F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C1046EFAD80AC1D3A3E1199498F86EB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C1046EFAD80AC1D3A3E1199498F86EB7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_FD0FA00471E491F8A330199498F8FC27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_FD0FA00471E491F8A330199498F8FC27" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_57CD7F4F3EB9839DF311199498F84397" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_57CD7F4F3EB9839DF311199498F84397" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TotalLeverageRatio" xlink:label="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedInterestCoverageRatio" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_64B6131DA485FDC7A9FD199498FC90B5" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_64B6131DA485FDC7A9FD199498FC90B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F37235A73B6D50517B28D4A13292412F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F37235A73B6D50517B28D4A13292412F_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_06F955A5EA645CE6A5F1836F1908222B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:to="loc_us-gaap_LoansPayableMember_06F955A5EA645CE6A5F1836F1908222B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_78053B08448A55B2A90AF54E7A9790B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_78053B08448A55B2A90AF54E7A9790B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3B1A2CC57D7BEDE311AED4A132921597_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3B1A2CC57D7BEDE311AED4A132921597_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_3D5E8070D6D55339B2B7C8ACDE202689" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_3D5E8070D6D55339B2B7C8ACDE202689" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_AF9B070CBB0F59819A9D2C30267B9809" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_AF9B070CBB0F59819A9D2C30267B9809" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_97DC364C85165EF3BB6CBF17E6B56CA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_97DC364C85165EF3BB6CBF17E6B56CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_10879C89FB5039DD0CA9D4A1329231A0_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:to="loc_us-gaap_VariableRateDomain_10879C89FB5039DD0CA9D4A1329231A0_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:to="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_94ED0E1786F7590F8DACDB512662EE9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:to="loc_us-gaap_EurodollarMember_94ED0E1786F7590F8DACDB512662EE9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_BDE9D69063AC55D1A3EFABA2B180B781" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_BDE9D69063AC55D1A3EFABA2B180B781" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_453C34395A2550A78F5F36754FB50CB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_453C34395A2550A78F5F36754FB50CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_40C1C98D6CC854A2BFF863696EAF9486" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_40C1C98D6CC854A2BFF863696EAF9486" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E099A8C81ADA83D4520FD4A132B128BC_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E099A8C81ADA83D4520FD4A132B128BC_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PromissoryNotesMember" xlink:label="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFF1F9FB84E5C8EA7E4DD4A132B1EA9B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFF1F9FB84E5C8EA7E4DD4A132B1EA9B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentAxis" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentDomain" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C_default" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentDomain" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthcareanalyticscompanyMember" xlink:label="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:to="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedicareRevenueMember" xlink:label="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:to="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:to="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:to="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OperatingCareCenters" xlink:label="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:to="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:to="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedalogixMember" xlink:label="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:to="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:to="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:to="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_483138024303B12788E8EF9F98D5E815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_HomeHealthMember_483138024303B12788E8EF9F98D5E815" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_EF51613E4B705FD9CC94EF9F98D6B1B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_HospiceMember_EF51613E4B705FD9CC94EF9F98D6B1B8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_540198EC370EA5BE5B79EF9F98D663A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_PersonalCareMember_540198EC370EA5BE5B79EF9F98D663A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitsettlement" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseLineItems" xlink:label="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:type="locator" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseTable" xlink:label="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseAxis" xlink:label="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:to="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseDomain" xlink:label="loc_amed_ShareRepurchaseDomain_2DCBE8F29A044FDAD8032EADD438E8A5_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:to="loc_amed_ShareRepurchaseDomain_2DCBE8F29A044FDAD8032EADD438E8A5_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseDomain" xlink:label="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:to="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_KKRShareRepurchaseMember" xlink:label="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:to="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageofSharesOutstanding" xlink:label="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Discountedclosingstockprice" xlink:label="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Percentageofclosingstockprice" xlink:label="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SubsequentEvent" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:to="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C5843339779FC70757D0D4A131B24E4B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:to="loc_us-gaap_SegmentDomain_C5843339779FC70757D0D4A131B24E4B_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:to="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_A8953A45DEF95AF7B666CF4E6B8CB175" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:to="loc_amed_HospiceMember_A8953A45DEF95AF7B666CF4E6B8CB175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2C0D6EE7C54808995C94D4A131B38486_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2C0D6EE7C54808995C94D4A131B38486_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4054549A187956B494F8FF7CEF361BF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:to="loc_us-gaap_SubsequentEventMember_4054549A187956B494F8FF7CEF361BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BED59AAF7159D364416FD4A131B387E7_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BED59AAF7159D364416FD4A131B387E7_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RoseRockHealthcareMember" xlink:label="loc_amed_RoseRockHealthcareMember_CA008BFFE65258A69D9440D8CEF0217A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:to="loc_amed_RoseRockHealthcareMember_CA008BFFE65258A69D9440D8CEF0217A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31FFBA93C40722FB75F1D4A13360C468_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31FFBA93C40722FB75F1D4A13360C468_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentCarryingAmountExcludingCapitalLeases" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:to="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6C478F6CB4A7DB038D8FD4A133612EF9_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6C478F6CB4A7DB038D8FD4A133612EF9_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08E408140EC162F55DEFD4A13361E8D0_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08E408140EC162F55DEFD4A13361E8D0_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:to="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_71F778C77AD217773158D4A13361E52C_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:to="loc_srt_NameOfMajorCustomerDomain_71F778C77AD217773158D4A13361E52C_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:to="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MajorSinglePayorCustomerMember" xlink:label="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:to="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassAxis" xlink:label="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:to="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassDomain" xlink:label="loc_amed_PayorClassDomain_DCBA23CFC625D434C188F734EF67A3F4_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:to="loc_amed_PayorClassDomain_DCBA23CFC625D434C188F734EF67A3F4_A8A4AC2698935ECBAE3A88CAB6B5A8A2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassDomain" xlink:label="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:to="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMedicareMember" xlink:label="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareMember" xlink:label="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceNonMedicareMember" xlink:label="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_DAE918E73FE15A97807430D8ADFFAA34" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_PersonalCareMember_DAE918E73FE15A97807430D8ADFFAA34" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_27DD056148480CF08616199358151D9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:to="loc_amed_CompassionateCareHospiceMember_27DD056148480CF08616199358151D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedicareRevenueMember" xlink:label="loc_amed_MedicareRevenueMember_A85EA2D6DDC74646D1AA199358166558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:to="loc_amed_MedicareRevenueMember_A85EA2D6DDC74646D1AA199358166558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_F8CB8C1613C9F52FDEB21993581705FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_F8CB8C1613C9F52FDEB21993581705FB" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearAxis" xlink:label="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearDomain" xlink:label="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:to="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C_default" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearDomain" xlink:label="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:to="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:to="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:to="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_11E2630B27F1C03272A219935818C8B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:to="loc_amed_HomeHealthMember_11E2630B27F1C03272A219935818C8B0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_FA8587AF263CFC2031E719935818D41F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:to="loc_amed_HospiceMember_FA8587AF263CFC2031E719935818D41F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:to="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:to="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A07E78E93689C62C17F719935819270C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:to="loc_srt_MinimumMember_A07E78E93689C62C17F719935819270C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_29D7EC03F11A10A0DEB319935819BF2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:to="loc_srt_MaximumMember_29D7EC03F11A10A0DEB319935819BF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26E8CB00BC881C4F47BE1993581A09DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26E8CB00BC881C4F47BE1993581A09DF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_7D500282597553C8F4AD1993582053B3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_7D500282597553C8F4AD1993582053B3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NonMedicareRevenueTermRates" xlink:label="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>amed-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:to="lab_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:to="lab_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) employer match</link:label>
    <link:label id="lab_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5_label_en-US" xlink:label="lab_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:to="lab_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:type="arc" />
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write off of deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return on equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:type="arc" />
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:type="arc" />
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:to="lab_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares withheld upon stock vesting</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:type="arc" />
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:type="arc" />
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A_terseLabel_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings under term loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A_label_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Borrowings Under Term Loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A_documentation_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from borrowings under the term loan.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsFromBorrowingsUnderTermLoan" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:to="lab_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:type="arc" />
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20_negatedLabel_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20_label_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20_documentation_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow during the period for redemption of noncontrolling interests.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:to="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:to="lab_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Non-Cash Financing Activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_CF1C2B70BDCC9E8AF641D4A133295313_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E5BCB9504975EF162D28D4A133290944_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E5BCB9504975EF162D28D4A133290944_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_3077A1A56524544F2CEED4A133295CEE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_3077A1A56524544F2CEED4A133295CEE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_C93F5DFA8C9129E883A64323653F3437_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="lab_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_BEDE53A3B146308BD6F5432365420501_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_BEDE53A3B146308BD6F5432365420501_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:to="lab_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_AFEAD3DC76FCCA9B43E44323654369B7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_AFEAD3DC76FCCA9B43E44323654369B7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_D502945C4FF1451AD51D4325F1B28997_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_D502945C4FF1451AD51D4325F1B28997_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:to="lab_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_E74F9B08DDCB5EE89D2943236543524A_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease ROU asset amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_E74F9B08DDCB5EE89D2943236543524A_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_FBD77BE9DD6A68CA4669432365435446_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_FBD77BE9DD6A68CA4669432365435446_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:type="arc" />
    <link:label id="lab_amed_FinanceLeaseCost_589948972AB485DED0C1432B8FA3643D_terseLabel_en-US" xlink:label="lab_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_589948972AB485DED0C1432B8FA3643D_label_en-US" xlink:label="lab_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_589948972AB485DED0C1432B8FA3643D_documentation_en-US" xlink:label="lab_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total amount of finance lease cost including amortization of ROU asset and interest expense</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceLeaseCost" xlink:label="loc_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:to="lab_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_AE22E07D5645F759949A43236544C16B_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_AE22E07D5645F759949A43236544C16B_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:to="lab_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9D6C15F1D706C2A5F6564323654422F2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9D6C15F1D706C2A5F6564323654422F2_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:to="lab_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_CB2B809C4DFE1AAFD5B74323654498FE_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_CB2B809C4DFE1AAFD5B74323654498FE_label_en-US" xlink:label="lab_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:to="lab_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_6DB4DCA6803B4C498D372EADD4339F27_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:to="lab_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:type="arc" />
    <link:label id="lab_amed_ShareRepurchaseTable_AF7B971FCF5E90846AF62EADD4385137_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_AF7B971FCF5E90846AF62EADD4385137_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_AF7B971FCF5E90846AF62EADD4385137_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseTable" xlink:label="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:to="lab_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="arc" />
    <link:label id="lab_amed_ShareRepurchaseAxis_C586D77C01015A737F4E2EADD438C24E_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_C586D77C01015A737F4E2EADD438C24E_label_en-US" xlink:label="lab_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_C586D77C01015A737F4E2EADD438C24E_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseAxis" xlink:label="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:to="lab_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="arc" />
    <link:label id="lab_amed_ShareRepurchaseDomain_2DCBE8F29A044FDAD8032EADD438E8A5_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_2DCBE8F29A044FDAD8032EADD438E8A5_label_en-US" xlink:label="lab_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_2DCBE8F29A044FDAD8032EADD438E8A5_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Share Repurchase [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseDomain" xlink:label="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:to="lab_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="arc" />
    <link:label id="lab_amed_KKRShareRepurchaseMember_745F704285C2E397E6272EADD439A0CF_terseLabel_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KKR Share Repurchase</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_745F704285C2E397E6272EADD439A0CF_label_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_745F704285C2E397E6272EADD439A0CF_documentation_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_KKRShareRepurchaseMember" xlink:label="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:to="lab_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="arc" />
    <link:label id="lab_amed_ShareRepurchaseLineItems_BBB9F89A411598ECF98C2EADD43965AB_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_BBB9F89A411598ECF98C2EADD43965AB_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_BBB9F89A411598ECF98C2EADD43965AB_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseLineItems" xlink:label="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="lab_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_71419A57A448B26CDD442EADD4393252_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_71419A57A448B26CDD442EADD4393252_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_871CCEB4B2A18A6AC2292EADD4395093_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_871CCEB4B2A18A6AC2292EADD4395093_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_B89917EBC5BA7D068A3A2EADD4395ECD_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_B89917EBC5BA7D068A3A2EADD4395ECD_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="arc" />
    <link:label id="lab_amed_PercentageofSharesOutstanding_A96A27B45B5665DC7E0E2EADD43ADEAD_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_A96A27B45B5665DC7E0E2EADD43ADEAD_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_A96A27B45B5665DC7E0E2EADD43ADEAD_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageofSharesOutstanding" xlink:label="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:to="lab_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FDD0C9E5C9A1081E5EA22EADD43A63F5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of company stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="arc" />
    <link:label id="lab_amed_Discountedclosingstockprice_48EA3523B34DD561CD262EADD43AD587_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_48EA3523B34DD561CD262EADD43AD587_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_48EA3523B34DD561CD262EADD43AD587_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Discountedclosingstockprice" xlink:label="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:to="lab_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="arc" />
    <link:label id="lab_amed_Percentageofclosingstockprice_DF9FF2525FEF823B2A092EADD43A38CD_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_DF9FF2525FEF823B2A092EADD43A38CD_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_DF9FF2525FEF823B2A092EADD43A38CD_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Percentageofclosingstockprice" xlink:label="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:to="lab_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="lab_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:to="lab_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="arc" />
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentAxis" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="arc" />
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentDomain" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:to="lab_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="arc" />
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093_terseLabel_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093_label_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093_documentation_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthcareanalyticscompanyMember" xlink:label="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:to="lab_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="arc" />
    <link:label id="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Revenue</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A_label_en-US" xlink:label="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MedicareRevenueMember" xlink:label="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:to="lab_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="lab_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="arc" />
    <link:label id="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Home Health</link:label>
    <link:label id="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE_label_en-US" xlink:label="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE_documentation_en-US" xlink:label="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:to="lab_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="arc" />
    <link:label id="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7_terseLabel_en-US" xlink:label="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospice</link:label>
    <link:label id="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7_label_en-US" xlink:label="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7_documentation_en-US" xlink:label="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:to="lab_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="arc" />
    <link:label id="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personal Care</link:label>
    <link:label id="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020_label_en-US" xlink:label="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020_documentation_en-US" xlink:label="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:to="lab_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="arc" />
    <link:label id="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4_label_en-US" xlink:label="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_OperatingCareCenters" xlink:label="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:to="lab_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:to="lab_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="arc" />
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="arc" />
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="arc" />
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_96C1001C89761EF8A9DAD4A131E9424F_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:to="lab_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_C3D23A45F2228C2B62FBD4A131E9FDB1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_C3D23A45F2228C2B62FBD4A131E9FDB1_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:to="lab_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_E3B140F32B8A6614CF46D4A132FF5A93_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_E3B140F32B8A6614CF46D4A132FF5A93_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:type="arc" />
    <link:label id="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E835B8E27A184ABEA09FD4A132FF1721_negatedLabel_en-US" xlink:label="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finance leases accumulated amortization</link:label>
    <link:label id="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E835B8E27A184ABEA09FD4A132FF1721_label_en-US" xlink:label="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance leases, Accumulated Amortization</link:label>
    <link:label id="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E835B8E27A184ABEA09FD4A132FF1721_documentation_en-US" xlink:label="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated amortization of finance leases</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeFinanceleasesAccumulatedAmortization" xlink:label="loc_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:to="lab_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:type="arc" />
    <link:label id="lab_amed_FinanceleaseRightofUseAssetNet_E456B184EAB331CBBCCBD4A132FF9163_terseLabel_en-US" xlink:label="lab_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease ROU assets, net</link:label>
    <link:label id="lab_amed_FinanceleaseRightofUseAssetNet_E456B184EAB331CBBCCBD4A132FF9163_label_en-US" xlink:label="lab_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease, Right-of-Use Asset, Net</link:label>
    <link:label id="lab_amed_FinanceleaseRightofUseAssetNet_E456B184EAB331CBBCCBD4A132FF9163_documentation_en-US" xlink:label="lab_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's right to use underlying asset under finance lease, net of accumulated amortization.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceleaseRightofUseAssetNet" xlink:label="loc_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:to="lab_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_93D0E37E67F7B15091AED4A132FFE340_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current installments of obligations under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_93D0E37E67F7B15091AED4A132FFE340_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_68FA77D86E5128CD8EA1D4A13300F3F3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of obligations under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_68FA77D86E5128CD8EA1D4A13300F3F3_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_594B59EBCD68F4A3ECD0D4A13300E28B_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_594B59EBCD68F4A3ECD0D4A13300E28B_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:to="lab_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:to="lab_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="arc" />
    <link:label id="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE_label_en-US" xlink:label="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE_documentation_en-US" xlink:label="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MedalogixMember" xlink:label="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:to="lab_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_D60D336DDCD095466AA2D4A132B146D9_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:to="lab_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_AC7E3D4DC422883FA6EDD4A132B1A7B8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_AC7E3D4DC422883FA6EDD4A132B1A7B8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="lab_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E7D650109EDF7E69E6C6D4A132B124CC_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E7D650109EDF7E69E6C6D4A132B124CC_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E099A8C81ADA83D4520FD4A132B128BC_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E099A8C81ADA83D4520FD4A132B128BC_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansPayableMember_2F9685F66BF9FE8CB82DD4A132B16A1F_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_2F9685F66BF9FE8CB82DD4A132B16A1F_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:to="lab_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_A775EB82B84D0022E0D3D4A132B14EC1_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_A775EB82B84D0022E0D3D4A132B14EC1_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="arc" />
    <link:label id="lab_amed_PromissoryNotesMember_237841571D73BD85A334D4A132B12B11_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_237841571D73BD85A334D4A132B12B11_label_en-US" xlink:label="lab_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_237841571D73BD85A334D4A132B12B11_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PromissoryNotesMember" xlink:label="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:to="lab_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_3C4579EA2D2043DAD455D4A132B13C6A_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_3C4579EA2D2043DAD455D4A132B13C6A_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_D5E077C4019B3D35A8D5D4A132B1E343_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_D5E077C4019B3D35A8D5D4A132B1E343_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:to="lab_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_EFF1F9FB84E5C8EA7E4DD4A132B1EA9B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_EFF1F9FB84E5C8EA7E4DD4A132B1EA9B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="arc" />
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_D1D1964AA7B9130F4942D4A132B1F46E_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_D1D1964AA7B9130F4942D4A132B1F46E_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_D1D1964AA7B9130F4942D4A132B1F46E_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="arc" />
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_E0207204048CD3C45C39D4A132B18EFD_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_E0207204048CD3C45C39D4A132B18EFD_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_E0207204048CD3C45C39D4A132B18EFD_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:to="lab_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="arc" />
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_FC0FCE8BE5A42DAE2B28D4A132B1CE49_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_FC0FCE8BE5A42DAE2B28D4A132B1CE49_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_FC0FCE8BE5A42DAE2B28D4A132B1CE49_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="arc" />
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_04453FDB28AEF17BAAF9D4A132B197D8_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">550 Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_04453FDB28AEF17BAAF9D4A132B197D8_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_04453FDB28AEF17BAAF9D4A132B197D8_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C14A5FE248EF95BDF61ED4A132B10FE5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C14A5FE248EF95BDF61ED4A132B10FE5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="lab_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_B6BD4B0A903BA40B7F19D4A132B1F1AA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_B6BD4B0A903BA40B7F19D4A132B1F1AA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_9D54E102BC88C84B8EE5D4A132B170C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_9D54E102BC88C84B8EE5D4A132B170C2_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_A5165005F84C8B5DF31AD4A132B19A11_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_A5165005F84C8B5DF31AD4A132B19A11_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:to="lab_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4C3E74D32ED0D0AB7568D4A132B14F80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4C3E74D32ED0D0AB7568D4A132B14F80_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:to="lab_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_C377EF330CB6D9992732D4A132B12BD3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_C377EF330CB6D9992732D4A132B12BD3_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_F3C7B3F3EE798207F30E2AE37B2B2977_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_F3C7B3F3EE798207F30E2AE37B2B2977_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:to="lab_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2EB740957C00E2FC9F1C2AE37B2C8BCD_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Financing cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2EB740957C00E2FC9F1C2AE37B2C8BCD_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94AE4D8B46FE9535313E2AE37B2C29E1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94AE4D8B46FE9535313E2AE37B2C29E1_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6ADEF72F29D0B05DA6242AE37B2C6A71_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6ADEF72F29D0B05DA6242AE37B2C6A71_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:type="arc" />
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_2B9B8F8D099CE7B2D0C62AE37B2C25D1_negatedLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_2B9B8F8D099CE7B2D0C62AE37B2C25D1_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_2B9B8F8D099CE7B2D0C62AE37B2C25D1_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:type="arc" />
    <link:label id="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_01E73ED7DD403C2866C72AE37B2C1DA4_terseLabel_en-US" xlink:label="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_01E73ED7DD403C2866C72AE37B2C1DA4_label_en-US" xlink:label="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_01E73ED7DD403C2866C72AE37B2C1DA4_documentation_en-US" xlink:label="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations" xlink:label="loc_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:to="lab_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:to="lab_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_2C9282DF449529E95C74199498F49883_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_2C9282DF449529E95C74199498F49883_label_en-US" xlink:label="lab_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:to="lab_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49_terseLabel_en-US" xlink:label="lab_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49_label_en-US" xlink:label="lab_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:to="lab_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861_label_en-US" xlink:label="lab_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:to="lab_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:to="lab_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:to="lab_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788_label_en-US" xlink:label="lab_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:to="lab_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="arc" />
    <link:label id="lab_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D_label_en-US" xlink:label="lab_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:to="lab_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="arc" />
    <link:label id="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6_label_en-US" xlink:label="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SwingLineLoanMember" xlink:label="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:to="lab_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:to="lab_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="arc" />
    <link:label id="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PriorCreditAgreementMember" xlink:label="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:to="lab_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:to="lab_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="arc" />
    <link:label id="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_AmendedCreditAgreementMember" xlink:label="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:to="lab_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="arc" />
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="arc" />
    <link:label id="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C_label_en-US" xlink:label="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_TotalLeverageRatio" xlink:label="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:to="lab_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="arc" />
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedInterestCoverageRatio" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="arc" />
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F_documentation_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:to="lab_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="arc" />
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="arc" />
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="arc" />
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest rate above Eurodollar rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="arc" />
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="arc" />
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EF77C0A27811491EC01ED4A1323676A1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3586D498A4A32B5AF2B5D4A132366EF6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3586D498A4A32B5AF2B5D4A132366EF6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:type="arc" />
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927_terseLabel_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost amortization period</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927_label_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Cost Amortization Period</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927_documentation_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected amortization period of debt issuance cost</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:to="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_070AC2A1396381D1DE78D4A132C07721_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_070AC2A1396381D1DE78D4A132C07721_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_E8D3D78AF4127AABA800298E317089C2_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:to="lab_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_D757EAB46833F2855A4D298E3170F170_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_D757EAB46833F2855A4D298E3170F170_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ED321F099192BDEB63FE0A7DFADEC450_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ED321F099192BDEB63FE0A7DFADEC450_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6150751632E70ECEFF3E0A7DFAE010F8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6150751632E70ECEFF3E0A7DFAE010F8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12C4B8E991D49061500E0A7DFAE020C6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12C4B8E991D49061500E0A7DFAE020C6_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="arc" />
    <link:label id="lab_amed_CompassionateCareHospiceMember_52534ED07272A8FD04BF0A7DFAE0C592_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_52534ED07272A8FD04BF0A7DFAE0C592_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_52534ED07272A8FD04BF0A7DFAE0C592_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:to="lab_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_940F20091D3475116EBA0A7DFAE0A310_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_940F20091D3475116EBA0A7DFAE0A310_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_258EE9BE2790BFA51A3F0A7DFAE072E6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_258EE9BE2790BFA51A3F0A7DFAE072E6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_0786D5AC5A1812EE741E0A7DFAE171F7_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_0786D5AC5A1812EE741E0A7DFAE171F7_label_en-US" xlink:label="lab_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:to="lab_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_36758EE73E8C20FFD0820A7DFAE17C57_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_36758EE73E8C20FFD0820A7DFAE17C57_label_en-US" xlink:label="lab_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:to="lab_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0058392CCD644D1A1C7C0A7DFAE15837_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0058392CCD644D1A1C7C0A7DFAE15837_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_64FA462401E2ACCBEC0C0A7DFAE15267_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_64FA462401E2ACCBEC0C0A7DFAE15267_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:to="lab_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_FE52B6413536685912C20A7DFAE2F3EE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_FE52B6413536685912C20A7DFAE2F3EE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_F657E55ADB91EA442F630A7DFAE2BB79_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_F657E55ADB91EA442F630A7DFAE2BB79_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="arc" />
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_E442285F0967B2DF6EE90A7DFAE2E2FC_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_E442285F0967B2DF6EE90A7DFAE2E2FC_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_E442285F0967B2DF6EE90A7DFAE2E2FC_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_51A7107B58432AEEED6F0A7DFAE217D2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_51A7107B58432AEEED6F0A7DFAE217D2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_1252C51BF590715AA3360A7DFAE2D655_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_1252C51BF590715AA3360A7DFAE2D655_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_E501844D5263791FC06F0A7DFAE21C5E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_E501844D5263791FC06F0A7DFAE21C5E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_A1066983195AC826F9DEF734EF66B61C_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8D1B9CA90BB37AA55C55F734EF66A7AA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8D1B9CA90BB37AA55C55F734EF66A7AA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="arc" />
    <link:label id="lab_amed_PayorClassAxis_9C3CC6E01061A04E51D2F734EF67CFA7_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_9C3CC6E01061A04E51D2F734EF67CFA7_label_en-US" xlink:label="lab_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_9C3CC6E01061A04E51D2F734EF67CFA7_documentation_en-US" xlink:label="lab_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassAxis" xlink:label="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:to="lab_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="arc" />
    <link:label id="lab_amed_PayorClassDomain_DCBA23CFC625D434C188F734EF67A3F4_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_DCBA23CFC625D434C188F734EF67A3F4_label_en-US" xlink:label="lab_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_DCBA23CFC625D434C188F734EF67A3F4_documentation_en-US" xlink:label="lab_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassDomain" xlink:label="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="lab_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="arc" />
    <link:label id="lab_amed_HomeHealthMedicareMember_85883B605DF9D53E4983F734EF67FF15_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_85883B605DF9D53E4983F734EF67FF15_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_85883B605DF9D53E4983F734EF67FF15_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMedicareMember" xlink:label="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:to="lab_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="arc" />
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_F9F2775520438E28058EF734EF67C42A_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_F9F2775520438E28058EF734EF67C42A_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_F9F2775520438E28058EF734EF67C42A_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="arc" />
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_673A39D9B96E9766DAE5F734EF689820_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_673A39D9B96E9766DAE5F734EF689820_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_673A39D9B96E9766DAE5F734EF689820_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="arc" />
    <link:label id="lab_amed_HospiceMedicareMember_17CE48407F84FD19340CF734EF68FC57_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_17CE48407F84FD19340CF734EF68FC57_label_en-US" xlink:label="lab_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_17CE48407F84FD19340CF734EF68FC57_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareMember" xlink:label="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:to="lab_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="arc" />
    <link:label id="lab_amed_HospiceNonMedicareMember_47B5E2C862895BED8BCDF734EF683174_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_47B5E2C862895BED8BCDF734EF683174_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_47B5E2C862895BED8BCDF734EF683174_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceNonMedicareMember" xlink:label="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:to="lab_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6116BA4235123BC40AA3F734EF68E29D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6116BA4235123BC40AA3F734EF68E29D_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:type="arc" />
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3C69CDAA4DD21F58F882F734EF681759_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3C69CDAA4DD21F58F882F734EF681759_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3C69CDAA4DD21F58F882F734EF681759_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_46B9847A9A96771643773ED1AAA8108A_label_en-US" xlink:label="lab_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="lab_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C833EF89806880F551843ED1AAB0CF93_terseLabel_en-US" xlink:label="lab_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C833EF89806880F551843ED1AAB0CF93_label_en-US" xlink:label="lab_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:to="lab_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_7F6D8490D5677FD44ADD3ED1AAB1090A_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_7F6D8490D5677FD44ADD3ED1AAB1090A_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:to="lab_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_2332FF878DB1A50F21413ED1AAB17193_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_2332FF878DB1A50F21413ED1AAB17193_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:to="lab_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_B6EEDFC6485DB23C37173ED1AAB16FE9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_B6EEDFC6485DB23C37173ED1AAB16FE9_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:to="lab_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_B53700EC21E0F2F74CF63ED1AAB216E9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_B53700EC21E0F2F74CF63ED1AAB216E9_label_en-US" xlink:label="lab_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:to="lab_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_A853A999F28D6E810A423ED1AAB2E386_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_A853A999F28D6E810A423ED1AAB2E386_label_en-US" xlink:label="lab_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:to="lab_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8C12CCCF219F67D79CB33ED1AAB2B99E_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8C12CCCF219F67D79CB33ED1AAB2B99E_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:to="lab_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E18431860ECACB765E203ED1AAB2C63D_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E18431860ECACB765E203ED1AAB2C63D_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:to="lab_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_AFA6E728DF5EA0DFBE8A3ED1AAB22C9F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_AFA6E728DF5EA0DFBE8A3ED1AAB22C9F_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:to="lab_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_BC6C5660EE7929B668A43ED1AAB254BB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_BC6C5660EE7929B668A43ED1AAB254BB_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:to="lab_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_3655CF4C77B5835454293ED1AAB38207_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_3655CF4C77B5835454293ED1AAB38207_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:to="lab_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_412A873FE887C85796543ED1AAB30DD0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_412A873FE887C85796543ED1AAB30DD0_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:to="lab_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_8C0D1A99BC3EB4D1BC7F3ED1AAB3A2D1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8C0D1A99BC3EB4D1BC7F3ED1AAB3A2D1_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:to="lab_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_A2F9D66C2E8A1DC1C5633ED1AAB38754_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_A2F9D66C2E8A1DC1C5633ED1AAB38754_label_en-US" xlink:label="lab_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:to="lab_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_B43C85CF049C3C6C102C3ED1AAB3FA69_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_B43C85CF049C3C6C102C3ED1AAB3FA69_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:to="lab_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_90E7979699F22B19D8F33ED1AAB3CA99_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_90E7979699F22B19D8F33ED1AAB3CA99_label_en-US" xlink:label="lab_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:to="lab_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_9E0CCA5F9C3A2EF1AA033ED1AAB530C8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_9E0CCA5F9C3A2EF1AA033ED1AAB530C8_label_en-US" xlink:label="lab_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:to="lab_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_69D9B611D86A70DE77FD3ED1AAB5E982_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_69D9B611D86A70DE77FD3ED1AAB5E982_label_en-US" xlink:label="lab_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:to="lab_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E7CBB3E99876A939B5643ED1AAB5A69E_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E7CBB3E99876A939B5643ED1AAB5A69E_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:to="lab_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4CBD7843190EB777C5843ED1AAB5E38A_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4CBD7843190EB777C5843ED1AAB5E38A_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:to="lab_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_BC57E4AB7D87D12FE11C3ED1AAB63680_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_BC57E4AB7D87D12FE11C3ED1AAB63680_label_en-US" xlink:label="lab_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:to="lab_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_E99CA780702A8C1303BB3ED1AAB694F8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_E99CA780702A8C1303BB3ED1AAB694F8_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:to="lab_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_2B733727852FD61B794E3ED1AAB6A22F_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_2B733727852FD61B794E3ED1AAB6A22F_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:to="lab_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_C98DECEBB8FFFDB5C9B53ED1AAB6863E_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_C98DECEBB8FFFDB5C9B53ED1AAB6863E_label_en-US" xlink:label="lab_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:to="lab_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_94F6785E312350146A0B3ED1AAB67574_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_94F6785E312350146A0B3ED1AAB67574_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_6746067F110B308017C43ED1AAB6FEB7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_6746067F110B308017C43ED1AAB6FEB7_label_en-US" xlink:label="lab_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:to="lab_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_49697B93961290A084213ED1AAB7BAFE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_49697B93961290A084213ED1AAB7BAFE_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:to="lab_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_AD5E83725A8B8A9AA71D3ED1AAB70813_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_AD5E83725A8B8A9AA71D3ED1AAB70813_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:to="lab_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7C128607A65310B5F0183ED1AAB7BB4B_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7C128607A65310B5F0183ED1AAB7BB4B_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:to="lab_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62F36EC1069A85D55DEC3ED1AAB72B7A_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62F36EC1069A85D55DEC3ED1AAB72B7A_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:to="lab_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_3B92B0D4DFD6A9BACAA33ED1AAB72F5D_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_3B92B0D4DFD6A9BACAA33ED1AAB72F5D_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:to="lab_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8195C09B64FC912565843ED1AAB7464B_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8195C09B64FC912565843ED1AAB7464B_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, Weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases, Weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases, Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1D952816D401375A4E4CD4A132C013A0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1D952816D401375A4E4CD4A132C013A0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_73982F1EC7280343711DD4A132C0903F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_73982F1EC7280343711DD4A132C0903F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2A1C30A46DD82A6C6604D4A13310E833_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2A1C30A46DD82A6C6604D4A13310E833_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:type="arc" />
    <link:label id="lab_amed_OperatingleasesTableTextBlock_68DD6E5E334024FE0DC5D4A133107135_terseLabel_en-US" xlink:label="lab_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_amed_OperatingleasesTableTextBlock_68DD6E5E334024FE0DC5D4A133107135_label_en-US" xlink:label="lab_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating leases [Table Text Block]</link:label>
    <link:label id="lab_amed_OperatingleasesTableTextBlock_68DD6E5E334024FE0DC5D4A133107135_documentation_en-US" xlink:label="lab_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Operating leases [Table]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_OperatingleasesTableTextBlock" xlink:label="loc_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:to="lab_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:type="arc" />
    <link:label id="lab_amed_FinanceleasesTableTextBlock_6F7C8608B76A5BB08DE0D4A1331155ED_terseLabel_en-US" xlink:label="lab_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_amed_FinanceleasesTableTextBlock_6F7C8608B76A5BB08DE0D4A1331155ED_label_en-US" xlink:label="lab_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance leases [Table Text Block]</link:label>
    <link:label id="lab_amed_FinanceleasesTableTextBlock_6F7C8608B76A5BB08DE0D4A1331155ED_documentation_en-US" xlink:label="lab_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Finance leases [Table]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceleasesTableTextBlock" xlink:label="loc_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:to="lab_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:type="arc" />
    <link:label id="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_DDCD4B3FF18E86FFD75AD4A13311E555_terseLabel_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information and Non-Cash Activity for Leases</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_DDCD4B3FF18E86FFD75AD4A13311E555_label_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information and Non-Cash Activity for Leases [Table Text Block]</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_DDCD4B3FF18E86FFD75AD4A13311E555_documentation_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information and Non-Cash Activity for Leases [Table Text Block]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock" xlink:label="loc_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:to="lab_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:type="arc" />
    <link:label id="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_3B1E7506F513A49469AED4A133113D6B_terseLabel_en-US" xlink:label="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term and discount rate</link:label>
    <link:label id="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_3B1E7506F513A49469AED4A133113D6B_label_en-US" xlink:label="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_3B1E7506F513A49469AED4A133113D6B_documentation_en-US" xlink:label="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Weighted average remaining lease term and discount rate [Table]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock" xlink:label="loc_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:to="lab_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:type="arc" />
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_CCAF8E281B5A627B1E84D4A133113316_terseLabel_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Liability Maturity</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_CCAF8E281B5A627B1E84D4A133113316_label_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liability Maturity [Table Text Block]</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_CCAF8E281B5A627B1E84D4A133113316_documentation_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liability Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LeaseLiabilityMaturityTableTextBlock" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:to="lab_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_8BB97445D23D76B22220D4A133851D21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_8BB97445D23D76B22220D4A133851D21_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:type="arc" />
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_2FC2ED8DE6E853A267BFD4A133857660_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_2FC2ED8DE6E853A267BFD4A133857660_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_2FC2ED8DE6E853A267BFD4A133857660_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FinancialInstrumentDetailsTableTextBlock" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4F65851BB7F551425AFBD4A1338570D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4F65851BB7F551425AFBD4A1338570D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4F46FBB8B0C309258B6BD4A1335FFEDB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4F46FBB8B0C309258B6BD4A1335FFEDB_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0F3B4CE1AF6134A39785D4A1335F2F06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0F3B4CE1AF6134A39785D4A1335F2F06_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31FFBA93C40722FB75F1D4A13360C468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31FFBA93C40722FB75F1D4A13360C468_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ACC31E396E9BAD3CBD7AD4A133605993_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ACC31E396E9BAD3CBD7AD4A133605993_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_17B53F0A42F88E2B80A7D4A1336081C4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_17B53F0A42F88E2B80A7D4A1336081C4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9A31FCC892EACF8316C8D4A13361D5E9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9A31FCC892EACF8316C8D4A13361D5E9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6458168140E12E7877CD4A13361C7F0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6458168140E12E7877CD4A13361C7F0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_0423F9199CCA6796F0BCD4A133618BC7_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Capital Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_0423F9199CCA6796F0BCD4A133618BC7_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Capital Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_0423F9199CCA6796F0BCD4A133618BC7_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Capital Leases</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentCarryingAmountExcludingCapitalLeases" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_B53E43F013EBDA79DF74D4A13361BE0E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_B53E43F013EBDA79DF74D4A13361BE0E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:to="lab_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="lab_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="lab_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:to="lab_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:to="lab_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $101,446 and $95,472</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF_label_en-US" xlink:label="lab_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:to="lab_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net of accumulated amortization of $36,799 and $33,050</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815_label_en-US" xlink:label="lab_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:to="lab_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:to="lab_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:to="lab_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746_label_en-US" xlink:label="lab_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:to="lab_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies&#8212;Note 6</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:to="lab_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:to="lab_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 36,599,273 and 36,252,280 shares issued; and 32,246,575 and 31,973,505 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:to="lab_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost 4,352,698 and 4,278,775 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:to="lab_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:to="lab_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:to="lab_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_BD80A0A05FAC08EB06F3D4A131F0D5EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_BD80A0A05FAC08EB06F3D4A131F0D5EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9794D07E37D35D1D4732D4A133291BD7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9794D07E37D35D1D4732D4A133291BD7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2EEC05958960FD50045ED4A133611003_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2EEC05958960FD50045ED4A133611003_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_5BC4875A6D2A79718725D4A13361144C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_5BC4875A6D2A79718725D4A13361144C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:to="lab_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_112A54B7BC43E448D237D4A133618D52_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_112A54B7BC43E448D237D4A133618D52_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:to="lab_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_71F778C77AD217773158D4A13361E52C_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_71F778C77AD217773158D4A13361E52C_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:to="lab_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="arc" />
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_C86ECAC53A0F1D786EC3D4A133618B22_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_C86ECAC53A0F1D786EC3D4A133618B22_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_C86ECAC53A0F1D786EC3D4A133618B22_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MajorSinglePayorCustomerMember" xlink:label="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:to="lab_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_10321E7C704FFE30A06AD4A133610FE5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8DE52C1D86179A9A0A72D4A13361EC60_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="arc" />
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_DEF99052A253B73F82B3D4A133613561_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_DEF99052A253B73F82B3D4A133613561_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_DEF99052A253B73F82B3D4A133613561_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:type="arc" />
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_8889B163B1EFCFA7B360D4A133616E60_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_8889B163B1EFCFA7B360D4A133616E60_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_8889B163B1EFCFA7B360D4A133616E60_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_AccountsReceivablePortionDerivedFromMedicare" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:type="arc" />
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_FE7A19009ACFAC94D37DD4A133610E76_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_FE7A19009ACFAC94D37DD4A133610E76_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_FE7A19009ACFAC94D37DD4A133610E76_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:type="arc" />
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_22CAF095BEB5BBAF7B47D4A13361A6A2_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_22CAF095BEB5BBAF7B47D4A13361A6A2_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_22CAF095BEB5BBAF7B47D4A13361A6A2_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:type="arc" />
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_E40FAE164D4E28D84247D4A13361F199_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_E40FAE164D4E28D84247D4A13361F199_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Episode Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_E40FAE164D4E28D84247D4A13361F199_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:type="arc" />
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_9A0A6B26E0289E64A323D4A133618273_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_9A0A6B26E0289E64A323D4A133618273_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_9A0A6B26E0289E64A323D4A133618273_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:type="arc" />
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_AA2A377DDB73CC07850CD4A13361CE47_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_AA2A377DDB73CC07850CD4A13361CE47_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_AA2A377DDB73CC07850CD4A13361CE47_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:type="arc" />
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1A98489E9AEB2F2FFD7FD4A13361E2A8_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1A98489E9AEB2F2FFD7FD4A13361E2A8_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1A98489E9AEB2F2FFD7FD4A13361E2A8_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6D61EA5B1D3A57376EBCD4A131F854F4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6D61EA5B1D3A57376EBCD4A131F854F4_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:to="lab_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:to="lab_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="arc" />
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitsettlement" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:to="lab_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:to="lab_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="arc" />
    <link:label id="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA_terseLabel_en-US" xlink:label="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fleet Leases [Member]</link:label>
    <link:label id="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA_label_en-US" xlink:label="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fleet Leases [Member]</link:label>
    <link:label id="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA_documentation_en-US" xlink:label="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fleet Leases [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FleetLeasesMember" xlink:label="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:to="lab_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8_label_en-US" xlink:label="lab_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:to="lab_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D0FB9A49AF6EAFE7DED429A52F473C8E_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D0FB9A49AF6EAFE7DED429A52F473C8E_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0F21BC4833D9DE8CA21C29A52F48BF25_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0F21BC4833D9DE8CA21C29A52F48BF25_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_8FF6237A86CCC85BF55329A52F484062_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_8FF6237A86CCC85BF55329A52F484062_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:to="lab_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_55A681814F20770D0E2029A52F480BFA_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_55A681814F20770D0E2029A52F480BFA_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_C34CBF495DA71F10CFD429A52F48E4D1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_C34CBF495DA71F10CFD429A52F48E4D1_label_en-US" xlink:label="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and Cost Method Investments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:to="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_84A55247285C3618840029A52F48E58D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_84A55247285C3618840029A52F48E58D_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_CC521F259185E640645D29A52F482A40_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_CC521F259185E640645D29A52F482A40_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:type="arc" />
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_B699050E8221F91CE32629A52F49203E_terseLabel_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_B699050E8221F91CE32629A52F49203E_label_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_B699050E8221F91CE32629A52F49203E_documentation_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for debt issuance costs.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:to="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7B1D0D34319D25A7733E29A52F493FF6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7B1D0D34319D25A7733E29A52F493FF6_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3FAE45408600329D98D029A52F4982AD_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3FAE45408600329D98D029A52F4982AD_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_AE1D6C5822E86C44444829A572DAE040_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_AE1D6C5822E86C44444829A572DAE040_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_D10D429A3B47CBB74EF6D4A13385095A_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_D10D429A3B47CBB74EF6D4A13385095A_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:to="lab_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:to="lab_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:to="lab_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="arc" />
    <link:label id="lab_stpr_TN_781CF099604C86D6A1CA034F0A520787_terseLabel_en-US" xlink:label="lab_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_781CF099604C86D6A1CA034F0A520787_label_en-US" xlink:label="lab_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN" xlink:label="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:to="lab_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="arc" />
    <link:label id="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B_terseLabel_en-US" xlink:label="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Christian Care at Home</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B_label_en-US" xlink:label="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B_documentation_en-US" xlink:label="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ChristianCareatHomeMember" xlink:label="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:to="lab_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="arc" />
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8_terseLabel_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">East Tennessee Personal Care Services</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8_label_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">East Tennessee Personal Care Services [Member]</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8_documentation_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">East Tennessee Personal Care Services [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_EastTennesseePersonalCareServicesMember" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:to="lab_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="arc" />
    <link:label id="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67_terseLabel_en-US" xlink:label="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67_label_en-US" xlink:label="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67_documentation_en-US" xlink:label="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RoseRockHealthcareMember" xlink:label="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:to="lab_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="arc" />
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4_terseLabel_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4_label_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4_documentation_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:to="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:to="lab_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="arc" />
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E72F48B7CD0BDE40C213D4A133C356CB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E72F48B7CD0BDE40C213D4A133C356CB_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_DBD68A8B23A07DBE40BAD4A133C39606_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_DBD68A8B23A07DBE40BAD4A133C39606_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_501AD3A9C68CE211B9A5D4A133C32E47_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_501AD3A9C68CE211B9A5D4A133C32E47_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3B16E62EDE4223BD8632D4A133C35BE9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3B16E62EDE4223BD8632D4A133C35BE9_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_576F881CF377B6C830DDD4A133C38E74_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_576F881CF377B6C830DDD4A133C38E74_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:to="lab_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F2068240D8E0E0E64FE3D4A133C3A2F0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F2068240D8E0E0E64FE3D4A133C3A2F0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_761144515D94CA44687CD4A133C35FB7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_761144515D94CA44687CD4A133C35FB7_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0519C162E1CF29BD6B95D4A133C33D7B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0519C162E1CF29BD6B95D4A133C33D7B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_15A773D7FADD17B6661ED4A133C3FEFC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_15A773D7FADD17B6661ED4A133C3FEFC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:to="lab_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7B8852F74336CF3FB026D4A133C34929_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7B8852F74336CF3FB026D4A133C34929_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_B125098F825BC2CA1B24D4A133D3C38B_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_B125098F825BC2CA1B24D4A133D3C38B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:to="lab_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_88B363765F1ADF7B9EBBD4A131CFB883_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_88B363765F1ADF7B9EBBD4A131CFB883_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="loc_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:to="lab_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4822EC7B26C3C453EFF1D4A13314ADAB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4822EC7B26C3C453EFF1D4A13314ADAB_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_EC7DBEA8479804D86A38D4A13303A470_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5EAE5A1AEA7D9DAB3A8FD4A13303DA7F_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9F4029C1BBDDB57F08C3D4A13303E648_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:to="lab_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367_label_en-US" xlink:label="lab_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:to="lab_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="lab_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:to="lab_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:to="lab_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:to="lab_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:to="lab_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="lab_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:to="lab_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="arc" />
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="arc" />
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="arc" />
    <link:label id="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092_label_en-US" xlink:label="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092_documentation_en-US" xlink:label="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SurrenderedShares" xlink:label="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:to="lab_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="arc" />
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:to="lab_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A0ED944412FAA6DA3A3B0A7908A3FDE4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A0ED944412FAA6DA3A3B0A7908A3FDE4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8E96FE415ACD185C3F1A0A7908A4CD68_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8E96FE415ACD185C3F1A0A7908A4CD68_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A6B8375E69EB971BB5600A7908A60EB6_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A6B8375E69EB971BB5600A7908A60EB6_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:type="arc" />
    <link:label id="lab_amed_NonVestedStockAndStockUnits_B1C4957405115FB6DDDD0A7908A6FB56_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_B1C4957405115FB6DDDD0A7908A6FB56_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_B1C4957405115FB6DDDD0A7908A6FB56_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_NonVestedStockAndStockUnits" xlink:label="loc_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:to="lab_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98ACC10CC6A182AD70D00A7908A625EB_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98ACC10CC6A182AD70D00A7908A625EB_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CF6E65E0C8033E5975600A7908A78458_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CF6E65E0C8033E5975600A7908A78458_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6F5EBCCD929C58502CE7D4A132D0A6FE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - 2019 (a)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6F5EBCCD929C58502CE7D4A132D0A6FE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C5B8F43CDF792CF21215D4A132D09A78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C5B8F43CDF792CF21215D4A132D09A78_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F2EB2798EEDB63DEC71AD4A132D04CB4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F2EB2798EEDB63DEC71AD4A132D04CB4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D16C9CFE391B3C1FD8BBD4A132D0E5FF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D16C9CFE391B3C1FD8BBD4A132D0E5FF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_311A266A22236202FA6BD4A132D0B958_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_311A266A22236202FA6BD4A132D0B958_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_BD1252DD728DCB64C613D4A132D0AD6F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_BD1252DD728DCB64C613D4A132D0AD6F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3589687480DEA5565610D4A132D015BE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3589687480DEA5565610D4A132D015BE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8DAC77E798ED7476CF2AD4A132D026C5_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating Lease - Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8DAC77E798ED7476CF2AD4A132D026C5_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1ADC00E18B34A8D5B470D4A132D02BA2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - 2019 (a)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1ADC00E18B34A8D5B470D4A132D02BA2_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_722F134F25F2BB76B83BD4A132D02502_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - 2020</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_722F134F25F2BB76B83BD4A132D02502_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_D3C907EA6152BB859DC9D4A132D0130D_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - 2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_D3C907EA6152BB859DC9D4A132D0130D_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8918D30527C1384282DBD4A132D01516_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - 2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8918D30527C1384282DBD4A132D01516_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_E0AE9F19B392BF3D7B0AD4A132D068B0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - 2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_E0AE9F19B392BF3D7B0AD4A132D068B0_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_8E3CB1DF296C46D24881D4A132D04959_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_8E3CB1DF296C46D24881D4A132D04959_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_A21D33FAFEBD1A0F20DAD4A132D0CF64_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_A21D33FAFEBD1A0F20DAD4A132D0CF64_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6BBFCAA7DDF240402197D4A132D012E7_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finance Lease - Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6BBFCAA7DDF240402197D4A132D012E7_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_06A6F80B25B969E610B9D4A133949930_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_06A6F80B25B969E610B9D4A133949930_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_2C7DCAC74206E2EE9B9ED4A132725210_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_2C7DCAC74206E2EE9B9ED4A132725210_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="lab_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_5998E4EAB3BC3ACF76A1D4A132822FA6_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_5998E4EAB3BC3ACF76A1D4A132822FA6_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_5998E4EAB3BC3ACF76A1D4A132822FA6_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_99A996148E7491A5C4E6D4A132823DA2_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_99A996148E7491A5C4E6D4A132823DA2_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_99A996148E7491A5C4E6D4A132823DA2_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_FF96E5D15A803E6AEE57D4A13282E441_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_FF96E5D15A803E6AEE57D4A13282E441_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_FF96E5D15A803E6AEE57D4A13282E441_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="arc" />
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_BFC35B67ECDF32A96B7ED4A13282E598_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_BFC35B67ECDF32A96B7ED4A13282E598_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_BFC35B67ECDF32A96B7ED4A13282E598_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_C77DEB41E4C6CDD63467D4A1328244EA_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_C77DEB41E4C6CDD63467D4A1328244EA_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_045676D75368D8175461D4A132829479_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_045676D75368D8175461D4A132829479_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_7306A0CAD49F23D70785D4A132822B26_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7306A0CAD49F23D70785D4A132822B26_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:to="lab_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_D772F83650C1232CC2B4D4A1328258EB_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_D772F83650C1232CC2B4D4A1328258EB_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:to="lab_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_D76F87D3903B0A33F4F4D4A1328223DE_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_D76F87D3903B0A33F4F4D4A1328223DE_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:type="arc" />
    <link:label id="lab_amed_ConsolidatedLeverageRatio_CAC160740B489B2963E4D4A132824461_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_CAC160740B489B2963E4D4A132824461_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_CAC160740B489B2963E4D4A132824461_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedLeverageRatio" xlink:label="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:to="lab_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_28917312E2D9A4FCF16DD4A1328282F1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_28917312E2D9A4FCF16DD4A1328282F1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="arc" />
    <link:label id="lab_amed_LetterOfCreditFee_27BA178C28454D493981D4A13282D5AB_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_27BA178C28454D493981D4A13282D5AB_label_en-US" xlink:label="lab_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_27BA178C28454D493981D4A13282D5AB_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LetterOfCreditFee" xlink:label="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:to="lab_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="lab_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:type="arc" />
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:to="lab_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:to="lab_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6_label_en-US" xlink:label="lab_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:to="lab_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity in (losses) earnings from equity method investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:to="lab_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:to="lab_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:to="lab_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="arc" />
    <link:label id="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F_label_en-US" xlink:label="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F_documentation_en-US" xlink:label="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearAxis" xlink:label="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:to="lab_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="arc" />
    <link:label id="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C_label_en-US" xlink:label="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C_documentation_en-US" xlink:label="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearDomain" xlink:label="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:to="lab_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="arc" />
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cap Year 2013 Through 2019</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF_label_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Nineteen [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:to="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="arc" />
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="arc" />
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net service revenue episode payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="arc" />
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="arc" />
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="arc" />
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="arc" />
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:to="lab_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="arc" />
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="arc" />
    <link:label id="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_NonMedicareRevenueTermRates" xlink:label="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:to="lab_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="arc" />
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="arc" />
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_235988C0425360AF186BD4A131B1B59A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_235988C0425360AF186BD4A131B1B59A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="lab_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_E4864C8129F16901F5CED4A131B492A3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_E4864C8129F16901F5CED4A131B492A3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:to="lab_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_415CA6BE4AE80428A11FD4A131B49A04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_415CA6BE4AE80428A11FD4A131B49A04_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_7600E55ADF4766AFCB522EAE0A0942C8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_7600E55ADF4766AFCB522EAE0A0942C8_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="lab_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="arc" />
    <link:label id="lab_amed_PayorsAxis_1F33DA70C4382975A3492EAE0A0AED05_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_1F33DA70C4382975A3492EAE0A0AED05_label_en-US" xlink:label="lab_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_1F33DA70C4382975A3492EAE0A0AED05_documentation_en-US" xlink:label="lab_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsAxis" xlink:label="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:to="lab_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="arc" />
    <link:label id="lab_amed_PayorsDomain_8D477478C4255DD165622EAE0A0AF371_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_8D477478C4255DD165622EAE0A0AF371_label_en-US" xlink:label="lab_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_8D477478C4255DD165622EAE0A0AF371_documentation_en-US" xlink:label="lab_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsDomain" xlink:label="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:to="lab_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="arc" />
    <link:label id="lab_amed_CompanysinsurancecarriersMember_41E453577861D3E1654D2EAE0A0A0A85_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_41E453577861D3E1654D2EAE0A0A0A85_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_41E453577861D3E1654D2EAE0A0A0A85_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CompanysinsurancecarriersMember" xlink:label="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:to="lab_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_270C7392F68F75F28A642EAE0A0B6A34_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_270C7392F68F75F28A642EAE0A0B6A34_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:to="lab_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_92AF642706E533BBC0B72EAE0A0BB39B_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_92AF642706E533BBC0B72EAE0A0BB39B_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="lab_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="arc" />
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_0A5B3C43BFD9D27A34442EAE0A0BEF0E_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_0A5B3C43BFD9D27A34442EAE0A0BEF0E_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_0A5B3C43BFD9D27A34442EAE0A0BEF0E_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:to="lab_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="arc" />
    <link:label id="lab_amed_AmedisysCIAMember_874DBD4BBD2E8A3F9F022EAE0A0B5E60_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_874DBD4BBD2E8A3F9F022EAE0A0B5E60_label_en-US" xlink:label="lab_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_874DBD4BBD2E8A3F9F022EAE0A0B5E60_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_AmedisysCIAMember" xlink:label="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:to="lab_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="arc" />
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_DB477F0075BE61647CBD2EAE0A0B88F8_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_DB477F0075BE61647CBD2EAE0A0B88F8_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_DB477F0075BE61647CBD2EAE0A0B88F8_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceCIAMember" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:to="lab_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="arc" />
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_BC75D15C5E1435621ACB2EAE0A0C2894_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_BC75D15C5E1435621ACB2EAE0A0C2894_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_BC75D15C5E1435621ACB2EAE0A0C2894_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="arc" />
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_72CDAEE6C16C50A9E2692EAE0A0C88D6_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_72CDAEE6C16C50A9E2692EAE0A0C88D6_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_72CDAEE6C16C50A9E2692EAE0A0C88D6_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="arc" />
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_8F52C7EA34A0AD423A392EAE0A0CE5D3_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_8F52C7EA34A0AD423A392EAE0A0CE5D3_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_8F52C7EA34A0AD423A392EAE0A0CE5D3_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_InternalAuditComplianceReviewMember" xlink:label="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:to="lab_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="arc" />
    <link:label id="lab_stpr_MA_4F9FBE0659E97762BE5E2EAE0A0C4B65_terseLabel_en-US" xlink:label="lab_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_4F9FBE0659E97762BE5E2EAE0A0C4B65_label_en-US" xlink:label="lab_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:label="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:to="lab_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="arc" />
    <link:label id="lab_amed_MorgantownWestVirginiaMember_7EAD70D213EFFE84B0AA2EAE0A0DC2E6_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_7EAD70D213EFFE84B0AA2EAE0A0DC2E6_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_7EAD70D213EFFE84B0AA2EAE0A0DC2E6_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_MorgantownWestVirginiaMember" xlink:label="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:to="lab_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="arc" />
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_7D2EEE134178ECFB146E2EAE0A0DE2D9_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_7D2EEE134178ECFB146E2EAE0A0DE2D9_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_7D2EEE134178ECFB146E2EAE0A0DE2D9_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:to="lab_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="arc" />
    <link:label id="lab_stpr_SC_8334047B960E69686CC62EAE0A0D780D_terseLabel_en-US" xlink:label="lab_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_8334047B960E69686CC62EAE0A0D780D_label_en-US" xlink:label="lab_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC" xlink:label="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:to="lab_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="arc" />
    <link:label id="lab_stpr_FL_941DB3C8DCD0490C4C3B2EAE0A0DAA21_terseLabel_en-US" xlink:label="lab_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_941DB3C8DCD0490C4C3B2EAE0A0DAA21_label_en-US" xlink:label="lab_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL" xlink:label="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:to="lab_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="arc" />
    <link:label id="lab_amed_LakelandFloridaMember_39C8CE5CCF44C37C0FB72EAE0A0D8883_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_39C8CE5CCF44C37C0FB72EAE0A0D8883_label_en-US" xlink:label="lab_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_39C8CE5CCF44C37C0FB72EAE0A0D8883_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LakelandFloridaMember" xlink:label="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:to="lab_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="arc" />
    <link:label id="lab_amed_ClearwaterFloridaMember_96668F9D02EA180F17472EAE0A0EF110_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_96668F9D02EA180F17472EAE0A0EF110_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_96668F9D02EA180F17472EAE0A0EF110_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ClearwaterFloridaMember" xlink:label="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:to="lab_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="arc" />
    <link:label id="lab_amed_InfinityHomeCareMember_6148277184A014BC42552EAE0A0F065E_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_6148277184A014BC42552EAE0A0F065E_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_6148277184A014BC42552EAE0A0F065E_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_InfinityHomeCareMember" xlink:label="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:to="lab_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_4426BF24E693E621301B2EAE0A0FAD74_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_4426BF24E693E621301B2EAE0A0FAD74_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_F1E2BCA00C34D73120102EAE0A104B6F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_F1E2BCA00C34D73120102EAE0A104B6F_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:to="lab_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="arc" />
    <link:label id="lab_amed_ExtrapolatedMember_F75A30F8C0CB74EBC3DB2EAE0A10C5B0_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extrapolated</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_F75A30F8C0CB74EBC3DB2EAE0A10C5B0_label_en-US" xlink:label="lab_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_F75A30F8C0CB74EBC3DB2EAE0A10C5B0_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ExtrapolatedMember" xlink:label="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:to="lab_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="arc" />
    <link:label id="lab_amed_UnfavorableMember_669E6E58C5BA971590912EAE0A106ECF_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfavorable</link:label>
    <link:label id="lab_amed_UnfavorableMember_669E6E58C5BA971590912EAE0A106ECF_label_en-US" xlink:label="lab_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_669E6E58C5BA971590912EAE0A106ECF_documentation_en-US" xlink:label="lab_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UnfavorableMember" xlink:label="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:to="lab_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_34E1F419B1844B86EE9B2EAE0A118528_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_34E1F419B1844B86EE9B2EAE0A118528_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="lab_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_7204E755FE1DAB478CAA2EAE0A1151E9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_7204E755FE1DAB478CAA2EAE0A1151E9_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="arc" />
    <link:label id="lab_amed_Numberofpatients_0FFC89413DEE02607DAB2EAE0A11AB1E_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_0FFC89413DEE02607DAB2EAE0A11AB1E_label_en-US" xlink:label="lab_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_0FFC89413DEE02607DAB2EAE0A11AB1E_documentation_en-US" xlink:label="lab_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Numberofpatients" xlink:label="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:to="lab_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="arc" />
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_DFFF3A5799144860E2E22EAE0A1224AD_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_DFFF3A5799144860E2E22EAE0A1224AD_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_DFFF3A5799144860E2E22EAE0A1224AD_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:to="lab_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_6976E8FC686AAB64D1662EAE0A126ABF_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_6976E8FC686AAB64D1662EAE0A126ABF_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_91A33E82A58E0DE78E992EAE0A129117_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_91A33E82A58E0DE78E992EAE0A129117_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_A6EC895E5965759D56E52EAE0A127F1F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_A6EC895E5965759D56E52EAE0A127F1F_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableCurrent" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="arc" />
    <link:label id="lab_amed_NumberOfBeneficiaries_96ACE6AF38F164AF13ED2EAE0A127DE6_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_96ACE6AF38F164AF13ED2EAE0A127DE6_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_96ACE6AF38F164AF13ED2EAE0A127DE6_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfBeneficiaries" xlink:label="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:to="lab_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="arc" />
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_4198109115AB0088A4C02EAE0A13A3BE_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_4198109115AB0088A4C02EAE0A13A3BE_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_4198109115AB0088A4C02EAE0A13A3BE_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="arc" />
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_BEE94A5543F7827CB7502EAE0A136209_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_BEE94A5543F7827CB7502EAE0A136209_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_BEE94A5543F7827CB7502EAE0A136209_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="arc" />
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_2360BB9BBBCE637F0A4A2EAE0A13C10E_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_2360BB9BBBCE637F0A4A2EAE0A13C10E_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_2360BB9BBBCE637F0A4A2EAE0A13C10E_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="arc" />
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_A9B237FF67ECDB1E5FAE2EAE0A13C5C5_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_A9B237FF67ECDB1E5FAE2EAE0A13C5C5_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_A9B237FF67ECDB1E5FAE2EAE0A13C5C5_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="arc" />
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6A9280AC5077B5B2D4702EAE0A139081_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6A9280AC5077B5B2D4702EAE0A139081_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6A9280AC5077B5B2D4702EAE0A139081_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_6975FBEF1EE8C04247122EAE0A13EF21_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_6975FBEF1EE8C04247122EAE0A13EF21_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_5BBD2C9EE1602400134B2EAE0A1350EF_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="arc" />
    <link:label id="lab_amed_ActualClaimsPayment_120AB7FD79619417DDF52EAE0A142DCF_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_120AB7FD79619417DDF52EAE0A142DCF_label_en-US" xlink:label="lab_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_120AB7FD79619417DDF52EAE0A142DCF_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ActualClaimsPayment" xlink:label="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:to="lab_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="arc" />
    <link:label id="lab_amed_ErrorRatePercentage_4029EF4B1F78B82C7EA52EAE0A149B29_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_4029EF4B1F78B82C7EA52EAE0A149B29_label_en-US" xlink:label="lab_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_4029EF4B1F78B82C7EA52EAE0A149B29_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ErrorRatePercentage" xlink:label="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:to="lab_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="arc" />
    <link:label id="lab_amed_IndemnificationAmount_5E396858472A3A255D522EAE0A1447FC_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_5E396858472A3A255D522EAE0A1447FC_label_en-US" xlink:label="lab_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_5E396858472A3A255D522EAE0A1447FC_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_IndemnificationAmount" xlink:label="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:to="lab_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="arc" />
    <link:label id="lab_amed_FloridaZpicRevenueReduction_389F703A01E61AF88DC62EAE0A147300_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_389F703A01E61AF88DC62EAE0A147300_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_389F703A01E61AF88DC62EAE0A147300_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_FloridaZpicRevenueReduction" xlink:label="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:to="lab_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="arc" />
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_9CC8BC10FDC308372E1C2EAE0A142541_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_9CC8BC10FDC308372E1C2EAE0A142541_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_9CC8BC10FDC308372E1C2EAE0A142541_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:to="lab_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="arc" />
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_0D0C41EEDB78559905A62EAE0A15EA1F_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_0D0C41EEDB78559905A62EAE0A15EA1F_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_0D0C41EEDB78559905A62EAE0A15EA1F_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="arc" />
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_20EAA8FE89563A7D5EB42EAE0A15D614_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_20EAA8FE89563A7D5EB42EAE0A15D614_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_20EAA8FE89563A7D5EB42EAE0A15D614_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:href="amed-20190930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>amed-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.amedisys.com/role/Acquisitions" xlink:href="amed-20190930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:href="amed-20190930.xsd#AcquisitionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:href="amed-20190930.xsd#AcquisitionsProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/AcquisitionsTables" xlink:href="amed-20190930.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:href="amed-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="amed-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="amed-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:href="amed-20190930.xsd#ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:href="amed-20190930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesDetails" xlink:href="amed-20190930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:href="amed-20190930.xsd#LeasesFinanceLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:href="amed-20190930.xsd#LeasesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesLeases" xlink:href="amed-20190930.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:href="amed-20190930.xsd#LeasesMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:href="amed-20190930.xsd#LeasesOperatingLeaseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="amed-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesTables" xlink:href="amed-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="amed-20190930.xsd#LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligations" xlink:href="amed-20190930.xsd#LongTermObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:href="amed-20190930.xsd#LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:href="amed-20190930.xsd#LongTermObligationsLongTermObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:href="amed-20190930.xsd#LongTermObligationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:href="amed-20190930.xsd#LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:href="amed-20190930.xsd#NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:href="amed-20190930.xsd#RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformation" xlink:href="amed-20190930.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:href="amed-20190930.xsd#SegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:href="amed-20190930.xsd#SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SegmentInformationTables" xlink:href="amed-20190930.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:href="amed-20190930.xsd#ShareRepurchaseNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:href="amed-20190930.xsd#ShareRepurchaseShareRepurchase" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEvent" xlink:href="amed-20190930.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:href="amed-20190930.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:href="amed-20190930.xsd#SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_D6A98B250FB554D0BB87334FE5A6F289" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_D6A98B250FB554D0BB87334FE5A6F289" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_27C914D1A6665E1F9FF326B4598CE1DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_AA4D5F1751FF45DE97F2034F0A5075AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_AA4D5F1751FF45DE97F2034F0A5075AE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5342FFD3A42082E9B3FE034F0A51C8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:to="loc_us-gaap_TradeNamesMember_DA82E97F28A8981A6D25034F0A526A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53AD9D02024B2ADCE17D034F0A512E40" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_06A2B7B65E6897CF3ACD034F0A526692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2743E5EFBC211EDB351F034F0A52D1A6" xlink:to="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN" xlink:label="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_EC045454DEBF019D13A4034F0A522A1C" xlink:to="loc_stpr_TN_781CF099604C86D6A1CA034F0A520787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_FE6D3502F95308092BA5034F0A5346AD" xlink:to="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_88DD1B5EB811D9B3E938034F0A5350DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_435692852038231154BC034F0A53FE49" xlink:to="loc_amed_HospiceMember_88DD1B5EB811D9B3E938034F0A5350DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7617ED06F4FB02DEF31E034F0A531632" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_6657FC1F34B7B4380C1C034F0A54F35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_CompassionateCareHospiceMember_6657FC1F34B7B4380C1C034F0A54F35B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ChristianCareatHomeMember" xlink:label="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_ChristianCareatHomeMember_5AD30E00F3A44D3C6E46034F0A54E74B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EastTennesseePersonalCareServicesMember" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_EastTennesseePersonalCareServicesMember_DD7C07E4A523768A86F3034F0A54D3D8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RoseRockHealthcareMember" xlink:label="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A5F69A91B08D9BB7BFC8034F0A540F43" xlink:to="loc_amed_RoseRockHealthcareMember_E315DFF696E4EFAA82BF034F0A54CD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D475BDB094AD15A27E46034F0A518B59" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageofSharesOutstanding" xlink:label="loc_amed_PercentageofSharesOutstanding_D111EA2EB84B1DDD97B3034F0A5558CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_PercentageofSharesOutstanding_D111EA2EB84B1DDD97B3034F0A5558CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7166B6D21DEB40F8D5FF034F0A55B89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_533D430596066C1684DF034F0A55F28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_672602B56D8B4698EDAA034F0A550BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_966F39DD2ADB2348D33F034F0A561EC3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_8386F3F8ABE32B3AAEF3034F0A56A5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A51D702C4015405FCFDC034F0A56709D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A51D702C4015405FCFDC034F0A56709D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_8586D0D8079CCA791E4D034F0A5626AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_OperatingIncomeLoss_5F2DE85E6EE049327680034F0A561E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_EAEA54E6CBD95FFCB4C2034F0A567A75" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_A980403390E46422D6BF034F0A572F2A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_E054357D49BFCA601934034F0A5722B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_F887B9466316372D22B8034F0A5777C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9BE93ADF2D7D5514A88E034F0A571776" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_ACEEB9C6B614143B4FB6034F0A574242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9FAF8EF4783DD58D59F7034F0A57B43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_49085AC0582D46EF577B034F0A58E337" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_8F441FF4A8F90314A67D034F0A58C444" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_480BC567CCC9B5DC5B02034F0A584586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_51A0393DB9CBBE53EA4A034F0A580042" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_51164F5633C8CD7B289C034F0A58B711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6AED17D0249D2157F575034F0A58AB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_31DC3EEEFCFF56C7589F034F0A58A024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_72EFEE8121084A74FAB6034F0A5978E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C68E6A0273B26C2DE247034F0A55BF13" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9BDD6ADB6AC6EE20D892034F0A599C73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/AcquisitionsProFormaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_872B447BC09155F4B508BDE6F30632A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_872B447BC09155F4B508BDE6F30632A7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2F49B0C1D7AC53DB9E1A96AFE1D4D692" xlink:to="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_4956FB79F8D45725AFD983C1B0BF9939" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534E7BDDE8E5C5BA3296D454CDF7BFF" xlink:to="loc_amed_HospiceMember_4956FB79F8D45725AFD983C1B0BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2B15E184A5B95194883363D77B9105CD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32AD42BE2105539CA9263AC03D2A217F" xlink:to="loc_amed_CompassionateCareHospiceMember_74291EDFD4EC5212A616644D774D9DFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D26B86AC1875AD696C2799FA64DD032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3BC1088BCB5E56F29C75D1581B1ABE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9234A1CBAB7457EEB9E8F19A8F816E8E" xlink:to="loc_srt_OwnershipDomain_50E3A35266EC56D2945C8628FC323C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A05D07F9AD15AE1BA6E8220175C4AE5" xlink:to="loc_us-gaap_ClassOfStockDomain_23795CA904C15842973D49ADAB223467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38134AF51297528BA0D7A5CA7B0C6249" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_CE115722B7A15A36A9A9A64B89775F4B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_EBBC60652B0D56D890BF14270903FB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_90FFDFD8E2F1530B887739660C230100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93222C90293950D79EB2059A614AD7BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1B8744BFBB7157B58AE296C85F930052" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_89DAA272E2D55E7BB5D63DA7B792FD50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7C222E0E9D455502AE09C08C1EBB0639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8F3F11D3061757F69D0DFE4E4310DC35" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A3322431149A5115A0435AD06B48C9E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EB1A184526DD5C32AB3F2DB90A251901" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_194D045CF3D95DDF9AAFAE4E57DB0631" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29928DA89BFD55ECB42AB422E859D11F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29928DA89BFD55ECB42AB422E859D11F" xlink:to="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsAxis" xlink:label="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorsDomain" xlink:label="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_E726DF88168057DEA04B82B7A28F1CAF" xlink:to="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompanysinsurancecarriersMember" xlink:label="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_F4D3876429825690969D9CF111931718" xlink:to="loc_amed_CompanysinsurancecarriersMember_603578E13A5E5A60A8952DE246E819F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_68E8B99A431658AAB24D18812ECAA206" xlink:to="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_UsDepartmentOfJusticeMember_1D9AA4A0D6F2561AB13E87D2A3EF2C46" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmedisysCIAMember" xlink:label="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_AmedisysCIAMember_1A803531D42B5A95961BD145AD3FEC4D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceCIAMember" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_5E385A1A2BEC598D9DCFBCE6F284862C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_ABE6C31C87B8530DBFD66B3DC0CA7716" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_E28AE94299DF52949E62313668E5A082" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_InternalAuditComplianceReviewMember" xlink:label="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3E5AD3EB4E6950F091D26B0FEB97FE8D" xlink:to="loc_amed_InternalAuditComplianceReviewMember_FB250F631F205275A2D609522F460F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_BE720AF3592A5FF580A70402006D6F7D" xlink:to="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:label="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_MA_6C781758119652ADBB7E4C3A9B634D6D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MorgantownWestVirginiaMember" xlink:label="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_amed_MorgantownWestVirginiaMember_61906D5216D25FBFAFC31DADE3BF6756" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_amed_ParkersburgWestVirginiaMember_34B158AF5C8E5E94B525C7B2D64667E1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC" xlink:label="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_SC_DD393BA4563059A8A3A474D92AEF4DC9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL" xlink:label="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_226E6D0A1CA1584DAFD2F6F60E779584" xlink:to="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LakelandFloridaMember" xlink:label="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:to="loc_amed_LakelandFloridaMember_5F9C8E50866154DBA7474940126E2354" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ClearwaterFloridaMember" xlink:label="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_CCE9364EC24652AB80DA9CA98437445D" xlink:to="loc_amed_ClearwaterFloridaMember_C795F3969F915B56B9590BADED3D4B71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16EEB118D5C05C0E86AC39D4B7438D69" xlink:to="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_858B27FBBBEC569C93D32CF0F57433C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:to="loc_amed_HospiceMember_858B27FBBBEC569C93D32CF0F57433C1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_36D35558DD275DE0842F1CCAA191655F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_C331D94718655CD4A0F1F49DA0E192A1" xlink:to="loc_amed_HomeHealthMember_36D35558DD275DE0842F1CCAA191655F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0B2198A8A6915EC6A03F25C310BF99F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_InfinityHomeCareMember" xlink:label="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F6605F0D31185D20ABBEAB57CB721739" xlink:to="loc_amed_InfinityHomeCareMember_F7B16E916C905FFBA4FA46A095B1BD77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_A868DDABD49A547397C309C5CBBAAFE8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ExtrapolatedMember" xlink:label="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:to="loc_amed_ExtrapolatedMember_82C27B4F5019562D933C67AFA37A4815" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UnfavorableMember" xlink:label="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_4D26F8093A1F523392E16059F6A2E594" xlink:to="loc_amed_UnfavorableMember_CF34613B78CB511CB60A113BB720B3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F43C05F5BB285C3DAD7B44313BEE2A2B" xlink:to="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8F2A0FD799D25F4F95248AC3AD5B38C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:to="loc_srt_MinimumMember_8F2A0FD799D25F4F95248AC3AD5B38C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2E54270A8B94507C978971F5B7F397BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3F5F56DAE38254F1BE0CA5C86795B497" xlink:to="loc_srt_MaximumMember_2E54270A8B94507C978971F5B7F397BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55DC287CEF215A41AA02796E2A182DA9" xlink:to="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_D36A52490ACB592897FC7D4535C95D93" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Numberofpatients" xlink:label="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_Numberofpatients_42E3BA79D42C58C183579BD3E3D0B036" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_F333265619915ED1AF1F6DC7B8DA6BFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_A5DF4A9F68E85775809FAFA008AE01E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_FEF5411D4FCB5CC695867568B4406D63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableCurrent" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_9932110660EC582E9F6607387E848C6C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitsettlement" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_ADBFE573699958BA924D13EFBD14B8E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_ADBFE573699958BA924D13EFBD14B8E9" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfBeneficiaries" xlink:label="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_NumberOfBeneficiaries_D951439AF6345D5AA6DE23854CAEAD23" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_D9CF719C67AC51DD93A3CC8976A2FD3A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_4FB30B50CA50510A8BF0874D83AAE654" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_6F9B35F5ED8A5800B25A352FAE5FAAF0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_D5331D12AFC959488A4D91267CD21F23" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_E6737AC58C0F55E6940498A4B8806E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_E3A0680B7E41547F8FC4893A29A6B15B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_B9502D4506B656E49E47167011566B1C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ActualClaimsPayment" xlink:label="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ActualClaimsPayment_0B825074669A52448EF9D44B6F325693" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ErrorRatePercentage" xlink:label="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ErrorRatePercentage_B506558D9C755845BFD9D8E446EAE081" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IndemnificationAmount" xlink:label="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_IndemnificationAmount_BB1F0FFB1D02568496BCA2B065F7F6C1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FloridaZpicRevenueReduction" xlink:label="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_FloridaZpicRevenueReduction_B967FBF9A9545A839F279FA273F4367A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_F02DAC64CC265578823C47992414E49D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_F02DAC64CC265578823C47992414E49D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_HealthInsuranceRetentionLimit_8B15A89D75D2532BB684990EA691354C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_BCFBA54197905EE6B7AFD5BF6C594416" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9572F5D9ACAE5C2F9DA6AEB210A52253" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_C6087D1609445B1E9B9B22CD4ACF21F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:to="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2829702452DEE22BB0BBEBBFA3CA81EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_C8DB52F62E6353F7257FEBBFA3CB12D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8BF61719F64F49F4B625EBBFA3CB4CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="loc_us-gaap_OtherAssetsCurrent_41F908C892D8A487CADBEBBFA3CB536F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_65F15441F8F415D88857EBBFA3CA5FD3" xlink:to="loc_us-gaap_AssetsCurrent_B78BAC1BD7A524F33279EBBFA3CB07D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_774CF1AC23D2D581E06EEBBFA3CB82E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D85AF7336B831059D9CDEBBFA3CB1DE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_D85AF7336B831059D9CDEBBFA3CB1DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_Goodwill_96303B2458A977C20470EBBFA3CC89DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7D028CE89D50EE580A2AEBBFA3CC57B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_15B331EF90AF5F81A4DCEBBFA3CC1D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_93B7252BE335F25E718BEBBFA3CC9B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EE4C027B7DBAD61C7962EBBFA3CA23E0" xlink:to="loc_us-gaap_Assets_92DBD8E49113B8B5CF42EBBFA3CC9815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70EFF44CA676ED45CF1CEBBFA3CABE71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_AccountsPayableCurrent_33C72D179FFAD1CDE2D4EBBFA3CD7F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CBBCB50F099031EE4ADBEBBFA3CD3D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_AF3E77A44E31DB1C7A3DEBBFA3CDD9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6B674A8A4E11ADBF6DA5EBBFA3CD5A7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0D5D5FA71F65B3E9F599EBBFA3CD7B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F44FED653E809FFBCB2BEBBFA3CDCC18" xlink:to="loc_us-gaap_LiabilitiesCurrent_27244AA05F733E436062EBBFA3CEBE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93C086FB9AF291FD93CBEBBFA3CEEE47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_554B9E9814D0AAE75242EBBFA3CE27C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_894C0FB4AB8DD7FD3BCAEBBFA3CE9E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_Liabilities_F4CF7F2211333EFB9A01EBBFA3CE1746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02450B953D8D3A7D8F07EBBFA3CE3A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_E6247AA4355E9E100BCBEBBFA3CF52DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1255F1789BE7794E555DEBBFA3CF1EFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8CB09DA2C67834B4BF02EBBFA3CFA073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_TreasuryStockValue_E10F234694A5681F9C89EBBFA3CFD92A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F182AA326CFFC9B0ABAEEBBFA3D0E8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D7A17522E18234626A30EBBFA3D0F091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_StockholdersEquity_36822FB38E68CDBD29EFEBBFA3D0640F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_MinorityInterest_58365FA27F6131458F13EBBFA3D02B4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_15952967F609D7FE9262EBBFA3CFB265" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E401FEDE300A74E09809EBBFA3D061B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8F83D1613E7AD7DB10FAEBBFA3CC2B1D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_A99ADFE3292ABE09CD8DEBBFA3D09EAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0A4C70B666075B759D195609676A0452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02805155FF7956D0B22C163A24383CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40B429C05A4D564189204A7497450538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6FE9A39B34E05D40A7D30E02EE3CC1F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D575DBFFD581553DA71D2C57C2EBE72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_EB3808024F655B1FBCA83D3636A7D2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6022F0FB97385DE297C09E8D7946DD8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A2F016A99D97562692F819F9124B0605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_CommonStockSharesIssued_A3AEB7E40A4C508FA70CC6419FEE6B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E03538A1772053FBA4D743B64B3EC25B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_309931AF60A95C06B07C82D8F28E349C" xlink:to="loc_us-gaap_TreasuryStockShares_781C27F16E9551EDAAE4044887B14653" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:to="loc_us-gaap_ProfitLoss_21A582C2679095CB3032EE99D4CB1267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_D2D37D8766EDF96A9F38EE99D4CC2D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_ShareBasedCompensation_0972BCE7110DB7E7EC6AEE99D4CCC5E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_PensionExpense_1139BBAB83740A874CAFEE99D4CCF4D5" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_AA2DBA655283EA5C0CC9EE99D4CCCD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_238E823090EA5A89A6B6EE99D4CC7B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_A25B23C63749B0211F3CEE99D4CDBA9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A46F97D189972FAEAD9FEE99D4CD7FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4740683B8A8E9822D05BEE99D4CD6C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0B898FCE45FBEFB803E1EE99D4CD6E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_8DE30194C4F16255BA6FEE99D4CD9936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258DD7B56E3D7CE61836EE99D4CB0A92" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76E2410B63E613E3FDC4EE99D4CE59B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17575266E9B6E5DD27BAEE99D4CE5925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD67C295D6B59824476DEE99D4CEA005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2E412251E3A2F17F0C2EEE99D4CE4062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDF7298E4706E139B6FCEE99D4CE48BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5FEC10DAED0986835BABEE99D4CEA3C5" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_86F59827C0647F21D557EE99D4CF1F28" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FC7CD657D7380F07A59DEE99D4CDEF9F" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_122CA97EE470D78DF8CEEE99D4CF1494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D72D8A4FCF87E64E15EBEE99D4C9799F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5A3FE1169E810D8FE122EE99D4CFC3FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_437DFDFE61060FB386DAEE99D4CFCD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_121CC8CA9972893FDD4CEE99D4D073DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_69E938AFB89A696AF557EE99D4D05ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B8FC110D4E22491E8F23EE99D4D0B4F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_88B1D90AA28564A66A50EE99D4D0133A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E3FE5B7C20FB8F751FF3EE99D4CF5E62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_992AF36A7E48CA7D3BADEE99D4D05487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_584E0E04A7C53801030CEE99D4D1F2B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_ProceedsFromStockPlans_2A301218F7C8EFEC6CA2EE99D4D1262A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E0807C1F28A6BC10DA52EE99D4D1FAB9" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_4F6398EEA985163CA8D0EE99D4D14246" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsFromBorrowingsUnderTermLoan" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_F2407C2A7D92F821B270EE99D4D1719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_62A4E8F6FB637570AB3EEE99D4D1EA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_21E68B60AC792ED7827DEE99D4D2673D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_AFAC30846A43ED829A56EE99D4D2FD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_4C487DE2C9AC449D7BD6EE99D4D2DA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_467FC474D1F343F9749BEE99D4D2753F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_53B8E1B9B19891C76C1AEE99D4D26D20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CF4CE5DE3B5301327940EE99D4D088A1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91B18A46F4549B25FD54EE99D4D2E60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_799644776A7DAECCB96BEE99D4D3FB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1826123C29AC074631D3EE99D4D3E096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68F7E104D2CBBCA48B15EE99D4D36CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:to="loc_us-gaap_InterestPaidNet_09AB8A4A6390F68F5A17EEE34E770433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_BA8F30ED7B26FD00E446EE99D4D38B9F" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_A3C1FDEE97C9327AEB04EE99D4D4947D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_592C6C71C94860100B5AEE99D4C94292" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_A6BB08D86B725D128078EE99D4D40DB8" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_04B6C086D512C051B1ECEE99D4D455E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1AE870710322986B8F65034EAFBE35F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1AE870710322986B8F65034EAFBE35F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C0135D400AEB286A879034EAFC08DAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8C0135D400AEB286A879034EAFC08DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:to="loc_us-gaap_LaborAndRelatedExpense_13C5BB431DF701B0369D034EAFC187D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_68CBA03FA67B02EED060034EAFC1C706" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:to="loc_us-gaap_ShareBasedCompensation_68CBA03FA67B02EED060034EAFC1C706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_36A67C6FA4C951C82671034EAFC05685" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_34AFF8D5DBE2D79EFEB6034EAFC12416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_F561854E41A7C3DD6DA7034EAFC14FDF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_DepreciationAndAmortization_F561854E41A7C3DD6DA7034EAFC14FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_CostsAndExpenses_3070DA1C78C3649A86F4034EAFC1BF12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_DF4BD80C9BA228413103034EAFC1B3BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_OperatingIncomeLoss_DF4BD80C9BA228413103034EAFC1B3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_D506AA23C81AB7C6CFA8034EAFC2A859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="loc_us-gaap_InterestExpense_F146168DD537B3AA6589034EAFC208C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_853728754726C9932133034EAFC2816F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_B1EE04B45826ACE29153034EAFC2675F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_D46DA50AC37578BA8314034EAFC2041F" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_34E94DB627CB03459D42034EAFC3AF2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_810433841F66CFA5AE8D034EAFC342BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ABA35611F3A59C93A401034EAFC3A5D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_ProfitLoss_7353CED8B3D32DB00FCD034EAFC35755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C20386F107AFB32083AF034EAFC36C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_NetIncomeLoss_9B3BE3DC4D2720151BE3034EAFC4EA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:to="loc_us-gaap_EarningsPerShareBasic_C30AB97095022DAB1365034EAFC4EFDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2CE80B53F7A959BD6DA1034EAFC4ECB4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CE729DBB2F74BC9953E3034EAFC4BC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80F78445B371C9896551034EAFBA772D" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3EC720CB0CDBBEED940F034EAFC5F2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94979820A748F8560C57034EAFC49ABA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5734D8CDF7364FF2BA60034EAFC5541A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BD753FBDAA8FF81BB95F3F1E25F84DB" xlink:to="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_450DCEFA862FC26D683DF3F1E25F2252" xlink:to="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_CommonStockMember_30AD78773E6D7DF76878F3F1E26090A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B5719D1DEC68CE6198D8F3F1E2608350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_TreasuryStockMember_72DEA0AE8070D6A009A0F3F1E26026FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CA8EBC7C3805A03EF432F3F1E26031D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_RetainedEarningsMember_42A3A1B3DE1B32E6A245F3F1E2619AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A2F158CC3C13D3E73587F3F1E260C0CC" xlink:to="loc_us-gaap_NoncontrollingInterestMember_61BE9769FA18766AF36FF3F1E261E626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EA0B71DBD34A40160BABF3F1E25F5367" xlink:to="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0BF9D9D5D7F8B9C40CFAF3F1E261BD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_SharesOutstanding_31938F1A93073FF0D139F3F1E261D30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_F1C6AC3667D8FCABB210F3F1E2621B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_DAF7E6595A805B05395FF3F1E262596F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9D259EA396F40537F7EAF3F1E2621C92" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_44D44458F5D4AEA5FFCDF3F1E262BF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11489340C743905B0A9BF3F1E26215F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_84528DE8D3197E00A355F3F1E2620FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_843E18ECCAD39985EC32F3F1E2639142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E17B04C9806DAE36C162F3F1E26384E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B27E1334420835E16DDFF3F1E263052A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SurrenderedShares" xlink:label="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_SurrenderedShares_3E31403CEEBAEEC8B5E3F3F1E2635092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2F26B46DA231EF6F5DD0F3F1E2634923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0ED48A958ECBCBFDA9C0F3F1E2635D97" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_D2DC06A1F404BFEB1776F3F1E26399F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4D1E4DCFE2F1D8F9E15EF3F1E2640599" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_ProfitLoss_4D1E4DCFE2F1D8F9E15EF3F1E2640599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_992EB84CE1D724ABA5C5F3F1E264B4ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_483A02F0FABAD84BC584F3F1E2616E6A" xlink:to="loc_us-gaap_SharesOutstanding_F08A747EFADA1EDB9BADF3F1E26460F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentType_538E35ECE8555DC7B96CEDDB8E037B8A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentQuarterlyReport_4B2697F529B051E2B916916911E4809D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentPeriodEndDate_42AB5886C8E35361BFFF9E1365862EFE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentTransitionReport_41DE09D8233155BFBB4B7DCBCBDC8DD9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityFileNumber_1029EBF123A45548A96901BE024C0B59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityRegistrantName_9FA8BF673D7A5E978D020B20E70F4259" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityIncorporationStateCountryCode_788451719ACD5BF1A070B19B17FD4CF3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityTaxIdentificationNumber_6989939F52365E04B227632A060FF720" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityAddressAddressLine1_23B134613ECA55D7967698CE04764229" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityAddressAddressLine2_FF3211E56EF2537DB0AD3D42063FE398" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityAddressCityOrTown_0304D61DFC705E2080EF759E573795E8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityAddressStateOrProvince_DC0B44F5AD4C5DAAAAFCEB378F6116F6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityAddressPostalZipCode_750405F553605915B825D514A5E8691C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_CityAreaCode_87E9AA7732325E359C2AEA0B7196C28F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_LocalPhoneNumber_E3A0ADA7A0295399AABD80388D3DF73C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_Security12bTitle_8547005285D85B1F890B1BAEF1F5652E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_TradingSymbol_79E952A541655F47A344E9E2B7E40948" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_SecurityExchangeName_E567FF35254254C8AA964C484B1D265B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityCurrentReportingStatus_E8CA610FFDAA598A8E00A81C7DE07B7D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityInteractiveDataCurrent_D8E86FE9136E5D0289683BC3ED21AE7B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityFilerCategory_5EC0CCA90DBA5013BD76007EA413AB4E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityEmergingGrowthCompany_9301352229AF501599A9B492D55C6A56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntitySmallBusiness_F6FEAE66ADB557908A20311C30FAB635" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityShellCompany_D2E7C5B0B7075CF6BF6F0C25E13E8C04" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_90EB118086115FD9A0EA3FA68BF56231" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_AmendmentFlag_72B3C547375959DF8465C9C63694A655" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentFiscalYearFocus_F744F53015A752F886F1E70822FB56C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_DocumentFiscalPeriodFocus_C0C34633853554E9A52693EC053C1BD7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityCentralIndexKey_86CF37A83C2950F9B5A1340B24930133" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_CurrentFiscalYearEndDate_2982C81D630D574B8A4C41A61CFF8B74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityVoluntaryFilers_9F7D2629AFB6580BA8428E157E285E6C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C2E662BE075F52A1A9FCE94149336873" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0C25B7E478CE5DF68E5674F436E6B488" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_DF26A95340F3137B458804F13139BCBD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DF26A95340F3137B458804F13139BCBD" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_69126481735E1F0052C204F2F209EC2D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FleetLeasesMember" xlink:label="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_754A57CD98543445F77504FEA8915AE4" xlink:to="loc_amed_FleetLeasesMember_9EA82546869353243ED804F3B5D501EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E2D717478250BBC1D24004F1313ADB6C" xlink:to="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E65884A92010627C418104F1313A4CEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:to="loc_srt_MinimumMember_E65884A92010627C418104F1313A4CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A64A8E0F7307A9088D5104F1313A8A27" xlink:to="loc_srt_MaximumMember_9E0C35F8C26D6388A2DD04F1313A4FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_F4086D3937CE48B8A2B304F13139DD76" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A4F06ACA533B191E201D04F1313B3579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_BF7D2E0E46CCD770E89004F1313B51F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_B33796A4DB997AFB809204F1313B451C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_83A9E69277A35358614B04F1313BDBDC" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_E78FA58D05F53496753104F1313C24F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_D7E076A00975597FAF0DE5CD51B9280F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeFinanceleasesAccumulatedAmortization" xlink:label="loc_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_amed_LesseeFinanceleasesAccumulatedAmortization_E5C05D4AA76B55BF9581CDD91A94170C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceleaseRightofUseAssetNet" xlink:label="loc_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_amed_FinanceleaseRightofUseAssetNet_CEE46DD4204B5DC392EEB2010EDE1389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_E0E44981611E5BD1A1CD89F53E97FC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_38901ABD9CEF562891521A5E170AAEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0A70FD5B5DA55ADBB59AC5DBCCA090CA" xlink:to="loc_us-gaap_FinanceLeaseLiability_A4B5D56DB70C531A83F19845D7BB958F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_OperatingLeaseExpense_4C64CB4FED7A53F0BC4612B46B317767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6059648FC14C5DB188A0C0DC553EDF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_OperatingLeaseCost_BC9750DC053752369395E2463CBA1BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8AA76B053E6A58ED841F1220631DF334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_C245B1F231CF51D1B79CA6EB7CE251F0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceLeaseCost" xlink:label="loc_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_amed_FinanceLeaseCost_0BFAA544A9EE555286E51F226E06EFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_VariableLeaseCost_6270F3301C1A503FAC5896E0F63B8D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_ShortTermLeaseCost_70D48A1321625CFCA86B4EC01586E252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9C86BA15F7A2505FB09E133C10C02114" xlink:to="loc_us-gaap_LeaseCost_139F63A9564B568C8994775D1186AC1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesLeases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_7F3CAF279D575528B8EA79771C711A6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7F3CAF279D575528B8EA79771C711A6E" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_62397DD6986E52DF83C1D1E033C713AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25D2EB2ACFD751269C6D73A5B41D0689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ACE9F27910EE5927959E0C7FF9B7CFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9B678355ADFD5DC490B31DDAD870238F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5313BBFAAF1C5B09A618C21B436C34C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_219252A7F55B5FB994D5A6AA5EB86BDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CD1B953620A859DFBA7F713BA05D48F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C59F22D05002562A8CEF316032ABF9A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8FF10DEE377450D985B92B0B7353052E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_71AA8EB9AD4D5BECABC3A2F68CB3F8C4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_OperatingLeaseLiability_71AA8EB9AD4D5BECABC3A2F68CB3F8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_AB3CBB1283F15157A6D6CD85FCB341FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_D8A579DCDBB75E77AEEF6B026CA8F1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_465E15DF73EF5C8B8A6641D9598BFCCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_F3C214C91CBF5EC59CE8123B3E9A2355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_EA16431A862E5990B417CA76C7653A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_670A22655ADB506A8299E93C76C6470D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_20A1AA06DB475291A71C94ADF94F5880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_544C891831A353EA9AF366BED3C22B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_5B1E509D96B751918177C315EFF91046" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1956EFCE61BB56A2A40DEEBBF8C5267E" xlink:to="loc_us-gaap_FinanceLeaseLiability_5B1E509D96B751918177C315EFF91046" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_F62F176ECA8B5186A1CC1E27FE074B34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F62F176ECA8B5186A1CC1E27FE074B34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1B0A1DF55D8E5469ADC02627544A666D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F62F176ECA8B5186A1CC1E27FE074B34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_EF51080790255431948975FF33280162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2B670819B20E5EEE95BD33483F247872" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F62F176ECA8B5186A1CC1E27FE074B34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2B670819B20E5EEE95BD33483F247872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F62F176ECA8B5186A1CC1E27FE074B34" xlink:to="loc_us-gaap_OperatingLeaseLiability_C2F731921608530395B4F42F2B3F9361" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_us-gaap_OperatingLeasePayments_5AD3E4A7FB3C558A9D275A1E6A57D5DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4FB4683E4FF453BF889F4837810E1288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22722D55BFA55962AE8B9C38759213B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0346A2F6F12B5ADC9BDCBDBFA67D77F3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_CE78FBC10BCC5F59B211ED742D1C13B2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations" xlink:label="loc_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_F14A18E6C8BF5D73849E8FCD32E65E8F" xlink:to="loc_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations_8FF8E39D840E569890F76CE94B881F05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_191C71EABF8450528B5FEAFA89D8E6FD" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OperatingleasesTableTextBlock" xlink:label="loc_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_amed_OperatingleasesTableTextBlock_E6F028BA8CD859A4A32C7E59F727D237" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FinanceleasesTableTextBlock" xlink:label="loc_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_amed_FinanceleasesTableTextBlock_EFD5F35050F95B7580CAD308FB7F213F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock" xlink:label="loc_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock_4E4EC1A53D98502EA127E359479AA1A1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock" xlink:label="loc_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock_8183E3B556225F9282620DB112604759" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LeaseLiabilityMaturityTableTextBlock" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4CFF2C3966345190A8FA1E135185D434" xlink:to="loc_amed_LeaseLiabilityMaturityTableTextBlock_A3E943F5CC1354458C490DE02825E86E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_3BD2289315DFA63448F7034F09F01003" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3BD2289315DFA63448F7034F09F01003" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_C1131EEF448FE836B33B034F09F0FD6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3BD2289315DFA63448F7034F09F01003" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_13F007DA5FCB4F30089B034F09F043A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3BD2289315DFA63448F7034F09F01003" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_CBF53B8B1F6EAB6E6DFF034F09F06978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3BD2289315DFA63448F7034F09F01003" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15112E444798FE7A530D034F09F098EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_857DC9B6B0D45E5495A65D49C390521C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_857DC9B6B0D45E5495A65D49C390521C" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4798B06E87BE5FF7BE5C196A55700A03" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_DF9E2711821355C9AA890A81A875B08A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DF9E2711821355C9AA890A81A875B08A" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D50F97F558B25FE793EBE13B933A9E74" xlink:to="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_32C373E8661F5EA6859F9D341238A03F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:to="loc_srt_MinimumMember_32C373E8661F5EA6859F9D341238A03F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4DA4696B5C4C5AEAA03B332E3AC11B3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B14628D8E2B95C3F82AA1204710408D3" xlink:to="loc_srt_MaximumMember_4DA4696B5C4C5AEAA03B332E3AC11B3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_49349A44858E513B8F154D62F7132CEF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_402C58D96FB653FB80FC4EE5250691FE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_CD569D66149054AC94733A0E76BEA5A2" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_93BEDFBF208B5AAAB060471166427231" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AAD48D7865365BE099945D4CD03C5D5C" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_B7439B4ED5C65062B8E5CDD850A52B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_055CA74696305983863C960BE9981EEB" xlink:to="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_E227E067ADC35A4582FB5156F2C0A80F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:to="loc_us-gaap_EurodollarMember_E227E067ADC35A4582FB5156F2C0A80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_F632F64A53E05F80A0063C66F06AC95C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3390135FABA25E579A51645DB78D51FA" xlink:to="loc_us-gaap_BaseRateMember_F632F64A53E05F80A0063C66F06AC95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_D555C2EC3F2556B99C61DFE117228A3D" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5109BDF2B2BC5350AA30879210A7CE16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4F8133D95B755863B6B7A37885EE2847" xlink:to="loc_us-gaap_CreditFacilityDomain_50CD3FA8C21C5093A267B06809E540B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_34DBB5CFF5575387B60904E11AB6ABC6" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedLeverageRatio" xlink:label="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_amed_ConsolidatedLeverageRatio_21274D472BC45FD79C6378900A0C5AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_FC54761F9C4D565B97CEB93ED2563719" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LetterOfCreditFee" xlink:label="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_amed_LetterOfCreditFee_EEBEA19BA69C5A9182DDBEC64D880FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D906B752E7D65E7D9F11EADD25D3E6D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_217DEEB94ED557B0AEF5AB7F3214759D" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D906B752E7D65E7D9F11EADD25D3E6D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7A1AF98779E85022BCF47A5CE425F5D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7A1AF98779E85022BCF47A5CE425F5D5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5E06E2CF2FBE554E87B8661166460B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7A1AF98779E85022BCF47A5CE425F5D5" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8A4E18AFC34B51FCBE67114E212F1442" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3DA09D91191A425435DB199498F26AFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3DA09D91191A425435DB199498F26AFF" xlink:to="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09643F8E1F7CBC11508C199498F31319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2D3EE56786A1C0AA541A199498F39127" xlink:to="loc_us-gaap_SubsequentEventMember_31895763D395BBB20B0F199498F3F8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2C9282DF449529E95C74199498F49883" xlink:to="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49C216A170D2EE3B31EA199498F4CF49" xlink:to="loc_srt_MinimumMember_B68591019B9A9EBAFE8F199498F4B861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_4BB0A70F78DB33C2C0BA199498F49F19" xlink:to="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:to="loc_us-gaap_BaseRateMember_4055536DC5537AC325E8199498F5A788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_CD7928E0CF6B560ADB67199498F5CA6C" xlink:to="loc_us-gaap_EurodollarMember_15300DD32E29060EF345199498F5115D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6D2F7A8C844913FA58C199498F5088F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SwingLineLoanMember" xlink:label="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_SwingLineLoanMember_46F988B0C5DB98DCB100199498F656A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LetterOfCreditMember_268133C459EEC69AA32F199498F694D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_896542C3271CB5454497199498F68366" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LoansPayableMember_896542C3271CB5454497199498F68366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_32BDA13EC5CE0101939A199498F65DAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_32BDA13EC5CE0101939A199498F65DAC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PriorCreditAgreementMember" xlink:label="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_PriorCreditAgreementMember_8BDE0549926E65527ECC199498F60E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_us-gaap_LineOfCreditMember_CAB75A558160BAE8CAC2199498F729FD" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AmendedCreditAgreementMember" xlink:label="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_88E5AB4041A2B35E0171199498F5102D" xlink:to="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5995108A52784F05DCAD199498F723F6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_AmendedCreditAgreementMember_D5539FDE01C60BFF5B77199498F7BCA0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="loc_amed_OneHundredMillionTermLoanMember_04417B370EC61766AAEB199498F8810F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_OneHundredMillionTermLoanMember_04417B370EC61766AAEB199498F8810F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C1046EFAD80AC1D3A3E1199498F86EB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C1046EFAD80AC1D3A3E1199498F86EB7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_FD0FA00471E491F8A330199498F8FC27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_FD0FA00471E491F8A330199498F8FC27" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_57CD7F4F3EB9839DF311199498F84397" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6C8C389A92C8F3041033199498F78AD4" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_57CD7F4F3EB9839DF311199498F84397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61778293B1FDA176BA22199498F3E0D4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_EE1229DEFE637CE32CDE199498F8139D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_AA76BADAA91BA33AC832199498F9C761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0CA80B185D457E378A73199508207F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78EF10FC18B6A165131E199498F9807F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_1F431C6E3009453E46DB199498F9E0E4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TotalLeverageRatio" xlink:label="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_TotalLeverageRatio_52E8363FF1FB0C039F4A199498F9931C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ConsolidatedInterestCoverageRatio" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_E732144405FB837C7BB4199498F9C7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5EA4338403279DE89697199498F977EF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_RevolvingCreditFacilityTotal_02AEA3879C9F3291BFB0199498FAA72F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5E07F7150DA616B842DF199498FACF32" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_4D45A30C75722BC9BDCF199498FA4360" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_C857AD7052DD8148EA09199498FA41B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7026EEA8EE0CE17166D6199498FA92C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_5CDD27420DB7880A803E199498FAD5DF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_C1D3A089764D8EFE11A3199498FBE134" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_848C9B7C9E151002846A199498FBD57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_DF26BCE654D1A706177F199498FB4788" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_B5336F21824D64EF34F3199498FB2482" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_14280C651FD74633A7FA199498FB4455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_12874A4DCE5B9D51E013199498FCC37B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_FAE31D9192C24FC1B4BC199498FCB505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_64B6131DA485FDC7A9FD199498FC90B5" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_64B6131DA485FDC7A9FD199498FC90B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7A1C1D611E5FE482E030199498FC5180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_563490F312E910B81100199498FC4B53" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_70D26E682C2D6E45C38D199498F845EC" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_6C5CAEFB658731417C21199498FC4534" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3E11A82755385D41AE3A4AC93D698D8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3E11A82755385D41AE3A4AC93D698D8E" xlink:to="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F364BD394785F49B79AB9B5F89F90F2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_06F955A5EA645CE6A5F1836F1908222B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:to="loc_us-gaap_LoansPayableMember_06F955A5EA645CE6A5F1836F1908222B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_78053B08448A55B2A90AF54E7A9790B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B48EA209AC157AE96307519E85DDDDE" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_78053B08448A55B2A90AF54E7A9790B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_D32DEE2AA2CA5BDFA31BE6406B448D46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_3D5E8070D6D55339B2B7C8ACDE202689" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_3D5E8070D6D55339B2B7C8ACDE202689" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_AF9B070CBB0F59819A9D2C30267B9809" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_AF9B070CBB0F59819A9D2C30267B9809" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_97DC364C85165EF3BB6CBF17E6B56CA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6E7B9F4012C95006B02A8B4BB1AF2139" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_97DC364C85165EF3BB6CBF17E6B56CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_A60408DC81AC59DD806FE2B4ECEB30A0" xlink:to="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_94ED0E1786F7590F8DACDB512662EE9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_F9DF368B2C435E06B2FBC4DE7D2F5916" xlink:to="loc_us-gaap_EurodollarMember_94ED0E1786F7590F8DACDB512662EE9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_77EAE22B8F1554988E7EC2ADEC00CA58" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_BDE9D69063AC55D1A3EFABA2B180B781" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_BDE9D69063AC55D1A3EFABA2B180B781" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_453C34395A2550A78F5F36754FB50CB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_453C34395A2550A78F5F36754FB50CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_40C1C98D6CC854A2BFF863696EAF9486" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8795FFA4A3535BF6B388478EB5F69A89" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_40C1C98D6CC854A2BFF863696EAF9486" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9B0CAAFB28045CD695FBCCB4810816DD" xlink:to="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E492F4C387B151399F74BA8219B3EC63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_LoansPayableMember_BBBA4D7544765511BD3F8958CAFECE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_D5877217C7ED540EAE8658CF92F40CE3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PromissoryNotesMember" xlink:label="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_amed_PromissoryNotesMember_A50A0671C35A57C9A77E6127A959FF4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89BE9DE1E5AF5D5AA0DE878B985A3BCA" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_16FB5E7D291E55738B0D17D5288CF01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B87AF7B991795E299355CBA4B8A939F5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_2C8706BC072758DE960572797D6E2541" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_OneHundredMillionTermLoanMember_543DB33747575666B5F1A332A5DFAC12" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_C7D4A47374295E28B9B5D631FEB775A1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0A004B19F0E3577CAF0CFE6A0F16EEDC" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_58EBDEA3EED45F0FA58A5A447AA62DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F26AD1685FDA5E419157F2D54C15527B" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9070B0AA472659EF9DA8D3E82CA28601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5E43C11C04355D8C82C292C8D73AB4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebt_E1D799784EAB5C8FADF535F53A29E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebtCurrent_0F6A71FD21C759DB9F9CA490B7305A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D4892CE397E85574B2BE460B4621B192" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_D59A931524955256B468CECD81840F04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C733B3E463DF533BB8C638E5B110A6F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C733B3E463DF533BB8C638E5B110A6F1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_BC5E0BFC3A89500195407F9DB9748B8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F44D6425C3E970FD9D37EBBFA3813B22" xlink:to="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_25E546D80A6AA3150EB6EBBFA382BAE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A7B76FB0A792029726C7EBBFA382B8A0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_86FA44257BC71A8CF166EBBFA382357C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentAxis" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_TypeofEquityMethodInvestmentDomain" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_FFE1A55C11ADE9716379EBBFA3827BCF" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HealthcareanalyticscompanyMember" xlink:label="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_21DCF6312F993620816BEBBFA383441C" xlink:to="loc_amed_HealthcareanalyticscompanyMember_70630CAB605E0E35155AEBBFA383E093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_38DE30ECC787F435D73CEBBFA383069A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41C7B08918A258F37AA9EBBFA383FC61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1CCE85A26CF40D914AE2EBBFA3840CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_C49A83167B569D3560FFEBBFA3847CDD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedicareRevenueMember" xlink:label="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5D2B342D4958E34A900BEBBFA384BBF6" xlink:to="loc_amed_MedicareRevenueMember_699CFCA69F41C179D5A6EBBFA384507A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13D76129F1C46F397620EBBFA3853F91" xlink:to="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_HomeHealthMember_9182A7E2387F50940D1EEBBFA385E4BE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_HospiceMember_7B7A37B812697419DC26EBBFA38529C7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_A24406B4A43BDE468EB5EBBFA385313D" xlink:to="loc_amed_PersonalCareMember_3E26D6239B42356BA524EBBFA385D020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_6288FF901B1C7B0422D8EBBFA3814BE5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_67243F69F9E265EF1873EBBFA386F84A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_OperatingCareCenters" xlink:label="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_OperatingCareCenters_1F5E25C62664A6538C49EBBFA3864FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_8E8E47084B5E963AC1D3EBBFA3862275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_OperatingLeaseLiability_5872C7AEE7FB3561EAB9EBBFA386891C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3FC24D0608B5F5ABEB86EBBFA3861BA7" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_54BE31309BF8C2B45D88EBBFA3874214" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_09C2FCC2DE4C11F9AE9FEBBFA387C70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_89DE6A5A675BBE0E641CEBBFA38708CD" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7B5DCBB0199A8EB4E988EBBFA386A9C7" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_C01734AAB135DB2A2DC5EBBFA3879186" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4A74A5CD1A87F9327AFD04E95B1B37BB" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_EAD718FAC345A22435DD04E95C05475A" xlink:to="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedalogixMember" xlink:label="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E4D112AF71F56D4AAE4004E95C07E426" xlink:to="loc_amed_MedalogixMember_92DE33BBB4FE91C6CE1C04EBD9A661AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_55AB094A9BDFFCED01EA04E95C094874" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2DC8BA7DDC1F1BEF9B4704E95C0A900E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_722769E8BC2123230AF204E95C04BA64" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_DE799600C82F1958925104E9B641855A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_893EAC1B1A83EDDB3AE004E95C0B0AF7" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_E823243D74B790C49F1304ED6B246FB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3547B4F24D7D28D17A8703F9E64AEA91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3547B4F24D7D28D17A8703F9E64AEA91" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C5B961183A2587E0ED5E03FA1A046CB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C635CFCE800A509588F7D0011C3CA797" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C635CFCE800A509588F7D0011C3CA797" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_49958BF8DA7256A9AC73ED9420E48889" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C21EBCF583A25DDF834DFFA81940FC10" xlink:to="loc_us-gaap_NumberOfReportableSegments_D751E9C4CBDD536695B465840BDE5F30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_9A5577F174A9A3D93E8FEF9F98D4E0B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9A5577F174A9A3D93E8FEF9F98D4E0B3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D9AF1A2701293F9D1EF2EF9F98D5E633" xlink:to="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_483138024303B12788E8EF9F98D5E815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_HomeHealthMember_483138024303B12788E8EF9F98D5E815" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_EF51613E4B705FD9CC94EF9F98D6B1B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_HospiceMember_EF51613E4B705FD9CC94EF9F98D6B1B8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_540198EC370EA5BE5B79EF9F98D663A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_amed_PersonalCareMember_540198EC370EA5BE5B79EF9F98D663A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_04B08A9437C799A1B963EF9F98D58504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_2EE2735E7CDCAE243BC0EF9F98D6C3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2D5CB32399AEC5BA16FEEF9F98D4CC3C" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_A7F75BE373AB776DEAF9EF9F98D61C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_EBA1BA9EFCC4CED77300EF9F98D6D7F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_50A92E1FDCCE5FDF7180EF9F98D72506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_DepreciationAndAmortization_5B526B32B6AF7F1B6A40EF9F98D8EEA4" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecuritiesClassActionLawsuitsettlement" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_E8D415910B18BC61F391EF9F98D9BB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_CostsAndExpenses_6662ED09154EBDDB5803EF9F98D9FF42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_405D87EC7CACE6A85E3BEF9F98D698ED" xlink:to="loc_us-gaap_OperatingIncomeLoss_D7A2C26F94F8C5EB1EA8EF9F98D9AAB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_8FFFC96934FE59BE85649AFFB5C588BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8FFFC96934FE59BE85649AFFB5C588BA" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38B59B70DF8E5ED8A47A0C903E28BD4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:type="locator" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseTable" xlink:label="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66B3317A998E5151AA1B82AC3500056F" xlink:to="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseAxis" xlink:label="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:to="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseDomain" xlink:label="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseAxis_2BC3BF2B60835D3EBF83F0DB1AF43D1B" xlink:to="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_KKRShareRepurchaseMember" xlink:label="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_DE818DC766595270ABEEEF032D89CE07" xlink:to="loc_amed_KKRShareRepurchaseMember_232FACFF9F9B588BA332A23E674D8B9C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ShareRepurchaseLineItems" xlink:label="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_7DE13E787CBB5D978857C4C4E96A2181" xlink:to="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_C98689FBC1CB50638731A95181C54F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_5E17231285705A33A240404BFDAE09B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6F6F0014CD7A503287B4EE2DFA9DD254" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageofSharesOutstanding" xlink:label="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_PercentageofSharesOutstanding_E5E66E8851A453FF8053EAE207C0DD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4165690DFD9956E0AF3F69FD4614C557" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Discountedclosingstockprice" xlink:label="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_Discountedclosingstockprice_73E81007564B5780984C0BC6877D3FF3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Percentageofclosingstockprice" xlink:label="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_6D791287C0895CA19BF04618B50F2B40" xlink:to="loc_amed_Percentageofclosingstockprice_0B25AB790C515F30A00850B991F0CD61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ShareRepurchaseShareRepurchase" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0462B08B5DF557BCBD54A8A4116C52E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="loc_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0462B08B5DF557BCBD54A8A4116C52E4" xlink:to="loc_us-gaap_TreasuryStockTextBlock_E006E2B34F465F64B4FD455FF3F0A9C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_979894FCC7055BE68EC456B06B63D06E" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_F5FA5D60F5355922953F0FA041FB09FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SubsequentEventNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F0A50A1FCED8586B8D90F2B9E9CE807C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F0A50A1FCED8586B8D90F2B9E9CE807C" xlink:to="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2BA94B93F05E5D2F8684B0C059F7D0A8" xlink:to="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_A8953A45DEF95AF7B666CF4E6B8CB175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F131613EA87858CDAF9132C3A23604C5" xlink:to="loc_amed_HospiceMember_A8953A45DEF95AF7B666CF4E6B8CB175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83791B18D46C5674A8D909F31AD4CF3F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4054549A187956B494F8FF7CEF361BF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8D16B7BCB5F952C9A44E380854AFDA01" xlink:to="loc_us-gaap_SubsequentEventMember_4054549A187956B494F8FF7CEF361BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8861F99B20B15383B84BDBE895EB23D7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RoseRockHealthcareMember" xlink:label="loc_amed_RoseRockHealthcareMember_CA008BFFE65258A69D9440D8CEF0217A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22784F1C64DB58869C014F28A7B3092B" xlink:to="loc_amed_RoseRockHealthcareMember_CA008BFFE65258A69D9440D8CEF0217A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E271D47C568756209E807AE29739C6F5" xlink:to="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_202A8CD1873A524599D0EF64C50E62DD" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_F9B76A7BA78053868E27611B2D6F8E0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FEF87613174B5901ADFC62F304C40119" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FEF87613174B5901ADFC62F304C40119" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2FD66BF2384556D18642A05DCE8B872E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_45FB849F3F5CECD258D219928A31035E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_45FB849F3F5CECD258D219928A31035E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_20429728717B169A97CA199289F91BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_B27BBC3486C728398FB1199289F9560A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9DF0F8947F1E5B7E0106199289F8788B" xlink:to="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_970079E6BD1A4511EE0A199289F9A927" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CFA6C6786A6B507F8ED32D19E1343857" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFA6C6786A6B507F8ED32D19E1343857" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4918B7BD0FCD554A9FA03AD7E1746F65" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D2546E08F88A59A58F598488A7E572BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_759E45ED8D345556B4BBAADC154FD79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1094FFC84F505D71BA4534676DAD3BF0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F5B3C36A75CD5AA780B6BB7DC9FAB33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18376E469B66551FA4F34CD86672F124" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtInstrumentCarryingAmountExcludingCapitalLeases" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases_3BC50C41F5FA56F08149B28BC00972CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72E1DF69978B5DD791F69DD860CCC25A" xlink:to="loc_us-gaap_LongTermDebtFairValue_6AD51A85422D5BBC9CF4ED5B9702667A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A9DDC02D8551518B91454128DD1A2D82" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_45B69434BB8554A389F28EBCC6561B80" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29122D52BF18509A870FB31C7762BF9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F4BDFA85D04052769E85A00F1ED3C7E8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A02846647B605713987E4AF033A27986" xlink:to="loc_us-gaap_AccountsReceivableMember_8E927D381FA559A29FBAA55914926446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_166D53EF360054419552181557214818" xlink:to="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MajorSinglePayorCustomerMember" xlink:label="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1F7C8509D7B35934833FBCACAECCCFF0" xlink:to="loc_amed_MajorSinglePayorCustomerMember_562C6926E6A758E1A02541372323E2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_981A72A5F44E58C1A3A5CD338D848BA4" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7482BAED3F75540D8307E60331B0CCE7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ECBBB61154D75891A77969B178010082" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_AB340348D7E550BD9C53E24988FA4050" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_AccountsReceivablePortionDerivedFromMedicare" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_606EBAD8BB255B69B090B8564313702E" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_EE08895B219A59FA833B9E2039769D67" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_5A8249C196465F04B0D7FC1779934544" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_F5B6C554212A5091B014DE1567172BAC" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_66E3C5DDDE3D57339D463B8056BA9DAE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_41E9304D5A405ED7A07CA468D44141C1" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1EB6853C86D5580EAE37A9485C73A7CA" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_67763F1930AC50B397F338D909F54CC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28B70AC1A4725BF996E3E90F311E0ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D5A71B6C66C75E2CAF2011BFECD36887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_UseOfEstimates_8CF6C33F67D65FB3BF537695A095A2D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2A74D6361DF95A7AAA596375DD511B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_2C1C6CAC5F3A5375B12490B485C94768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4DCEDA5CB5365208803820EACC137357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_BC29B085B81655379E05FC028F1B5894" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_569E45A280965838AD3684B94B89172D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3434634B24EF5D569FCD18821CA94543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_93FB3812F2CF52EA924C6CBA0A78CDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9D2D8EDBEC7B55B78C82A4F03D2EEB59" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_B2F85B9F88F55FDB876BC78E1EB2D089" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_4950CF14E78151C483677155BA34EA41" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassAxis" xlink:label="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:to="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PayorClassDomain" xlink:label="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_77605010FFFE5109AC0EB73465E27181" xlink:to="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMedicareMember" xlink:label="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthMedicareMember_7D01A17557EE5EE8894DC7C3E6F2BCE6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_97DDA8F4946E546DA9371505D311446E" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_BBAADC6A857A5C04803EC09D0A20C384" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareMember" xlink:label="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HospiceMedicareMember_37CFFDA148A45269B3DF1F9C60DF3882" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceNonMedicareMember" xlink:label="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_HospiceNonMedicareMember_645B82660D285D3CAD22AE99817342D6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PersonalCareMember" xlink:label="loc_amed_PersonalCareMember_DAE918E73FE15A97807430D8ADFFAA34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_FF92E30CECD954D9B275C8D0D4B7C7FE" xlink:to="loc_amed_PersonalCareMember_DAE918E73FE15A97807430D8ADFFAA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_73951CEFB4CD5434A298C60F37549D25" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_0D1CE56AE649524D9EED17D23604B843" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_A43D89302B6B5C7DAF663E7158A9A8C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_AD7A0A17959E3CAE08A219935814ADBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AD7A0A17959E3CAE08A219935814ADBA" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BEEC3A9C963E17AB605A19935815F2C8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CompassionateCareHospiceMember" xlink:label="loc_amed_CompassionateCareHospiceMember_27DD056148480CF08616199358151D9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CD20ED868A7D9966354E199358150837" xlink:to="loc_amed_CompassionateCareHospiceMember_27DD056148480CF08616199358151D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7C4C2D38C155BFE8EE1D1993581531E3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_MedicareRevenueMember" xlink:label="loc_amed_MedicareRevenueMember_A85EA2D6DDC74646D1AA199358166558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F3D3DF69C1A8067CDE9019935816C430" xlink:to="loc_amed_MedicareRevenueMember_A85EA2D6DDC74646D1AA199358166558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_F2A3CF1D1CD17764D17719935816EE15" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_F8CB8C1613C9F52FDEB21993581705FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B8E0082DA0B9A8263C0199358168844" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_F8CB8C1613C9F52FDEB21993581705FB" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearAxis" xlink:label="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearDomain" xlink:label="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_D9EF5B99BA7E67F6E589199358172A2F" xlink:to="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_AF0A0F33C87E1F24CBCA19935817A43C" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_23F3BA869C5BEEE38C4E1993581724DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3C2121DD254ADFAF2C8B19935818D153" xlink:to="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HomeHealthMember" xlink:label="loc_amed_HomeHealthMember_11E2630B27F1C03272A219935818C8B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:to="loc_amed_HomeHealthMember_11E2630B27F1C03272A219935818C8B0" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMember" xlink:label="loc_amed_HospiceMember_FA8587AF263CFC2031E719935818D41F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_F682B8777E44700FA36F19935818DDC6" xlink:to="loc_amed_HospiceMember_FA8587AF263CFC2031E719935818D41F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D5182672AAB4D4F69B9519935819749B" xlink:to="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A07E78E93689C62C17F719935819270C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:to="loc_srt_MinimumMember_A07E78E93689C62C17F719935819270C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_29D7EC03F11A10A0DEB319935819BF2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D12C75B192EC3A78561019935819630C" xlink:to="loc_srt_MaximumMember_29D7EC03F11A10A0DEB319935819BF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1E3BDC54A89DF6F373EB19935814E845" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26E8CB00BC881C4F47BE1993581A09DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26E8CB00BC881C4F47BE1993581A09DF" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_06CF2398175C89769FE01993581AFC70" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_60D6369DADAE61A3C31B1993581AF513" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_A588F00F50D7041704FD1993581A7358" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1EDB442E5FDF053B5ED71993581A1576" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_0FF27DDC19227EE8AD3D1993581FBB7F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_SecondThresholdOfServicesRequired_1369DC9130E7D45604F119935820A184" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_781849812451EA6EC0401993582032F8" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_7D500282597553C8F4AD1993582053B3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_7D500282597553C8F4AD1993582053B3" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NonMedicareRevenueTermRates" xlink:label="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_NonMedicareRevenueTermRates_21E134642E4425FA858619935820932F" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_A6936F9404DA8DD3BC5919935820FA05" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7229C1DFCBCC85E3B967199358195242" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_D65E0019B25D9CBCEEDA199358209310" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B42D756B4DA35D8AB43C2CC714AE1B43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B42D756B4DA35D8AB43C2CC714AE1B43" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_2DB18B4295B65D0DA374944C9C574246" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_FinancialInstrumentDetailsTableTextBlock" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B42D756B4DA35D8AB43C2CC714AE1B43" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_23E7704600C15018A410E278EC2C7D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B42D756B4DA35D8AB43C2CC714AE1B43" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_69BC3D8914A1552E9A66B48FED86399E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_65B1DB13D9495907BD8BC3F36D8EBDEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65B1DB13D9495907BD8BC3F36D8EBDEC" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6FBB9F5E0C4159E4A51FB8188DE6B16A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65B1DB13D9495907BD8BC3F36D8EBDEC" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2C13161D1DD35355AEA7D59F3C2258AB" xlink:type="arc" />
    <link:loc xlink:href="amed-20190930.xsd#amed_NonVestedStockAndStockUnits" xlink:label="loc_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8763A18029935B03B9B864976E233612" xlink:to="loc_amed_NonVestedStockAndStockUnits_E524B78E1EA0557F9071F4EA9B1D04EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65B1DB13D9495907BD8BC3F36D8EBDEC" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DBED37BD7DDA5756B997DDA361DADB15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65B1DB13D9495907BD8BC3F36D8EBDEC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80A5DC325BFA58829FB61793AEAC263E" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %-EEC@B:29UCC499G. !]:Y_P 0>,++
M1=T$6+F[_P">:GA/]X_TZ_2O.=5UW4-9FWWTY90<K$O"+]!_7K7/4KQAHM68
MSK1CIU.WU?XA6EL6BTJ+[5(./,;A!_4_I]:XO4_$>J:MD7=TWEG_ )9)\J?D
M.OXUET5Q3JSGNSCE4E+<****R,PHHHH **** "BBB@ HHHH ='+)#()(7:-U
M.0RG!'XUTVE^/=4L2J7FV]B'_/3AQ_P+_'-<O151G*.S*C)QV/8-'\4Z9K6$
M@E\J<_\ +&7AOP['\*V:\&!(.1P:ZG0_'5]IQ6+4-UY;],L?WBCV/?\ '\Z[
M*>)3TF=4,1TD>H454TW5+35K47%C,)$[CNI]".QJW76FFKHZD[[!1113 ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
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M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
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MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
M9NL&ZA7%O=DN,?PO_$/Z_C[5ZE6?K>DQ:UI,MG+@%AF-\?<8=#_GM656GSQL
M9U(<\;'BU%2W-M+9W4EO<(4EB8JRGL145>4><%%%% @HHHH **** "BBB@ H
MHHH ]6\!_P#(IP_]='_]"KHZYSP'_P BG#_UT?\ ]"KHZ]:E\"/3I_ CRCQU
M_P C=<_[B?\ H(KG:Z+QU_R-US_N)_Z"*YVO,J?&SSZGQL****@@**** "BB
MB@ HHHH **** "O6/!FB_P!DZ*LDRXN;K$DF>JC^%?R_4FN-\%:!_:VJ?:;A
M,VEL06R.';LO]3_]>O4Z[<-3^VSKH0^TPHHHKM.L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
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M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
MMD*IW7@S0[I<?8Q"?[T+%?\ ZU#PLNC!X>7<\CHKNM1^&[JK/I=X'/:*88_\
M>'^%<=?:==Z;<&&^@>%_1AU^A[UA.G*&Z,90E'=&MX>\67FB2K'(S3V>?FA8
M_=]U]/ITKU&PU"VU.S2ZLI1)$_<=0?0CL:\/K9\-^(IM OMPS);2$":+U]Q[
MBMJ-9Q=I;&M*JXZ/8[#XD?\ (#M?^OD?^@M7FU>B_$">.Z\-64\#AXI)PRL.
MX*-7G53B/X@JWQA7LGAC_D5]/_ZXBO&Z]D\,?\BOI_\ UQ%:87XF5A_B9JT4
M45WG:%%%% &?X@_Y%S4?^O:3_P!!->+5[3X@_P"1<U'_ *]I/_037BU<&*^)
M''B-T%>B_#;_ )!=Y_UV'_H->=5Z+\-O^07>?]=A_P"@UGA_XB(H?&=I1117
MIG>%%%% !45U<Q6=K)<7+A(HE+,Q["I:\\^(.MF6Z728&_=Q8>;'=NP_ <_C
M[5G4FH1N1.?)&YB^(_$USKUR1EHK1#^[AS^K>I_E6'117E2DY.[/.;<G=A17
M5>'_  /=:HBW.H,UK:L,J,?.X]AV'N?RKMK3PEHEFH"6$<A'\4WSD_GQ6T*$
MY*^QI&C*2N>/T5[8^C:7(N'TVT8>\"_X5C:EX$TF]C8VJ-9S=FC)*Y]U/],5
M;PLELRWAY+8\LI59D8,A*LIR"#@@U>U?1[O1+TV]ZF,\HX^ZX]0:H5S--.S.
M=IIV9Z9X-\5G5%^P:@P^UHN4?_GJ!_4?K76UX7;7$MI<QW%NY26-@RL.Q%>S
MZ1J*:MI-O>QC'FKEE_NMT(_.O0P]1R7*]SMHU.969=HHHKI.@XWXAZ5Y^G1:
MC$OSVYVR8_N'O^!_G7G%>Z75M'>6<MM,,QRH48>Q%>)W]G)I^H3VDP^>%RI]
M_0UY^)A:7-W.+$1L^8KUW_PYU3=%<:9(W*_O8OIT8?R_,UP%7]%U%M*UFWO%
MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
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MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
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MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
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MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
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M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
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M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
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M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,\1
MZG_9.@W-T#B3;LC_ -X\#_'\*3:2NQ-V5V><^,]4_M+Q%*$;,5O^Z3!ZXZG\
M_P"5<_2DDDDG)/4TE>/*3DVV>9)\SN7='T]M5U>WLT_Y:/\ ,?1>I/Y5[5%&
MD,*11C:B*%4#L!7#?#G2\+<:G*O7]U$3Z=6/\A^==W7H8>'+&_<[*$;1OW"B
MBBNDZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802085008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 3,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808791824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th"><div>Jan. 30, 2015</div></th>
<th class="th"><div>Apr. 23, 2014</div></th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,284<span></span>
</td>
<td class="nump">$ 124,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,703<span></span>
</td>
<td class="nump">$ 188,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009', window );">Indemnity receivable related to amounts withheld prior to August 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice | Extrapolated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice | Unfavorable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Massachusetts | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Morgantown, West Virginia | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Parkersburg, West Virginia | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember', window );">Amedisys CIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember', window );">Compassionate Care Hospice CIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FloridaZpicRevenueReduction', window );">Florida ZPIC revenue reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CorporateIntegrityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CorporateIntegrityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FloridaZpicRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue as a result of the Florida ZPIC audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FloridaZpicRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=115931803&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_AmedisysCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803306160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration', window );">Episode of care as episodic-based revenue (days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate (days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FirstThresholdOfTherapyServicesRequired', window );">First threshold of therapy services required (visits)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SecondThresholdOfServicesRequired', window );">Second threshold of therapy services required (visits)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ThirdThresholdOfTherapyServicesRequired', window );">Third threshold of therapy services required (visits)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember', window );">Cap Year 2013 Through 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember', window );">Medicare Revenue | Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember', window );">Compassionate Care Hospice [Member] | Cap Year 2013 Through 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodeOfCareAsEpisodicBasedRevenueDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FirstThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the first threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FirstThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SecondThresholdOfServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the second threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SecondThresholdOfServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ThirdThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the third threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ThirdThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790226624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases', window );">Debt Instrument Carrying Amount Excluding Capital Leases</a></td>
<td class="nump">$ 240,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">236,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingCapitalLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Capital Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingCapitalLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799989104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 494,631<span></span>
</td>
<td class="nump">$ 417,335<span></span>
</td>
<td class="nump">$ 1,454,955<span></span>
</td>
<td class="nump">$ 1,228,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">288,708<span></span>
</td>
<td class="nump">249,739<span></span>
</td>
<td class="nump">854,734<span></span>
</td>
<td class="nump">730,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">99,941<span></span>
</td>
<td class="nump">79,367<span></span>
</td>
<td class="nump">293,127<span></span>
</td>
<td class="nump">232,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">6,298<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
<td class="nump">18,451<span></span>
</td>
<td class="nump">12,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">48,474<span></span>
</td>
<td class="nump">40,335<span></span>
</td>
<td class="nump">140,284<span></span>
</td>
<td class="nump">124,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,366<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">12,440<span></span>
</td>
<td class="nump">9,882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">447,787<span></span>
</td>
<td class="nump">377,447<span></span>
</td>
<td class="nump">1,319,036<span></span>
</td>
<td class="nump">1,109,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">46,844<span></span>
</td>
<td class="nump">39,888<span></span>
</td>
<td class="nump">135,919<span></span>
</td>
<td class="nump">118,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,778)<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="num">(11,459)<span></span>
</td>
<td class="num">(5,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in (losses) earnings from equity method investments</a></td>
<td class="num">(812)<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="nump">6,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
<td class="nump">2,782<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(2,600)<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
<td class="num">(4,876)<span></span>
</td>
<td class="nump">3,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">44,244<span></span>
</td>
<td class="nump">41,373<span></span>
</td>
<td class="nump">131,043<span></span>
</td>
<td class="nump">122,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(9,919)<span></span>
</td>
<td class="num">(9,825)<span></span>
</td>
<td class="num">(31,105)<span></span>
</td>
<td class="num">(29,984)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">34,325<span></span>
</td>
<td class="nump">31,548<span></span>
</td>
<td class="nump">99,938<span></span>
</td>
<td class="nump">92,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="num">(760)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 34,132<span></span>
</td>
<td class="nump">$ 31,377<span></span>
</td>
<td class="nump">$ 99,178<span></span>
</td>
<td class="nump">$ 91,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,211<span></span>
</td>
<td class="nump">31,815<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
<td class="nump">33,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">33,002<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
<td class="nump">32,944<span></span>
</td>
<td class="nump">33,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6782336240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES Weighted Average Remaining Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted average remaining term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, Weighted average remaining term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted average discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>21
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    "  -0UY/F5R<(Q &  "<)P
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MGX?QUJ7[[G(X>7D8VM-\\%I<3W_7_P-02P,$%     @ #4->3RG,)1Z8 @
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M/0G/V)2'NOL[VKS635GT44)7BOS[^7-_[#[?^_@?S7 #[AOPI4%X]F<-5-]
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M>3J%>@D@1V%(#;@>2$.*4-*0(E31D!I,M 80K3"D1E*H2?S']OP=A!G/JWL
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M,.1BU*4:CL.JX8!J>'X$G.1[1SJ*UQB<E YA\T LTL;PPOD4X)+-(^6YS0-
MN7H D^@K$E\]@/O("/F,8FES0-J\F"EP"Z-T\7&QU!D6-X?$32R?E*W '>ZD
M!Y0G@Z7-(6D3(P?2IDL53H>5S:&:%O=X3DJ6-N+19!\J3P?KFD.ZQCV> S6M
M1-NEY<:"Y9"KYQ[/22D2[!%[/1Z(4O)XA.6,D.?G'H^D (5@2F^F$)8@0IZ?
M6SP"#%[QMZ,F?:@\'4S@A#P_MW@$"-Q[4[CL$&9O NPM+!XAQHW<V_:A\G0P
M]1%R]2(=\*#;!E[PF?;"\H0P/1(J07%Z)% .LIPH9GVH/)W""T6 ((7!(U#
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MIJM[E^Y#WU\O=?5XOMG63]UP&?OK]G1R=KKIFL-T*K@\'TW>_P]02P,$%
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MZKFE9"G^,UQ!^?"@Q.>H4-FXDFJT#O7"XJ5H\3KOLH_[--]DZ0+;!_ %P%?
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M+AQO_=G,8S8;3@_I!Y'E&U=_ %!+ P04    "  -0UY/Z0"1W+0!  #2 P
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M/+MIS"8CV'[^06SYQN5O4$L#!!0    (  U#7D],ZT@8M0$  -(#   9
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M>U/Y9-B*L.:*-RY[+6F6Y.3JA1;,:<;0#>8=09SZ:D%C%B?Z#YW&Z?MHA?M
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M#G,]6XSFXG_"!;B%NTQLC$)R[;^H&+218E:QJ0CV/JUMY]=Q.DF2F18FT)E
M%\+>QR%3()_Y S,L3Y4<D9IZWS-WQ?&!VMX4SNE;X<]L\MIZ+SG=[5-R<4(S
MYCAAZ H3+PABU9<0-!3B2/^CTS!]$\QPX^F;-3W>A062H$#B!9)_2OQV56(
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M%^.FB9VKH;\,"R/;L762J7\7?P%02P,$%     @ #4->3YF\;2O% 0  -P0
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M:LA/2#0<\,&0*$&!YR6(XJIV\\S$7GB>L;,D50TOW!%G2C'_NP;"VI7KN]?
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M!C'G_,B8!&71>U)+4JJW91@0.$K=356?=S=L-Y"LZ1\/-+Q@^3]02P,$%
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M&]7G]LJR \F&Z3I&\W]"\1=02P,$%     @ #4->3U]>U(B< @  (@D  !D
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MK\PRU6O1C>UNHWC;WTB"X5HT_PM02P,$%     @ #4->3]T3*#"D!   MA@
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MXP))MG]?P%ZO W3;/ 08GSDS9[@N;XP_BS.E,GAIFTZLPK.4_2**Q/Y,6R(
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MID%#CU)W<]7GPX4\#"3KQ[=&-#UXUG\ 4$L#!!0    (  U#7D\RK8,L.@(
M ,@'   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)55VXZ;,!#]%<0'
MK#&87%8$*=FJ:J56BK9J^^R024!K,+6=L/W[VH9EL\D@I2^Q/3YSSLR0\62=
M5"^Z!##!:RT:O0I+8]I'0G110LWU@VRAL3<'J6IN[%$=B6X5\+UWJ@6)HVA&
M:EXU89YYVU;EF3P9436P58$^U357?S<@9+<*:?AF>*Z.I7$&DF<M/\(/,#_;
MK;(G,K+LJQH:7<DF4'!8A6OZN*$SY^ 1ORKH],4^<*GLI'QQAZ_[51BYB$!
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M8-QV;O>JGRW]P<AVF)MD'-[Y/U!+ P04    "  -0UY/U<+W$HL"  #7"
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R-ENUNFS 4AF\%<0$8FX]
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M2IGI0<_%^&^/@>+]]&RA^>W,_@)02P,$%     @ #4->3Z3U0#3P 0  504
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MK)E;Y+G?H+7RUZ4%9?L#*,T)2C,)= "Z\K#'N@"Z\HCPPRFFWQN0M1/ $"8
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M/_BS26.6#*>'^0>1Y1M7?P!02P,$%     @ #4->3\6* G?8!0  R2   !D
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MKUWSHP]N;)[JZOYTL*T?^N%KXKZWQY?KQX.^.4P_'%B=?KUP^Q]02P,$%
M  @ #4->3U;?7N]4 @  XP<  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&ULC57ICILP$'X5Q ,$FRLD(DA--E4KM5*TU;:_G<0): %3VTFV;U_;.)1C
MLEU^@&V^8\;C([TQ_BIR2J7S5I6U6+FYE,W2\\0AIQ41,];06OTY,5X1J;K\
M[(F&4W(TI*KT?(1BKR)%[6:I&=OQ+&47618UW7%'7*J*\#]K6K+;RL7N?>"Y
M..=2#WA9VI S_4'E2[/CJN=U*L>BHK4H6.UP>EJYG_!RBWU-,(B?!;V)7MO1
MJ>P9>]6=K\>5BW1$M*0'J26(^ESIAI:E5E)Q_+:B;N>IB?WV7?VS25XELR>"
M;ECYJSC*?.4FKG.D)W(IY3.[?:$VH<AU;/;?Z)66"JXC41X'5@KS=@X7(5EE
M550H%7EKOT5MOC>K?Z?!!-\2_(Z@O-\C!)80_".$[Q)"2P@_2H@L(1H1O#9W
M,YE/1)(LY>SF\'8]-$0O.[R,5+D.>M!4Q_Q3\RG4Z#6+@R3UKEK(8M8MQA]@
M%D/,!L"$:(AYFF+\(6([16 <=!A/9=*EXX/I^$8@&(2!88$ % B,0#@0&$6Y
M;C&QP=1ME$@_L$\(^H2 3S#R@3 A;!*!)M%$P$=X5)1HDLRH;-LI B<X1#X<
M20Q&$@.I1+# '!28?[RP"2B0 !'$HT7<8J)>IGZ(DP ]F/0%:+0 C.8C(PB3
MP"88P?L6_;^V&PN:E.[!2L4/C@@,1#O9_RTHZ5G-@]DB6O2>!Z[P3L;^U#5"
M8U<(-%X67N\LU-??=\+/12V</9/J6#6'WXDQ294@FJGBY^K&[3HE/4G=G*LV
M;Z^=MB-98Z]4K[O7L[]02P,$%     @ #4->3R!RT%4W @  Q 8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&ULC57M;ILP%'T5Q /4?!-%@-1\3)NT
M25&G=;\=<A-0#6:V$[JWGVU<DH#7]@^VK\\Y/O<:+EE/V0NO (3SVI"6YVXE
M1+=$B)<5-)@_T Y:N7.DK,%"+MD)\8X!/FA20U#@>0EJ<-VZ1:9C.U9D]"Q(
MW<*..?S<-)C]70&A?>[Z[EO@J3Y50@50D77X!#]!_.IV3*[0J'*H&VAY35N'
MP3%W'_WE=J'P&O!<0\]OYH[*9$_IBUI\.^2NIPP!@5(H!2R'"ZR!$"4D;?PQ
MFNYXI"+>SM_4O^C<92Y[S&%-R>_Z(*K<7;C. 8[X3,03[;^"R2=V'9/\=[@
MD7#E1)Y14L+UTRG/7-#&J$@K#7X=QKK58S_LI(&AV0F!(00C09[]'B$TA/"S
MA,@0HBLA>I<0&T)\)22ZO$/NNI@;+'"1,=H[;'@=.JS>.G\9R^LJ55#?CMZ3
M]>0R>BF2.,C010D9S&K !#<8WY]@UA;,/6([1R1Q.&*0=#E:#6Q65\%,8&KB
M0\1FCO#]<&)TCDD\N\_06M)0\\.[1".[0&05B+1 ="<03U(=,(G&M$.JOC=)
M=HX)HS2U.XFM3F*+D\0ND%@%DL_7(K4*I!_78IO.\DP][S]7MK">LK"<DDZ^
M@L7L%-^;5'P]QP0S(^CFTVR G72?Y$Y)SZU0K]U-=&S%C[H]3>)K?[D9.NI5
M9NCO/S [U2UW]E3(QJ$_[R.E J1%[T'>:25_*>."P%&H:2KG;&BLPT+0SOPS
MT/CC*OX!4$L#!!0    (  U#7D^K1-8(WX8  .D6 @ 4    >&PO<VAA<F5D
M4W1R:6YG<RYX;6SLO>E3&UF6./KY]_Z*##_7*X@0M!;$8L],A IC%]VVH0%W
M1<^+]R&14I!M*5.3F0(S?_T[Z[WGYB*$7=4S,3$540:DS+N<>^[9EW\IRRI:
M9^E_K)/3?)U5__KJ<'S\*OJV7&3EO[ZZKZK5FS_]J9S>)\NXW,]720;?S/-B
M&5?P9W'WIW)5)/&LO$^2:KGXT[#?/_S3,DZS5__V+V7Z;_]2_=MI_I 4T5Y4
MWL=%4O[+GZI_^Y<_X3?\[4GT*<^J^S(ZRV;)K/[M=;+:CT;]7C3L#T[J7UY,
MJ_UH.&[_DF==Q7?)?OVK=_ETO4RR*KIY6B7U+P?]O;]VOO#7=5Q42;%XBJZ2
M55Y4]0>K8MT8T+U\F11I/L-]1N_BJO&<;O7_^C__IVT_?M%%G)5IE>99QR+F
M\:)LC'Z656GU%+U/%TGT>;V\38KZ$_V]X<'PL-_QXE5REY853%U%G^-E8_C)
MI[-WY]=_OX[./Y]VC'">3?,"UAOCTGO1=04PB/(B(IPKGN#GK F[LX[!;N)O
MT?D,P)'.TRF-V+&KP6!O-!@-COI=&YO,9H"5)2ZH  QNW=WH>'P0399P?M,X
MBWZ+GYX=:YVV'#!^&$V>>_<4_JH_\TM<X7'GZ[NN@S7;:,&MC\_.>IF75;R(
M_CU=M1[$4?]X<-BX8C0"7/[65X;#<6,9^13FN+S/LRXD')X,]X;]T:#^^4U:
M >+F\RB)I_?1=!&7#4)RFB^7 *3K*I]^[<'%+Z*'>+%.HM?]_7Y_$*V &A %
M:@Q=Q+,TNXNNGY:W^:(-L>N?(8JXM23?IO=Q=@<?9-'C?0J?%'15DJ))S3Y/
MKM]-&M1%CN)T711XO_E2TXK@*->-??Z]24/=#8-9XVF5/B1(86(=<@,M@.L'
MZ'*7%PV4^Q@7L*G)=)K 4_#,C)_O&.L,+L<=KOE#D3]6]X 0RU6<==V3ZV6\
M6$2_K,LT2YH'J0_=)_#0YH'",[\F!A-=K"O Y0P/M7&:0$%G1$7?+^+&MX[$
MOD]+1-2_)X!$[^'#QA(W$FAY6\A]Z_M_'75M" 8HX.5S8(;?HK\DC8WWX;_C
MD\/AX;"!_X(_=O%=O&9O;S#<:]ZRTXO/UQ<?S]]-;L[>1;],/DX^GYY%U[^>
MG=U< __^<OTNVGF]&[V.TBRZN<_7)0"YL;5WR138V("8\G'7&N'Z)E7YIO%U
M7-Y',&@TQ5^2_UBG<(7A^<8DET#R:9SI%+E'"7=NFL##MXO&5B^+9!6G,[BG
M(+F4S;MS4=W#+9@&"VN0B!QIX^9G+@L0C0HX0EP_+GV%R-"+,N I0"M@I>OE
M>D$7:9: Q#1-F6W!=Z\'_4'OX."07GU],NX='#5.]V*%MQ!OV"*)RR0JTKM[
M&G@-?[2OZ$.>SQ[318.D 9D @I4"K.3%UD7&2Z1"_^D7.3KL'9V<\!I'HUY_
MW."H[Y)Y B": 7Y,<R"15?RM"]Z;X-S^G:+.(HUOTP7(/TD3?R:*#JOXJ147
MXJ<B!Z)"1[1<+?*G)(ENDRR9I\T)83"0YKH11Q=$U)IAM,BSNSV@P<LHOUVD
M=P2[;=[+:X=K]K@9%3<\^+%M+3V8H"S=Z[*$YW#-S++E '3&6T&#][-A'TCB
MTPKO4DGG=@K: BPMR:;P\/_S?Q\/!\.WGW,0K.KB"2HP;\I5/$W^]17<MS(I
M'I)7_Q8U""]<U>JI@4I -@292V8N*D:H7-&+QCV@Q?B_:#91O*[N\R+]SV3V
M-LI0QDG+$C$(A-R\FR<)#^N<YK"_:1ZXE>.3D][P:$30@3^'XV%O>.P>YC6\
MY6_AFP-XX6C,?PYZ)T>CWK@_UH<W+!,D15(ZX+20GNX!#YC&JQ1.KRE0 =:L
M0:*7+<55- 7I,CKHC6!IAR?'-/D!K/FX=W3DYY[#8QX4+=?1T::<:3:(!D5R
M#Y<3!1ZF.?6WKI(*5%&\Q7&1P:XZ\ _D@EE:/@%Z@Y:RSPNXSQ>SI& 4.WI+
M)+TIF'_.85I@V4!5\+ZD*($E91=E:Q^C<04<"VD^NXE#[US&>"GODPK4E,7N
MUAR;- :27. (WJ=9#%<+Y9=<M,S_=W*+FM^T^O^VY7E=S&X+3M3%@IZ]GU[@
MWUF7,R_N[S[[IK].T0[CXO/OR,W>^GESL3I?"@G!UOL)7]MB,^$+S^PD?'B;
M;837W]W^S@DL1E_?P(]/9Y\!FR_>1Q>79U>3FW-XP."RDC6#T+UG$'RTM8FI
M(;">LR3CKTCW9?@,,A0RF70*TEGRD&1-4] I @(NF3S60^5QL29H!C(A7J=-
MR/\!1!;4$NBYV3+-R#1#>I]**PV&=ATOXD*)2Y?, ^1LCV1OI*TP3NOLQ-V;
MLM\+UN\%C$ZIW#W13M=9PA Y<T=&V6UL^ESH<<<H[FL9H%TV0-S:6>1 H,I=
MQT>B>9$OA4A'RP0N'8J]#S#8LDUA^01*&:BS<98 CI*\W<X%F+.Y#<FZ6U\0
MU+Q-YGF1;!2YS]UW71M%W&T'D?\&;G)5I+?K"B7KJ,I1Q-F*]VT8(N2[3:M7
MF4X]Q%?,\XD<(1%HG/;6$P6"AO#Y7G1+TSU#;7]+4/%"YO0 &'J7M$A.;J0.
MBO<N7:PK(Y+\X1N;R82_Q];<6"\GY]<W%Z=_^?7BX[NSJ^N?H[._?CF_^;NA
MK-N**W11-AG_-DBNER*YGCXCN;:/8T03IC^G@01ZOED"/>N00&LBY'G7-?H%
M"'B&3./:'&XD) JXK#6\''6\'.VD@F- RIY[YQPD WH).1;Q\CVO-?,'JW4Q
MO4<5<07#_^C[G3C5-M!!?[#S=7?K><WCST[SIYTI_@!JC5BSB\, J=M#VJX"
MW0^\VCG]V;>DF*:E67:^:E69.Q^TI]M@_Z2QS] J+7;2QA-\VXM$#Z5IOFXG
M^$ 32B9*+:S^R@TGP&@;X:6HOE%DZT#U;=[IG/#/Z^S%$V[SSE:7>=L)MWEG
M*Y V3-M;@+3KG:U NNV$&]_9P'E.)]>_1N\_7ORVO1F;3-'O%_FC2'I>()V@
M@Z7#_CC[QUH$0.3-(! #OJ/'-?,,' 4G^(ND[%61/Z2@DD2W3\8&&'=/(&1,
MJ&@1+>-J>M]T<AC++8KBZ7(5IX5J^'5CXQ:6Y(\@_*)_"R[Z*B]13)WCVEMT
M_VX)^CL%YTG-##U3Q7J6W%:DO!*BH(I9_HD^@T62%;B%$:^+#+>1Z*)TUL;A
MDT>/E$QS+ 0:VFY@$!7;.0)Y*E9T&)]M)\T3W&!;;9/ZMD*3YW#WG#;Z#.Y>
M%ODT26;R"AQR$H#;*H3,1CO=(&88D)+<4-LAS+E'!<*:%CQ)FCN^%!Y3;C_1
MQ)P2OG4KWDASI 1\.LTV7ZZ>#EP;7)DL[F4G(]:VEYQ,VI!NUBO$Z6VEA^=&
M _KT$B%/I(;'M+J_3Q8S7@R_)^#8O(#;O"CR1R(,:Q1/(G(8+/+F3,^\5R0/
M^>*!+A:<(QT?G%K:0@96\1/C%Y[Z]PYS60 ]3U=D#??#;>7R>->D7%WX+$9Q
M]("W"YZM-&)'4'(WFCO\ZL9)42X+(D<[LX1_0].#7( M_+&=CEODVK?)79HA
M[:?+25[Q%[T/8FOWF]?KU6I!"B0<Q3L@_8L<-#@F!.ZV 07D@#4XCG:G,[F(
MX9E.D;3^E+>V.')1)'/ (?5%MT5_W'RY.@L-F[W(BRWP=S3Y_"ZZO#J[!LF%
M/X"GWY]_GGP^/9]\-%)-@ZT4=W$F;+*'/K(R7Z0S+P)<H@,,8*1LU)OYG0)>
M;K)M_HY+KYDL>E$,DNLB?@0Z$@418CM5?I>0GHW4)4IAA5.W,52GUK=E.DO)
MJMF+G,4="!B\DZ3(H2+TW@S[;]V4]/?@K7[^F-0_6?MGX)SEPWQ=R(=P+0 G
MH^5Z4:5[)86PR<TK$*SWB!7W2;RH[GOP1[E"8S#"'Y"W) O$%+<I]E\FFU&\
M@B&^I8">R>(I.CKXB:2T=:%69&#"!>(3$[Y/L!,:!/$0^6MU7R0\2884:V^)
MMFZY+25>'M3XDA4<\BTL4J5GMM&&,X]^HD]_< 7;+> XPB,K5PF%*RV>]J,)
MW=F6E?:B1R"$CVA#P3E8 DK0FSEP:]F; L=/YRE\;,Z H3U-\$X#B@Q&1^TO
M\#G9AVFFP="=VQY_:9\ !!L=1X0#?)#P 4+C2Y;BZJ[Y"QP'/WU'.C(+B*?Y
M8KV\3>/]""V<M.W@?IYG!/Q\E69T$?!]C'0A/H!T=)W%ZQG- A=BA@;=67@U
MYNYZE_YZH^8=X[7 " BCJ>S@JRF++C $H@*IZD P%TC,UD5!',2_L@LD#]"W
MC(LGO&XK7GPT!RT#7X:U^P6LQ(W8$X0JX>J41@^AJ 0Z5_B:R/^<Y"-<*.RY
MF!&7I(OR9?]Z/[ICWP?, U\CLLPT"@@7N6*VO #([\CEI;<^3":7[@H[.I\N
MS4(+C;O;CRZZ5NI07E]7+!<0X&( 1;*\<A!*%ZAIS"A*]8$8.KYO1Z>C;LR
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M'0(ZH8CT^,X'#=C2(3@X#TNN%:EQ@$'<(.],265(Q8F"E+#S+B.Y8==IV75
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M#4@>F@-1>(C3DMJ%8:H16K=*<I:+T=]JAQ+5XKCC,YMBX=I+A7;=@N:%M P
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MJ(/H;XH>P7>X@Y/H^AY6PO&KP;<#<IZ()\&":] G>(UP<.W;Q$GAWHBQ51Y
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M>6.-?^+'&%'QL'G;OB>&@,N'D.09>G8>\YZ8?2G_XAO[@TJB^Z7Z"\CIM1O
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M7W^]=B]?G'\(._3!:%SQB0L:.-LF#5+J]N,%\*/9D[<&)+";J9JKG(:RXL;
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M/>TYY4'"&P@/33? I=Y<I69?4E270O?T_ .@IW.*+YY:$%/=D]+LVM@<*73
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M8VJ?KMU$J$ZNIU@]K **GY)<P6(<XK0QY,")BK'LR5@/@$&1(]141_JMU7*
M*>MDA#"& RZX>(>W!;,LW<3:!BU %D$GCA%KF!I(3@"NWF<Q,0CBC4WJ7X/>
M J#?+W*R1O38>HB" #!;\E%9VA1'B$"1<UT1Q-F^9.7:6*U@6#6O+R7YIQHN
M<)_[4=T:?'TYO^Q&2S%280/C]K'Q\/@H]4&?,_OTMC!OX'(3[M3A,)NU0NF8
M\+8NJ/B 6]XRH?ABD/.1U)G^TT\V^LZ?OBL9C ,JP(V!(@B)2!W[0@F1C?1B
MNZ?*<%&P 6<939<^]YJ$A5NJ(,?B 3FN2<=\!-VXO$]7WDS57$^M7!X>LK,N
MS].,7;EXUH/#\#1=;F-"IA.@!*L\,+ 8XU*W95WS(04)+0Z@LH/1D1X5 F#T
M6$"&$SQD@S!S:'= M?@#3ZP\R?&5%7T'<S^_!B&@"4SL#H:KNTBE0FDV%Q()
MKQ]=<X1&<B=!T?(ZF]?2$LL,R-DHM'M.96N#"G(^UAOBU0IX9!G9!N\7!4BH
M*/\X,&C+,4SAHL<ON4^,:16LS$LV5$E16I <S:IH\=6ZR- F-LGJ @4($=$_
MUABQLO-J\O'/KW:1@=/!8135?;+@LB!4PE3O,7NBC&Z",3IMOB+)]6);H#[,
MIW[HS*F*)#"[FWN63%-4<-SQV@.4\ZUA$<L8[D4NNUU(, R%UY#X(^G&J$/8
M,7U:3ZT=,3WMDEHPRY?2'$R;!VN7U0B7GI=93Q1;9GJQ=G(Y;-01#Z-=HU(B
MSM%QJTKN;X5@P2FL<XJB(5][GWC3G,<%ZL?%W5I5=[HKV)*QY.*&T@Q/^RQR
M2B,_Q?P  8E<\0&4%L"@S]0.APOXE=IY]0[.FV+L-$ZFP][>O1T]MXVQ@>YM
MTB?@: @]G;3.!^,/;\>?BXGTUR/:C01#?%A3J5>.DEN ?E&A?$I924MI@"H;
MD5/2WDVN;Q#)X5(!OS7(4[T;2'TPOYWLKDTRXR13%%BJ!1\.U^A/EAE[_H0$
MKPJL!\ \0Y?7PKYL/29K2S:LFD?"6@H!0PNONNL5136Z;]-*VI"LX@S XV2"
MR1+&1/3@NOO1Q_CQ"1<XD1QS?,5[%CQNVMW\;,SJ0@C2PH- &IJ9_NL4^&G#
M/O>I$Q%).$X3E 9<5&8IX0@T&=(E.K&BA%MY?6!:S& Q@G!T)#FOL<:-RXY@
M7\@CJXCLPZM<Y6B)I0\(L*^9R=)CF!#1TDBE[CC9IN9\HV;+QGNFICHQ%C0@
M@\RQ7C_?0T5)MI!4=T]K7;^>PSDC'1_63\XQ&"O3+HDZ+)QL2^>'2L\'4GI4
MG>A%'_<_[I_ZR#!]PJM8+#+W[(I;!:#24+8IFXU9J?$-:&3)3K:D19UG\Y1@
M^BL.@ 8\690F4Y*TM/H]1,=@78'DY_O490WT&!/XY43@[Z.. [C2@ BJ*)8H
M,Z5-7L8+X"T N@^_3&!['P'BK_0SD#*\YM&$!J[]8_P5H(_ID?RJ_LT/B/;X
MBE75]A$N@; L%G&I(YPN0+AX1*>E'4/+K[CE:E0W/N*8>!SP3"\T$^%CYP*C
MA,<W5P6>2#LV?#+B!LD9!R8,72]-ZS9Y!>N,8NEI;T=#SPR%V_L&4/VPF06W
M9]'''+?DWK@Q)YXF1>&J)F2MJSUHN>'M$&U9;?^/6BV?G0/:E2$''AWE!LF0
MMTGUB)S:";/LV*5]>VHX&&E8RDVXT>^?@A-)W%4[T0DF)1$R*JN.(0Y.:/5)
M&M)M_IQ&D-_/&X':+%+Q56T1*9[!,2/",&,D;G=H<%0#G3>-W8$2K8./3#.5
ML#GF/<F<CR(4ZX:[=TR1'RDU;!5W)(S_D-[EH&"5BR?-C4FYOSL*;BZ_V]8Z
MHM<3=K)2X ?)QODBOWMB 5DD+C*H3+U>:CR,G62BT?U3WU]+(UDOYM4%G#8Y
M3VN)ZSU1+MJ@Y-R[2"LI#8W> I@GX3-!? YSGUYH=+<!;CZ0P)5P5YXNVPNY
MQ?;Q.,ZH$@++-!*-%OGC'AJ(O2G/Q0911% ]KDF--+7PJ1W3*RXX%7/GT"@N
MFK67@IQ\&YP&XM\Z"]^%-T ZJR2&S4D$(>^PVE?(/> &()G+DMQ5EK&WPTJO
M6#QH(U!8DAT=&Q*^PX%-(,%AA+ZV'A46*$CE+BU?= FV)-FCFXPHD6@G!#T?
MXR23AC@9II1O<1%VF4R=&%(2(*Y04SU78"_W&!'ES=!Z].1(+RF((N/NNY;F
M=M*>;>5H#=8S<4(-(7IP9!HWM@?HD:F ^UEOJ1 2H:C-8]MFRJWG*,/P,/SU
MKA]$5_1@-JN%+[)ZZQ4!5&Q(RY'THY>$+':6-)7>88EJ\EB=]3%79;<7WOQ>
MJ)O%S'REXFY$$1/<76OSTGY(&VOLX6@C&KT>F/7#0UX3*QG<=$E9\U0L2)WL
M!*A?HH9)/.A<>R]HM*THSPG?;1_J4[:T(>'F'#J ]V]Z,XOKZ,M.0(!U3E'#
M8I@FCS(LQ=>KAD'F"8<R^*Z\V&3]/EU0MR,7 :6>N.8"V%4MK;.H77'YU7CV
MDL5\CUZ2/<:!N]=6Z\:H/4=!F0;2?7/]ZNO):&V-6J0;0*G=U#%4C6_GC+&,
MF@U@X0K? )QQPYEU8YZ<6X1S-*,%<CW4F0BR*X1O;'_RJX[ARF;HL[X4!9XV
M89*/Y2:<\OV,'5$%S *1A^0;\J^Y$$2:BX(54C1][T?76$/&\6Z?Q.D+06-N
M?_% WQ4J>$C0Z7HE)(#:"9%&X8LT4?4_3GX7;[/'"G(P8Z;_BL,$"-3$_P>&
M1\RE:@[:R!^XOQ2A$%'HN?24V82\M0DQO (1!QM2F F][+RBAHM3<D4Z-T$[
M]F\UMFU$:,=N)!M>GWW S+_H_//[BZM/5#"X\4AR1X3BBO "#Z8[E[!E.&[H
M91,&* Q:3"8XG,]W$X\';IX+(# N<N$V#5PM>3WEF^@>14.E)6K3)+JA^:RH
M4PHF^&=U!,W10" ^8AR3$XNL'Y7MI=+%TB,$>SVQ6>EMHKXB5[T<#N@N*;"@
M&,="3V%C63I%$[SC[X7O%@8'Q2&Y!37O1KJ1(@G2$"B)M"')8TD R2J_QRH&
M@J:;5'_<75@;=@67-F7)Q'G28=0YAK<@EY:58.LZC"'2 Y$[F6*C'4"G5-NJ
M!?!MFTW>9_](;3<DYI:E$%*?&$@)B#&V9(13@;T&]1))+- JB=-\L5YFS733
MBIF>%+AF7S\1+VO0]J&P)N"QQ?!:KE<4_3-?9QH%[YM&6H6G=);#F-O:4Q$B
MZ2+0<[&=MORLU+NYHU >4TZ!@S?=LJ@YTE0Z(?3@"R X/+H/Z3:+QN!Y#;@#
MU%O#0%2\85UH;\OPZ?WHDX= PJUBDU)U51=1B@VMN+F\'RP0HMMZKS,E=Y=7
M[VRS>G"FXPN;]3&9+G&%2^>@0EEK34UN*&:@4X>%'$HAPX=5:C#EG<1+QHH7
MC8M-1V0"W[R%V:7P)1&OI[4&S5,*ZO,P<B[()2A(+CV\$&NM#.J;,5"]RO;R
MZ_O?U12*C*#B==&XT$N]SZ2+<68$U]5N[SL^&J#,^3H:' ZI+/X0>R*9RNG2
MF/PTESY:/$!/8L08"J9W#1V.+=<W.#X&'>3X +LP84,#'7@(GQ]I;L F;TET
M-,:Z_U@+? 1L]J /RQR,L6GNN\T34W'+ ^KBA-W-#X(6ZF[TX>$8!Z1M#X[A
MUP,T5AT<' 6]C>0V[*"2O4M=VF%4^#$@8 VI,<(.O2G?'G_'@1[_+@<Z/$%'
M%K:HXCX'@Q/J(F\.=( =YG_@0+'GPQ@''^"IN@,].-GR0 _1/#'$7A%XH".4
MU@9#'&KS@6)I,A2&^$#[V(:^]4#'./(1=@J"C1Y&(SR5T=%1</R-\QS1)1@>
M[W/+>@3<SDC/<W2R_UT=V'Z/XSPY0+,YK' \I)KXAT/"/'^<@][!&$_\NP]T
M3#=_>##&2W((O^K8QW3+MCE18.OP\@DBP F=)I[/P7A _0,VS3VBIB%#:A5R
M!$\/ANVW].@8%S:BBS4>TX-X)H/>B-"[^V '@*C'=!O&]/.0@+G#K],#H_'W
M'.[O<U>/C_J$=Z,^G^IX3&=L#W<XQ.XIWW^X(VQ(-("!A]$!_JIC'XVP6<-6
MA]O'EP\'=+CCZ 3Q<'2(8-]\MD,BOL=TMFB708BW'>T!7FI@L##^&-\!- *D
MZ WZ.-N&DQWQQ3@^D'8N=+#T,GT-Q/RHH=/\.KDZBZ[.+K]<G?XZN3Z+ZA_4
M7SCC<C8;M*1G!FC,2(3ANL(N]:"%:65^C=R],&5WAV/3M0(MZVM*2"7[,JI5
MS4RN*.9<@O\DCWE)DQ2)*?\O*60<\>PBRU#S,8^I!Z'?MZ8H,HB80C_2T),G
M"<,\M5#Q?O2EO=BW6\BC5A-?<%>%W*Z#NHYJ[*D)]R9['2"/"-&V@0$(I;<+
M7) .0HH867S3!Q1$[;/L@T3KH%=H8E]$7:/<I0 3:C48AF\JA7)Z:C.Z--P1
MN\4H)>=J#>,.^K?CO4&T6L2<CL6UBR3"H##%G PL)*Q>G"G..Q?TFS!/LX<,
M:VG[L)O;)ZLD&7=WMB:ZAC'Z'"AN+5#-^JO2#)9:29".0L\]H!K'.H8&P,CI
M^"IB07H$AO#D!;E<IO$JK6J [+EAG*W E",SQ5IYR1*J.5.CEZ(0E4MF- KK
M4Y KK/UZ-.RZI,N_H'+C/O.':X*3N>-:;N- :YT]^M8<LVC8.X#/1OT#7Z:3
M+YBY!?%\GJ+NSPKV7_YRY2I0S1[2DD+UOUSO2A $?(TY :ZP)E?U3O;NX\5<
M7O^9*CAD>YI>=9\O.)!4U'$7TP+P/MH?_.1"XES93DL19*6:F<+O_ER&E(+M
MLNR#:#8V>8W"Y8$)$E \5#>$E%XEI2]TE?F#Y,LAJP%:^?IHM']R*.3.@:.,
M3@[=AE!!HRW0&L,^*^W[R,/#U' >OP:=GP,ARI(MPQ@X65!+1$7,AAGOZNSC
MY.;L770YN;KY._9!_WP].>7N7]U?-081>'$*S8VE>MV\;/OA3_8WK"5ZQQ?(
M(3E5'XSA'(R5U!1@!V3[E,SB17Z7?L.(++;L2581>9*EL%LL$2OQXJG"K&]1
MS]]&I@2(A VK_48\ ;X G-2G8V_LOB[5W_47EFFE_3FS.]LBFNZ^O@D;I%J3
M-A(F+'W::ZM'0GD/I7CN':Q^+@TL@)U4:.IIXM/UET^?)E=_CR[>1]?G'SZ?
MOS\_G7R^B2:GIQ=?J#I<='GQ\9P*Q.U<2@[G;GV07V(IH'+)MX<DO*T>PO R
M[F,,PB69M9" 3.7L$/CKC#)GV._6YH'SI26,+TYK:2._Y(+ _/F.F SI.N<+
MA#^L2&IA%,C+"PX3=J_L1@!LX#"4BY-KLQ%@+2EZ(#3UEQ>@Q?,YB:>UO(7/
M#?!%+MI$#2H X;TP\#5BU\Q8'K4EQ<)D1M%;'R:3RR M@B*=TZ59:*$6?K;R
MMA?BT% >?5VQW?=;42.60H@-IM1)$"^E$SW\Z*&'0&=(N%<6I7PZWS'7+4DD
M29]E%/8\^K15^HHX_ T'>7 :Y[VF*F(]"+DR_Q#KKBW6^QP6V1)WW$//-K#%
M,2:<$'WE$K[?8_#/H+_W%[<YVE5']&V3,&.$)L4JRR&#Z,^B/:VH]GST;;EX
M4Z[B:?*OKU;B1'LE@\!13&8YX4SG<$$\MY*L@+4W1]!TE#+Z0JXY3!>Y_O)J
MEX+8]OK#GK8&W;F!2ST%!6RX^S:"1VC#>WV8YR/"]0P>(G)\B=R&3-QGH/3-
M4HTB([;DZN^XP2(S&,:@GYK.L=CU$SL]2=*N><NMBI.@_0BPG!OLH8"[#-[>
ML1WD>M$K-Q1L58,0N6MM0DG51>Y*H59^Y43JX^E]SPD8+O4XH=R3TH&3PSA(
MQ4A,C1M:M2OY(<%#6L?4M?=CQ81M_:Q6F:UCO?3$M?KV#4R\/SNNM4)]D@H3
M=_?57C[?6Z.P3)U"=EZY3KZO=EWPF:Q2DF0HJ1=$P)CKK\9P?B#7HQN&.V:1
M@I([RW?T-0G=+/$MR(TT)NVX(&>=UDP)$KK=O*S/A)(4]W_3BRU19FHO>"N"
M';\@V$/C^+Q"#AO"@!92<<4DH5!S5HW&(!3=HNDUKK>U3=@3-9#12)YD+/BY
M7JP6E:%UL?G L:L51J/BI>_56)(%K&;PJ$]=-<69*QY;FL(S3BBR:.I(O@M_
M1QR8<5 >^V.%1T@<8HV\:(C.8Y!CP\[$DBJU@WZ[D@R=E:,,B5(&":F7=",E
M3W%E[AR!ESB(=F7#3;P"*OE59*2V<5_Y.&WDR%QVA_5%[D,MCOJ4,N$SUY?#
MAZ_S#=*"?%-QT_&G-1QASQ6?9*BS&$75)V#!]<-;"&@U*ZD NQ;1;^Z#$ETE
M$0QCV'&F1"AMR4B_X!@M9J]TP[Q5 UY9B^:T1)LBEC^B9:/?D!"S&5E)A^"#
MP?#SG<&N<'Y_55#,@F,WC<!Q;<T.S%(V*PSYTA[>!8;L<H%M>GV^P&_KO=^9
MQN\,=X/UX^P6TYG,:&=P H0I74O5%'1KK@L*4<M978 _[@>!ZS[%K+:P8)_B
M[R]0O,]91;:MV.M:0L6)>&K6V8_JHL,7#K$_TSB;Y[XGP<](DRSK:."'*]<"
MN$[QS%XH1?&2TD*X1I*2L.^2TUO[:J&[U,;Z9A0GL5Y*,R'N$,+I5=[.I<)?
MXHI3OT1=H#FLUD'2'B:-55S/AR58+H$!/'^.C(4C@)&#N<4VU*M++Z,#\'W[
MP1;]:,.C$I_U?:J0QK2K9K666,4)YDF53W &Y]ETWZDEW,@E:C9R 6@ >[0W
MBA2#J<MLDJ&)JUB3@@]-E+J9E9>??US5ZX7%[F"X6YR"+8&!FA^7QO!KXB5K
M(OWW05GCP<.B^#.UQID6#XW2DANASC<$DW=IQ:Z!C1;2=^VF^%Z0=;F^ZY(I
M**6*84_,.N:=^U$V?$6%,3P<@KFI:J1J<MQ'*:9(38D:UA:T_&WL^ZA(F#)U
MN_+%"2AH*IV[N&E*D9!69*YW@-YS'M3%FY1&:_9)<$%S.NRHJ%5DN#))O2^!
M"?KUY_Z/'+Z/,(]W73AI>BXR!HE66>="-T00MZ&3U*&@<Q05W@,;]X)[ELK%
MSE$C.?]82Y9E>(Z!*J8INDN">SM?K*DL08?E2V&? [5#8.4%]UP2A?XAK[PY
M5(5(?_*4W=Q]^O6J!1THP%+(;9Y_Q8SSM4B_-71_#*'4M1VZ@([347+P:&PL
MR61U&XVM':XK"CM(W5(UOF&E(P&O-.A1CW=_8;>S'T (WRPKCK"7J[T3<C >
M;"B%M@.-,4+*R7X'IFE<MBP\29J6;?%[7WFA<4MS1^.].K#4I4Y$6O.M5 2C
M;GM4T:MIA1,[P<%>_Z077=E13L-13MTH8O8X[!_N6E/#> ]KQKYXB#> ;-AC
M+W9NOS.G'[XCZTO-3#&Y/L47T;?#@A.U\ P%6)O:T!9W_HBB9I66<S:XV3!!
M&_3N&S)YD&)H'/)^7+-6R00Q=IF2TT.#;87IA: 7,8[NM5P<E>. &XKR[%L:
M/=;R7USB')-Z:LC(-<Y(OS3AQQ3+JOQ"*9"16-C#4[IP2)>I/B,CS-2%:H0^
M)O(!<1Q&?JLZF(>,$$8MEKRON*",Q"L792?$*0:73B:E(LRT@P<NS10$:H85
MN1LYZRZVMV467"AMUI2UMX +0J;K]\7,3>H9I>5GTZ<@U!K4KH5V*EW=/Y5(
M[[/R9ZS/9G+3<:K001W[IZV'6A8'X'>1G'<Y962%A],%5*^VUBA#C+Y>%Z[J
MZ2A6;$.C[EL?SAE:33%:W]D><M*OGR1^5A1#():LS@1E!.3N*O=@ZX/7BYS!
M+'2RAG[^!AZ':-P%!"<\KC.'8%%>F"1D^X5ONDTU^FP0,-TSHB<,_ZW&VX3O
MMJL EZ&<>7'3QZ\7;,:B?KCN:AA)<#I=%X[MSN(G"OUX3)*OVVWEMZ1F&&S"
MV:'D78&YEM*:ETA0XP+V7-[FK4UKQ6>!J*'J7;GZJ?0'3X&&)\X3 >P^^];U
M79#&+*G%@1?,M\7(ZRD (!/OL4R\BI_(LW+>N08W#U7%7-='IHPK& 4CBC3Q
MRLWFBN3Q-+U@?3XS2$I,:J4V7Z#9/JX=OUS]+I"HO6#"Q)C-*; %O#(:J:]=
M,<16I_%1OA#]'&2-O2K?PY_ATYC6="M65VW_JWS"-2SHOI.%;>U0!KM!NV-+
M.&#(JS%^GB;=B ?!-.J/8O,%"65:GX!JGJD]MG!6%^&^#H7X&V:W:(DC=B4G
MI#U';+U'/EH?C]-Q&3:B6&,+&['*A_[(W!37](]<_F8[K+^IU/_$Y['YI V3
MOP9H<>?]KEKPE1.59(MA$6)8/<@[4Q.1Q)2P\R[;J).. U+A2"KJ23 E?13(
M0;*#<(=F6[Q9J?Q?IJ#MQ(6[Z#9>AFW>R.01JOXRZ02*3"8:HUD9)W9)_HF5
M(ES#A%!F\9P:$ZQ\5:>YI?0_V\1/UZ>5)5$M+=)SI4-[!B$P/@<UE)BJZ7*P
MVXPEFF8JZ;ZO4V(.)[3('AVX "$K =:Z)]>O\8^U_:6##U<QXJZ\LIK6#LZ_
MYQKJNBZU,2!$G*E>TV0B-J'*G(/-V=22 ;YFJL_KW6FM"[O;<_S'V1I"78%5
MOPH=L)54AJ7]6VH[XQHAOAL'F^M\L=8:\ZF) M2/(>#?31)F'"9U3M9%B3SY
MH35HT0(FP&K?IMQ@K2&I/'&F]T8JTCD]@^T1RG*J@'XHO[*DW=6(;J'7SX"@
M6VJQL/C=&'5O,Z?> L@J+]JT/TU;ZV 0A?!WLFN<G/R$X]=J&WG0.T;!_(>2
M>6%N#-/0@BL4\MC*]^EY3GTLWVS(&RI;DA&Z,Q=:GR8:0Y?<_V82&=[X'1Z,
MHI^B<1_^.3C WP;PS^<\VW,/[$5GJ[3$^O1[#/\3>$+_/VX^C7\F\H:<V  '
M'0R#?UQ_@\&N6<T(GQSBDD9]_2T8G]XW_X>9&+0#W(K\Q-CVMG_1K3G1:FD;
MFB_D)DQ_8"CW%2AO5V@S_=5SS5S[2C@'N<T<:;-MN4WIEVW)(_:R>_.>KWUL
MHE5<>8BG$C#!UP&_]$6VO;:=^4X(";9OYR!X7X_3Y%[S:9HZRW%%>G)<U:J[
M>'+L)U(_AU)V&W;>:XL[WXEWJ5H9VA9\.6\T6W(3)I(>?*HF+A;MP.ML7:Y%
MNRPQ9FIGBA25*.2@_Y._FD62+F^Q;/Q2O.Q*#@L)D=]]&^W<[G)EHFA=I0M-
M='&59?TV%<8?OUSZ+DDIRQ(^X/X!'48E+7-.@7- Y9)'[!.Q,]TEPP>7M#%[
M==80;X43&T0F8K$NFK1?$L6HLV++BTZC:KPK!0=-LCII/7S>L+H9KZZQ;3[=
M]4H$/EM'M8A73[:)A%RR'1)4?<F/*2< U-19BB F7Y=WO3/PI$O7 E5Q@Q0X
M#GD!6^IV@%C\#7[K$<PK$+[1$H3*T"-:&!-<#@Y-PE.)'I(23S[9K1V>0(-3
MT^7*.<W80;LG\2/J7;&ES,G;;R^4@[\;B@:N!5&622$I]KH$6-Y\U^FH(CW@
M6=2O:!E<;LER=G=;DI DN.)NMZZT=H\ZYY9N2;1,OTD2" ZU IX+V$VMZKRX
MS=JGK;G()DQ4"KA:4J@.F'YR2@2QM()*DZXL7) 1$M4+WZKEUAN+'3*R $9A
M>9A !-24K<QTJ]QFY9A[1)?('8)MM*/#/AF;J."V/@HP+D35XT[N\ 36E@99
M1UJ"('ZEI2DH26$\V"-;QL,@'K[$=)N<Y:N'1 !K=*=88HM0>HF6E!7+QE@2
M#R^20TY)1&+=KY6*LT?.&2+%4AAV!;CE5VY!H 3,6"9Q%E0ZLW[=M#2-'1>)
M^)%2J=J!"\:@G-@+\O@H7;_X&^4%SM&138DKM!YV8A$10Q;VE?7C# @U,0HV
M&&/I#"$Q*,^NDH0:4X1$IR<1,%31E-(PF&@Q]XPI(\M=9GM/?-B;].*Q=0*,
MS9KC)[R,Z(S-]?@7*24BK>>">1M9*OA8=K=(.DRH7'2B(.^+W!QKUX\-M6@X
M-[Q-V-1)PFJ48C9P@=JQL22X:$EE(^Z"B:]G0R%F9V)QI?S=XMR:=EX)[K[:
M93%ZX_8C8WLF_R.W!RV#%>'JX8[$5&%OX8K:NO: Y7HI\;IR%YS%^"[/A<ZT
MZ$AG9)1)9M:2P+(9"@]*"T1.$]>/]6H4^5[!%<:$JL'%6*W5.]L3$4-];$9)
MB<4HLDBRN^K>, (?E.GHA3C96ZBV#[%$(F_71@V&//UU2KQO22H52PQEUM(J
MN#P7 6< QR0[2 %TU:-]=&*-;5 FP+=>7>#J-429UI3 &^L8TYI/PO/JL% [
M \8Z(^R GF*TD;N6:1C0HP6HE6L8]C:E,BBE!+FY/I8A)W6,T]579N\[^V>4
M>@*&H OA>7V9\D8I?X2I:: \!]%(DH_U-:FOJ('#O"!L+=%<V!]E</_-6BK8
MH!IS@VQT<0=+_J]2^1T3 0K'T;%NQ<V&.,[?[D4-@K T4)/Z9:[R6L-L3":?
M6@BIKV#H73MMMFL@P[;D7:C=D-1/U]QMS] KL4%GF-8BL>O<.X'>D <9$)3B
MA/[DIY7CC8+16K0<0PK;ML\7U/LV%?$,M21O65W,]LYCJ@@@3?$J4W>1]A T
MDG/66R6=H6V&!"XW5IX9\:G->8BNX8UE'#ML_+04!%C8MLD= >?&VD+WR)*Y
M@:$W4_HN8SX'S"XYE4:A5 -5,\6]%N3130%>[V#0Z#;^\E"FP#2C5HR:N4@^
MKM5=-,XP+W4 U\^X97D0Y-*@61Y?W"SBT5)!AVK;8IH9L0KC:(A!'4["W'?3
MIN@A9ESQ[2+O0:I^0!&\XDJ4- W2_@>*<@OUX"RYRRL&/]=!J#NON5H=8<-)
M_R<\!*I^SMF>1FW:;[.B.4!^*+@N<M- Q(8=.EA,J:<\S=H:-?]$^;4Q( -"
M<IL:,00[P3@O+/5*BCU6;&2I_QRWI3_C+;V6*IAL<E@RY:7X%*2V.MQ= ."@
M15F+89<C^IPH4/< VX.T"$S%*COMZ[W6^IR6ZU':EP^N\@?4<%+KU2-]*(ZP
M^@LFR7J2C.!O=2]9V%+Q1.(@G(X5E&'%_31JS\99X.+;<_VVU+S:9A35[QID
MY0_'^A"*UM@I0F;'EY%FL/L8)ZZ)2-W6U@7=>Q<48IIZSCEEY2%9&*[G]#J>
ML^T9NE4YEK5.Q%2A1332+(R,,Y8"4LN=ZPT%#>K[2\4VK\Q@M:#SDV/V2I*4
MQ)C"M\/8&(*&<K^3?[0M#M>MY>CW64OTO8[2F_M$C@&K4I>8/(/X%6(%^2P-
M8-^$9C1O-%)+D#O>3.R!M\D3L&%O>:IE&]"&8'Z=I."BO%+HAPB2O_0*$;2R
M8'H=9@3/]F @US3GW!FP&?/@@T# $B,VF6C%]+B(,;,,8>QV@+5VV5Q2)'=
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M[CS+-I^_I*XQU!$EAT3<&P6[*D:1&-S.E?MCXTHC:,:B$GB0G'*>*Q$?W64
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MI<2WR]&-9J"28L'<:I_G!'Y:KQ___7]02P,$%     @ #4->3WZ./FM6 @
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MBU195DTY;CZ:ZC;.WYR__ =02P,$%     @ #4->3R4:.3S$ 0  3QP  !H
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MH0=-^X.F]*!9?]",'B1#(..0GX2PYFLM@&OA>RT ;.&++8!LX9LM &WAJRV
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  -0UY/9_Z><NX    K @  $0
M        @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  -0UY/
MF5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    (  U#7D]O _G)/@,  * /   8              "
M ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  -0UY/
MRC)G&H,$   )%@  &               @ %K#   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ #4->3RG,)1Z8 @  < D  !@
M     ( !)!$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M  U#7D\\G>)**P4  ,H8   8              "  ?(3  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  -0UY/S(5HKM0'   8+@  &
M            @ %3&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ #4->3TVI9QZ9!0  IAP  !@              ( !72$  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  U#7D](C-*SL0$  -(#
M   8              "  2PG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  -0UY/XU!#6;0!  #2 P  &               @ $3*0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #4->3QZ9G(RU
M 0  T@,  !@              ( !_2H  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    (  U#7D\ZR:<7M@$  -(#   9              "
M >@L  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #4->
M3^D D=RT 0  T@,  !D              ( !U2X  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  -0UY/3.M(&+4!  #2 P  &0
M        @ ' ,   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   (  U#7D^)6'HMM@$  -(#   9              "  :PR  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ #4->3S"1/V6U 0  T@,
M !D              ( !F30  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  -0UY/^4W$$[<!  #2 P  &0              @ &%-@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  U#7D]E5B;9
M/P(  -0'   9              "  7,X  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ #4->3Y#XH(S0 0  G 0  !D
M ( !Z3H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  -
M0UY/KP= ;,8!   W!   &0              @ 'P/   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  U#7D]B R$[^@$  ,L%   9
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M970R,RYX;6Q02P$"% ,4    "  -0UY/7>/=".\"  "P#0  &0
M    @ $V3   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M  U#7D^L?_5I* (  *L&   9              "  5Q/  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ #4->3T!#,4TZ @  S08  !D
M             ( !NU$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  -0UY/:Z42(/T!   ?!@  &0              @ $L5   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  U#7D]?7M2(G (
M "()   9              "  6!6  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ #4->3]T3*#"D!   MA@  !D              ( !
M,UD  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  -0UY/
MCUI57*X"  #\"   &0              @ $.7@  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    (  U#7D\RK8,L.@(  ,@'   9
M      "  ?-@  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ #4->3]7"]Q*+ @  UP@  !D              ( !9&,  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  -0UY/@.13G_0!  !'!0
M&0              @ $F9@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    (  U#7D^D]4 T\ $  %4%   9              "  5%H  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #4->3[ACZEH1
M @  U04  !D              ( !>&H  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  -0UY/7TH^QL,!  "'!   &0
M@ ' ;   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  U#
M7D]?_>9TL@(  %L*   9              "  ;IN  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ #4->3W7SNB*L @  3@H  !D
M         ( !HW$  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    "  -0UY/!9$DP$4"  "R!P  &0              @ &&=   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  U#7D^1)G>7J0,  '05
M   9              "  0)W  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ #4->3U)F5Y(N!0  ,1\  !D              ( !XGH
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  -0UY/!!9T
M\ML%  !B(P  &0              @ %'@   >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    (  U#7D^TK=B=O $  -(#   9
M  "  5F&  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M#4->3\6* G?8!0  R2   !D              ( !3(@  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  -0UY/5M]>[U0"  #C!P  &0
M            @ %;C@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    (  U#7D\@<M!5-P(  ,0&   9              "  >:0  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ #4->3ZM$U@C?A@
MZ18" !0              ( !5),  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ #4->3WZ./FM6 @  7 P   T              ( !91H! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  -0UY/Y*&_J"<$  #W'@  #P
M        @ 'F' $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #4->3R4:
M.3S$ 0  3QP  !H              ( !.B$! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ #4->3[1F&&*[ 0  9!P  !,
M     ( !-B,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #< -P#S#@
&(B4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789959488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> and ASU 2015-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The implicit price concession represents </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's consolidated net service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>73%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of our consolidated net service revenue for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for price concessions related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts we estimate to be realizable for services provided.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine our estimates for implicit price concessions related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Periods Ended September 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Periods Ended September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Home Health:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice (1):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Home Health Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on an established Federal Medicare  home health episode payment rate, that is subject to adjustment based on certain variables, including, but not limited to (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> or fewer; (c)&#160;a partial payment if a patient transferred to another provider or we admitted a patient transferring from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the </span><span style="font-family:inherit;font-size:10pt;">sixth</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">fourteenth</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">twentieth</span><span style="font-family:inherit;font-size:10pt;"> visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#160;changes in the base episode payments established by the Medicare Program; and (g)&#160;adjustments to the base episode payments for case mix and geographic wages. Medicare rates are based on the severity of the patient's condition, service needs and goals, and other factors relating to the cost of providing services and supplies, bundled into an episode of care, not to exceed </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Expected Medicare revenue per episode is recognized based on a pro-rated service output method, utilizing our historical average length of episode prior to discharge.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record this estimate during the period in which services are rendered as an estimated price concession and a corresponding reduction to patient accounts receivable. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the company's average percentage of days complete on episodes as of the end of the year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Episodic-based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms which generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of Medicare rates.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-episodic based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make adjustments to non-episodic revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hospice Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>97%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. There are two separate payment rates for routine care: payments for the first </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days of care and care beyond </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make adjustments to Medicare revenue for implicit price concessions, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record it during the period services are rendered.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report and pay their estimated cap liability by February 28</span><span style="font-family:inherit;font-size:9pt;">th</span><span style="font-family:inherit;font-size:10pt;"> of the following year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accrued expenses for estimated amounts due back to Medicare for the Federal cap years ended October&#160;31, 2013 through September 30, 2019; approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of this amount is related to the cap liability acquired as part of the Compassionate Care Hospice ("CCH") acquisition. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make adjustments to non-Medicare revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Care Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for price concessions. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patient Accounts Receivable</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We report accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there is no single payor, other than Medicare, that accounts for more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent </span><span style="font-family:inherit;font-size:10pt;"><span>59%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>56%</span></span><span style="font-family:inherit;font-size:10pt;"> of our patient accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, is limited due to our historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Home Health</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> of our estimated payment for the initial episode at the start of care or </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </span><span style="font-family:inherit;font-size:10pt;"><span>120</span></span><span style="font-family:inherit;font-size:10pt;"> days from the start of the episode, or </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Hospice</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Issuance Costs</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the nine-month period ended September 30, 2019, we recorded </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our condensed consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 5 - Long-Term Obligations). As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018, we had unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, recorded as long-term obligations, less current portion in our condensed consolidated balance sheet. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance during the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> will be amortized over a weighted-average amortization period of </span><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Financial Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value as of<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted-Average Shares Outstanding</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:52%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested stock and stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><span style="font-family:inherit;font-size:10pt;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span>. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795421520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of operating lease ROU assets</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease ROU asset amortization</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease interest expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of finance lease cost including amortization of ROU asset and interest expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888369&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784643712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease cost</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for the three and nine-month periods ended September 30, 2019 are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.78752436647173%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three-Month Period Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingleasesTableTextBlock', window );">Operating leases</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinanceleasesTableTextBlock', window );">Finance leases</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our condensed consolidated balance sheet. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our condensed consolidated balance sheet.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current installments of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock', window );">Supplemental Cash Flow Information and Non-Cash Activity for Leases</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.73489278752436%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flow from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flow from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions to ROU assets resulting from reductions to lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock', window );">Weighted average remaining lease term and discount rate</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease terms and discount rates for our leases as of September 30, 2019 are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:77%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LeaseLiabilityMaturityTableTextBlock', window );">Lease Liability Maturity</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities as of September 30, 2019 are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:126px;text-indent:-78px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Excludes the nine-month period ended September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceleasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Finance leases [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceleasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Maturity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingleasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Operating leases [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingleasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information and Non-Cash Activity for Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Weighted average remaining lease term and discount rate [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787820544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.81286549707602%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promissory notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$725.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$550.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Applicable Rate is </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum for Base Rate loans and </span><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.39766081871345%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:11%;"/><td style="width:27%;"/><td style="width:18%;"/><td style="width:13%;"/><td style="width:18%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pricing Tier</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitment Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Letter of Credit Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eurodollar Rate Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Base Rate Loans</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">I</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8805; 3.00 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.00%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">III</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The final maturity date of the Credit Facility is </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">February 4, 2024</span></span></span><span style="font-family:inherit;font-size:10pt;">. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) </span><span style="font-family:inherit;font-size:10pt;"><span>0.625%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>1.250%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>1.875%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period commencing on April 1, 2023 and </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>$5 million</span></span><span style="font-family:inherit;font-size:10pt;"> or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the nine-month period ended September 30, 2019.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than </span><span style="font-family:inherit;font-size:10pt;"><span>95%</span></span><span style="font-family:inherit;font-size:10pt;"> of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than </span><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span><span style="font-family:inherit;font-size:10pt;"> of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our weighted average interest rate for borrowings under our </span><span style="font-family:inherit;font-size:10pt;"><span>$550.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;"><span>3.8%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>3.9%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our weighted average interest rate for borrowings under our </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> Term Loan Facility was </span><span style="font-family:inherit;font-size:10pt;"><span>3.8%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>3.9%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three-month period ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the period February 4, 2019 to </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our consolidated leverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span><span style="font-family:inherit;font-size:10pt;">, our consolidated interest coverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span>19.5</span></span><span style="font-family:inherit;font-size:10pt;"> and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our availability under our </span><span style="font-family:inherit;font-size:10pt;"><span>$550.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> Revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;"><span>$452.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> as we have </span><span style="font-family:inherit;font-size:10pt;"><span>$67.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding in borrowings and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding in letters of credit.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Joinder Agreement</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790028624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. RELATED PARTY TRANSACTIONS</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, we made a </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three and nine-month periods ended September 30, 2019, we incurred costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in connection with the usage of Medalogix's analytics platforms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>27
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20193009x10xq.htm": {
   "axisCustom": 3,
   "axisStandard": 18,
   "contextCount": 222,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20193009x10xq.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20190930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 549,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 37,
    "http://www.amedisys.com/20190930": 13,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 56
   },
   "keyCustom": 83,
   "keyStandard": 319,
   "memberCustom": 34,
   "memberStandard": 26,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeLeasesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - LEASES LEASES",
     "role": "http://www.amedisys.com/role/LeasesLeases",
     "shortName": "LEASES LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeLeasesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LongTermObligations",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SegmentInformation",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/ShareRepurchaseShareRepurchase",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/AcquisitionsTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - LEASES (Tables)",
     "role": "http://www.amedisys.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SegmentInformationTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:EquityAndCostMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "amed:DebtIssuanceCostsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "amed:DebtInstrumentCarryingAmountExcludingCapitalLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "amed:DebtInstrumentCarryingAmountExcludingCapitalLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - ACQUISITIONS - Pro Forma (Details)",
     "role": "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
     "shortName": "ACQUISITIONS - Pro Forma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - LEASES (Details)",
     "role": "http://www.amedisys.com/role/LeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - LEASES Lease Cost (Details)",
     "role": "http://www.amedisys.com/role/LeasesLeaseCostDetails",
     "shortName": "LEASES Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - LEASES Operating Lease (Details)",
     "role": "http://www.amedisys.com/role/LeasesOperatingLeaseDetails",
     "shortName": "LEASES Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:FinanceleasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - LEASES Finance lease (Details)",
     "role": "http://www.amedisys.com/role/LeasesFinanceLeaseDetails",
     "shortName": "LEASES Finance lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:FinanceleasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - LEASES Supplemental Cash Flow Information (Details)",
     "role": "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "LEASES Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:WeightedaverageremainingleasetermanddiscountrateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404407 - Disclosure - LEASES Weighted Average Remaining Term and Discount Rate (Details)",
     "role": "http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails",
     "shortName": "LEASES Weighted Average Remaining Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:WeightedaverageremainingleasetermanddiscountrateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404408 - Disclosure - LEASES Maturities (Details)",
     "role": "http://www.amedisys.com/role/LeasesMaturitiesDetails",
     "shortName": "LEASES Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405405 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "I2019Q1Feb04",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SegmentInformationNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segments",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "I2019Q1Feb252019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "role": "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "I2019Q1Feb252019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410401 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "role": "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "role": "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/Acquisitions",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20193009x10xq.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year Two Thousand Thirteen Through Two Thousand Nineteen [Member]",
        "label": "Cap Year Two Thousand Thirteen Through Two Thousand Nineteen [Member]",
        "terseLabel": "Cap Year 2013 Through 2019"
       }
      }
     },
     "localname": "CapYearTwoThousandThirteenThroughTwoThousandNineteenMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ChristianCareatHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Christian Care at Home [Member]",
        "label": "Christian Care at Home [Member]",
        "terseLabel": "Christian Care at Home"
       }
      }
     },
     "localname": "ChristianCareatHomeMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingCapitalLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Capital Leases",
        "label": "Debt Instrument Carrying Amount Excluding Capital Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Capital Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingCapitalLeases",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtIssuanceCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for debt issuance costs.",
        "label": "Debt Issuance Costs Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_EastTennesseePersonalCareServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "East Tennessee Personal Care Services [Member]",
        "label": "East Tennessee Personal Care Services [Member]",
        "terseLabel": "East Tennessee Personal Care Services"
       }
      }
     },
     "localname": "EastTennesseePersonalCareServicesMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total amount of finance lease cost including amortization of ROU asset and interest expense",
        "label": "Finance Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FinanceleaseRightofUseAssetNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease, net of accumulated amortization.",
        "label": "Finance lease, Right-of-Use Asset, Net",
        "terseLabel": "Finance lease ROU assets, net"
       }
      }
     },
     "localname": "FinanceleaseRightofUseAssetNet",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FinanceleasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Finance leases [Table]",
        "label": "Finance leases [Table Text Block]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceleasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "550 Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FleetLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fleet Leases [Member]",
        "label": "Fleet Leases [Member]",
        "terseLabel": "Fleet Leases [Member]"
       }
      }
     },
     "localname": "FleetLeasesMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthcareanalyticscompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Healthcare analytics company [Member]",
        "label": "Healthcare analytics company [Member]",
        "terseLabel": "Healthcare analytics company [Member]"
       }
      }
     },
     "localname": "HealthcareanalyticscompanyMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_KKRShareRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "KKR Share Repurchase [Member]",
        "label": "KKR Share Repurchase [Member]",
        "terseLabel": "KKR Share Repurchase"
       }
      }
     },
     "localname": "KKRShareRepurchaseMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Liability Maturity [Table Text Block]",
        "label": "Lease Liability Maturity [Table Text Block]",
        "terseLabel": "Lease Liability Maturity"
       }
      }
     },
     "localname": "LeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeFinanceleasesAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amortization of finance leases",
        "label": "Lessee, Finance leases, Accumulated Amortization",
        "negatedLabel": "Finance leases accumulated amortization"
       }
      }
     },
     "localname": "LesseeFinanceleasesAccumulatedAmortization",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "negatedLabel": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Episode",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfEpisode",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OperatingleasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Operating leases [Table]",
        "label": "Operating leases [Table Text Block]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingleasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentsForRepurchaseOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of noncontrolling interests.",
        "label": "Payments For Repurchase Of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Paymentsrelatedtotaxassetandworkingcapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments related to tax asset and working capital",
        "label": "Payments related to tax asset and working capital",
        "terseLabel": "Payments related to tax asset and working capital"
       }
      }
     },
     "localname": "Paymentsrelatedtotaxassetandworkingcapital",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsFromBorrowingsUnderTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from borrowings under the term loan.",
        "label": "Proceeds From Borrowings Under Term Loan",
        "terseLabel": "Proceeds from borrowings under term loan"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsUnderTermLoan",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Episode Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RoseRockHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RoseRock Healthcare [Member]",
        "label": "RoseRock Healthcare [Member]",
        "terseLabel": "RoseRock Healthcare [Member]"
       }
      }
     },
     "localname": "RoseRockHealthcareMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase [Axis]",
        "label": "Share Repurchase [Axis]",
        "terseLabel": "Share Repurchase [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseAxis",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Share Repurchase [Axis]",
        "label": "Share Repurchase [Domain]",
        "terseLabel": "Share Repurchase [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseDomain",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplemental Cash Flow Information and Non-Cash Activity for Leases [Table Text Block]",
        "label": "Supplemental Cash Flow Information and Non-Cash Activity for Leases [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information and Non-Cash Activity for Leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeofEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnamortizedDebtIssuanceCostAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected amortization period of debt issuance cost",
        "label": "Unamortized Debt Issuance Cost Amortization Period",
        "terseLabel": "Unamortized debt issuance cost amortization period"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceCostAmortizationPeriod",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WeightedaverageremainingleasetermanddiscountrateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Weighted average remaining lease term and discount rate [Table]",
        "label": "Weighted average remaining lease term and discount rate [Table Text Block]",
        "terseLabel": "Weighted average remaining lease term and discount rate"
       }
      }
     },
     "localname": "WeightedaverageremainingleasetermanddiscountrateTableTextBlock",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20190930",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r135",
      "r187",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/LeasesDetails",
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/LeasesDetails",
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/LeasesDetails",
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/LeasesDetails",
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r134",
      "r187",
      "r189",
      "r331",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r188"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r24",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r196",
      "r197",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r53",
      "r81",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r81",
      "r250"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r130",
      "r303",
      "r317"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings (loss) per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings (loss) per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r216",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price for acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r202",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r88",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase during the period in capital lease obligations due to entering into new capital leases.",
        "label": "Capital Lease Obligations Incurred",
        "terseLabel": "Capital leases"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r83"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r164",
      "r309",
      "r324"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 36,599,273 and 36,252,280 shares issued; and 32,246,575 and 31,973,505 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r244",
      "r245",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r244",
      "r245",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r113",
      "r114",
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue",
        "verboseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r244",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r224",
      "r232",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r304",
      "r305",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r11",
      "r175",
      "r305",
      "r316"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r249",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r32",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r33",
      "r92",
      "r179",
      "r180",
      "r181",
      "r182",
      "r248",
      "r249",
      "r251",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r25",
      "r250"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r90",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r156"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r127"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r52",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r313",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r52",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r313",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAndCostMethodInvestmentsPolicy": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.",
        "label": "Equity and Cost Method Investments, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityAndCostMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r50",
      "r75",
      "r81",
      "r325"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r194",
      "r237",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r191",
      "r192",
      "r194",
      "r237",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r191",
      "r192",
      "r194",
      "r237",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r191",
      "r192",
      "r194",
      "r237",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r88",
      "r242",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r258",
      "r265",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r257",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails",
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current installments of obligations under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of obligations under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payments, Due",
        "terseLabel": "Finance Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Finance Lease - Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "Finance Lease - 2019 (a)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Five",
        "terseLabel": "Finance Lease - 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Four",
        "terseLabel": "Finance Lease - 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "Finance Lease - 2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "Finance Lease - 2020"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Finance Lease - Less: Imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r260",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Financing cash flow from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r258",
      "r265",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease ROU asset amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r272",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases, Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, Weighted average remaining term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r155",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r149",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r95",
      "r302",
      "r311",
      "r328"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r50",
      "r81",
      "r128",
      "r142",
      "r310",
      "r325"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in earnings from equity method investments",
        "terseLabel": "Equity in (losses) earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r129",
      "r206"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r148",
      "r152"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $36,799 and $33,050"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r48",
      "r126",
      "r247",
      "r250",
      "r314"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r273",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lessee, Finance Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Operating Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Operating Lease - Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "Operating Lease - 2019 (a)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "Operating Lease - 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "Operating Lease - 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "Operating Lease - 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "Operating Lease - 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Operating Lease - Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lessee, Operating Lease, Option to Terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r307",
      "r321"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r27",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r27",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r176",
      "r305",
      "r318"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt and Capital Lease Obligations",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.",
        "label": "Long-term Debt and Capital Lease Obligations, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r33",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r38",
      "r306",
      "r320"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r46",
      "r47",
      "r51",
      "r82",
      "r104",
      "r312",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r47",
      "r226",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r266",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesMaturitiesDetails",
      "http://www.amedisys.com/role/LeasesOperatingLeaseDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
      "http://www.amedisys.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
      "http://www.amedisys.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r261",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating cash flow from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
      "http://www.amedisys.com/role/LeasesOperatingLeaseDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r272",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other",
        "verboseLabel": "Other General and Administrative Expense"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Financing Activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r70",
      "r195"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.",
        "label": "Payments Related to Tax Withholding for Share-based Compensation",
        "negatedLabel": "Shares withheld upon stock vesting"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r65",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investments in equity method investees",
        "terseLabel": "Payments to Acquire Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Cost (Reversal of Cost)",
        "terseLabel": "401(k) employer match"
       }
      }
     },
     "localname": "PensionExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r143"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r199"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r46",
      "r47",
      "r74",
      "r130",
      "r133",
      "r223",
      "r225",
      "r227",
      "r230",
      "r231"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r158",
      "r323"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $101,446 and $95,472"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r276",
      "r278",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r193",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r193",
      "r277",
      "r278",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations",
        "terseLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r183",
      "r319"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised good or service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r270",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r270",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r33",
      "r92",
      "r179",
      "r180",
      "r181",
      "r182",
      "r248",
      "r249",
      "r251",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r27",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r91",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r267",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r130",
      "r147",
      "r160",
      "r161",
      "r162",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails",
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails",
      "http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails",
      "http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r178",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r13",
      "r14",
      "r178",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r178",
      "r183",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r178",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r178",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r178",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r140"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r221",
      "r222",
      "r229"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets",
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r15",
      "r21",
      "r88",
      "r137",
      "r138",
      "r139",
      "r141",
      "r308",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r36",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r36",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r14",
      "r178",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ShareRepurchaseShareRepurchase"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r36",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost 4,352,698 and 4,278,775 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r178",
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r268",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LongTermObligationsNarrativeDetails",
      "http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r102"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r96",
      "r102"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfOperations",
      "http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write off of deferred debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918431-209957"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r333": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r334": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r335": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r336": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r337": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r338": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6782443776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Lease - 2019 (a)</a></td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Lease - 2020</a></td>
<td class="nump">29.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Lease - 2021</a></td>
<td class="nump">22.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating Lease - 2022</a></td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating Lease - 2023</a></td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Operating Lease - Thereafter</a></td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Lease - Total undiscounted lease payments</a></td>
<td class="nump">90.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Lease - Less: Imputed interest</a></td>
<td class="num">(7.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">83.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease - 2019 (a)</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease - 2020</a></td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease - 2021</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease - 2022</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease - 2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance Lease - Thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Lease - Total undiscounted lease payments</a></td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Lease - Less: Imputed interest</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6610844896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, we acquired Compassionate Care Hospice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$327.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of cash acquired of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. During the three-month period ended September 30, 2019, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$327.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total estimated consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired include Medicare licenses, certificates of need, trade names and non-compete agreements. The trade names and non-compete agreements will be amortized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CCH contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$45.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and operating income of </span><span style="font-family:inherit;font-size:10pt;">$0.9 million</span><span style="font-family:inherit;font-size:10pt;"> (inclusive of acquisition and integration costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;">) during the three-month period ended September 30, 2019 and </span><span style="font-family:inherit;font-size:10pt;"><span>$123.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and an operating loss of </span><span style="font-family:inherit;font-size:10pt;">$4.2 million</span><span style="font-family:inherit;font-size:10pt;"> (inclusive of acquisition and integration costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$13.4 million</span></span><span style="font-family:inherit;font-size:10pt;">) during the nine-month period ended September 30, 2019. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table contains unaudited pro forma condensed consolidated statement of operations information for the three and nine-month periods ended September 30, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-<br/>Month Periods<br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>467.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,471.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,373.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and other intangibles including non-compete agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and tradenames of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the three-month period ended June 30, 2019. The non-compete agreement will be amortized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span><span style="font-family:inherit;font-size:10pt;"> years. RoseRock contributed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating income during the three-month period ended September 30, 2019 and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net service revenue and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in operating income during the nine-month period ended September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795312240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 84,124<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">26,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">56,619<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 83,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801910832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,255,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804649968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2017</a></td>
<td class="nump">$ 516,426<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 568,780<span></span>
</td>
<td class="num">$ (53,713)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,747,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">12,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(5,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(181,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactofRepurchaseofNoncontrollingInterest', window );">Repurchase of noncontrolling interest</a></td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">92,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,885<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2018</a></td>
<td class="nump">445,495<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">592,539<span></span>
</td>
<td class="num">(240,536)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">92,089<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,146,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2018</a></td>
<td class="nump">409,061<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">585,137<span></span>
</td>
<td class="num">(237,947)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">60,712<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,044,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">2,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">4,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(2,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactofRepurchaseofNoncontrollingInterest', window );">Repurchase of noncontrolling interest</a></td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">31,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,377<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2018</a></td>
<td class="nump">445,495<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">592,539<span></span>
</td>
<td class="num">(240,536)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">92,089<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,146,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2018</a></td>
<td class="nump">482,633<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">603,666<span></span>
</td>
<td class="num">(241,685)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">119,550<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,252,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">6,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">18,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(9,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">99,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,178<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2019</a></td>
<td class="nump">603,465<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">634,854<span></span>
</td>
<td class="num">(251,070)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">218,728<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,599,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2019</a></td>
<td class="nump">562,942<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">623,309<span></span>
</td>
<td class="num">(246,175)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">184,596<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,445,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(4,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">34,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,132<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2019</a></td>
<td class="nump">$ 603,465<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 634,854<span></span>
</td>
<td class="num">$ (251,070)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 218,728<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,599,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactofRepurchaseofNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact of Repurchase of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactofRepurchaseofNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789844720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next </span><span style="font-family:inherit;font-size:10pt;"><span>nine years</span></span><span style="font-family:inherit;font-size:10pt;">. We also have finance leases covering certain office equipment that expire at various dates over the next </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">. Our leases do not contain any restrictive covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our office leases generally contain renewal options for periods ranging from one to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our fleet leases include a term of </span><span style="font-family:inherit;font-size:10pt;"><span>367</span></span><span style="font-family:inherit;font-size:10pt;"> days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease cost for the three and nine-month periods ended September 30, 2019 are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.78752436647173%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three-Month Period Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of ROU assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our condensed consolidated balance sheet. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our condensed consolidated balance sheet.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease ROU assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current installments of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.73489278752436%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine-Month Period  Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flow from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flow from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions to ROU assets resulting from reductions to lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease terms and discount rates for our leases as of September 30, 2019 are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:77%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities as of September 30, 2019 are as follows (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:126px;text-indent:-78px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Excludes the nine-month period ended September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789844720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASE <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019 Stock Repurchase Program</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our outstanding common stock through </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 1, 2020</span></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the program, we are allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We are allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not repurchase any shares pursuant to this stock repurchase program during the three or nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Share Repurchase</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 4, 2018, we purchased </span><span style="font-family:inherit;font-size:10pt;"><span>2,418,304</span></span><span style="font-family:inherit;font-size:10pt;"> of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then-current holdings in the Company and </span><span style="font-family:inherit;font-size:10pt;"><span>7.1%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate outstanding shares of the Company's common stock for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$181.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> including related direct costs. The Company repurchased the shares at </span><span style="font-family:inherit;font-size:10pt;"><span>$73.96</span></span><span style="font-family:inherit;font-size:10pt;"> which represents </span><span style="font-family:inherit;font-size:10pt;"><span>96%</span></span><span style="font-family:inherit;font-size:10pt;"> of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795665600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. During the three-month period ended September 30, 2019, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$327.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities acquired</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total estimated consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table contains unaudited pro forma condensed consolidated statement of operations information for the three and nine-month periods ended September 30, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-<br/>Month Periods<br/>Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>467.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,471.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,373.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Amedisys, Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6646224656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803807552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>state </div>
<div>care_center</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>state </div>
<div>care_center</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 83,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">$ 84,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum ownership percentage for cost method investment (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Medicare Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790082432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 2,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance expense</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod', window );">Unamortized debt issuance cost amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected amortization period of debt issuance cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnamortizedDebtIssuanceCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789844720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in the following legal actions:</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding </span><span style="font-family:inherit;font-size:10pt;"><span>53</span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding </span><span style="font-family:inherit;font-size:10pt;"><span>66</span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding </span><span style="font-family:inherit;font-size:10pt;"><span>68</span></span><span style="font-family:inherit;font-size:10pt;"> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to accrued expenses in our condensed consolidated balance sheet related to this matter as of September 30, 2019.&#160; Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Investigative Matters - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Corporate Integrity Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#8220;CIA&#8221;) with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA required that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> that ended on April 21, 2019. We filed our final annual report on July 19, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 30, 2015, Compassionate Care Hospice (&#8220;CCH&#8221;) entered into a CIA with the OIG. The CIA requires that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization (IRO) to complete claims review for hospice services rendered in New York. The OIG has waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA requires that CCH report substantial overpayments that CCH discovers it has received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The CIA has a term of </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> that will end on January 30, 2020. </span></div><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Party Audits - Ongoing</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;) and Medicaid Integrity Contributors (&#8220;MICs&#8221;) in which third party firms engaged by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for </span><span style="font-family:inherit;font-size:10pt;"><span>16</span></span><span style="font-family:inherit;font-size:10pt;"> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a balance owed of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, including interest, based on </span><span style="font-family:inherit;font-size:10pt;"><span>9</span></span><span style="font-family:inherit;font-size:10pt;"> disputed claims (originally </span><span style="font-family:inherit;font-size:10pt;"><span>16</span></span><span style="font-family:inherit;font-size:10pt;">). We filed an appeal to the Medicare Appeals Council on the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>9</span></span><span style="font-family:inherit;font-size:10pt;"> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Medicare has withheld payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. Accordingly, the Company reduced its indemnity receivable from </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> impact was recorded to general and administrative expenses, other within our consolidated statements of operations during the three-month period ended December 31, 2018. As of  </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have an indemnity receivable of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the amount withheld related to the period prior to August&#160;1, 2009.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of </span><span style="font-family:inherit;font-size:10pt;"><span>$34.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Lakeland Care Centers on a universe of </span><span style="font-family:inherit;font-size:10pt;"><span>72</span></span><span style="font-family:inherit;font-size:10pt;"> Medicare claims totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in actual claims payments using a </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> error rate and an overpayment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Clearwater Care Center on a universe of </span><span style="font-family:inherit;font-size:10pt;"><span>70</span></span><span style="font-family:inherit;font-size:10pt;"> Medicare claims totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in actual claims payments using a </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> error rate.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$26.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the alleged overpayment for the Clearwater Care Center has been reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from </span><span style="font-family:inherit;font-size:10pt;"><span>$38.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount </span><span style="font-family:inherit;font-size:10pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> is subject to indemnification by the prior owners) to </span><span style="font-family:inherit;font-size:10pt;"><span>$29.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have an accrued liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$17.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this matter. We expect to be indemnified by the prior owners for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the total </span><span style="font-family:inherit;font-size:10pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The net of these two amounts, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, was recorded as a reduction in revenue in our condensed consolidated statements of operations during the three-month period ended September 30, 2017. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of receivables have been impacted by this payment suspension.</span></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insurance</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our health insurance has an exposure limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> per incident and our professional liability insurance has a retention limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> per incident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795490160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><span style="font-family:inherit;font-size:10pt;">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span>, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2019 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842);</span><span style="font-family:inherit;font-size:10pt;"> ASU 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">; ASU 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:inherit;font-size:10pt;">; and ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "Topic 842") using a modified retrospective transition approach, which requires the new standards to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are using the standards' effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides several optional practical expedients that can be adopted at transition. We have elected the "package of practical expedients" which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.  </span></div>The new standard also provides practical expedients for an entity's ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. We are applying the short-term lease recognition exemption to certain information technology leases; therefore, we did not recognize ROU assets and lease liabilities for these leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAndCostMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;">. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was </span><span style="font-family:inherit;font-size:10pt;"><span>$35.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have less than a </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> and ASU 2015-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The implicit price concession represents </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's consolidated net service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>73%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of our consolidated net service revenue for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for price concessions related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts we estimate to be realizable for services provided.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine our estimates for implicit price concessions related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Periods Ended September 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Periods Ended September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Home Health:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice (1):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Home Health Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on an established Federal Medicare  home health episode payment rate, that is subject to adjustment based on certain variables, including, but not limited to (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> or fewer; (c)&#160;a partial payment if a patient transferred to another provider or we admitted a patient transferring from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the </span><span style="font-family:inherit;font-size:10pt;">sixth</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">fourteenth</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">twentieth</span><span style="font-family:inherit;font-size:10pt;"> visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#160;changes in the base episode payments established by the Medicare Program; and (g)&#160;adjustments to the base episode payments for case mix and geographic wages. Medicare rates are based on the severity of the patient's condition, service needs and goals, and other factors relating to the cost of providing services and supplies, bundled into an episode of care, not to exceed </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Expected Medicare revenue per episode is recognized based on a pro-rated service output method, utilizing our historical average length of episode prior to discharge.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record this estimate during the period in which services are rendered as an estimated price concession and a corresponding reduction to patient accounts receivable. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the company's average percentage of days complete on episodes as of the end of the year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Episodic-based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms which generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of Medicare rates.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-episodic based Revenue.</span><span style="font-family:inherit;font-size:10pt;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make adjustments to non-episodic revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hospice Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>97%</span></span><span style="font-family:inherit;font-size:10pt;"> of our gross Medicare hospice service revenue for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. There are two separate payment rates for routine care: payments for the first </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days of care and care beyond </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make adjustments to Medicare revenue for implicit price concessions, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> on Medicare claims, and record it during the period services are rendered.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report and pay their estimated cap liability by February 28</span><span style="font-family:inherit;font-size:9pt;">th</span><span style="font-family:inherit;font-size:10pt;"> of the following year. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accrued expenses for estimated amounts due back to Medicare for the Federal cap years ended October&#160;31, 2013 through September 30, 2019; approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of this amount is related to the cap liability acquired as part of the Compassionate Care Hospice ("CCH") acquisition. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make adjustments to non-Medicare revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Personal Care Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for price concessions. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patient Accounts Receivable</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We report accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there is no single payor, other than Medicare, that accounts for more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent </span><span style="font-family:inherit;font-size:10pt;"><span>59%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>56%</span></span><span style="font-family:inherit;font-size:10pt;"> of our patient accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, is limited due to our historical collection rate of over </span><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span><span style="font-family:inherit;font-size:10pt;"> from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Home Health</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> of our estimated payment for the initial episode at the start of care or </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </span><span style="font-family:inherit;font-size:10pt;"><span>120</span></span><span style="font-family:inherit;font-size:10pt;"> days from the start of the episode, or </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Hospice</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Issuance Costs</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the nine-month period ended September 30, 2019, we recorded </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our condensed consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 5 - Long-Term Obligations). As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018, we had unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, recorded as long-term obligations, less current portion in our condensed consolidated balance sheet. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred debt issuance during the three and nine-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The unamortized debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> will be amortized over a weighted-average amortization period of </span><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Financial Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value as of<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></td></tr></table>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted-Average Shares Outstanding</span></div>Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><span style="font-family:inherit;font-size:10pt;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span>. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtIssuanceCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAndCostMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAndCostMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784708256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES Supplemental Cash Flow Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="num">$ (26.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow from finance leases</a></td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">106.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</a></td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations', window );">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6796071904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, Finance Lease, Term of Contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after one year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after three years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=amed_FleetLeasesMember', window );">Fleet Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">367 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=amed_FleetLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=amed_FleetLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6782415056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 101,446<span></span>
</td>
<td class="nump">$ 95,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 36,799<span></span>
</td>
<td class="nump">$ 33,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">36,599,273<span></span>
</td>
<td class="nump">36,252,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,246,575<span></span>
</td>
<td class="nump">31,973,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">4,352,698<span></span>
</td>
<td class="nump">4,278,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802236320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6647110032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of our revenue derived from Medicare for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;">-month periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>73%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>74%</span></span><span style="font-family:inherit;font-size:10pt;"> of our revenue derived from Medicare for the three and nine-month periods ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we owned and operated </span><span style="font-family:inherit;font-size:10pt;"><span>321</span></span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified home health care centers, </span><span style="font-family:inherit;font-size:10pt;"><span>137</span></span><span style="font-family:inherit;font-size:10pt;"> Medicare-certified hospice care centers and </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> personal-care care centers in </span><span style="font-family:inherit;font-size:10pt;"><span>38</span></span><span style="font-family:inherit;font-size:10pt;"> states within the United States and the District of Columbia.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2019 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842);</span><span style="font-family:inherit;font-size:10pt;"> ASU 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">; ASU 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:inherit;font-size:10pt;">; and ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;"> (collectively, "Topic 842") using a modified retrospective transition approach, which requires the new standards to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are using the standards' effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides several optional practical expedients that can be adopted at transition. We have elected the "package of practical expedients" which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.  </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard also provides practical expedients for an entity's ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. We are applying the short-term lease recognition exemption to certain information technology leases; therefore, we did not recognize ROU assets and lease liabilities for these leases. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;">. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was </span><span style="font-family:inherit;font-size:10pt;"><span>$35.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities in which we have less than a </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6782612000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 25, 2019</div></th>
<th class="th"><div>Jun. 04, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 181,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember', window );">KKR Share Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,418,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Discountedclosingstockprice', window );">Discounted closing stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageofclosingstockprice', window );">Percentage of closing stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Discountedclosingstockprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounted closing stock price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Discountedclosingstockprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageofSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageofSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageofclosingstockprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing stock price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageofclosingstockprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804808624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Feb. 04, 2024</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="nump">$ 2,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 725,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,820,000<span></span>
</td>
<td class="nump">$ 91,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,300,000<span></span>
</td>
<td class="nump">$ 244,300,000<span></span>
</td>
<td class="nump">244,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,800,000<span></span>
</td>
<td class="nump">$ 172,800,000<span></span>
</td>
<td class="nump">$ 172,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452,800,000<span></span>
</td>
<td class="nump">452,800,000<span></span>
</td>
<td class="nump">$ 452,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000,000.0<span></span>
</td>
<td class="nump">67,000,000.0<span></span>
</td>
<td class="nump">67,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="nump">30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.875%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795896448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,211<span></span>
</td>
<td class="nump">31,815<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
<td class="nump">33,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">33,002<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
<td class="nump">32,944<span></span>
</td>
<td class="nump">33,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787587168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.81286549707602%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promissory notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.39766081871345%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:11%;"/><td style="width:27%;"/><td style="width:18%;"/><td style="width:13%;"/><td style="width:18%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pricing Tier</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Leverage Ratio</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitment Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Letter of Credit Fee</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eurodollar Rate Loans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Base Rate Loans</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">I</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8805; 3.00 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.00%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">III</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt; 0.75 to 1.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>402</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ConsolidatedStatementsOfStockholdersEquityStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Acquisitions</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - LEASES LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesLeases</Role>
      <ShortName>LEASES LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligations</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ShareRepurchaseShareRepurchase</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RelatedPartyTransactionsRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/AcquisitionsTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/Acquisitions</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LeasesLeases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligationsLongTermObligationsTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SegmentInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NatureOfOperationsConsolidationAndPresentationOfFinancialStatements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesRevenueByPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesDebtIssuanceCostsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Debt Issuance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfSignificantAccountingPoliciesWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - ACQUISITIONS - Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/AcquisitionsProFormaDetails</Role>
      <ShortName>ACQUISITIONS - Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - LEASES Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>LEASES Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - LEASES Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesOperatingLeaseDetails</Role>
      <ShortName>LEASES Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - LEASES Finance lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesFinanceLeaseDetails</Role>
      <ShortName>LEASES Finance lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - LEASES Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>LEASES Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404407 - Disclosure - LEASES Weighted Average Remaining Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesWeightedAverageRemainingTermAndDiscountRateDetails</Role>
      <ShortName>LEASES Weighted Average Remaining Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404408 - Disclosure - LEASES Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LeasesMaturitiesDetails</Role>
      <ShortName>LEASES Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligationsScheduleOfLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligationsFeesAndRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LongTermObligationsNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformationOperatingIncomeOfReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ShareRepurchaseNarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amed-20193009x10xq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amed-20193009x10xq.htm">amed-20193009x10xq.htm</File>
    <File>amed-20190930.xsd</File>
    <File>amed-20190930_cal.xml</File>
    <File>amed-20190930_def.xml</File>
    <File>amed-20190930_lab.xml</File>
    <File>amed-20190930_pre.xml</File>
    <File>amed-20193009xexx101.htm</File>
    <File>amed-20193009xexx311.htm</File>
    <File>amed-20193009xexx312.htm</File>
    <File>amed-20193009xexx32.htm</File>
    <File>amed-20193009xexx321.htm</File>
    <File>amed-20193009xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794985376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6796365184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 494,631<span></span>
</td>
<td class="nump">$ 417,335<span></span>
</td>
<td class="nump">$ 1,454,955<span></span>
</td>
<td class="nump">$ 1,228,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">288,708<span></span>
</td>
<td class="nump">249,739<span></span>
</td>
<td class="nump">854,734<span></span>
</td>
<td class="nump">730,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">154,700<span></span>
</td>
<td class="nump">124,500<span></span>
</td>
<td class="nump">451,900<span></span>
</td>
<td class="nump">369,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,366<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">12,440<span></span>
</td>
<td class="nump">9,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">447,787<span></span>
</td>
<td class="nump">377,447<span></span>
</td>
<td class="nump">1,319,036<span></span>
</td>
<td class="nump">1,109,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">46,844<span></span>
</td>
<td class="nump">39,888<span></span>
</td>
<td class="nump">135,919<span></span>
</td>
<td class="nump">118,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">311,500<span></span>
</td>
<td class="nump">294,900<span></span>
</td>
<td class="nump">940,200<span></span>
</td>
<td class="nump">870,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">188,900<span></span>
</td>
<td class="nump">181,800<span></span>
</td>
<td class="nump">562,400<span></span>
</td>
<td class="nump">532,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">75,500<span></span>
</td>
<td class="nump">68,800<span></span>
</td>
<td class="nump">220,900<span></span>
</td>
<td class="nump">205,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">265,400<span></span>
</td>
<td class="nump">251,400<span></span>
</td>
<td class="nump">786,400<span></span>
</td>
<td class="nump">740,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">46,100<span></span>
</td>
<td class="nump">43,500<span></span>
</td>
<td class="nump">153,800<span></span>
</td>
<td class="nump">130,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">162,400<span></span>
</td>
<td class="nump">103,400<span></span>
</td>
<td class="nump">452,600<span></span>
</td>
<td class="nump">302,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">84,500<span></span>
</td>
<td class="nump">53,400<span></span>
</td>
<td class="nump">245,900<span></span>
</td>
<td class="nump">155,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">35,800<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="nump">99,700<span></span>
</td>
<td class="nump">61,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">120,700<span></span>
</td>
<td class="nump">75,100<span></span>
</td>
<td class="nump">346,800<span></span>
</td>
<td class="nump">217,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">41,700<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
<td class="nump">105,800<span></span>
</td>
<td class="nump">84,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">20,700<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">62,100<span></span>
</td>
<td class="nump">55,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">15,300<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
<td class="nump">42,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">18,400<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="nump">55,900<span></span>
</td>
<td class="nump">52,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">40,400<span></span>
</td>
<td class="nump">31,300<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">92,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">33,300<span></span>
</td>
<td class="nump">129,900<span></span>
</td>
<td class="nump">99,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="num">$ (43,300)<span></span>
</td>
<td class="num">$ (33,300)<span></span>
</td>
<td class="num">$ (129,900)<span></span>
</td>
<td class="num">$ (99,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6806628688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>amed-20193009x10xq_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20190930"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20190930.xsd" xlink:type="simple"/>
    <context id="FD2019Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q4Oct252019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2019Q2Apr042019_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-01</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_amed_FleetLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">amed:FleetLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2019Q1Feb04_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Feb04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2020Q1Feb042019-Mar312020_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2019Q1Feb04_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="D2023Q1Apr012020-Mar312023_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2024Q2Apr012023-Feb042024_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-02-04</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2019Q3Feb0419-Sep3019_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2008Q1Jan01-Mar31_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="D2016Q2Jun27_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_ParkersburgWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="D2015Q1Jan302015_srt_LitigationCaseAxis_amed_CompassionateCareHospiceCIAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-30</startDate>
            <endDate>2015-01-30</endDate>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2014Q2Apr23_srt_LitigationCaseAxis_amed_AmedisysCIAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-04-23</startDate>
            <endDate>2014-04-23</endDate>
        </period>
    </context>
    <context id="D2015Q4Nov03_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_MorgantownWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="D2015Q2May21_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_stpr_MA_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FI2018Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-04</startDate>
            <endDate>2018-06-04</endDate>
        </period>
    </context>
    <context id="D2019Q1Feb252019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="I2019Q1Feb252019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="day">
        <measure>amed:day</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="Segments">
        <measure>amed:Segments</measure>
    </unit>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember"
      decimals="INF"
      id="Fact-DDCD2484F4385067A726DD0D81500DBF-wk-Fact-DDCD2484F4385067A726DD0D81500DBF"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember"
      decimals="INF"
      id="Fact-A45DD2F0100A5A6CA452DEC04CB49B8E-wk-Fact-A45DD2F0100A5A6CA452DEC04CB49B8E"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember"
      decimals="INF"
      id="Fact-E0A5744A95515F089C93660FAB3BDB48-wk-Fact-E0A5744A95515F089C93660FAB3BDB48"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember"
      decimals="INF"
      id="Fact-ABBA60EE3EF453B28FFB1267C7CE80AE-wk-Fact-ABBA60EE3EF453B28FFB1267C7CE80AE"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember"
      decimals="INF"
      id="Fact-913FAE28065354A09A60DB9CCE6D0013-wk-Fact-913FAE28065354A09A60DB9CCE6D0013"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember"
      decimals="INF"
      id="Fact-028D16549C8D562EBEBF7C85BEE31100-wk-Fact-028D16549C8D562EBEBF7C85BEE31100"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="3"
      id="Fact-C9322829F79F54C892E2C634A7F69751-wk-Fact-C9322829F79F54C892E2C634A7F69751"
      unitRef="number">0.035</amed:DebtInstrumentInterestRateatPeriodEnd>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="3"
      id="Fact-05E0E941706B514EB54EBDE9DE3D9436-wk-Fact-05E0E941706B514EB54EBDE9DE3D9436"
      unitRef="number">0.036</amed:DebtInstrumentInterestRateatPeriodEnd>
    <amed:EpisodeOfCareAsEpisodicBasedRevenueDuration
      contextRef="FD2019Q3YTD"
      id="Fact-7A0BA1D8225B5D73A1D7D245E62F86A0-wk-Fact-7A0BA1D8225B5D73A1D7D245E62F86A0">P60D</amed:EpisodeOfCareAsEpisodicBasedRevenueDuration>
    <amed:FirstThresholdOfTherapyServicesRequired
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="Fact-FBED4D611B9353F3BAB26FA12D36590D-wk-Fact-FBED4D611B9353F3BAB26FA12D36590D"
      unitRef="visit">6</amed:FirstThresholdOfTherapyServicesRequired>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="FD2019Q3YTD"
      id="Fact-77DFBEB67AFB50FE865AC53A52781914-wk-Fact-77DFBEB67AFB50FE865AC53A52781914">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:SecondThresholdOfServicesRequired
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="Fact-546815BA86A155AE8DE269B0759B4AFB-wk-Fact-546815BA86A155AE8DE269B0759B4AFB"
      unitRef="visit">14</amed:SecondThresholdOfServicesRequired>
    <amed:ThirdThresholdOfTherapyServicesRequired
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="Fact-EE56F77C1C2D58D5BDBC8B1E42BD2ADA-wk-Fact-EE56F77C1C2D58D5BDBC8B1E42BD2ADA"
      unitRef="visit">20</amed:ThirdThresholdOfTherapyServicesRequired>
    <dei:AmendmentFlag
      contextRef="FD2019Q3YTD"
      id="Fact-864D560A133C5515AED6E21CED8BEC76-wk-Fact-864D560A133C5515AED6E21CED8BEC76">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q3YTD"
      id="Fact-81533095FC6A53D7A951AB005EC9E7CF-wk-Fact-81533095FC6A53D7A951AB005EC9E7CF">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q3YTD"
      id="Fact-C17310B7AFF15D5698563D449F075BCD-wk-Fact-C17310B7AFF15D5698563D449F075BCD">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q3YTD"
      id="Fact-4D7985236F4B54F1B40BB9B2DD034400-wk-Fact-4D7985236F4B54F1B40BB9B2DD034400">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q3YTD"
      id="Fact-BE8CB1FD722E55A29D02910F4220F84B-wk-Fact-BE8CB1FD722E55A29D02910F4220F84B">0000896262</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="FD2019Q3YTD"
      id="Fact-6DB194118F165514B141208568002FC3-wk-Fact-6DB194118F165514B141208568002FC3">AMEDISYS INC</dei:EntityRegistrantName>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-263CC87A9FE155C3BAD223B15A338513-wk-Fact-263CC87A9FE155C3BAD223B15A338513"
      unitRef="usd">95472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q3"
      decimals="-3"
      id="Fact-B6607FED019B5DC4A91F9E5E406FA258-wk-Fact-B6607FED019B5DC4A91F9E5E406FA258"
      unitRef="usd">101446000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-7FB3E0AB369A56D5BC8861BC472C1AAD-wk-Fact-7FB3E0AB369A56D5BC8861BC472C1AAD"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-3D0B0FEB5DBA527AB5F6342026E6845D-wk-Fact-3D0B0FEB5DBA527AB5F6342026E6845D"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-69F7A80E327D56BBABC49591749FAE6F-wk-Fact-69F7A80E327D56BBABC49591749FAE6F"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-74AF3D59D6DE5E7E9B2EAD7A3A233BD6-wk-Fact-74AF3D59D6DE5E7E9B2EAD7A3A233BD6"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-19D8AB3F78225349BA72BCBCA5FD8DA1-wk-Fact-19D8AB3F78225349BA72BCBCA5FD8DA1"
      unitRef="shares">36252280</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-64E5C174B84C5E8B983ADA590F48822C-wk-Fact-64E5C174B84C5E8B983ADA590F48822C"
      unitRef="shares">36599273</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-BB70B4F683D35F74BEA0E13E6C081852-wk-Fact-BB70B4F683D35F74BEA0E13E6C081852"
      unitRef="shares">31973505</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-0F88BB33E8425E799DBEDD0809A0B697-wk-Fact-0F88BB33E8425E799DBEDD0809A0B697"
      unitRef="shares">32246575</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="Fact-D9CB007691535640BD547C4BE1AE43B6-wk-Fact-D9CB007691535640BD547C4BE1AE43B6"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      id="Fact-E51D6BDF340C5D3FA31635BA37CAB168-wk-Fact-E51D6BDF340C5D3FA31635BA37CAB168">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum. </us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      id="Fact-B060C1406E425165910B38330B9E53E8-wk-Fact-B060C1406E425165910B38330B9E53E8"> Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months </us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      id="Fact-39EDA7F85B92559889B4F25C3B96B3E9-wk-Fact-39EDA7F85B92559889B4F25C3B96B3E9"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="INF"
      id="Fact-F0C14B1EBA4859D588757B9C687533C9-wk-Fact-F0C14B1EBA4859D588757B9C687533C9"
      unitRef="usd">175000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      id="Fact-F00923F4825F549483B71F35034608B8-wk-Fact-F00923F4825F549483B71F35034608B8">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      id="Fact-3BD8298B75B358A6A8AD5AE11F689714-wk-Fact-3BD8298B75B358A6A8AD5AE11F689714">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-7F2EAE2D04655C5DA4052110E7063206-wk-Fact-7F2EAE2D04655C5DA4052110E7063206"
      unitRef="usd">33050000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q3"
      decimals="-3"
      id="Fact-3490C8BDBBE853CC8FC3DFCF14B78BFA-wk-Fact-3490C8BDBBE853CC8FC3DFCF14B78BFA"
      unitRef="usd">36799000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="Fact-989B9E39B94D6AF7549DEEE8037F3315-wk-Fact-989B9E39B94D6AF7549DEEE8037F3315"
      unitRef="usd">1455000000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-1C2BD8E7793D548AB1B378D95E811971-wk-Fact-1C2BD8E7793D548AB1B378D95E811971">Option for early termination of lease after three years</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-5559187B984059028FB2ECAA30DA5759-wk-Fact-5559187B984059028FB2ECAA30DA5759">Option for early termination of lease after one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember"
      id="Fact-6BB9AE7599FB5004860D333B71E381D7-wk-Fact-6BB9AE7599FB5004860D333B71E381D7">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="Fact-2F63574A903E54A3B84821DDAA05E9B1-wk-Fact-2F63574A903E54A3B84821DDAA05E9B1"
      unitRef="usd">900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="Fact-47CA2AB2CCE85C9881A05B25A989CA5B-wk-Fact-47CA2AB2CCE85C9881A05B25A989CA5B"
      unitRef="usd">-4200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="Fact-98564944728E53839B3CA9D4E6106F2B-wk-Fact-98564944728E53839B3CA9D4E6106F2B"
      unitRef="usd">80000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="-5"
      id="Fact-4E69C15E4DFD5B66B97619A2396177B7-wk-Fact-4E69C15E4DFD5B66B97619A2396177B7"
      unitRef="usd">800000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-E0FC5AD8A85E5E8EAF001A422327D96D-wk-Fact-E0FC5AD8A85E5E8EAF001A422327D96D"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-58CAF82E3EDD5C5C8D5E163FF73EDB8F-wk-Fact-58CAF82E3EDD5C5C8D5E163FF73EDB8F"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-6CCFCB7D50455903BCF200A17305336D-wk-Fact-6CCFCB7D50455903BCF200A17305336D"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-C3480840CD1B5BD789A6D3A43340FF73-wk-Fact-C3480840CD1B5BD789A6D3A43340FF73"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-C60A4BA0535E5CCB8ED96CF6F88AB648-wk-Fact-C60A4BA0535E5CCB8ED96CF6F88AB648"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-9ECF508E107C576AB43596B09B495CE4-wk-Fact-9ECF508E107C576AB43596B09B495CE4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-B888A840EC095F8CA177DC37C1B8EB13-wk-Fact-B888A840EC095F8CA177DC37C1B8EB13"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-A4114A567ED552D99E6211BB45BE14F4-wk-Fact-A4114A567ED552D99E6211BB45BE14F4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-4B86BB953F385AA78EC953B82E0334E4-wk-Fact-4B86BB953F385AA78EC953B82E0334E4"
      unitRef="shares">4278775</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-8B86565AC4DE5CF58120E2DCC246CA8A-wk-Fact-8B86565AC4DE5CF58120E2DCC246CA8A"
      unitRef="shares">4352698</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2019Q3YTD"
      id="d131209688e386-wk-Fact-1DA953ECECE8505197BBA27114306A65">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q3YTD"
      id="d131209688e419-wk-Fact-9984C909F95550819F990001A719FA51">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q3YTD"
      id="d131209688e431-wk-Fact-EB2545D7E628543691AF2875BF4B563A">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q3YTD"
      id="d131209688e451-wk-Fact-58967381CFC25F80A7430918C40C649A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q3YTD"
      id="d131209688e470-wk-Fact-1B92ECDADA4F533C95BFCD4E1F97E564">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q3YTD"
      id="d131209688e540-wk-Fact-1EAB8829366655A6856A94604C9D130F">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q3YTD"
      id="d131209688e550-wk-Fact-5BD21805BA205CCDA9EC0EF3FB8F63D8">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q3YTD"
      id="d131209688e575-wk-Fact-C8CDFF4F582D5240A5662EC0EED2BED4">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="FD2019Q3YTD"
      id="d131209688e580-wk-Fact-7C5DF9BA877E530BB967855D24F0EC07">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q3YTD"
      id="d131209688e585-wk-Fact-5127A12615D35D62B6D738807E23FF5D">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q3YTD"
      id="d131209688e590-wk-Fact-C07045EAD5285A3999BCAE9A9D49426A">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q3YTD"
      id="d131209688e595-wk-Fact-6AEC0E21B44D5D8D9CA762C22AD7BE68">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q3YTD"
      id="d131209688e607-wk-Fact-33A251E1A30A5A21B96D5627D7ADC3B4">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q3YTD"
      id="d131209688e612-wk-Fact-9011A73A39E0566DB306F86A91E0BBEF">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q3YTD"
      id="d131209688e681-wk-Fact-57245F3DDB4551C1907581DB9B6BCB09">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q3YTD"
      id="d131209688e691-wk-Fact-D5BDDEDB30C956C4BB2B7810328C97B4">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q3YTD"
      id="d131209688e701-wk-Fact-8E57F552BA875AF18BEAB1D659C94CCF">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q3YTD"
      id="d131209688e708-wk-Fact-E12196EF02415FCC9682586000887142">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q3YTD"
      id="d131209688e719-wk-Fact-1BC80983689B5075B8A38E76593DB485">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q3YTD"
      id="d131209688e787-wk-Fact-4084756887AE5AF391BBD8321A183C73">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q3YTD"
      id="d131209688e889-wk-Fact-BC3F0E5C02645D33A8A2301E9E47D3C3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q3YTD"
      id="d131209688e941-wk-Fact-62DECFCFAC2158EAA4826298B17963CB">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q3YTD"
      id="d131209688e971-wk-Fact-AD21957E86FD54A2B6856F0B28BCBB14">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q4Oct252019"
      decimals="INF"
      id="d131209688e980-wk-Fact-99155C72A70A563A9965364A2215301D"
      unitRef="shares">32255257</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e507-wk-Fact-5B458D36A5AF5DC1A4CC7C8988414378"
      unitRef="usd">20757000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e526-wk-Fact-4CA6620396B25DD49702768F70290CC9"
      unitRef="usd">20229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e541-wk-Fact-89FB6A1DAB385D1F96F8D169B6D046FD"
      unitRef="usd">254703000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e560-wk-Fact-0EB7D4D08B98588D8A9B0F68362E8879"
      unitRef="usd">188972000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e580-wk-Fact-530AAE3ED0DC54DFB35ED9933979E3C2"
      unitRef="usd">10601000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e599-wk-Fact-77199500CEAD5D2CAF0D34053879CDE9"
      unitRef="usd">7568000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e619-wk-Fact-45B2B22FB5FA567DB02615B600F75B19"
      unitRef="usd">13458000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e638-wk-Fact-3B5E069EFCAC57908287A8AEE91B7A91"
      unitRef="usd">7349000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e658-wk-Fact-AB0E1539A4D45F16B848E0DC397B1908"
      unitRef="usd">299519000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e677-wk-Fact-BCA90CE3BE7D5AAA8F4DDF28F93C15F1"
      unitRef="usd">224118000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e697-wk-Fact-E0D797DEE6C957E2AD2225EEEEDE9963"
      unitRef="usd">29969000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e716-wk-Fact-EEBE44144C3E5334AE3EB0298D13AA5D"
      unitRef="usd">29449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e736-wk-Fact-2BB4F990345C55C3AD37EFC37FBEC454"
      unitRef="usd">84124000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e755-wk-Fact-666B1D1124BC53D3957DF5BD2F15512B"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e775-wk-Fact-96A2653F94B95B0DA174757754DB5BC4"
      unitRef="usd">660472000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e794-wk-Fact-FDB954BCBB7852DF98A73A5C9D827C1C"
      unitRef="usd">329480000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e815-wk-Fact-661A1B09FD42506EAE9250F814DD21D3"
      unitRef="usd">66468000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e834-wk-Fact-E5CD11FA9EB15EF09A729AF3BC2C0F7A"
      unitRef="usd">44132000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e854-wk-Fact-2646B2EA69885D169184F4499D59B480"
      unitRef="usd">17568000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e873-wk-Fact-CCB5316F47A059AFA8736BF75B401246"
      unitRef="usd">35794000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e893-wk-Fact-53B7DE63BFA75C548881C02B4164B88C"
      unitRef="usd">54260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e912-wk-Fact-F8A653F6B8A356C0BE214B560AFB6E56"
      unitRef="usd">54145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e937-wk-Fact-62B16D113C9F58F497CC6A35C5B488C1"
      unitRef="usd">1212380000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e956-wk-Fact-5C8CC2D0F82E59AEAF0F42B90A068276"
      unitRef="usd">717118000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1058-wk-Fact-EB7C0EEC0A545B2EBD4904EBBF510D02"
      unitRef="usd">35901000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1077-wk-Fact-761A58ACCF6758F6B55E4A29E5BD29AC"
      unitRef="usd">28531000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1092-wk-Fact-494156663B0550F392F54E545FED878D"
      unitRef="usd">115899000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1111-wk-Fact-04ED939407A45AC2B1A3EED0B2904005"
      unitRef="usd">92858000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1131-wk-Fact-E5B9C3BD048F5A479DEF3FB9A17B4143"
      unitRef="usd">127111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1150-wk-Fact-8E86396853E55FC49E8F0523FB702667"
      unitRef="usd">99475000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1170-wk-Fact-7A0D36B0106B55F686437A0005719B89"
      unitRef="usd">8959000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1189-wk-Fact-38FDB57FD51C547799F45112DF0426D0"
      unitRef="usd">1612000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1209-wk-Fact-FD0596A08350546D87A563A8A2F930A7"
      unitRef="usd">26783000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1228-wk-Fact-BE26BC9FDEF758E1B598F27E63D68663"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1249-wk-Fact-72A462AD2BC35AC0BA4A410D9BD2AA80"
      unitRef="usd">314653000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1268-wk-Fact-618121DD40235D68A070034F3CCB5815"
      unitRef="usd">222476000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1288-wk-Fact-3C3D1BD2ADCF573BAB804233A8AEDD28"
      unitRef="usd">231641000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1307-wk-Fact-D05496C5F3515024A913F39B5B1C3829"
      unitRef="usd">5775000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1327-wk-Fact-E09C75818D985539B519941692286E4B"
      unitRef="usd">56619000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1346-wk-Fact-38124F982EB15EB99A3F02930E96C5D5"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1366-wk-Fact-AE8B5A8D4F8052879264984E8409F7C1"
      unitRef="usd">6002000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1385-wk-Fact-A49E94DE13645FA7817088AE78C7EE8B"
      unitRef="usd">6234000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1405-wk-Fact-343F693CE58B5BC2B9FC1B035E2AE75F"
      unitRef="usd">608915000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1424-wk-Fact-10CE796BC1B15419BF7C5F9924FD4968"
      unitRef="usd">234485000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q3"
      id="d131233436e1444-wk-Fact-47C74217BB0A50D99F3655CEC892FC17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1525-wk-Fact-E34A2ABE12A0503FBF83297311163F8D"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1544-wk-Fact-A34C0DED1E0A5E9390F5819858750441"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1564-wk-Fact-16E3E76D0E895531BDAEC8C37102DB7D"
      unitRef="usd">37000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1583-wk-Fact-CFE448C129305997A1FC61B5E95FE6EF"
      unitRef="usd">36000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1603-wk-Fact-72D7B971C5345A1BA41CB0FB1F5F8944"
      unitRef="usd">634854000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1622-wk-Fact-93364A8E68DC58388954F65261431797"
      unitRef="usd">603666000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1642-wk-Fact-5B2C897849E159E1A444BFEF53384667"
      unitRef="usd">251070000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1662-wk-Fact-3E3E9D9DEDF95AD4A8E4C2D9BA0D499D"
      unitRef="usd">241685000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1684-wk-Fact-2D821D6E3D3053DCB7EE5A4F28E221BE"
      unitRef="usd">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1703-wk-Fact-C7D3F23582765A8495F7ADE91B73882F"
      unitRef="usd">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1723-wk-Fact-EADC611865D959B598F979852B1BC76E"
      unitRef="usd">218728000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1742-wk-Fact-85040A2F41715A98B6962949575984D1"
      unitRef="usd">119550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1762-wk-Fact-4E1E8B632FCC5B828244E43D5FEA7E4F"
      unitRef="usd">602564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1781-wk-Fact-D85C6A08037A5FF2BF4C56D283F4F0AF"
      unitRef="usd">481582000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1801-wk-Fact-E5E80DFD2D2256AC90A49752A8D6FB74"
      unitRef="usd">901000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1820-wk-Fact-36678F9429A154EABEA15A10E17F6584"
      unitRef="usd">1051000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1840-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16"
      unitRef="usd">603465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1859-wk-Fact-3A4847BF8CC05471AB47677C18ED37FD"
      unitRef="usd">482633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131233436e1884-wk-Fact-5DDE1FD78AEB514696E8880455E818CD"
      unitRef="usd">1212380000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131233436e1903-wk-Fact-8B67C43A1B8059E99C6CB122D34B4D2D"
      unitRef="usd">717118000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e561-wk-Fact-598A6E82F5C05E998D91640F1D12B716"
      unitRef="usd">494631000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e580-wk-Fact-D0A40BF54DF752D5B5E15F8BACD71F03"
      unitRef="usd">417335000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e599-wk-Fact-9B5CA803ECC55EA0906AF00E9A8AAA7B"
      unitRef="usd">1454955000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e619-wk-Fact-63DD06D0AD8256AF824DECA986BD42F7"
      unitRef="usd">1228200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e634-wk-Fact-11DBFECCB503527EAB7C0891CCB0497F"
      unitRef="usd">288708000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e653-wk-Fact-7EBF34EE228255F4B141A9EDA98CA166"
      unitRef="usd">249739000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e672-wk-Fact-CAEBF4F1BB385739B4BEAD938A23B3B1"
      unitRef="usd">854734000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e692-wk-Fact-916310D77D4D5F289271C2E9076A645B"
      unitRef="usd">730612000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e794-wk-Fact-ACEE864C3D9F51DDBAD1988C3F3883B8"
      unitRef="usd">99941000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e813-wk-Fact-29BA6CBFEF885A6EA04C27DFAA907B8E"
      unitRef="usd">79367000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e832-wk-Fact-675F62BB38AB51F88C15650E2FACF205"
      unitRef="usd">293127000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e852-wk-Fact-2E22961F197950499EAD94647996CFC7"
      unitRef="usd">232213000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e872-wk-Fact-757100BD57955B9990B7BF68EE5B9561"
      unitRef="usd">6298000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e891-wk-Fact-FCA027B3D1655D67AEF6FA76A3F2E6C1"
      unitRef="usd">4842000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e910-wk-Fact-4341C80739FA5B1D8BEF530041F3D12F"
      unitRef="usd">18451000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e930-wk-Fact-D74B12412EAE58B6B28311DA1812C160"
      unitRef="usd">12653000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e950-wk-Fact-64D602D245185FBF91782FBCB9E830A4"
      unitRef="usd">48474000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e969-wk-Fact-163406C243DA5B87914A0A946CC2B20B"
      unitRef="usd">40335000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e988-wk-Fact-CE7A83A7752951CEB120C1387B11A6D9"
      unitRef="usd">140284000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1008-wk-Fact-979DE5C5D2035F81992A18CB385C73F0"
      unitRef="usd">124119000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1028-wk-Fact-C59913AFDE885E6AB087F12FEA1D3842"
      unitRef="usd">4366000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1047-wk-Fact-ABBE40ECAE495CA1B2F6343D611E695F"
      unitRef="usd">3164000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1066-wk-Fact-0F22A7FE8BE252B78F0258F658FB350D"
      unitRef="usd">12440000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1086-wk-Fact-6BFE83D49A595882BD4AAC1F7D8CB0FA"
      unitRef="usd">9882000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1106-wk-Fact-7846832CF8515DBCA965A276FA125D3B"
      unitRef="usd">447787000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1125-wk-Fact-617FD2D74E555237AF1B77516AF41B3B"
      unitRef="usd">377447000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1144-wk-Fact-4444C6577EBD5D66A3AFD79C2934C7B3"
      unitRef="usd">1319036000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1164-wk-Fact-807B7ABB6FFA51FABF0FDFA74DDB0849"
      unitRef="usd">1109479000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1184-wk-Fact-6689DE4324DA5A95ACF7D188864A5408"
      unitRef="usd">46844000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1203-wk-Fact-1A228D07E3565FBCB20D3ADC5C147346"
      unitRef="usd">39888000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1222-wk-Fact-A9362601345E55358683B32A8482FA59"
      unitRef="usd">135919000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1242-wk-Fact-0063F0C430815495ADC32F01AA8D846D"
      unitRef="usd">118721000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1345-wk-Fact-2F98DF574C12581AA30C374A406A9AA2"
      unitRef="usd">15000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1364-wk-Fact-3C1490626FC55179AE04605729A9504F"
      unitRef="usd">29000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1383-wk-Fact-FC1F5E3272875034A2CD1D575E16EA55"
      unitRef="usd">59000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1403-wk-Fact-E942ACAF18C651C6ADDABB7B0E3142B6"
      unitRef="usd">263000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1423-wk-Fact-E81E1F18CA1053BAA6717BDEAF6B63DE"
      unitRef="usd">3778000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1443-wk-Fact-9FF276785AA5546394D3AD65AB22E984"
      unitRef="usd">1991000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1463-wk-Fact-D7769975C2E35636AD97A7FC11BDA12E"
      unitRef="usd">11459000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1484-wk-Fact-57FDE185A0565E5CA4450DA8D384B7BF"
      unitRef="usd">5834000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1505-wk-Fact-A13F190DFFC251F3BAA62200F9D0F451"
      unitRef="usd">-812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1525-wk-Fact-40B8D0E2A8145CEAA748BE14B6D0B859"
      unitRef="usd">1625000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1544-wk-Fact-639E153B9FD15FE29A870E935A51BF90"
      unitRef="usd">4120000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1564-wk-Fact-041416182B46531998B9E6782D465AC9"
      unitRef="usd">6461000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1584-wk-Fact-A34C1B7ADF5D5894B178E582576EC5EC"
      unitRef="usd">1975000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1603-wk-Fact-188D8FD063BE5BE493C984B75D889486"
      unitRef="usd">1822000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1622-wk-Fact-E0AC9AFA275355E6AC1AD48EC1AF2731"
      unitRef="usd">2404000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1642-wk-Fact-C6673A4F64D6510186426F47A15E270E"
      unitRef="usd">2782000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1662-wk-Fact-8FA1EDC4E1A5571FA9F21321F9845AC7"
      unitRef="usd">-2600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1682-wk-Fact-67141299A3C0565096E2BDA7A3985258"
      unitRef="usd">1485000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1701-wk-Fact-DB8B9DE3C3E75DFC83F70E8D1C5591AC"
      unitRef="usd">-4876000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1722-wk-Fact-3440895D092955A4A2D0A6F6F19489A7"
      unitRef="usd">3672000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1742-wk-Fact-798DEDFD1DD55A6BA9F2C188C9A47FE7"
      unitRef="usd">44244000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1761-wk-Fact-4E5CEB259F2B589991257B14D567D328"
      unitRef="usd">41373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1780-wk-Fact-BF7183FABB315F06A2F67D9DBA551336"
      unitRef="usd">131043000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1800-wk-Fact-7DBA8130386E5C599AF3DBABEBCF22E6"
      unitRef="usd">122393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1820-wk-Fact-90E550D1CDA159C59C53AB35C0941FA4"
      unitRef="usd">9919000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1840-wk-Fact-CA831D59D0AA522CB1CA826FE6CA7DB8"
      unitRef="usd">9825000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1860-wk-Fact-FB64EDB3A41653D8B0A640F0FA8AB1C8"
      unitRef="usd">31105000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1881-wk-Fact-014CAB37BE1B5981923841BBD3B696D6"
      unitRef="usd">29984000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1902-wk-Fact-3C758350A806512D9A9AA28BFF0CD296"
      unitRef="usd">34325000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e1921-wk-Fact-0DD2105951DB5013A2B9E0EFA59AEF67"
      unitRef="usd">31548000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e1940-wk-Fact-E182736C69245E579EAB5E886D6344BD"
      unitRef="usd">99938000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e1960-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD"
      unitRef="usd">92409000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e1980-wk-Fact-FA91E367E7C75A409B7ED260D8CCB5B6"
      unitRef="usd">193000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e2000-wk-Fact-3B50B1D5B02155BDA43A8DC5A61D66E9"
      unitRef="usd">171000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e2020-wk-Fact-CAE197BFFA2F5336A233673A50F3E0C4"
      unitRef="usd">760000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e2041-wk-Fact-5D942C3DEDCA5EC593CDDC5BCD13C268"
      unitRef="usd">524000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e2067-wk-Fact-3052EC66FCF05D57A3ADB91ABD397752"
      unitRef="usd">34132000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e2086-wk-Fact-1597EF7ACA3C59B597CC39DCD7FA77AE"
      unitRef="usd">31377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e2105-wk-Fact-2CF272BA3AD6545E9038A10BD728391B"
      unitRef="usd">99178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e2125-wk-Fact-F2F85C88C2FC5D8CA2948693E64CB90E"
      unitRef="usd">91885000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d131212750e2228-wk-Fact-4E72A175B1485D1993706CEE0B4BDE19"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d131212750e2247-wk-Fact-623617FB568559C797B02DAEFAE0E917"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131212750e2266-wk-Fact-DFDD1795853A50B1A6F45A060280615B"
      unitRef="usdPerShare">3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d131212750e2286-wk-Fact-D846E5878AFE5E7FAE24F24FE5E6FC10"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e2301-wk-Fact-CD11DC571B9851778D9F4ABC891E8923"
      unitRef="shares">32211000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e2320-wk-Fact-93B2D8D871FA5DDFA6739CE528068113"
      unitRef="shares">31815000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e2339-wk-Fact-89F85BF475A95C96A5BBDBF1DB638438"
      unitRef="shares">32096000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e2359-wk-Fact-6C2CAE056DF9575186ED2BE686165C73"
      unitRef="shares">33075000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d131212750e2466-wk-Fact-275F916EA3545BF0B3BF3C76E65C07E4"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d131212750e2485-wk-Fact-7E20A5070B3E52D8B493FC8CCA8C436E"
      unitRef="usdPerShare">0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131212750e2504-wk-Fact-D3F9A136E8FC5437A78C6637976984A9"
      unitRef="usdPerShare">3.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d131212750e2524-wk-Fact-38085835207C5A6F825994A933CF3F33"
      unitRef="usdPerShare">2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131212750e2539-wk-Fact-28CF598E0CB95194B9F5F379A14254DD"
      unitRef="shares">33002000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131212750e2558-wk-Fact-85B676CCD8CD502C93833B814DEDEB3C"
      unitRef="shares">32691000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131212750e2577-wk-Fact-FE6C4CE2C1BE5BC79A55744349AD541D"
      unitRef="shares">32944000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131212750e2597-wk-Fact-5655AC2AEFFB5F57B1BE932580F9E145"
      unitRef="shares">33852000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d131227501e906-wk-Fact-205C3B9E36D8504099A6C7E5751C9979"
      unitRef="usd">562942000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e920-wk-Fact-43B43743B08156E59B51ECAA1CE48FC8"
      unitRef="shares">36445591</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e939-wk-Fact-5E2B7D6E36A65CF7B24A50F0331076E3"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e959-wk-Fact-C16CDD9FF9595CD6A3EEEDFA5FDD0FCC"
      unitRef="usd">623309000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e978-wk-Fact-87740D865AA5583590FDB69D511DFA28"
      unitRef="usd">-246175000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e998-wk-Fact-5FFC4FABE90659B69A95ED011734AD25"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e1018-wk-Fact-5A121754E0B35C67A33F46274D813D77"
      unitRef="usd">184596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e1037-wk-Fact-8A1E8B8044325E68A93412B01D055C06"
      unitRef="usd">1161000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1052-wk-Fact-7098743CF6AD5DCB9CD3A84605B3F2CD"
      unitRef="usd">850000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e1071-wk-Fact-731D4F4AA8B55EBDAB3B90DA9801CAF3"
      unitRef="shares">8230</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e1105-wk-Fact-95218B7595B2569FA2D6A2C816EC0275"
      unitRef="usd">850000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1202-wk-Fact-0B0B7726AD0651D2A3E8DD478D220ED4"
      unitRef="usd">2353000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e1221-wk-Fact-43F2F663D6D3561C8A99BE6F6EBFECE0"
      unitRef="shares">19381</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e1255-wk-Fact-848710950E245568BAC6FB6E0A77A089"
      unitRef="usd">2353000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1352-wk-Fact-9D0B8D08C3B953D78F3B5D4ED81CEE71"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e1371-wk-Fact-7615C67D512C5F8997B17111AB6B24F9"
      unitRef="shares">88334</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e1385-wk-Fact-ED2A983ED3F44244B52EEBCE20B01F7D"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e1405-wk-Fact-F38CE69F7DC95C61B7A76F07BC71986A"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1503-wk-Fact-5E9D839B10685225BA9C49CE2F45E7D7"
      unitRef="usd">2045000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e1522-wk-Fact-0B5515AEFFC455DB9B60B984C4EEF94D"
      unitRef="shares">37737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e1556-wk-Fact-9BE4B78E18A752C5AC87EBEFA822DE2A"
      unitRef="usd">2045000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1653-wk-Fact-FEC4B23F33215E78AC93B12B8A437761"
      unitRef="usd">6298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e1706-wk-Fact-C11AF203E09C5CA99B20243C25F01558"
      unitRef="usd">6298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1803-wk-Fact-EB8AA6102CEA520FA3EDDE2D52E94807"
      unitRef="usd">4895000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e1876-wk-Fact-BC3C03E151C05C20B4D50D5CE3AA9FE5"
      unitRef="usd">4895000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e1955-wk-Fact-5324FA014A135B5BB7F4A6627486D258"
      unitRef="usd">453000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e2086-wk-Fact-77AEA78BCFB75212A79FFC9FFB16FCBF"
      unitRef="usd">453000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131227501e2108-wk-Fact-3C758350A806512D9A9AA28BFF0CD296"
      unitRef="usd">34325000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e2219-wk-Fact-8D867608644355449F046ECE4CDC19CC"
      unitRef="usd">34132000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e2238-wk-Fact-2E8A37502B075F7DA5316C75B256BCDC"
      unitRef="usd">193000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131227501e2263-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16"
      unitRef="usd">603465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e2277-wk-Fact-720EEAFDFB275616868BF4AAECE2F904"
      unitRef="shares">36599273</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e2296-wk-Fact-B7BF2DC31E2C5246B114096AA9A3635A"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e2315-wk-Fact-E4A2BF2C6B415C16B9547F2C4F7697CA"
      unitRef="usd">634854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e2334-wk-Fact-D2FCBBAE888451F6972C2E7758FC4E84"
      unitRef="usd">-251070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e2354-wk-Fact-A7A697394B575449BAA41877B890DB17"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e2374-wk-Fact-0E802A87000355839C413996A73AF994"
      unitRef="usd">218728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e2393-wk-Fact-1058523278555BA790C34BDBBC18C2E9"
      unitRef="usd">901000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-3"
      id="d131227501e3064-wk-Fact-0EA241F713A05A5E9A188669C9449DE9"
      unitRef="usd">409061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e3078-wk-Fact-88266939999D5FED9BD5493423FDE769"
      unitRef="shares">36044177</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e3097-wk-Fact-D1F9CE689550522B8A2D054F8E51E9DF"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3117-wk-Fact-1782A5370F80578780C027E7B8DCD5CE"
      unitRef="usd">585137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e3136-wk-Fact-6214BA7373E5504180B7994F9FA69265"
      unitRef="usd">-237947000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e3156-wk-Fact-91C370F320405C1493559F32C23C5DAE"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e3176-wk-Fact-0B1971EDA43A5FF695C4CD1AAC9BD79E"
      unitRef="usd">60712000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e3195-wk-Fact-99D089390A25532C8E453F0480A6834E"
      unitRef="usd">1108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3210-wk-Fact-F718ADF5EEC05AA09B8FE5860DF2ABC7"
      unitRef="usd">630000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e3229-wk-Fact-12C74857584E51F995A64CD731B43DB6"
      unitRef="shares">8673</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3263-wk-Fact-2DB37B710304507BBF00F26698BEF115"
      unitRef="usd">630000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3360-wk-Fact-BDCAB6401E325621AF624225ED6E3D85"
      unitRef="usd">2404000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e3379-wk-Fact-B2866FCB7DBB5DC39D5FCF5BD1BC9D9A"
      unitRef="shares">28123</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3413-wk-Fact-55A0B0302518568D867BADD2FCFF188E"
      unitRef="usd">2404000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3510-wk-Fact-EAF7EF928B6A5F9AA5D8B5E5B78B3136"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e3529-wk-Fact-198D4DBF81055CAF95996C9101FCAD43"
      unitRef="shares">63098</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e3543-wk-Fact-A472D04AB4BB5C7E9267113C31F9CAEE"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3563-wk-Fact-EDE2387504EC5E60B0966ED5AC901AF2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3660-wk-Fact-9D4D72EFF1075D77A0999F97F7CD22C9"
      unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e3679-wk-Fact-6CBF35F7F8A95069A6037EE2FBAF8702"
      unitRef="shares">2578</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3713-wk-Fact-5ACDF133581A52A1893423DD435AA90D"
      unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3811-wk-Fact-C71FB8B3C09F5876A685B5EE8F10AD49"
      unitRef="usd">4842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e3864-wk-Fact-B01AD87718665D7C9C34EC54117E3CE5"
      unitRef="usd">4842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e3961-wk-Fact-7C5103F7B4BA5181B31A077ED51490E5"
      unitRef="usd">2589000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e4034-wk-Fact-B3BDEF67A88D523AAD34A05DB14E5E79"
      unitRef="usd">2589000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e4113-wk-Fact-716225786DFB5A26A8402BD760200654"
      unitRef="usd">180000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e4244-wk-Fact-77E21BB7B91B58F6AB0E56501F5B612C"
      unitRef="usd">180000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e4265-wk-Fact-849BBEC67D29E9504302EE96DA2518F2"
      unitRef="usd">361000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e4319-wk-Fact-A4B582646B33BBBB6083EE9734AE254B"
      unitRef="usd">614000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e4397-wk-Fact-AB89222A68EE1450CEEAEE97D74035C3"
      unitRef="usd">253000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131227501e4417-wk-Fact-0DD2105951DB5013A2B9E0EFA59AEF67"
      unitRef="usd">31548000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e4528-wk-Fact-76BB92DDF2635226890392555E11624A"
      unitRef="usd">31377000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e4547-wk-Fact-0D4AE645E4E05E2C9DF4F939195F8ABD"
      unitRef="usd">171000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3"
      decimals="-3"
      id="d131227501e4572-wk-Fact-18C1C855DD705C73BF021B045678C942"
      unitRef="usd">445495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e4586-wk-Fact-E6B5AF128DB751DDA8F4654EAAB5609E"
      unitRef="shares">36146649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e4605-wk-Fact-1CB212C0AC115A7CBF7F7C1326604AE5"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e4625-wk-Fact-049CC4660519535FBC8083C2FAD260EC"
      unitRef="usd">592539000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e4644-wk-Fact-B9B0790FF6FF5AB0A2823ACD7B7E3BFE"
      unitRef="usd">-240536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e4664-wk-Fact-6A7C0F9CA6055F8F94619E9CC0018994"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e4684-wk-Fact-0F4E56BD75DF53B0BDB4F8042330CBB0"
      unitRef="usd">92089000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e4703-wk-Fact-03AA0B1C5545585C9B3D25624CDD1385"
      unitRef="usd">1352000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131227501e5374-wk-Fact-3A4847BF8CC05471AB47677C18ED37FD"
      unitRef="usd">482633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e5388-wk-Fact-C975FB1181EA508B99C702A2E9EB7298"
      unitRef="shares">36252280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e5407-wk-Fact-C8DF3D7CE457509393498F44D92DD97C"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e5427-wk-Fact-7AAB1D678B69529C8DA1E0620FF00636"
      unitRef="usd">603666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e5446-wk-Fact-6CCB23F1B4855A1081AB7A68F2D044F6"
      unitRef="usd">-241685000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e5466-wk-Fact-6C87214BD39D5A0D8CDE7965E3C9D7E5"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e5486-wk-Fact-2C3DCDD23C4B54808D3856A18244AF2D"
      unitRef="usd">119550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e5505-wk-Fact-68E22870DA18588D8D3A39BABAF45C17"
      unitRef="usd">1051000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e5521-wk-Fact-2885E2C0E32E5F239530B60CA4893539"
      unitRef="usd">2384000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e5540-wk-Fact-A8EA412063DC5837A9D80839055FC312"
      unitRef="shares">23267</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e5574-wk-Fact-F78D575155A55D40B5D8D874F9400B16"
      unitRef="usd">2384000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e5671-wk-Fact-8EFECC12D5685B8EA59843461BBF2A08"
      unitRef="usd">6966000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e5690-wk-Fact-F13457DC993654ABA7CF510431A7C01D"
      unitRef="shares">57783</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e5724-wk-Fact-77E1DEB7225B55349B66BE19CE509CEC"
      unitRef="usd">6966000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e5821-wk-Fact-31D4E17E089A5992B41BAB77E10FFFF8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e5840-wk-Fact-8378013ECA54507094FFBD8C0657B5C6"
      unitRef="shares">185515</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e5854-wk-Fact-99F54C2FA6A1B4D3D9E0EBCF5914FA71"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e5874-wk-Fact-239E90F8C18554B88E77CC16E18DF8C9"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e5972-wk-Fact-ED8E829D09D750FE998ABF91B8C5416B"
      unitRef="usd">3388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e5991-wk-Fact-A5E7490898CA55A1B022CFA53D89BD0A"
      unitRef="shares">80428</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e6025-wk-Fact-AE251DBF019651E9BA338ECD55D314D5"
      unitRef="usd">3388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e6122-wk-Fact-A574E6D5726B58F987507C59C63F9B55"
      unitRef="usd">18451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e6175-wk-Fact-887AFC16FB3F576FA5463B259E8134A6"
      unitRef="usd">18451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e6272-wk-Fact-D2BEC671149D54B3BB9DBA1E409474CF"
      unitRef="usd">9385000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e6345-wk-Fact-000F5B3EF25955878AC93C072B2112C2"
      unitRef="usd">9385000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e6424-wk-Fact-E882B852046851D7888222D08542C3BA"
      unitRef="usd">910000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e6555-wk-Fact-7B29F4E8AE975FA99ECE36D2505A45BF"
      unitRef="usd">910000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131227501e6576-wk-Fact-E182736C69245E579EAB5E886D6344BD"
      unitRef="usd">99938000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e6687-wk-Fact-0D5C75DD182E596085B7458E4601B597"
      unitRef="usd">99178000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e6706-wk-Fact-16957CA6764952E393397F36D904B6FA"
      unitRef="usd">760000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131227501e6731-wk-Fact-784846BCDFBA50318FAEC38DBBBA1D16"
      unitRef="usd">603465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e6745-wk-Fact-720EEAFDFB275616868BF4AAECE2F904"
      unitRef="shares">36599273</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e6764-wk-Fact-B7BF2DC31E2C5246B114096AA9A3635A"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e6783-wk-Fact-E4A2BF2C6B415C16B9547F2C4F7697CA"
      unitRef="usd">634854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e6802-wk-Fact-D2FCBBAE888451F6972C2E7758FC4E84"
      unitRef="usd">-251070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e6822-wk-Fact-A7A697394B575449BAA41877B890DB17"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e6842-wk-Fact-0E802A87000355839C413996A73AF994"
      unitRef="usd">218728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e6861-wk-Fact-1058523278555BA790C34BDBBC18C2E9"
      unitRef="usd">901000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-3"
      id="d131227501e7533-wk-Fact-AB8FD3F7DB9353A4ADD9BD01E9C5D213"
      unitRef="usd">516426000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e7547-wk-Fact-5D86963196E151EEAE23DA0C71CF614A"
      unitRef="shares">35747134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e7566-wk-Fact-CDEF8D2AEFC15B34BCDD1D9113B1F881"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e7586-wk-Fact-1B61660144AD5B0DAFB840C1B342CD6B"
      unitRef="usd">568780000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e7605-wk-Fact-673050B9566F5D218D25D7FA1952E2CD"
      unitRef="usd">-53713000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e7625-wk-Fact-6C48C65366695D81B1E650B6C8CB1B90"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e7645-wk-Fact-BCD2D33C90DC5D749B5EC8EC4EF5F721"
      unitRef="usd">204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e7664-wk-Fact-A2B9FAEC4F9753BB99F363226B6C76E9"
      unitRef="usd">1105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e7679-wk-Fact-6477091DE2E55782B02B8E68FBDAE79C"
      unitRef="usd">1787000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e7698-wk-Fact-3F48DE8BC0BD56239CF485DD2BB1D6A0"
      unitRef="shares">32909</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e7732-wk-Fact-E72C1E53AD68573C8CE9C9836205DB29"
      unitRef="usd">1787000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e7829-wk-Fact-D98F0FAB43485407B6B4CEC8D21AF4F4"
      unitRef="usd">7185000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e7848-wk-Fact-AA5BF39CE08157ECB8424844AAB7FE41"
      unitRef="shares">113082</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e7882-wk-Fact-1774DB5964B955B58BBC76826208E331"
      unitRef="usd">7185000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e7979-wk-Fact-5038FCA8F0855E2680B8ADDDE03CBF99"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e7998-wk-Fact-44532C8FDA01562EBAC837C7EC5A9FF6"
      unitRef="shares">169811</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e8012-wk-Fact-356D9AEAC81B5305825906239C57C231"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e8032-wk-Fact-775466C1C1AC551BB0539D87190ACDC5"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8130-wk-Fact-DB69769BEEF95578B1CC92ADAD70576E"
      unitRef="usd">2749000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e8149-wk-Fact-F8F033B8C9785E8CA4EEE2232981EC4D"
      unitRef="shares">83713</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e8183-wk-Fact-691EE2164D2B53468EDD21631EDFD9EF"
      unitRef="usd">2749000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8280-wk-Fact-2D4F047F63D450438883A3ECA2A6E265"
      unitRef="usd">12653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e8333-wk-Fact-380ED50CD6425E878F0403DD28C9D402"
      unitRef="usd">12653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8430-wk-Fact-D741CD868C5D5443BCA727F18C277479"
      unitRef="usd">5421000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e8503-wk-Fact-B88CAF9782C5536F8E6E42F8DAFDF887"
      unitRef="usd">5421000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8582-wk-Fact-A4D2C1E3808958B4AE579895A369EB67"
      unitRef="usd">181402000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e8655-wk-Fact-E66DA40CADC656D2BD9C81DEE8EAA733"
      unitRef="usd">181402000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8734-wk-Fact-9EEB3F691FC35DE89DA1E5BEC7D18A15"
      unitRef="usd">530000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e8865-wk-Fact-A1546ECD05345DB1877CD4ACA9C93B03"
      unitRef="usd">530000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e8887-wk-Fact-9B3E2C99460DC4420707EE98A11A8041"
      unitRef="usd">361000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e8941-wk-Fact-DD2573CD22BFB4C150D3EE98A54C4E71"
      unitRef="usd">614000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e9019-wk-Fact-D4948D74DDF8FFFA9DFCEE98AB2A7923"
      unitRef="usd">253000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131227501e9039-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD"
      unitRef="usd">92409000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e9150-wk-Fact-2165655D74355BFA85FE86400D36C431"
      unitRef="usd">91885000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e9169-wk-Fact-361D174FE4AF50A790B36CCF54022663"
      unitRef="usd">524000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3"
      decimals="-3"
      id="d131227501e9194-wk-Fact-18C1C855DD705C73BF021B045678C942"
      unitRef="usd">445495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d131227501e9208-wk-Fact-E6B5AF128DB751DDA8F4654EAAB5609E"
      unitRef="shares">36146649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d131227501e9227-wk-Fact-1CB212C0AC115A7CBF7F7C1326604AE5"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d131227501e9247-wk-Fact-049CC4660519535FBC8083C2FAD260EC"
      unitRef="usd">592539000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-3"
      id="d131227501e9266-wk-Fact-B9B0790FF6FF5AB0A2823ACD7B7E3BFE"
      unitRef="usd">-240536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d131227501e9286-wk-Fact-6A7C0F9CA6055F8F94619E9CC0018994"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d131227501e9306-wk-Fact-0F4E56BD75DF53B0BDB4F8042330CBB0"
      unitRef="usd">92089000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d131227501e9325-wk-Fact-03AA0B1C5545585C9B3D25624CDD1385"
      unitRef="usd">1352000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e508-wk-Fact-E182736C69245E579EAB5E886D6344BD"
      unitRef="usd">99938000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e527-wk-Fact-6D94A3E4BF945824BBC567EB681CE3DD"
      unitRef="usd">92409000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e583-wk-Fact-48E7D98293975891AFADB3ADC04E2515"
      unitRef="usd">12440000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e602-wk-Fact-EE6080AF0F7E5B56A340B663FB7B84D5"
      unitRef="usd">9882000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e622-wk-Fact-4341C80739FA5B1D8BEF530041F3D12F"
      unitRef="usd">18451000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e641-wk-Fact-D74B12412EAE58B6B28311DA1812C160"
      unitRef="usd">12653000</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e661-wk-Fact-3E9A598B98A950BFA9FB7BB310CE7F87"
      unitRef="usd">7545000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e680-wk-Fact-46503FDACA2C58ADB834675475EF8E26"
      unitRef="usd">6934000</us-gaap:PensionExpense>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e700-wk-Fact-7AA2BC955D6B56D2B52DD88793F363F3"
      unitRef="usd">27014000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e719-wk-Fact-27731EAE13605255A8EE60F999E830BF"
      unitRef="usd">0</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e739-wk-Fact-F0ABF54DE11E5A2FBD52C6EB5FA290FF"
      unitRef="usd">-6000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e758-wk-Fact-4D5F423B1F0C5CD98A05F80C9CEBA3AA"
      unitRef="usd">-738000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e778-wk-Fact-9DB5E202FDB65AA5A0EB1C74216189E7"
      unitRef="usd">17798000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e797-wk-Fact-24BA7C619FC151978EDCEAA9DB00E1FB"
      unitRef="usd">14916000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e818-wk-Fact-639E153B9FD15FE29A870E935A51BF90"
      unitRef="usd">4120000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e838-wk-Fact-041416182B46531998B9E6782D465AC9"
      unitRef="usd">6461000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e859-wk-Fact-F74BD6D7258054708E3C3ACF118E41D8"
      unitRef="usd">653000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e878-wk-Fact-4347109F210858269E7CD9B53BF0F559"
      unitRef="usd">596000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e898-wk-Fact-91C96D25FACB52A9924F4CA5FDF36936"
      unitRef="usd">3727000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e917-wk-Fact-234B471AF58A56619C314DCC3000A913"
      unitRef="usd">4373000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e978-wk-Fact-63F03CFF28FC5BD3918812490FF2F5C4"
      unitRef="usd">39469000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e998-wk-Fact-7F398646E5FF5CC2BA56527D5398B6F1"
      unitRef="usd">-6166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1018-wk-Fact-8C0055D614DC54DD816E5557D0C3C826"
      unitRef="usd">10194000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1038-wk-Fact-FA98F0828E3D50FEAD962F7AB133F7BC"
      unitRef="usd">32000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1059-wk-Fact-E7706B2F270E543E8963B9FD426BB7AE"
      unitRef="usd">-202000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1078-wk-Fact-B8E6BAD2239B5591A866715F706FAE5D"
      unitRef="usd">-726000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1098-wk-Fact-D116C6D5BB1D5299803EF016605FB6B5"
      unitRef="usd">-8145000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1118-wk-Fact-2E2DF3D074315C7298BF6851088E1193"
      unitRef="usd">-670000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1139-wk-Fact-98A5FD90944355EF9E2621C684675CDE"
      unitRef="usd">27903000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1158-wk-Fact-23BD85D443875190977BBE8A658DFD63"
      unitRef="usd">14758000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1178-wk-Fact-BF078DEEE3DD51CAA41FE169C3A3CCA0"
      unitRef="usd">-231000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1198-wk-Fact-E612250DAC04542FB37CCCCF5BB3C638"
      unitRef="usd">2462000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1218-wk-Fact-730D5B781A0950AF9C2201BA10228527"
      unitRef="usd">-24116000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1238-wk-Fact-D2AD26A72752581396ED13143FF165CD"
      unitRef="usd">0</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1259-wk-Fact-02A3C5E094925C4699F980451136F8DB"
      unitRef="usd">-2622000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1279-wk-Fact-238B603B617E5040B3A382449A0566EE"
      unitRef="usd">0</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1299-wk-Fact-E6DCDCA835B653E5A08FC1B9010C47B7"
      unitRef="usd">126780000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1318-wk-Fact-5F9542F128EF5B00BFE682462B65912A"
      unitRef="usd">159450000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1379-wk-Fact-3AB790327D6B5C28B261DBC91BABF813"
      unitRef="usd">287000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1398-wk-Fact-B4C37633A31C5D0599E127034BB9E52A"
      unitRef="usd">563000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1418-wk-Fact-7CD139248687524F8ADDA73C89A323B7"
      unitRef="usd">158000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1437-wk-Fact-CE1D417D4BDF5E9C924161F2AFC9A509"
      unitRef="usd">51000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1457-wk-Fact-FE7F0A414AF35054A308564A4DC56132"
      unitRef="usd">210000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1477-wk-Fact-B3C0EFB6D2EE58698C9A212DF1E35B6F"
      unitRef="usd">3477000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1498-wk-Fact-1260A36DA2BA55F99002E0FAD4DD2F2E"
      unitRef="usd">6337000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1518-wk-Fact-DA52EF503A1054308A7AE5B8CC59C829"
      unitRef="usd">5684000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1539-wk-Fact-89B428D6ED775A2E9139F8F9F99478C6"
      unitRef="usd">345460000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1559-wk-Fact-4F939374EB915535814F70B6F45A91E9"
      unitRef="usd">4074000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1580-wk-Fact-4AC8DFB727765072BAA7F59278CC3560"
      unitRef="usd">-351562000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1600-wk-Fact-45D1983FDAA15140A3A65E40B4FABAF8"
      unitRef="usd">-12621000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1662-wk-Fact-F9FD188D9B8F59168017EB86CFAA5387"
      unitRef="usd">3388000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1681-wk-Fact-A37525F67D545B26B2397D70F9A47E36"
      unitRef="usd">2749000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1702-wk-Fact-0AAB40A144705AD99D2E67B1E10B8F74"
      unitRef="usd">2384000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1721-wk-Fact-D9E6D9A8498D5BA9AF71BD3A70B6FF77"
      unitRef="usd">1787000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1741-wk-Fact-EE2ED0FF511F58C8B88B87959177A884"
      unitRef="usd">9385000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1761-wk-Fact-7190352750AB50FAB6CB95FC0C7734FF"
      unitRef="usd">5421000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1782-wk-Fact-919791E97C385470AA07AB00A0D52ED5"
      unitRef="usd">910000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1802-wk-Fact-87415B2C40CE5837AB0A1727CD8BC7FF"
      unitRef="usd">530000</amed:CashDistributionToNoncontrollingInterest>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1823-wk-Fact-BFBF1DF9A78E5AE7AA0A3EBCD36788BA"
      unitRef="usd">175000000</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1842-wk-Fact-E78901ED93C0535F9F423779EBD3FD5B"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1862-wk-Fact-CAB6B159DD665634A7EFCEB715A04FA3"
      unitRef="usd">192500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1881-wk-Fact-EAD43FCBEAA95B75A396D47B4ADF863B"
      unitRef="usd">127500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1901-wk-Fact-8E27EA96C4795C51A543A79E779F9FCD"
      unitRef="usd">133000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1921-wk-Fact-06ED20AF4AA853FA9A1C57D565B4AA79"
      unitRef="usd">70000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1942-wk-Fact-9B918460AD5A513293E33FDE3BC578D3"
      unitRef="usd">3820000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e1962-wk-Fact-A07C10896E565579B76F340DCB51C826"
      unitRef="usd">91071000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e1983-wk-Fact-543F7F8234DA57DEA889B707534EDE31"
      unitRef="usd">847000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2003-wk-Fact-D77ABF4B79F45856A2F3946C8217F890"
      unitRef="usd">2433000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2024-wk-Fact-A78D52875E6851289ADB95F61FDB5E09"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2043-wk-Fact-305804EB1A615F7AA21F44622777A755"
      unitRef="usd">181402000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:PaymentsForRepurchaseOfNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2064-wk-Fact-08BF5251B25CC82E7C50EE99D034CA6F"
      unitRef="usd">0</amed:PaymentsForRepurchaseOfNoncontrollingInterest>
    <amed:PaymentsForRepurchaseOfNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2083-wk-Fact-8DF05E33A44ACA17DA0EEE9A030BFE1D"
      unitRef="usd">361000</amed:PaymentsForRepurchaseOfNoncontrollingInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2104-wk-Fact-C0DD1034D47E5863B84C8CA7AE826B04"
      unitRef="usd">225310000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2123-wk-Fact-C579988DA07F56E58EFE81E633321BC0"
      unitRef="usd">-219182000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2145-wk-Fact-8A5183083A2C5C90A598EB019CBA78C4"
      unitRef="usd">528000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2164-wk-Fact-660B9D2A5754510F8B3DA079A9B01E42"
      unitRef="usd">-72353000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d131217219e2185-wk-Fact-4CA6620396B25DD49702768F70290CC9"
      unitRef="usd">20229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d131217219e2204-wk-Fact-F1F082EE8F595EAFBE34DC4E8B7CB65C"
      unitRef="usd">86363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d131217219e2229-wk-Fact-5B458D36A5AF5DC1A4CC7C8988414378"
      unitRef="usd">20757000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d131217219e2248-wk-Fact-9C5C0DA6BBA45232A716DD616C8C7FFC"
      unitRef="usd">14010000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2309-wk-Fact-8367724E75F453EAA862FA9DC4771AAF"
      unitRef="usd">7756000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2328-wk-Fact-B0A5AEDEF18455F9981CED39C6CD10B6"
      unitRef="usd">2989000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131217219e2348-wk-Fact-F002D082D8315E70A90E1C2C36F66D78"
      unitRef="usd">17656000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131217219e2367-wk-Fact-51752773533D5DB2950C8D9BA2C3073F"
      unitRef="usd">11017000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-A842DB817E335812A5DA86B4FA857BFD-0-wk-Fact-C5C9BB0FEDCC51FFBDA4D8E7EC622073">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a multi-state provider of home health, hospice and personal care services with approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our revenue derived from Medicare for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our revenue derived from Medicare for the three and nine-month periods ended September 30, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we owned and operated &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;321&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Medicare-certified home health care centers, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Medicare-certified hospice care centers and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; personal-care care centers in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; states within the United States and the District of Columbia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 28, 2019 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, the Company adopted Accounting Standards Update ("ASU") 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842);&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ASU 2018-01, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;; ASU 2018-10, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;; and ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively, "Topic 842") using a modified retrospective transition approach, which requires the new standards to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are using the standards' effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The new standard provides several optional practical expedients that can be adopted at transition. We have elected the "package of practical expedients" which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The new standard also provides practical expedients for an entity's ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. We are applying the short-term lease recognition exemption to certain information technology leases; therefore, we did not recognize ROU assets and lease liabilities for these leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131231509e357-wk-Fact-3C6E291B447857B3936D0F1F88262283"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131231509e369-wk-Fact-829FC6725DC1203FB633EBD2F624E871"
      unitRef="number">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131231509e373-wk-Fact-39BDCD1925757C832BE6EBD370D7C03B"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="INF"
      id="d131231509e386-wk-Fact-A1A40A933F64539889CBB106A52D990B"
      unitRef="care_center">321</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131231509e390-wk-Fact-8DA5A36620225AAC825789DFC15AED68"
      unitRef="care_center">137</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="FI2019Q3_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="INF"
      id="d131231509e394-wk-Fact-2D1F9194073152E690E078B168C1D14F"
      unitRef="care_center">12</amed:OperatingCareCenters>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131231509e398-wk-Fact-7122BEBCC4265326A7E8D437A4A12EFC"
      unitRef="state">38</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-708276F12951595BB60A7DEC6C787AB5-0-wk-Fact-06C19239CB235643B8B1702F7DDB46F4">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 28, 2019 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-2F250E4D4C195D98A93F2A1F80C34762-0-wk-Fact-251782FA89D6516D9D220C6AB9552077">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, the Company adopted Accounting Standards Update ("ASU") 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842);&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ASU 2018-01, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;; ASU 2018-10, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;; and ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively, "Topic 842") using a modified retrospective transition approach, which requires the new standards to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are using the standards' effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The new standard provides several optional practical expedients that can be adopted at transition. We have elected the "package of practical expedients" which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.  &lt;/span&gt;&lt;/div&gt;The new standard also provides practical expedients for an entity's ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. We are applying the short-term lease recognition exemption to certain information technology leases; therefore, we did not recognize ROU assets and lease liabilities for these leases.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan012019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d131231509e460-wk-Fact-9EBD1B8346D65B50BA2F1C19D031E9B3"
      unitRef="usd">80000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q3YTD"
      id="TextSelection-6866F0396A9752B981BEAE97AE7D2DC3-0-wk-Fact-798EBAD501D15A048F6985FBC00F2ADF">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-926E07992CF45BB0BFF4456BAD64880A-0-wk-Fact-03D94774134A54C1B6D383D5536A1E96">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityAndCostMethodInvestmentsPolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-808EE9F1028353C4B12C23D4E6EE3669-0-wk-Fact-149307E2EC0055D980E0060E344CE38C">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityAndCostMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131231509e515-wk-Fact-48B868AE06CA577E94499104D3240E1D"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131231509e522-wk-Fact-7EA380A6477152ACBB848104103BF61F"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131231509e526-wk-Fact-3248FF2AA68456B2BAF96F495A692A91"
      unitRef="usd">35400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131231509e530-wk-Fact-725955E70BCD57169649890C1D0E88E0"
      unitRef="usd">35100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <amed:MaximumPercentOwnershipForCostMethodPercent
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131231509e545-wk-Fact-2A68B019987E5F2CA50D640D0BC5C1B7"
      unitRef="number">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9BB63133510E52F1BEB14065BF855720-0-wk-Fact-DA45AE110E5D5B6B8BACF6E659BFF53F">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for revenue from contracts with customers in accordance with ASU 2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and ASU 2015-14, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The implicit price concession represents &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Company's consolidated net service revenue for the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our consolidated net service revenue for the three and nine-month periods ended September 30, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for price concessions related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts we estimate to be realizable for services provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine our estimates for implicit price concessions related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Home Health:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Personal Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&#x201c;PPS&#x201d;) based on an established Federal Medicare  home health episode payment rate, that is subject to adjustment based on certain variables, including, but not limited to (a)&#160;an outlier payment if our patient&#x2019;s care was unusually costly (capped at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or fewer; (c)&#160;a partial payment if a patient transferred to another provider or we admitted a patient transferring from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sixth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;fourteenth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twentieth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#160;changes in the base episode payments established by the Medicare Program; and (g)&#160;adjustments to the base episode payments for case mix and geographic wages. Medicare rates are based on the severity of the patient's condition, service needs and goals, and other factors relating to the cost of providing services and supplies, bundled into an episode of care, not to exceed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Expected Medicare revenue per episode is recognized based on a pro-rated service output method, utilizing our historical average length of episode prior to discharge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims, and record this estimate during the period in which services are rendered as an estimated price concession and a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the company's average percentage of days complete on episodes as of the end of the year. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&#x201c;RAP&#x201d;) on episodes in progress and the associated estimated revenue was recorded to accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms which generally range from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make adjustments to non-episodic revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our gross Medicare hospice service revenue for the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our gross Medicare hospice service revenue for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. There are two separate payment rates for routine care: payments for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days of care and care beyond &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#x201c;RN&#x201d;) or medical social worker (&#x201c;MSW&#x201d;) for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We make adjustments to Medicare revenue for implicit price concessions, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;th&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the following year. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in accrued expenses for estimated amounts due back to Medicare for the Federal cap years ended October&#160;31, 2013 through September 30, 2019; approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of this amount is related to the cap liability acquired as part of the Compassionate Care Hospice ("CCH") acquisition. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make adjustments to non-Medicare revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for price concessions. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there is no single payor, other than Medicare, that accounts for more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our patient accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, is limited due to our historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our estimated payment for the initial episode at the start of care or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#x201c;final billed&#x201d;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the start of the episode, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the nine-month period ended September 30, 2019, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our condensed consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 5 - Long-Term Obligations). As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2018, we had unamortized debt issuance costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, recorded as long-term obligations, less current portion in our condensed consolidated balance sheet. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in deferred debt issuance during the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The unamortized debt issuance costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be amortized over a weighted-average amortization period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value as of&lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Month Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:26px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations&lt;/span&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6369DE78F1C054EEB6B5D930CD999FAE-0-wk-Fact-D5EFA67D05555AB6AD3832715AC48CED">&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for revenue from contracts with customers in accordance with ASU 2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and ASU 2015-14, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The implicit price concession represents &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Company's consolidated net service revenue for the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our consolidated net service revenue for the three and nine-month periods ended September 30, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for price concessions related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts we estimate to be realizable for services provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine our estimates for implicit price concessions related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Home Health:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Personal Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&#x201c;PPS&#x201d;) based on an established Federal Medicare  home health episode payment rate, that is subject to adjustment based on certain variables, including, but not limited to (a)&#160;an outlier payment if our patient&#x2019;s care was unusually costly (capped at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or fewer; (c)&#160;a partial payment if a patient transferred to another provider or we admitted a patient transferring from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sixth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;fourteenth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twentieth&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f)&#160;changes in the base episode payments established by the Medicare Program; and (g)&#160;adjustments to the base episode payments for case mix and geographic wages. Medicare rates are based on the severity of the patient's condition, service needs and goals, and other factors relating to the cost of providing services and supplies, bundled into an episode of care, not to exceed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Expected Medicare revenue per episode is recognized based on a pro-rated service output method, utilizing our historical average length of episode prior to discharge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims, and record this estimate during the period in which services are rendered as an estimated price concession and a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the company's average percentage of days complete on episodes as of the end of the year. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&#x201c;RAP&#x201d;) on episodes in progress and the associated estimated revenue was recorded to accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms which generally range from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make adjustments to non-episodic revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our gross Medicare hospice service revenue for the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our gross Medicare hospice service revenue for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. There are two separate payment rates for routine care: payments for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days of care and care beyond &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;60&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#x201c;RN&#x201d;) or medical social worker (&#x201c;MSW&#x201d;) for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We make adjustments to Medicare revenue for implicit price concessions, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;th&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the following year. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in accrued expenses for estimated amounts due back to Medicare for the Federal cap years ended October&#160;31, 2013 through September 30, 2019; approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of this amount is related to the cap liability acquired as part of the Compassionate Care Hospice ("CCH") acquisition. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Explicit price concessions are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make adjustments to non-Medicare revenue for any implicit price concessions, based on historical experience, to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for price concessions. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). &lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131214993e406-wk-Fact-3C6E291B447857B3936D0F1F88262283"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131214993e414-wk-Fact-829FC6725DC1203FB633EBD2F624E871"
      unitRef="number">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_amed_MedicareRevenueMember"
      decimals="2"
      id="d131214993e418-wk-Fact-39BDCD1925757C832BE6EBD370D7C03B"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e436-wk-Fact-72A7494C32D0510F85ADC4BDA0F2CC8B"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-FFCBA3E0D6E1579F94EBB7C80C197BB3-0-wk-Fact-166D8F9460235DAC87DCBE25D591D61E">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Periods Ended September 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Home Health:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Personal Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember"
      decimals="2"
      id="d131214993e663-wk-Fact-D59E82B81F7F569B8FFB9F06E47693E3"
      unitRef="number">0.43</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember"
      decimals="2"
      id="d131214993e678-wk-Fact-1DD311278A175E409F0D11999E13E339"
      unitRef="number">0.50</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember"
      decimals="2"
      id="d131214993e693-wk-Fact-CB3E1A3EB3C854578EC60640BE72F36D"
      unitRef="number">0.44</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthMedicareMember"
      decimals="2"
      id="d131214993e708-wk-Fact-0AC2B99AB0905FF082F678A5A914FF59"
      unitRef="number">0.51</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember"
      decimals="2"
      id="d131214993e725-wk-Fact-942AC1E6295752DFA7755D892243EC81"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember"
      decimals="2"
      id="d131214993e740-wk-Fact-B12EADE2EBD95B8FB86E4DCA967ABB1A"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember"
      decimals="2"
      id="d131214993e755-wk-Fact-68BA94A08733583080B9DC2D7D0B9796"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareEpisodicBasedMember"
      decimals="2"
      id="d131214993e770-wk-Fact-2BC419573D9E5CD2BDDC32B998F9A9B9"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember"
      decimals="2"
      id="d131214993e787-wk-Fact-D355BF8B9D235C8D8667DF84D463B521"
      unitRef="number">0.11</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember"
      decimals="2"
      id="d131214993e802-wk-Fact-581FFCCFC84854A082F271C40138609C"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember"
      decimals="2"
      id="d131214993e817-wk-Fact-91834E5B1CD8583DA9A1359C88D8F816"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HomeHealthNonMedicareNonEpisodicBasedMember"
      decimals="2"
      id="d131214993e832-wk-Fact-21CBF57071F354CF9E9EEA5E19CB5B9D"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember"
      decimals="2"
      id="d131214993e911-wk-Fact-23566AD0DC59503B8C9F66946942813B"
      unitRef="number">0.31</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceMedicareMember"
      decimals="2"
      id="d131214993e926-wk-Fact-853918F2B4705484AA97BD94F8DDAFE6"
      unitRef="number">0.23</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember"
      decimals="2"
      id="d131214993e941-wk-Fact-65A989562E0F5F57A5567C6BACF0F201"
      unitRef="number">0.30</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceMedicareMember"
      decimals="2"
      id="d131214993e956-wk-Fact-A531E5988AE55833B3226EEDBCA778DC"
      unitRef="number">0.23</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember"
      decimals="2"
      id="d131214993e973-wk-Fact-C13D9E3A813752298BF0633E5B96A23B"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember"
      decimals="2"
      id="d131214993e988-wk-Fact-F68E96D3EB785DA09814D7D96FC5329B"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember"
      decimals="2"
      id="d131214993e1003-wk-Fact-656DBDC98F4C5CAC89CF7EB5CE133EAB"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_HospiceNonMedicareMember"
      decimals="2"
      id="d131214993e1018-wk-Fact-2C85B9F074A1505A8D8335559252566E"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember"
      decimals="2"
      id="d131214993e1035-wk-Fact-AA6BF04279A95947959BACA9E776A539"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD_amed_PayorClassAxis_amed_PersonalCareMember"
      decimals="2"
      id="d131214993e1050-wk-Fact-ED9F20519BDE577C8104AEEB9E057AE3"
      unitRef="number">0.05</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember"
      decimals="2"
      id="d131214993e1065-wk-Fact-4163BE914194562C870F1BF63A152FCB"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD_amed_PayorClassAxis_amed_PersonalCareMember"
      decimals="2"
      id="d131214993e1080-wk-Fact-9FB28468FA455CAEBECDDA9061C91760"
      unitRef="number">0.05</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d131214993e1097-wk-Fact-F0CD9E091FDE5D18B6C9DFDB72A46E31"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d131214993e1112-wk-Fact-9B74E505319E57368458418DA2ED8164"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e1127-wk-Fact-5C42A7084F7456929CFB2B4698549AF3"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d131214993e1142-wk-Fact-DC170A4B13385D8C97E59734CCF150E0"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131214993e1228-wk-Fact-90374F847C9B57B3A4C3126F79D2867D"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131214993e1232-wk-Fact-4A08E5EBD0F55FA6923C2E310EA85D2D"
      unitRef="visit">4</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="2"
      id="d131214993e1262-wk-Fact-1D11ADC6D17859F7BDD5E3DBFC50DAA6"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NonMedicareRevenueTermRates
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember"
      decimals="INF"
      id="d131214993e1281-wk-Fact-23C97B9529BB5144A427234AAEFD0656"
      unitRef="number">0.90</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember"
      decimals="INF"
      id="d131214993e1285-wk-Fact-161C563A6B465F3699FEF267F0ED1B61"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d131214993e1304-wk-Fact-75237BBF332157D88CDC860C9554234B"
      unitRef="number">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e1308-wk-Fact-A6EAC9AE67A252B7A3CBB47D7C2A0D8A"
      unitRef="number">0.99</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d131214993e1316-wk-Fact-3CD8E6559652518CB982FE2F59A1E5B9"
      unitRef="number">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d131214993e1320-wk-Fact-0DFE0FD813982F1CD288EBDFF352AE33"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131214993e1347-wk-Fact-F4D88F2F3BE558518917A5127A27589C"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember"
      decimals="-5"
      id="d131214993e1365-wk-Fact-70B1970E88CA5451BC976CEC068AE315"
      unitRef="usd">5300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="FI2019Q3_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember"
      decimals="-5"
      id="d131214993e1369-wk-Fact-CD6FD2CA457F5FD9A6F92E3E075562C7"
      unitRef="usd">1900000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="FI2018Q4_amed_CapYearAxis_amed_CapYearTwoThousandThirteenThroughTwoThousandNineteenMember"
      decimals="-5"
      id="d131214993e1378-wk-Fact-C336F88A0AA454628F8C5E203274D12F"
      unitRef="usd">1700000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-F2764A373B0453368BB62FF4A14F1EA2-0-wk-Fact-9A7C87DB0CC45BBFB317DA887548BA06">&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there is no single payor, other than Medicare, that accounts for more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our patient accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, is limited due to our historical collection rate of over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our estimated payment for the initial episode at the start of care or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#x201c;final billed&#x201d;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the start of the episode, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131214993e1418-wk-Fact-7F217A0DAC065150AF8DF70AA60EF85A"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="FI2019Q3"
      decimals="2"
      id="d131214993e1422-wk-Fact-434B8185CB865BACB4DF19D1481BB7B3"
      unitRef="number">0.59</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="FI2018Q4"
      decimals="2"
      id="d131214993e1426-wk-Fact-7C9EFDDDFE31597EA621E2386A0D4555"
      unitRef="number">0.56</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e1439-wk-Fact-72A7494C32D0510F85ADC4BDA0F2CC8B"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e1452-wk-Fact-A4363600314D5D16BB54D27E0066BEFB"
      unitRef="number">0.60</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d131214993e1456-wk-Fact-8D0271494D785FC893B479D608B85AE3"
      unitRef="number">0.50</amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare>
    <amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131214993e1460-wk-Fact-E542D24AC029550F8D91FF2BF8E3A4BB"
      unitRef="day">120</amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode>
    <amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131214993e1464-wk-Fact-7670435167B15C539BB3204ED96BC105"
      unitRef="day">60</amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid>
    <amed:DebtIssuanceCostsPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EE6A38CB8E7851989EDB730C481352B4-0-wk-Fact-64661A1AC73A554AB0AD60FD4114A6C3">&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the nine-month period ended September 30, 2019, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our condensed consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 5 - Long-Term Obligations). As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2018, we had unamortized debt issuance costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, recorded as long-term obligations, less current portion in our condensed consolidated balance sheet. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in deferred debt issuance during the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The unamortized debt issuance costs of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be amortized over a weighted-average amortization period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;</amed:DebtIssuanceCostsPolicyPolicyTextBlock>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131214993e1501-wk-Fact-E20CC861121E500C959BF84DAF457F87"
      unitRef="usd">3700000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131214993e1505-wk-Fact-8467D6AF6E9C50669CFFCC02D1D16221"
      unitRef="usd">3500000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131214993e1509-wk-Fact-B2F517F5704452AAB0E884E768FD9187"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131214993e1514-wk-Fact-2D9EAB083A005877AEB57D6D5CA44AB4"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131214993e1522-wk-Fact-E20CC861121E500C959BF84DAF457F87"
      unitRef="usd">3700000</us-gaap:UnamortizedDebtIssuanceExpense>
    <amed:UnamortizedDebtIssuanceCostAmortizationPeriod
      contextRef="FD2019Q3YTD"
      id="d131214993e1526-wk-Fact-0335FB81AF3154C3B63409AC96210F31">P4Y3M18D</amed:UnamortizedDebtIssuanceCostAmortizationPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-8CA8E3D3E4B15B3192E9AB98A16D8630-0-wk-Fact-82A383A32E7056059304CD7E87A9356C">&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value as of&lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:47px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DEF75CF2A1F85AB7AE8572BE3448D484-0-wk-Fact-1F4149D7B847523F8F98AB8286ADDBA0">&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value as of&lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingCapitalLeases
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131214993e1779-wk-Fact-655A6156CACD59B0BECD82C962C2D218"
      unitRef="usd">240600000</amed:DebtInstrumentCarryingAmountExcludingCapitalLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="1"
      id="d131214993e1798-wk-Fact-42AE5B714ADD5FEB86380CE4D4D35960"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-5"
      id="d131214993e1817-wk-Fact-A581F7DC34FD54F7AF53AD5EF6EDBA72"
      unitRef="usd">236000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="1"
      id="d131214993e1837-wk-Fact-6F4928329B4551BF8D2FC11BEA8B644A"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-12EBBA161834579BAC62DA85BC382142-0-wk-Fact-97AC8AD49687557287EB58A23B521D97">&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9E3B17785EE35D44B882D36C1FF5619D-0-wk-Fact-7A49A2B4D39A571DB247D37992945744">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Month Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:26px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131214993e2064-wk-Fact-CD11DC571B9851778D9F4ABC891E8923"
      unitRef="shares">32211000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131214993e2078-wk-Fact-93B2D8D871FA5DDFA6739CE528068113"
      unitRef="shares">31815000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131214993e2092-wk-Fact-89F85BF475A95C96A5BBDBF1DB638438"
      unitRef="shares">32096000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131214993e2106-wk-Fact-6C2CAE056DF9575186ED2BE686165C73"
      unitRef="shares">33075000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131214993e2184-wk-Fact-B101B5F595315592B6F4282E93179A89"
      unitRef="shares">532000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131214993e2198-wk-Fact-14BA2FFDEDE455DA8F3B5CA574288F1E"
      unitRef="shares">561000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131214993e2212-wk-Fact-4A22D7B51FAC50D4B1BF565ECA1698F1"
      unitRef="shares">543000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131214993e2226-wk-Fact-54FEA63AAF4259E196743CA96E887026"
      unitRef="shares">464000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131214993e2242-wk-Fact-5A8271CD48D750CA89EF9187D6D2929F"
      unitRef="shares">259000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131214993e2256-wk-Fact-419570FF74975D2EB4052B0566868630"
      unitRef="shares">315000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131214993e2270-wk-Fact-5E785FBDEF175339B7C829D9F3592182"
      unitRef="shares">305000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131214993e2284-wk-Fact-069B1D088FA150D79E494E0E74FC0E60"
      unitRef="shares">313000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131214993e2300-wk-Fact-28CF598E0CB95194B9F5F379A14254DD"
      unitRef="shares">33002000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131214993e2314-wk-Fact-85B676CCD8CD502C93833B814DEDEB3C"
      unitRef="shares">32691000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131214993e2328-wk-Fact-FE6C4CE2C1BE5BC79A55744349AD541D"
      unitRef="shares">32944000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131214993e2342-wk-Fact-5655AC2AEFFB5F57B1BE932580F9E145"
      unitRef="shares">33852000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d131214993e2358-wk-Fact-5FDC2368708153D7B1A6ED004F52EF10"
      unitRef="shares">133000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d131214993e2372-wk-Fact-2DDC8ECDB66A55A0B5241C26DEB47611"
      unitRef="shares">51000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d131214993e2386-wk-Fact-388728C9425752768CC3E3D40FF37F5A"
      unitRef="shares">154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d131214993e2400-wk-Fact-C40CF847B16F51FE9AE581ADF67D7377"
      unitRef="shares">76000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-CC8F3EBDC7955E77923A1015E112214F-0-wk-Fact-D29A1BCEAFA6551C90809F703A633386">&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations&lt;/span&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DC92A77AE7DC5B05B49AF95F4D189DA8-0-wk-Fact-B7D9B9FCC7CC5E84A8028833868B7DAF">ACQUISITIONS&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 1, 2019, we acquired Compassionate Care Hospice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$327.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of cash acquired of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. During the three-month period ended September 30, 2019, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$327.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total liabilities acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total estimated consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;327.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets acquired include Medicare licenses, certificates of need, trade names and non-compete agreements. The trade names and non-compete agreements will be amortized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;CCH contributed approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in net service revenue and operating income of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (inclusive of acquisition and integration costs totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) during the three-month period ended September 30, 2019 and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$123.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in net service revenue and an operating loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$4.2 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (inclusive of acquisition and integration costs totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) during the nine-month period ended September 30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information for the three and nine-month periods ended September 30, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Month Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;467.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,471.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,373.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Amedisys, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#x2019;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and other intangibles including non-compete agreements of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and tradenames of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the three-month period ended June 30, 2019. The non-compete agreement will be amortized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. RoseRock contributed approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in net service revenue and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in operating income during the three-month period ended September 30, 2019 and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in net service revenue and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in operating income during the nine-month period ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e361-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48"
      unitRef="usd">327900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e365-wk-Fact-11067BD03D6C5A85A4E2B985B909481D"
      unitRef="usd">6700000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EE49EEA4C6935E44B49A79FC279B19BC-0-wk-Fact-E736E0896AD351C6892947FB012D78F4">&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. During the three-month period ended September 30, 2019, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$327.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total liabilities acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;315.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total estimated consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;327.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e374-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48"
      unitRef="usd">327900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e424-wk-Fact-5C605A124F455A11B4D7E54430DC034D"
      unitRef="usd">26300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e439-wk-Fact-C61542A62CD6577F9B50DB206915268C"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e459-wk-Fact-461267C2A88550F3BB26826153D9F995"
      unitRef="usd">200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e479-wk-Fact-6A2353EA575050CAA690D016FE04D29F"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e499-wk-Fact-27952BAFC0B95B779EEA7EEC94FC9C61"
      unitRef="usd">24400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e519-wk-Fact-D97A76BEE2C1EFF9BA73EEB213AB2066"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e539-wk-Fact-0616E8343A06555B9D088AE3799E870C"
      unitRef="usd">55300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e559-wk-Fact-2C4C20DCF77D5565AD821C95B237954B"
      unitRef="usd">15900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e580-wk-Fact-3A496B17C37059609C730D32D152F5A1"
      unitRef="usd">11800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e601-wk-Fact-09FAADB9B4F058EEB19D0AED26D36A8A"
      unitRef="usd">11000000.0</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e623-wk-Fact-65BF8E8BF06D56DDAEA1858F8B56968F"
      unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e644-wk-Fact-D564565497541A1B9762EEB550B534A3"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e665-wk-Fact-965223E05C655109A4E639E4A2A4D37D"
      unitRef="usd">42500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q1Feb012019_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e686-wk-Fact-D9384B590C465F7BA10547C28133CED8"
      unitRef="usd">12800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e706-wk-Fact-53A674204CC9546E9AC02E78F48943FA"
      unitRef="usd">315100000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q1Feb01_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e731-wk-Fact-5EC85C6B99CE5EFB970C16D842EABB48"
      unitRef="usd">327900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      id="d131234774e743-wk-Fact-43CB1204B9A05D5DA2DC4D3887806827">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      id="d131234774e747-wk-Fact-EFC0471194B952BE98B271E4C9C3F159">P2Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e755-wk-Fact-B539F17F63C15A03BFED94288D3DD0FA"
      unitRef="usd">45600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e763-wk-Fact-4180CFEF77BB5C3A8377BC300C85B1FA"
      unitRef="usd">3400000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e767-wk-Fact-056FE771379958EBA20C8F2D16F8C5BE"
      unitRef="usd">123600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e776-wk-Fact-618D96A545E354EDB965D739477BCDE0"
      unitRef="usd">13400000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D705A365248554E597436889E71D74A5-0-wk-Fact-32F7D9656BB75F00A2FE1C99AD48BEC5">&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information for the three and nine-month periods ended September 30, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Month Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;467.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,471.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,373.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income attributable to Amedisys, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e990-wk-Fact-523160FFB8A3516D8F74A5426E18884E"
      unitRef="usd">494600000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1009-wk-Fact-E138CCF602CD578FBC1DF4790C633C30"
      unitRef="usd">467300000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1028-wk-Fact-8CCB815CA1585AA8A4764F2A53582540"
      unitRef="usd">1471000000.0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1048-wk-Fact-5C3072210825536E9AB7DD799910CE8B"
      unitRef="usd">1373400000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <amed:Businessacquisitionproformaoperatingincomeloss
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1063-wk-Fact-5D664B8BC24853369C026C26226250C4"
      unitRef="usd">46800000</amed:Businessacquisitionproformaoperatingincomeloss>
    <amed:Businessacquisitionproformaoperatingincomeloss
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1082-wk-Fact-3A4E6348BE1D544FBE82940E8CEB7CB0"
      unitRef="usd">47000000.0</amed:Businessacquisitionproformaoperatingincomeloss>
    <amed:Businessacquisitionproformaoperatingincomeloss
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1101-wk-Fact-BEC7C0F4AC295F12A53C16F8BBE232AC"
      unitRef="usd">142200000</amed:Businessacquisitionproformaoperatingincomeloss>
    <amed:Businessacquisitionproformaoperatingincomeloss
      contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1121-wk-Fact-6A2D641554535CB38E5C435BC102D961"
      unitRef="usd">136900000</amed:Businessacquisitionproformaoperatingincomeloss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1141-wk-Fact-E651D7CA6227555189E7F9479DA46D3A"
      unitRef="usd">34100000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1160-wk-Fact-51AEEF4DC1ED5427BBD72CA17D4C1CBB"
      unitRef="usd">34200000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1179-wk-Fact-751E3110FA525C02A7ECD8780EAA9984"
      unitRef="usd">102900000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1199-wk-Fact-B4C6C19D46945EB68F7A8F02C8651ECE"
      unitRef="usd">97900000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1219-wk-Fact-B16D4704524C5DD8987E47E97ACE36F2"
      unitRef="usdPerShare">1.06</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1238-wk-Fact-92A60DECEBBA5374B0A4956315996949"
      unitRef="usdPerShare">1.07</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1257-wk-Fact-7FE608906AD4545686914EAA1063A681"
      unitRef="usdPerShare">3.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1277-wk-Fact-F64FFAA3675055CB8EF537EC7FE45A48"
      unitRef="usdPerShare">2.96</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1302-wk-Fact-9E610C437D985775B9942B0405AAEC20"
      unitRef="usdPerShare">1.03</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1321-wk-Fact-B758F882A8425ED78292425EF20381CF"
      unitRef="usdPerShare">1.05</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1340-wk-Fact-B4C5BEEA148853D8A6937195D59AECB0"
      unitRef="usdPerShare">3.12</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_CompassionateCareHospiceMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="2"
      id="d131234774e1360-wk-Fact-E8BEEFCF3EBB5DE6BDEAA401A59FD959"
      unitRef="usdPerShare">2.89</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q2Apr042019_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1375-wk-Fact-5B369437C79D5F80858CE94A69FCF28E"
      unitRef="usd">17500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1379-wk-Fact-E31E9AFB7BD0512C98C3DCEE74714932"
      unitRef="usd">15800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1383-wk-Fact-57F0CEC243F8511BA73F67CC2EF68BC5"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1387-wk-Fact-D57FCAD17E58524A9245673DE7C339B3"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      id="d131234774e1391-wk-Fact-616F364E356D5428A1A26ECD1382CB46">P2Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1396-wk-Fact-E7A9007958F3553DB192383F16C9CA3E"
      unitRef="usd">2200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1400-wk-Fact-85A4DC2B64D55F589FCE886939D4B286"
      unitRef="usd">300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1404-wk-Fact-E73D9064E44EEE0333C6EBED7615C9FE"
      unitRef="usd">4700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_amed_RoseRockHealthcareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131234774e1408-wk-Fact-16B90C5A7B610749070DEBEE159B70B7"
      unitRef="usd">800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DCB1F45C2EF254748839C30EFC860505-0-wk-Fact-92DC4774CB7452E090813AC1DA3D729A">LEASES&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We also have finance leases covering certain office equipment that expire at various dates over the next &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Our leases do not contain any restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our office leases generally contain renewal options for periods ranging from one to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our fleet leases include a term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;367&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#x201c;TRAC&#x201d;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease cost for the three and nine-month periods ended September 30, 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.78752436647173%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three-Month Period Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine-Month Period  Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our condensed consolidated balance sheet. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.73489278752436%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine-Month Period  Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(26.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;106.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease terms and discount rates for our leases as of September 30, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturities of lease liabilities as of September 30, 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Finance &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019 (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:126px;text-indent:-78px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(a) Excludes the nine-month period ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3"
      id="d131230659e355-wk-Fact-4DB203B3751C52E182EF899564E5C9A7">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="FI2019Q3"
      id="d131230659e359-wk-Fact-259536B06B5B5715999420695419EB6A">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember"
      id="d131230659e368-wk-Fact-380307E80E585E2DBBD62E336A217410">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_amed_FleetLeasesMember"
      id="d131230659e377-wk-Fact-BD77750525B8B1485AF7036B9EFE5FB6">P367D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-2826537A8FBD5552B1F53A053A10180F-0-wk-Fact-ACA10ADB0CE25380B217EDA8B82EB358">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease cost for the three and nine-month periods ended September 30, 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.78752436647173%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three-Month Period Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine-Month Period  Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e516-wk-Fact-13D20104BE6252A39D4324C6E9644F4C"
      unitRef="usd">8800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e535-wk-Fact-2B2ADB4A80525B42A6C4B97F87D2733A"
      unitRef="usd">26000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e550-wk-Fact-060350A830EA5CF2803C136419523A7B"
      unitRef="usd">700000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e569-wk-Fact-203AA32A6BF55098BAAEF250773FF480"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e589-wk-Fact-F86AB4AA11CC5D69B7D793745BFEA3D7"
      unitRef="usd">9500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e608-wk-Fact-983092A5EF7F54CF85848EACAE3B4680"
      unitRef="usd">27000000.0</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e710-wk-Fact-F3381F7D53BA50AF820536957FB4BBD3"
      unitRef="usd">500000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e729-wk-Fact-29098B1F2C885F58AEF44609C8461EF9"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e749-wk-Fact-15B919CC73515D8F95DD9A74C4413E51"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e768-wk-Fact-1C612101680556369F8CB74AE6E9D66F"
      unitRef="usd">100000</us-gaap:FinanceLeaseInterestExpense>
    <amed:FinanceLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e788-wk-Fact-F8A9A7107CE8549F8BDB205234F4B00C"
      unitRef="usd">500000</amed:FinanceLeaseCost>
    <amed:FinanceLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e807-wk-Fact-EF2D9CC57A395425BDF0D27EC6443F24"
      unitRef="usd">1400000</amed:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e869-wk-Fact-BBB5FC411A9B52D1A5558143006FD49D"
      unitRef="usd">700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e888-wk-Fact-F7795E44F91B52DDA1A82228967DE6BA"
      unitRef="usd">1900000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e908-wk-Fact-EC0BDB2551E351C99A038A8759F1857B"
      unitRef="usd">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e927-wk-Fact-F8E4C08EC4DA535FA3EB9176F2A434FF"
      unitRef="usd">200000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131230659e993-wk-Fact-356E7D8ED6665C00BFDD525C57DEB0E1"
      unitRef="usd">10800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1012-wk-Fact-21EA3E6AB16D5CD1803D770A90E3F33B"
      unitRef="usd">30500000</us-gaap:LeaseCost>
    <amed:OperatingleasesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-65E394E3C6545191A2B791A75034B947-0-wk-Fact-08DE99A1578057FD94F16B29DF368080">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</amed:OperatingleasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1074-wk-Fact-A09E255371915BC0A94C68E56FD0A372"
      unitRef="usd">84100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1110-wk-Fact-3A5AA0D149DD512FBE4DD8D751E1AF8F"
      unitRef="usd">26800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1130-wk-Fact-5BA1C23C134C554B96EAAF3BE282D809"
      unitRef="usd">56600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1155-wk-Fact-AEF641B80376572E9D3D96FBE9798E14"
      unitRef="usd">83400000</us-gaap:OperatingLeaseLiability>
    <amed:FinanceleasesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-807F0E85547D5E21AD5EC6B0FAF9B29E-0-wk-Fact-67953B4177F55F3DA0CBC364C074A97D">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reported in the condensed consolidated balance sheet as of September 30, 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our condensed consolidated balance sheet. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</amed:FinanceleasesTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1217-wk-Fact-E085FD729F845BFBBECDA20AD2D00344"
      unitRef="usd">5100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <amed:LesseeFinanceleasesAccumulatedAmortization
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1232-wk-Fact-CE7FDD12E83950D18D79BC4A4C535805"
      unitRef="usd">1400000</amed:LesseeFinanceleasesAccumulatedAmortization>
    <amed:FinanceleaseRightofUseAssetNet
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1253-wk-Fact-4FB22436860250F1A38E6006E05C4BD6"
      unitRef="usd">3700000</amed:FinanceleaseRightofUseAssetNet>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1294-wk-Fact-565EA7B8788C52669C23B1B843F77076"
      unitRef="usd">1700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1314-wk-Fact-9909ECC4CF7B50FDA530E26766698696"
      unitRef="usd">2000000.0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1339-wk-Fact-DD96E1C7B3A459DDBBA91BE2FCBB945F"
      unitRef="usd">3700000</us-gaap:FinanceLeaseLiability>
    <amed:SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EC0D50A3BE9854089D3EAB31253593F8-0-wk-Fact-39DA7210E41859BE9E2CCCC530AF6761">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.73489278752436%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine-Month Period  Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(26.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;106.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</amed:SupplementalCashFlowInformationandNonCashActivityforLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1425-wk-Fact-F375D7FB74505CF0B1E6AD9BDDF3C7AE"
      unitRef="usd">26700000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1441-wk-Fact-8710F998BC79541E9E693B329EE072BC"
      unitRef="usd">1200000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1504-wk-Fact-64EBA052049F596A895D004BE46BCDA0"
      unitRef="usd">106900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1524-wk-Fact-D162FE79BE15586D99044C88C24DECB5"
      unitRef="usd">2700000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230659e1586-wk-Fact-8477E15CB75F52639D054400412CD629"
      unitRef="usd">1200000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations
      contextRef="FD2019Q3YTD"
      decimals="-6"
      id="d131230659e1608-wk-Fact-78CD79EC9DB352DFAB53F7CD3FE8C869"
      unitRef="usd">0</amed:LesseeFinanceleaseReductiontoROUassetsresultingfromreductionstoleaseobligations>
    <amed:WeightedaverageremainingleasetermanddiscountrateTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-A3E530CD21D8520799A8269546B1B96C-0-wk-Fact-970FF943AEBC55CA9F366D88586805F0">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease terms and discount rates for our leases as of September 30, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.15984405458089%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</amed:WeightedaverageremainingleasetermanddiscountrateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q3"
      id="d131230659e1686-wk-Fact-51AE795A46DA5A03860AF45F759493A6">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q3"
      id="d131230659e1701-wk-Fact-BE4A8F9F4E74556B8114F7C9FD1CFA58">P2Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q3"
      decimals="3"
      id="d131230659e1748-wk-Fact-E682E3B4136353938845D921A99F4651"
      unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q3"
      decimals="3"
      id="d131230659e1764-wk-Fact-BDCB8331A7AF5F3F9D5D878A24B048CA"
      unitRef="number">0.053</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <amed:LeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-5A0FA7B1EFB75DE29E863FDBCE609550-0-wk-Fact-6FE90204170A5F26A1D52EBD5009F64D">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturities of lease liabilities as of September 30, 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Finance &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019 (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;83.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:126px;text-indent:-78px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(a) Excludes the nine-month period ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;</amed:LeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1857-wk-Fact-7C8191AD2CCF569E8AB00E791F3BA785"
      unitRef="usd">6300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1876-wk-Fact-71D901D961045FCA9D3B4D3BBC0DBA5B"
      unitRef="usd">500000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1891-wk-Fact-BBCBCABB25F35D2188296C4C361F8214"
      unitRef="usd">29800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1910-wk-Fact-353F5A59B4675EEC834CEB575B326F92"
      unitRef="usd">1800000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1930-wk-Fact-3F570761672C5432BB9722259151CB74"
      unitRef="usd">22100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1949-wk-Fact-CD0A9BCD23655380A6E244308C6FA773"
      unitRef="usd">1400000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1969-wk-Fact-45A9D0CCE90550CFB81D0A7BE36F8367"
      unitRef="usd">13100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e1988-wk-Fact-B615F799203F599EADC18A169394D908"
      unitRef="usd">200000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2008-wk-Fact-9C3CF86AEE365FDFAE2EAAD488D2AA87"
      unitRef="usd">8200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q3"
      decimals="-6"
      id="d131230659e2027-wk-Fact-FE8C49CE6A1E52DC910EA342BAC6A2E8"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2047-wk-Fact-CB9817337F1356FABBBC3F2C3BBB8D45"
      unitRef="usd">11000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q3"
      decimals="-6"
      id="d131230659e2066-wk-Fact-58C957633BBF55F9AD41735C9EF6B483"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2086-wk-Fact-1FF005F7CFEB5C94910C8CFBA9A9972B"
      unitRef="usd">90500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2105-wk-Fact-0C661BF00B285CE2BD6AD4B508DF59FE"
      unitRef="usd">3900000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2125-wk-Fact-C9574D2BB9B15251AC0F7D7B06544C48"
      unitRef="usd">7100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2145-wk-Fact-95C9B8402F005BDD9A13974CAA8E2D36"
      unitRef="usd">200000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2171-wk-Fact-AEF641B80376572E9D3D96FBE9798E14"
      unitRef="usd">83400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230659e2190-wk-Fact-DD96E1C7B3A459DDBBA91BE2FCBB945F"
      unitRef="usd">3700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7D6DCA79DCB55E4F8A6BF8EC7435962D-0-wk-Fact-AB6F01B712EC51E69FB21C59427E2CB6">LONG-TERM OBLIGATIONS&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.81286549707602%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Promissory notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;First Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$725.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which includes a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$550.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$175.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Applicable Rate is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum for Base Rate loans and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.39766081871345%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Pricing Tier&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitment Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Base Rate Loans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;II&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.30%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;III&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.20%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The final maturity date of the Credit Facility is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;span style="white-space:nowrap"&gt;February 4, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.625%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.250%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the period commencing on April 1, 2023 and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or (b) any debt issuance that is not permitted under the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the nine-month period ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our weighted average interest rate for borrowings under our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$550.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Revolving Credit Facility was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three and nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Our weighted average interest rate for borrowings under our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$175.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Term Loan Facility was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three-month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the period February 4, 2019 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our consolidated leverage ratio was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our consolidated interest coverage ratio was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our availability under our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$550.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Revolving Credit Facility was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$452.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as we have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$67.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; outstanding in borrowings and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Joinder Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-173DA99A06A15D35A6961C0EDCD6957F-0-wk-Fact-ADBDFD8990D65500B0C0F9963EEC5BF6">&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.81286549707602%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;172.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Promissory notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;240.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="-5"
      id="d131230578e432-wk-Fact-8F5ECD47278B563C807C358EA2AAA24C"
      unitRef="usd">172800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="-5"
      id="d131230578e451-wk-Fact-EAE3DD35960E56ACA5B1DC71C67DD2AD"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d131230578e466-wk-Fact-D5A39AB87F0A56A9A5DDF777B6395DBE"
      unitRef="usd">67000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d131230578e485-wk-Fact-0C8878B6DFF556FA8CBE3885C04F5C4E"
      unitRef="usd">7500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember"
      decimals="-5"
      id="d131230578e505-wk-Fact-263C3A1C41EC534AB5BA7807A794A4CE"
      unitRef="usd">800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_amed_PromissoryNotesMember"
      decimals="-5"
      id="d131230578e524-wk-Fact-5D86455C22245F01ADEE149F7D82B63A"
      unitRef="usd">1100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember"
      decimals="-5"
      id="d131230578e544-wk-Fact-96370ADB744A593EBEDC304BCFFC994D"
      unitRef="usd">3700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember"
      decimals="-5"
      id="d131230578e563-wk-Fact-C1DFCF5B53A25D91A2F97865C160C08F"
      unitRef="usd">2300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230578e583-wk-Fact-ED53AA76226A5AD4B8DEADC8DF8EB92E"
      unitRef="usd">244300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131230578e602-wk-Fact-F46D4F22FBA75289857607F05AE06532"
      unitRef="usd">10900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230578e622-wk-Fact-5C1CC49866D05348B2A703E2C08DD872"
      unitRef="usd">3700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131230578e642-wk-Fact-F67F7A9E5FE25FCFBA679ABAF6D3F547"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230578e663-wk-Fact-5F7F17A675CA547D9EEFDF3C061A8762"
      unitRef="usd">240600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131230578e682-wk-Fact-9662723D13D653E48498E667FD6B3B6C"
      unitRef="usd">7400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230578e702-wk-Fact-2BC6C1E3C401528AB8DA80E3B2F375CE"
      unitRef="usd">9000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131230578e722-wk-Fact-3AA4362682075C5A99CF6CA79627BA22"
      unitRef="usd">1600000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d131230578e748-wk-Fact-28638BF0548252B0867BA7F68796F2BF"
      unitRef="usd">231600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d131230578e767-wk-Fact-72E6C1A2AF705B57AFDE277E9C11719F"
      unitRef="usd">5800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2019Q1Feb04"
      decimals="-5"
      id="d131230578e788-wk-Fact-621F87680B50564EBF957B5EE9D5BAD8"
      unitRef="usd">725000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="-5"
      id="d131230578e792-wk-Fact-5FE5992888DE5204A8A49B1B0BABBED9"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q1Feb04_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="-5"
      id="d131230578e796-wk-Fact-CF65B158826F5739B032CADDFB2F8D2E"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="INF"
      id="d131230578e810-wk-Fact-76CF38EE2A9E5141B151227C7861B9D7"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="INF"
      id="d131230578e814-wk-Fact-0F49BE71FB1B5516A6BCD6B4CB45BC65"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d131230578e822-wk-Fact-34E3154144C45F98A7725D9DE2F7239E"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d131230578e826-wk-Fact-2B8B6B3CB51C5372A9F6132222257DE5"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3BB83B06CA5158AE8A7AD0BA9E4CF5AB-0-wk-Fact-DD68E00FCA9657E58B7D31E40AF34AFD">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.39766081871345%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Pricing Tier&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitment Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Base Rate Loans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;II&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.30%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.75%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;III&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.20%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember"
      decimals="INF"
      id="d131230578e895-wk-Fact-CAD118BD2E0650FB8EEB7669E002600D"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember"
      decimals="INF"
      id="d131230578e900-wk-Fact-D46B9D18943557C69671139147451B26"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d131230578e905-wk-Fact-5FD815B2ADBC5ACC9F1598144739FC25"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheOneMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d131230578e910-wk-Fact-575376D014EB5EA9A27150C7C38A40C9"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember"
      decimals="INF"
      id="d131230578e926-wk-Fact-C5A7C8423B3D51C0975A38DA3E85D06D"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember"
      decimals="INF"
      id="d131230578e931-wk-Fact-99FCE19AA8D25F7DA28D399D3C6857A2"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d131230578e936-wk-Fact-C4C4F92AF4935C77827AD07C88CBC29D"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d131230578e941-wk-Fact-48F6AC0385BA560380F88AECDE9DCF09"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember"
      decimals="INF"
      id="d131230578e957-wk-Fact-246D290B6F055490AEEDC13431653C2F"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember"
      decimals="INF"
      id="d131230578e962-wk-Fact-C18CA013CC0B5F0A9AAD0B311E213ACC"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d131230578e967-wk-Fact-72041134F1CB5374B1E81100EC0CB28A"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d131230578e972-wk-Fact-140813D2AA1F5C17A3CED216371386E5"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember"
      decimals="INF"
      id="d131230578e988-wk-Fact-3FA784FC17595819987B8B00D4201EB4"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember"
      decimals="INF"
      id="d131230578e993-wk-Fact-E77B0F1DFFD155C7A2193F3EB3424FAA"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d131230578e998-wk-Fact-495D7E9D1F93596CAA7F2BF15CAB3AA5"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_DebtInstrumentByLeverageRatioTrancheFourMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d131230578e1003-wk-Fact-C85283B6847A5F04AA282BCE0230CAE1"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="D2019Q1Feb04_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      id="d131230578e1014-wk-Fact-16076887F2175867A98C77735071867D">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="D2020Q1Feb042019-Mar312020_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d131230578e1018-wk-Fact-2294352741AA559BBC7361F63F7BA67C"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="D2023Q1Apr012020-Mar312023_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d131230578e1022-wk-Fact-5ACCC1001B225B00B9D2ADFA42E8BF18"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="D2024Q2Apr012023-Feb042024_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d131230578e1026-wk-Fact-A52CD87945255A4FA6F079DE141165F1"
      unitRef="number">0.01875</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="D2019Q1Feb04_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="-6"
      id="d131230578e1033-wk-Fact-256024227A7E588593A5E046F69ABCE4"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="INF"
      id="d131230578e1051-wk-Fact-39AB70D0B046539E80A9931C3F12B47C"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="FD2019Q3YTD_us-gaap_LongtermDebtTypeAxis_amed_AmendedCreditAgreementMember"
      decimals="INF"
      id="d131230578e1055-wk-Fact-F317830706E95DFEACA6FEBFBA5310C5"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      id="d131230578e1064-wk-Fact-0FC425A394ED535F95B1EB11AEC5A761"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="3"
      id="d131230578e1068-wk-Fact-76E257A18D96573D99747C6B68DB0008"
      unitRef="number">0.038</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="FD2019Q3YTD_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="3"
      id="d131230578e1072-wk-Fact-E2BB5EC984D9387EE379EC1FBC70D714"
      unitRef="number">0.039</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="INF"
      id="d131230578e1080-wk-Fact-C399BD88F96A5B239AEDD4545FBCB6CF"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="FD2019Q3QTD_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="3"
      id="d131230578e1085-wk-Fact-F6603246AC515F65BB46E15B165B8194"
      unitRef="number">0.038</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="D2019Q3Feb0419-Sep3019_us-gaap_DebtInstrumentAxis_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember"
      decimals="3"
      id="d131230578e1089-wk-Fact-EDDE5655AD1793FF1FD5EC215D34D067"
      unitRef="number">0.039</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131230578e1109-wk-Fact-D13EA4E437DA5B8EB5F709502B99BC45"
      unitRef="number">1.0</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="FI2019Q3"
      decimals="INF"
      id="d131230578e1113-wk-Fact-4544B6785B515BB293F411DE07690550"
      unitRef="number">19.5</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d131230578e1125-wk-Fact-C016A99C81D15A58847E1E2D626577DE"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d131230578e1129-wk-Fact-D5EFDFCABA9258E78F3B4E945C097B5F"
      unitRef="usd">452800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d131230578e1133-wk-Fact-D5A39AB87F0A56A9A5DDF777B6395DBE"
      unitRef="usd">67000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d131230578e1137-wk-Fact-099AA4E6B78D5AAB89005E1653937E7F"
      unitRef="usd">30200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3E28ABB7F5885038B358D484039A24F1-0-wk-Fact-B1E4338A11625F9099805FD451A36EF3">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are involved in the following legal actions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#x201c;Subpoena&#x201d;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On November&#160;3, 2015, we received a civil investigative demand (&#x201c;CID&#x201d;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to accrued expenses in our condensed consolidated balance sheet related to this matter as of September 30, 2019.&#160; Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Investigative Matters - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#x201c;CIA&#x201d;) with the Office of Inspector General-HHS (&#x201c;OIG&#x201d;). The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA required that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; that ended on April 21, 2019. We filed our final annual report on July 19, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compassionate Care Hospice Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 30, 2015, Compassionate Care Hospice (&#x201c;CCH&#x201d;) entered into a CIA with the OIG. The CIA requires that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization (IRO) to complete claims review for hospice services rendered in New York. The OIG has waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA requires that CCH report substantial overpayments that CCH discovers it has received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The CIA has a term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; that will end on January 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:21px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#x201c;PSCs&#x201d;) and Medicaid Integrity Contributors (&#x201c;MICs&#x201d;) in which third party firms engaged by the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with a balance owed of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including interest, based on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; disputed claims (originally &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;). We filed an appeal to the Medicare Appeals Council on the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Medicare has withheld payments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Accordingly, the Company reduced its indemnity receivable from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; impact was recorded to general and administrative expenses, other within our consolidated statements of operations during the three-month period ended December 31, 2018. As of  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have an indemnity receivable of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the amount withheld related to the period prior to August&#160;1, 2009.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$34.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Lakeland Care Centers on a universe of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Medicare claims totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in actual claims payments using a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; error rate and an overpayment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Clearwater Care Center on a universe of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Medicare claims totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in actual claims payments using a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$26.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the alleged overpayment for the Clearwater Care Center has been reduced to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$38.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is subject to indemnification by the prior owners) to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$29.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have an accrued liability of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to this matter. We expect to be indemnified by the prior owners for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the total &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The net of these two amounts, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was recorded as a reduction in revenue in our condensed consolidated statements of operations during the three-month period ended September 30, 2017. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of receivables have been impacted by this payment suspension.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our health insurance has an exposure limit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per incident and our professional liability insurance has a retention limit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per incident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amed:Numberofpatients
      contextRef="D2015Q2May21_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_stpr_MA_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e369-wk-Fact-22F8ECE2E9EA5FF0B8D8EE133BA49F79"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="D2015Q4Nov03_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_MorgantownWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e376-wk-Fact-FCAD0A5E2BF95A6DB3CA448E0CF604A0"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="D2016Q2Jun27_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_srt_StatementGeographicalAxis_amed_ParkersburgWestVirginiaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e386-wk-Fact-86AA8E24225C5253A974498BC8A24D47"
      unitRef="patient">68</amed:Numberofpatients>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e393-wk-Fact-23FD2D8E0E5A52CDBDC2BD503E5217E8"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="D2014Q2Apr23_srt_LitigationCaseAxis_amed_AmedisysCIAMember"
      id="d131230865e413-wk-Fact-5D6137D879E95301826154DB469A2B2D">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="D2015Q1Jan302015_srt_LitigationCaseAxis_amed_CompassionateCareHospiceCIAMember"
      id="d131230865e423-wk-Fact-23B7F9D6A9A45604833F05D9520C2B25">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:NumberOfBeneficiaries
      contextRef="D2008Q1Jan01-Mar31_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e436-wk-Fact-18731E511B5F59A584FBF4C4C2FBB203"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e440-wk-Fact-0ED52F781FFC50189DD3BC5EE7C610CD"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e444-wk-Fact-CB921A265BFA5BB8BF20F2A3ABE95E07"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="I2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e448-wk-Fact-903513F79C53599F8FCEDB3191908919"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e452-wk-Fact-26AB57F36AA9573E94C51C9F09EAA588"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="D2011Q2Jun06_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e457-wk-Fact-0ED52F781FFC50189DD3BC5EE7C610CD"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="D2016Q1Jan18_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="INF"
      id="d131230865e461-wk-Fact-26AB57F36AA9573E94C51C9F09EAA588"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_LossContingenciesByNatureOfContingencyAxis_amed_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e469-wk-Fact-A72C695BEF76542696F0EEB4AA7C08B4"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <amed:IndemnificationAmount
      contextRef="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e473-wk-Fact-FDCC1D78CF7B5C6A9B3522C43B0E6FBE"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="FI2018Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e477-wk-Fact-55D66D450738501985E5087A5378F87D"
      unitRef="usd">4900000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="I2019Q1Jan102019_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e482-wk-Fact-A40A31F75D135FECA69468B87DE6465A"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="FD2018Q4QTD_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e486-wk-Fact-EA7A5BCBA9FE5D68BAE477464EC7177C"
      unitRef="usd">2100000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <amed:LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009
      contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_SC_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131230865e494-wk-Fact-BCCF928DA2A15C4CA9D83E498A4BAC82"
      unitRef="usd">2800000</amed:LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e501-wk-Fact-0C70A69B051656D5A2D82022BC3EED83"
      unitRef="usd">34000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="INF"
      id="d131230865e505-wk-Fact-F787B8A2531850C3B2360D067B821AE3"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e509-wk-Fact-D21F34451E8B528FAB1052D42EDF7EDB"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="INF"
      id="d131230865e513-wk-Fact-681BA50C712453779F935DF26C15C1A8"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e517-wk-Fact-0240B49DB9B45C08A77EF5C976825CFD"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="D2017Q3Aug01-Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="INF"
      id="d131230865e522-wk-Fact-0A1B344664E054ECA53ED6F35959223A"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e526-wk-Fact-FAF48FA7C8D85FEF9ACC5120CE9AE345"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="INF"
      id="d131230865e530-wk-Fact-61B577D602285520A711D7C33469B8DE"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_LakelandFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e537-wk-Fact-43ADEC7565EA5C13B8A5C8834683E3C6"
      unitRef="usd">26000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_amed_ClearwaterFloridaMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e541-wk-Fact-4EF67B4C7A4A5A50935AEE7E69B24326"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember"
      decimals="-5"
      id="d131230865e545-wk-Fact-993F8C64C1175D898F9E2A93703D8C99"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e553-wk-Fact-0F13561B1BB659CEAEE83B42103D65B8"
      unitRef="usd">6500000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e557-wk-Fact-79BCE801625359D4A5BCF9C7AA3AD84F"
      unitRef="usd">38800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="I2017Q3Aug31_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember"
      decimals="-5"
      id="d131230865e561-wk-Fact-993F8C64C1175D898F9E2A93703D8C99"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e565-wk-Fact-C3EB60D808C7589DAC0D95D3402EAAD8"
      unitRef="usd">29300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL"
      decimals="-5"
      id="d131230865e576-wk-Fact-0DFE9DB7ACC4525CB209573A951DE457"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL"
      decimals="-5"
      id="d131230865e580-wk-Fact-FA6A69BD1249568BBD371E23352A1F4F"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL"
      decimals="-5"
      id="d131230865e584-wk-Fact-A03E490F438751259EF59866FAF6878C"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:FloridaZpicRevenueReduction
      contextRef="FD2017Q3QTD_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e593-wk-Fact-65E49CBC1C795A8593CD8561D41A9651"
      unitRef="usd">6500000</amed:FloridaZpicRevenueReduction>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3_srt_LitigationCaseAxis_amed_SafeguardZoneProgramIntegrityContractorMember_srt_StatementGeographicalAxis_stpr_FL_us-gaap_BusinessAcquisitionAxis_amed_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131230865e601-wk-Fact-D74E073951B25579835D2B4F8BD695AC"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230865e614-wk-Fact-A224D68B7A8B58339862FDAC7D6C220C"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230865e618-wk-Fact-9DA7EDB408F75AAB91DA609ED22972CF"
      unitRef="usd">1000000.0</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131230865e622-wk-Fact-EF22D2BAA4845D129DC52C4545854E0C"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1B9946C2ACF753F28D428F10488E5A5C-0-wk-Fact-75E4C0E43D6559128250EC308FBA8634">SEGMENT INFORMATION&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our operations involve servicing patients through our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Period Ended September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;188.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;265.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;447.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Period Ended September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;294.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;417.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;181.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;249.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;251.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;377.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month Period Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;940.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,454.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;562.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;854.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;451.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;786.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;346.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,319.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;153.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month Period Ended September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;870.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;302.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,228.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;730.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;205.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;369.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;740.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;217.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,109.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(99.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d131253740e358-wk-Fact-3DCD0C4E10D857879386C793CD19F2C2"
      unitRef="Segments">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9B05BFCDC6705C528A5A0E75271CDE19-0-wk-Fact-9F1F6D8902855ABA9DFE9D2DBC33CDA0">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Period Ended September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;188.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;288.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;265.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;447.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three-Month Period Ended September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;294.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;417.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;181.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;249.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;251.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;377.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(33.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month Period Ended September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;940.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,454.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;562.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;854.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;451.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;786.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;346.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,319.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;153.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine-Month Period Ended September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Home&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Personal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net service revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;870.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;302.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,228.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;532.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;730.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;205.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;369.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;740.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;217.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;99.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,109.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(99.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e620-wk-Fact-E70BCAD04CCB56FDBAF187C726AB4DE2"
      unitRef="usd">311500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e639-wk-Fact-D7C09AAF43D35444A70F94B9152BA0E0"
      unitRef="usd">162400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e658-wk-Fact-34B64EA55D265622AEC430BC9932CAC5"
      unitRef="usd">20700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e678-wk-Fact-EAC8873237CF5F1D905677DC16B7253C"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e697-wk-Fact-E6ADFC5ED04D5FF9A35A97580773B7DB"
      unitRef="usd">494600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e712-wk-Fact-76C3229443035568AE6A18FFF715BE5D"
      unitRef="usd">188900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e731-wk-Fact-27FBA3B435AA5FA1A50B775E550EA813"
      unitRef="usd">84500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e750-wk-Fact-A5786BEDD3925C67AEFF943C1EF0153E"
      unitRef="usd">15300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e770-wk-Fact-DE6C439C1EE5510E9716A9572F555363"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e789-wk-Fact-3D1B783CCF53FC064D5DEC2BDF12524E"
      unitRef="usd">288700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e809-wk-Fact-BCBC5AF239BA55B3AA4D91A3779C496F"
      unitRef="usd">75500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e828-wk-Fact-1A6C831D76935D09BAD83FDD30EB6FD3"
      unitRef="usd">35800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e847-wk-Fact-380A49373F43551597CFBE8B70BD0DC2"
      unitRef="usd">3000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e867-wk-Fact-DA060BAD5F9353F2BD9F51FB060610BB"
      unitRef="usd">40400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e886-wk-Fact-9925906F52585C8EAE09B2FC61DC4DB4"
      unitRef="usd">154700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e906-wk-Fact-2E383E6CA8675704BFF1382537E90EE0"
      unitRef="usd">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e925-wk-Fact-881F8850163A5EC5AF0AF8F8BD75EBD6"
      unitRef="usd">400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e944-wk-Fact-2A2C3A2B675657B1866A1330D0D85589"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e964-wk-Fact-DAFBFA623D19515E9A1BED9BEF404504"
      unitRef="usd">2900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e983-wk-Fact-FB9CCFAECEE0F5F04FBBEFA39819F6BC"
      unitRef="usd">4400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1003-wk-Fact-39B721350131513EA08080DD3DB2BF07"
      unitRef="usd">265400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1022-wk-Fact-378DF17992F25132B58E22BFAE477525"
      unitRef="usd">120700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1041-wk-Fact-5DF59E3069105B85BF6ABAD066710A19"
      unitRef="usd">18400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1061-wk-Fact-DBB239B26FE154798D30620E76982A92"
      unitRef="usd">43300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e1080-wk-Fact-19A2D23B31705254BAC74CE0376D01C4"
      unitRef="usd">447800000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1105-wk-Fact-1E9A61671139550983FBFA415A6234A8"
      unitRef="usd">46100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1124-wk-Fact-14FD8A6AC05C5BA0998258059E247A7D"
      unitRef="usd">41700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1143-wk-Fact-A92FBC966C365AEC8B29622C1291EA76"
      unitRef="usd">2300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1163-wk-Fact-BF3980137BF559E6945E9F155CA9C9D4"
      unitRef="usd">-43300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d131253740e1183-wk-Fact-6E3CE31EE6BC576EA7BDF8580AA791B1"
      unitRef="usd">46800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1515-wk-Fact-FB96413548135846B721B8F87301FBBA"
      unitRef="usd">294900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1534-wk-Fact-CF5487BDF6CA5604823A45D99673439D"
      unitRef="usd">103400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1553-wk-Fact-3504B25067D95D479120EAEE3C3E6147"
      unitRef="usd">19000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1573-wk-Fact-5824530F84755C419A0BDED5D8E79E0C"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e1592-wk-Fact-F31DB09FE1905F959FCAED82FDBB8392"
      unitRef="usd">417300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1607-wk-Fact-71B9C23161BE5C24BE0A2639636B6260"
      unitRef="usd">181800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1626-wk-Fact-BE7407F2F58E59168AA51EA828953C4C"
      unitRef="usd">53400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1645-wk-Fact-67DFB18A1EB655638D7A081EE2F26FDE"
      unitRef="usd">14500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1665-wk-Fact-A269E05DFBEA521C8823E1C219EF0A74"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e1684-wk-Fact-48DCD6DB78FE5C9BBCBD610533E97EB6"
      unitRef="usd">249700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1704-wk-Fact-57371C30206C55B3BB5E020EB7844FFF"
      unitRef="usd">68800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1723-wk-Fact-35BD65C7CD4254A39DFF1E46658D2818"
      unitRef="usd">21400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1742-wk-Fact-AD77F28EABC951788C87D3FAD57CDD26"
      unitRef="usd">3000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1762-wk-Fact-49982FDAD5E25796816809BF2099B51B"
      unitRef="usd">31300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e1781-wk-Fact-499811EDEECA543C81E4031D0E3C70DF"
      unitRef="usd">124500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1801-wk-Fact-4F036D10B5965C3DAEFFAB6D36E5C741"
      unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1820-wk-Fact-4EF14D70610B5C179B4F2449839C2999"
      unitRef="usd">300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1839-wk-Fact-51A2B15ECE5454D4AE346A2DB2E6C86F"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1859-wk-Fact-ED420F59525758EC8FB0E514460A49A3"
      unitRef="usd">2000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e1878-wk-Fact-54C7856B43F457D1BFFFBBD310C092B9"
      unitRef="usd">3200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e1898-wk-Fact-7B0718050B085F6E9CF810C2D1A7322B"
      unitRef="usd">251400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e1917-wk-Fact-674DD4E032C55EE2A90D001F88AD188D"
      unitRef="usd">75100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e1936-wk-Fact-B62BD3939F1556FF9E56BD9D29FCB4FB"
      unitRef="usd">17600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e1956-wk-Fact-0BBC94A9169053D995B2C8D41E8F995A"
      unitRef="usd">33300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e1975-wk-Fact-F42F5A447239531089364C6CCAC5DFBD"
      unitRef="usd">377400000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2000-wk-Fact-EADC5903FB955FB3A7B3E660BFD12885"
      unitRef="usd">43500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2019-wk-Fact-7370FBDF78E859259904173551848F1C"
      unitRef="usd">28300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2038-wk-Fact-C1C47F9C9D5C5325A9373216FE0E1435"
      unitRef="usd">1400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2058-wk-Fact-7060AB431BEE52DC8CF5A6221EAD7845"
      unitRef="usd">-33300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d131253740e2078-wk-Fact-BBEB55B080E654F7A7D014C10B55F828"
      unitRef="usd">39900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2409-wk-Fact-4703C5E5C31A54278D5F14D494E3E8BD"
      unitRef="usd">940200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2428-wk-Fact-05E86A79B7155538A0059C00AC79C449"
      unitRef="usd">452600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2447-wk-Fact-EA13E10BEE8B52BCBCD91684DB8C67AD"
      unitRef="usd">62100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2467-wk-Fact-DA375D692F095A59AA43504D8459139A"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2501-wk-Fact-6E0B8974CBEF5A5F87327733FBD33349"
      unitRef="usd">562400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2520-wk-Fact-E8BD2377064A54C4B13E4194E286C4F2"
      unitRef="usd">245900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2539-wk-Fact-8377FF0D517753C1AF5016E1EB8B98CC"
      unitRef="usd">46400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2559-wk-Fact-E815A33CA3CC544BBE56B9FCA91F9DE2"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131253740e2578-wk-Fact-8BB832B9151A57DDB454918EDC3CAFAA"
      unitRef="usd">854700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2599-wk-Fact-2487AA15F73D5634B5E9986BEF271F91"
      unitRef="usd">220900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2618-wk-Fact-F52C34596992554FAC2C6D23F32EFB6A"
      unitRef="usd">99700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2637-wk-Fact-B6C03EC49E53507886D8F90635011D84"
      unitRef="usd">9300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2657-wk-Fact-3401CB564AD95D5695F95A667047338B"
      unitRef="usd">122000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131253740e2676-wk-Fact-C29477259B205417B00084FF4A025C73"
      unitRef="usd">451900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2696-wk-Fact-8336C6AFB3FE55FC9F3CDB56A5A53303"
      unitRef="usd">3100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2715-wk-Fact-2DA712FEA6755E558C58EFA7B721658F"
      unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2734-wk-Fact-AD95752D4B99507093071C47B7B26450"
      unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2754-wk-Fact-A61E62B2F3CF5D14B4906DF03DD813E5"
      unitRef="usd">7900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131253740e2773-wk-Fact-4D252E62C7F8517AA6E6F9F9E6D0E330"
      unitRef="usd">12400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2793-wk-Fact-58F2F056077F567280639D03FAE023A9"
      unitRef="usd">786400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2812-wk-Fact-F2A14943405454DDA3CB36AC9F788FED"
      unitRef="usd">346800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2831-wk-Fact-EBE74144ED8F5791941A9104F996DF77"
      unitRef="usd">55900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2851-wk-Fact-C92A6CADDE265288852F5D13BE371157"
      unitRef="usd">129900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131253740e2870-wk-Fact-5D59517E47345EF6818472AAA2B6CD2D"
      unitRef="usd">1319000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e2895-wk-Fact-C47A0F3329F35F54ADB86892097D75C3"
      unitRef="usd">153800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e2914-wk-Fact-EE1BC792D5B153429DD7D3709DE1647E"
      unitRef="usd">105800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e2933-wk-Fact-133890600C325A76B6F5B185A0EF97A1"
      unitRef="usd">6200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e2953-wk-Fact-264A4994442F5B4EA458C91253A6D69A"
      unitRef="usd">-129900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d131253740e2973-wk-Fact-92D035DF46585DB9AF651D51809EBF6C"
      unitRef="usd">135900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3304-wk-Fact-80C3204A058E5A768ADDF0D764804BC3"
      unitRef="usd">870500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3323-wk-Fact-C0DE73DEB8805FE9BF0589ECCF54C425"
      unitRef="usd">302100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3342-wk-Fact-BDD38481D10D5401BAE5FFFDF2109A52"
      unitRef="usd">55600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3362-wk-Fact-35A6A9FEA4EC54968BEA6E24CCFEDB26"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3381-wk-Fact-C2B348E9D7DB5A27B809E4422CAD95B6"
      unitRef="usd">1228200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3396-wk-Fact-BCCB54E6959F557DA0ABDC392EF52261"
      unitRef="usd">532700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3415-wk-Fact-B3677C40F6F358F687253334891C8203"
      unitRef="usd">155200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3434-wk-Fact-58F6B5810EEC51ED826234D42CADE760"
      unitRef="usd">42700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3454-wk-Fact-3ED38EA90F2C5C658B1FB3B6126E37F1"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3473-wk-Fact-090BEFE753CE5FBDBEE23D29397ED2E4"
      unitRef="usd">730600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3493-wk-Fact-B976A56D2F485D12946649DABFED0DB7"
      unitRef="usd">205200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3512-wk-Fact-534A86706E3559159A696A3C8CB1B42B"
      unitRef="usd">61700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3531-wk-Fact-10F9541E0BFA56F59E50AC0A97FBA6EB"
      unitRef="usd">9500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3551-wk-Fact-15C3777DCBA0521FB2F70C5F5925D336"
      unitRef="usd">92600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3570-wk-Fact-F5A2383EC2055618B0D8F034092D62FC"
      unitRef="usd">369000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3590-wk-Fact-B7068E2D2F215AE9AB1A80C774BD639A"
      unitRef="usd">2400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3609-wk-Fact-E17FFF03F295519D834A1F8796A0894E"
      unitRef="usd">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3628-wk-Fact-668304A95BC450DF85009E2F7C756177"
      unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3648-wk-Fact-8948B554018D576388307B4A4C45BEBA"
      unitRef="usd">6500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3667-wk-Fact-E1C86F14BCC857578DA3F6A752A4E94D"
      unitRef="usd">9900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3688-wk-Fact-F1216BEBAFA55BC3BB97790A0B2B5E6E"
      unitRef="usd">740300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3707-wk-Fact-E68EA3061BEC55A0AAC5DF0DD077F9F1"
      unitRef="usd">217700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3726-wk-Fact-98F5C10C2F84569EAD67D945FBE0ACC5"
      unitRef="usd">52400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3746-wk-Fact-D1BC84099E075559BD9191F3414D9DF5"
      unitRef="usd">99100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3765-wk-Fact-E43B1B3C0F0756120573EC2C3FB099B3"
      unitRef="usd">1109500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HomeHealthMember"
      decimals="-5"
      id="d131253740e3790-wk-Fact-433692E50BFC5997B2F47ADF0CB92834"
      unitRef="usd">130200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_HospiceMember"
      decimals="-5"
      id="d131253740e3809-wk-Fact-5AF0AD6AF0DE556B8C3D028B65D4C5B7"
      unitRef="usd">84400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_amed_PersonalCareMember"
      decimals="-5"
      id="d131253740e3828-wk-Fact-028BD406EEAB542F84D6A9BC9B1EC8C1"
      unitRef="usd">3200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember"
      decimals="-5"
      id="d131253740e3848-wk-Fact-A8A8ABE8B55657D59C4B7E6F1ED0264C"
      unitRef="usd">-99100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d131253740e3868-wk-Fact-D22C5ECEC44758068D0EFFA48BCF5678"
      unitRef="usd">118700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:TreasuryStockTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7C2E26EA1D655199AEFA469F62284D7F-0-wk-Fact-DF9C8B3E04015D8B847DD4E81FF5E1FA">SHARE REPURCHASE &lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2019 Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our outstanding common stock through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;span style="white-space:nowrap"&gt;March 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the program, we are allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We are allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We did not repurchase any shares pursuant to this stock repurchase program during the three or nine-month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2018 Share Repurchase&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On June 4, 2018, we purchased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,418,304&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then-current holdings in the Company and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the aggregate outstanding shares of the Company's common stock for a total purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$181.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; including related direct costs. The Company repurchased the shares at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$73.96&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which represents &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2019Q1Feb252019"
      decimals="-6"
      id="d131231163e359-wk-Fact-6B8DBE78D25E57EFAC04D1A254AE2BE5"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="D2019Q1Feb252019"
      id="d131231163e363-wk-Fact-33714902318E563FAB42B5B7215C7F74">2020-03-01</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember"
      decimals="0"
      id="d131231163e383-wk-Fact-3F6BACF27FD25507B35527928C9903BB"
      unitRef="shares">2418304</us-gaap:TreasuryStockSharesAcquired>
    <amed:PercentageofSharesOutstanding
      contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember"
      decimals="3"
      id="d131231163e387-wk-Fact-25997DAE7A1554E3A309004393924901"
      unitRef="number">0.071</amed:PercentageofSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember"
      decimals="-5"
      id="d131231163e391-wk-Fact-ABBE44153D7E5D21B1B9B4DF2E857403"
      unitRef="usd">181400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:Discountedclosingstockprice
      contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember"
      decimals="2"
      id="d131231163e395-wk-Fact-DB833EE0A8065052A867474CF7930D2D"
      unitRef="usdPerShare">73.96</amed:Discountedclosingstockprice>
    <amed:Percentageofclosingstockprice
      contextRef="D2018Q2Jun04-Jun04_amed_ShareRepurchaseAxis_amed_KKRShareRepurchaseMember"
      decimals="2"
      id="d131231163e399-wk-Fact-F242028A9FED524C99B5B56D6F6C239B"
      unitRef="number">0.96</amed:Percentageofclosingstockprice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8DE6E60C7E19B8FB20CE03F8E1501AA6-0-wk-Fact-052E7662332423B0B32F03FA1A0E8FD6">&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;9. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2018, we made a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three and nine-month periods ended September 30, 2019, we incurred costs of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in connection with the usage of Medalogix's analytics platforms.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember"
      decimals="-5"
      id="d131231273e353-wk-Fact-DD6AB2B4AF11039B73DB04E9B64FF77A"
      unitRef="usd">7000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember"
      decimals="-5"
      id="d131231273e357-wk-Fact-7F75F4F58E4127C7951104ED6B4F1F8B"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_amed_MedalogixMember"
      decimals="-5"
      id="d131231273e361-wk-Fact-768760A53A24EDFBA5AF04EEB3E3161A"
      unitRef="usd">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790052160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,454.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>562.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>854.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>451.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>786.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,319.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>870.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,228.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>730.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>740.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801556416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details) - day<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare', window );">Rate of request for anticipated payment submitted for subsequent episodes of care</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode', window );">Maximum days to submit final bill from the start of episode</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid', window );">Maximum days to submit final bill from the date the request for anticipated payment was paid</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803656528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,335<span></span>
</td>
<td class="nump">$ 1,454,955<span></span>
</td>
<td class="nump">$ 1,228,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,888<span></span>
</td>
<td class="nump">135,919<span></span>
</td>
<td class="nump">118,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,400<span></span>
</td>
<td class="nump">452,600<span></span>
</td>
<td class="nump">302,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="nump">105,800<span></span>
</td>
<td class="nump">$ 84,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice | Compassionate Care Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset', window );">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice | RoseRock Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member] | Hospice | Compassionate Care Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member] | Hospice | RoseRock Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Hospice | Compassionate Care Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Hospice | RoseRock Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790028624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations involve servicing patients through our </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Period Ended September&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,454.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>562.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>854.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>451.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>786.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,319.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month Period Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Home</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hospice</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Personal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>870.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,228.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of service, excluding depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>730.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>740.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0000896262-19-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-19-000014-xbrl.zip
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M9TBH7&*#\\#6L*K9>A?B!()D%37AU_NRY@ZT,[%-LGSGW3?V\<2B=TS5%(1
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M:_'%>[ZU, [NB/URBF)+<P7F^?6'_P-02P,$%     @ #D->3YG7/D5Y&@
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M+-_;J+0O2]GO,=H;G T'/2ZX')SK?E\,=7^H>N=T.&PBK/+$WG9-D)8!W._
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MV$0<A7?2*@##Q@'5?^B*H>TB="87H!F-JF4^-0N75]4#?/B?^73OW1U']<]
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MQ7@1VX.G+[7)C$8K@^")IE<L#A\"[NN61=CYC1/,.0(KD52*4,>DUH1A!II
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M5*NZ!#=U!Q#U)1R_369EM3J:>SQNV]1?CH"73]5)TOE<VF5WG<_]]?& ;X\
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MFZWQ['D%P=:P&71.YXI 4U7I1KE5,B,,^4 ZYZXNF4AU7)G",IG&$8%![ C
M HHVTL&1^E%4'6=RML+J%^+3"DA][?"O#??PG>X[.V62,\.E\UIQ1AGC44H.
M5 :C-.8FL&'G=C9GWA'2T BI'U4NSB,/![(\AR0.+1F#<5H4BT=U;?_M\"\:
M9AK&0C@32FC84 FCP2L8(;7<<X1# Q=S5[I]&W"7+6)2<_*V?#E\(%YBR60J
MD6JMPYXPM-[9C+<-KK<ZW5%\MMVZ"2*=<_'HN\*-8$8%%"5%TFBDE.=X,VZ
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MM%M$"\2E\Y_H6 B<<"0T;E#=O[-C]N9,*GM"JU,Y^/2U;"X'VX=DSG,!*Z#
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MQ0Q+1_"6$M[ YTPNV>?<#*5O_.[OEM&/H]MBO)P6WQ^G/76$@BEWMVK[XUP
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M5RW6$07*I02]%KD8A$$1BQ!\_>N(>@[6;5TV3@/F,H-UB5,2">N0))(K'[1
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M[JYBN_T5$).<#8KIQ[=B7?[S'_\'4$L#!!0    (  Y#7D^G Y"Q_?0  ,V
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MLYN+:TZ%5^=,FZ8&'"ED 8$82T%VL2GG393B939=6/T^MNN[Y<+OR[?#ZGF
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MOE#6INCIQ]9?Y+U8MP^*9:&&:JNM(: F#D##B!8[V==Q:IO+9F&)?7A#?N6
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MY'RSCOJTGBW78]0TUF[,('X,,7X\/U;,:K:NOK1?YXN%#XE\6>7>1 XAC6Z
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MRIII1B2%6 /(:LH&$+66+$9Z,IL^X0+/.?%VLP09_U9 [@8)4ZX3MD6<JO5
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MBY#<H_"7IKII/(;)[4MNOZ2XHVF:@.B.]Z'+V7'2X]OW\T7;E]L]EU)RR[A
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MIQAS:H6MG4M*8R Y9+4M+$U;:-N4MX]GOR9ENHTB,DR-CL5AG!P-]$TDQ^T
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MY-DI9>R1R&$67YHU,G$_@9DBER==_IZ9OAVRNW.H[I9+?Z+"&UV;AAI"+94
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M).J*;/Z^P,V!K=VQ;$YCXW:T%UW>/C9:=;9E^Z%NC),WRH@ JA8"(R &>QQ
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M83VT70W-!D@7>Y"&W)[^#/E<,4R%IC6&6C. F!$UWT$!,N@%HZ( 3K:0W.G
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M.IP02Q3YU'LVHX4GQQY9M>JA5=VB^KX%%S$7YN<Y91/M2!2/W%+;T/UI1_<
M-$HD2VRQO4Q?\(9;AA:8XO9;#K<.;L9EXRVLLO6N;O;9U<?V>[NX:\7B\NS*
M;"^.R_[>^*#2G_VE<;UW9=S]KMB[,.X+IO[MFU/P'V>_+=K+7<'4>;LZE[AI
MB(6 0:0)\N]JV]U2""(6?DUB.I!+GP,^*(?_X!A_N?%[<V-_N.QOY+O/6FPJ
MY7^]FRUG"S=LJM]ZY]YVWKMJM>>>^Q+'RNK0R?ZD^TO DF@Z:,M-*GN]Y.RJ
MVGI9.>C^Q\'1:N/I?5C>^UKM.]O_DWUW-_6M-PY7O<?5OLM_S$X34YQ\,JC+
M+^D.2,VB70]RLRJM-X&UT8_5,"\M%J?7,R:PM)P@*=VD1W-BE)8.^ %*@""K
M%<' :HI(TPAJ=XMKA#!."L>.A.VH<=<K<I<UHCI6VT:&3A-LUC$QTOB@*$,<
M=*RF3@QX)MCD.2*;O(,Y/ES)0VM(7'+D!IQ8 ')L[U^*-$[2"E$[X=L'5_KG
M.=[OW6062S<FOO:)_ZM_678K!P(RB@32RF#)-0:F!D-<HU1#9?1^>#[3A0,"
MW5ZU2__FX.63-VH2]L0S,AZQ,WX:LE/VQP=Z>ZAOJO</R[?MXWU3]8A/L%$>
MS.9KV^7YFV5"F^8%G'MNZ[P4AV,J7WYL;V9S+_U/ZS]881J@.?#9_,@J()%4
M PB)ZZ"55R'3A75TAZR:?9_-G1^;*VMW"]<9_1[3MG39Q<,K;>,+88YIC#")
M/6$[Q$GL^Y>*8=ZWS13+8;[,Y0&!+=0HTQ#84LX%%,7,QF&PP+9KKS8#CK.[
M]6H]6_AGGH>'G0100!, #+8&,6CJ9J@"IS!@0?5KLADK+*)[@*KK#=9^S[Y'
M&ZF5HWD-5,=C4AJIA_<,;B5Q#]V;D[P$]QI;AQ0O%]$3T;AL[CQ6M;P\I:6>
MZ79UL9S?^@7_V=5^HD>? 7*.28-X;1L #0>U9 #4.PA(XB8]_6RDX>*+[1TZ
M/RH?9*!57SS",7EH8TE/R44[(M\C\]$><?\@'6V3K';*I+3#/ 8GIF5JCFE(
M9!G7#B:H9>5OQ)47;W*V_M NY]VE65R>$X65,%82S&@#$* *@IUA//JB:*RY
MXC+Y0A)^/U9GZVJ#M')01U^0B&8ZX'SQ^"2/TL9I\3OZJDE)GC-?*HG@>\SM
MD4>,Q-T32:5S J=FF1UZ_>['.*Y"0VW5W=S,U_W6KUA<JFZQ=L%]N[B8MRL]
M7UU<=ZN[92N^.'"SB_6YL92J6D#J9BO$@5$U,!H)T,"&4") 8-@7:50" 1C"
MD&B-50.%;"S4DCL<V/594$[;]G#V&7T/D%;W4*N_#V#_UW'COB@B#P1^91ID
M&I%?(=^Z8W3I F/Y<_O[6CI^_G'>8$:TDP^!1 ,E%M;]SS"8B;$D9N$<:1IP
MI&N$E6TTQUI;+H05!AE,M:Q)$S6D4PIIGOW\\[O//YM?/G^JQ"^Z4F>_?'[W
MR[^87]0[\RENU9R;\XP"6H;N4@KJT58]W"EJZ([+L2(:WRA_(!5-<"Y%1E,Y
M#-51<7'A-S>=Y0_=]=S;W@DWU[:VC"-J@<&2FAK4ONH<9-PRREAHILD("^7&
MZCVH:D!ULL#F98(.#, ,K$YCL.5PI,O>X^(&T:^+[0NY[>5^\HGY_;9=K-IS
M6"/(*6044 D(%YPJL37*@111)Y$C314.-O;0/<J+:S< XP*.L;R&"=01*8T3
MJ7TV'Z;!F5?8+*)3AWDZH%69")Z&7N5RIBO2"2,G_[W\XK,K.U\XDSYSPR?-
MG4M(I50-8D0YPXU/*P:#24SJH+I060P5UJP'-SFZJV?R>2,/%\>Q&AA4'8O0
MR+#J$9?/).\>.;8ZP-.AZ"H'O=/0JSRN/(ZP\O$3=-CW@CIZ>_M0-AO(YYS6
M->6&2 T$P@ 84^_$4G!(@P_]\IH]6>SE-:R:[0_-VQYQQ!E5Y@8(. L\'?>Y
M@C0/]>$]P0\GICWBB/!T]*<=%?I Z<)?XGNFGS\_JX\\,8PBZ*63PS(L3^ $
ML9!C7?$>&I^\]]Q>74UKH:  #2<- QIH0]EFZUO5E$(0FZ?WG U$.9,U,8Q*
M@ZWU_ZL )P)CYZJH2Z?DO3_[Y5_>?C8??Z[.Y/MW_R(^OSO[)?(\(9F]L!CY
M&,0EY(],XB#@!6Y>R9<;P^8THN'17CR3!3>>E5"Y\?=_VW^_<Y.C^=X?&^S.
M6)EN-&7"(@"I$%*PNH:<F0;0FG'U6EVL5[^?.W<XLDK1&F-I"#,*8>(<E*31
MSLUR0^8>4K7!=+)M^I?(.3!F1O,YC4$SWHTN<S\;-VSNAZFFF!HA$6%-8R'#
M6" ]C!OK_ALS3[]LQ6(KL":UQ0W&'$*.&UM;42-@9<UMZ0VN3[_*3^;__=7\
M\KDR_^;^-VZ2'D%>FNB4X6VTZIQLJGZ1GPCAB>=TFLJ3X,<KTI/*3+#V7'QK
M+^^NV[,K>;>:+]K52ES\^]U\U9>Z7LD?>S]]]CGSYT8W$-B:^_N24ALG?-8M
M5:BV0GLQC).D6.,NW&Z0L!A 3C%D4M2:"JP$E;4B$)5^]'? ZQ?L ^)J'_*;
MZLN/_0_<L/2X7QZ11VJ30*4[97-$"F#VEBBCC9&,'I+,4HTS$24MYMYC@2W+
M8ZCN/F-<_#Y?G1. :XH!::"AM5'&VF8[E'TNB(TJX/^2#2@!-H A@27'@"/F
M B07OU(J.:BQTH55]+GQZE9-#EFD3B9S&":'QZ O3O52F"NB:R]0<T"^QI(Y
M#94:[467MXN-UQS_QV7;ZLZ7QS@'4"')C LD-.*U'T?U;N1 )W=CU>>AM08*
MC: TT/F$&ZX$AZ01JFXT%!#0TL_K/C>:WE0#QNKO&Y09-"F2XW1U*D?O>)V*
M8?9HFO6 L$CU2B-[NCJ6Z$^ HHUA*BC]0G4WM[/5RC_.M&[5;-G^:[>ZG5^T
M/[<W7]KE.8:X04;7%%(HF-4UDG88<<HMI8/S+5ZQ0Q'DP&BKD5$8 B@(( 0A
M)]M(<UU\'^T!NLK#J[;XJK]O$ 9J619. U(HCDAGG'Y-B\F(K(@C,IJ6!C&&
MV;"\A\,4O)3HD(FX"60VY/*DR]^MXJ+5=XN+[J;]Y#I87PWSO2=UB(\YJJUC
MQH50#7(K/4",6Y9OQXQH0-0FY"$[;DXBDA&A *-8:,*)@I1S*PC2NFY*/Z:T
M@5;ML%4#N*3E\BA"PX+28W$9)^?)-!:)0P]P=" "S<'L-&+/+)YT^?M=%G7:
MQK@0,V.XBW$IKZ45&(AF-Z=3:*+6T8<M-5*!FC&I)#:86,@5Q1I@!B00TC!R
M.H5*6CZ/I'642A5@-)M.G63%?)"G>*V*Y'?2:A7K2YA>)3'TFF*MENMS_^#3
M<O5M?MLK8DT9T5@H+  #T!B*P+ #!2BP0?</GGXKAPT20$DA*<+4&,D-LX"[
M)0USX02+RL%**3$[@(F*C1+(.:PQ97F)TY-@2D+4PSFVIQSNI\>J\<3S9Q0B
MG9W3JL$(W-W8?I$PR@<=(=1/F+0Q3,':6ETSN.O*"L>/\^WWXMHTHL&0$+?>
M(QIRA!4CD%G5P$:ATN>'>]TZ*L9(HBABM!=@)WF\YX@7XD;\BU'!&(XF-.IC
MD3\W[I.\#\[D&J()=3U;K<ZN/JV[BW]LIK0:LX9#I;3?E0%.='SAN$TG=W\3
MI ,!5D2-=4TM%RY6<=\LA5,QZ+H,Q0H)4_J=CAZ/3P?J$25MD(Q@,&SA<1SR
M(O>ZHW@KDR7U$BV'TJ%&4SF-]44&/QXG.&5B)KC2W9Z9K< 19 4B$-7 0*&4
M-*J^'RZ01 G.,U\/&\JQ$KQ&RHT^7WBBT<@Y)21T,14I?9'Y\8A)VNA(82U,
M9 H3-DY=3K*/\921 \(R@KYI*,H8!QY7@!O+Q8C,I/?N@W=.R%;GUF H"0(-
M;@AAF .HAA@=VL:8D4E)]X: 9!0A::6D %.)F3/ B6+8\L9% *5/>Y[/[O/P
MJA[?^$RD"$[#M.9H=,:I3CJ3Q\H\VK$4EW043^XT-"F/*Z^G&J7R,T*G5A^6
MG>V6-[./[?=V<=>>6X*IP5AHR8$1"$%+FF%H.31\I%P]L:<,<!Y"**EP45U#
M!'?_(4@R3BFVJ/0[L[^TZVK5+K_[%([E!M)HG8KG-%FNBM(Y7K7>5 Y?U0.L
M/K["[K&TZS%E<1*63/ADE2S=H]<%;21;0=F3@]G9O=G;97?EK7:W[7+F"Y7.
M^P.K:_\>K7'##SH=K3FA$FI+C.'#6'3!@PK.IHRU*Z4B-7%Q2ZTQT<P? 0,$
M:<WKQDI<.EO\;(!4;3!5?_:H_A*1!YB;Y\.:=VJ*$[5O#VGEH%8]UJI[3/[U
MH2>TRU,?D9)YPB9(2]'\_*T]Q/RFV_N_K=;^-S<5K&:K:G[5?_!E:$GWVU_F
MBVVIQ>7^CZOJV^RR^M*V"__I[77;U\5:;_YYZ]CHG_3MKJK9]NO_.C(G-*X-
MGIG/2K;D!')&2WG6E1\'^>)W%\ANTC+>>_L8" IJOW! #13&&$V&5",(J ZZ
M,Q!OE?LC2*N9$QF FUHR1FG#":D5;&I0ERZ/[6/Y31OD"^$C:1T?R)=C-&\X
M[\G>9GS]^?W!4.+H@?T#"A/#^[1FF'Z0G^A71*@_AKD10CB8-[.EGW]7']KE
MIV^S9?]"YL4Y@!@J#*3%O*9NY2&:A@P#5Q.,1^KA8>.\@1 J7D/><%QKRHV$
M-7;K'H"$IK+TQ:H>1-5NH0T1D)NTJI7'.%HK1S*?+)G'(SVO<@YX?;W:JD?\
MIG_H]^+D"GJ0T3@AS=,XD]733.Z]+JLY>2R@KGI^?>>6/^<&NTZ&D,:0-)0#
MJ^J]P$CAL8=<KYEG7 L!J5O=:HP-E1)KTFA!)>70:EPZ\-S".('&!O.?765+
M4%]>9[>H)ZNT6WQYM#:VB?YP:AOM8+K>IG$9JK@?V^N9^_8/L^7ZQ^?E;+&:
M7?0Q]7.U;Q66G # &@$QHZ8V&INZL0*(&A$EHXI?Y[1;6&,_FO?BL]'5!_'Q
M\_]7??XH?ODD5$)5[*Q4AZGJJ5B.D],MRJJ'6>WCG$9-[0@6#\AGB;:8AFX6
M\:PKWY-CE;(_2/S87G1?%YOZ+(M+W5ZURV5[N?W+7;UC 6I".&L QT(Q2"S7
MQM(&&4N()."U,Z@DF\@%XLH"9"@#&"C$&D+=NA=+X>P*5'0 ]TBJ/9S]0[D#
MTN$$_F0EOF-X/#B$"S3'5,9P"=>>#.)B_,67[=W:^]1WZM6_MK/K]3=?HN-L
M^76VV+XQLBEDR320OMQ2+65#A<!883P,9N$^2*O<&VZ?NB4V4,9*I#1&S?\A
M[TV;VTBR=,V_$F;3-K?:C%GM^S+]R=<JV55*:DE5;3UIUV 0&9+0!2+8 *A,
MUJ\?CP "!#?0/<(C$)F3M20I4CCGO.[^^/&=*"2%8<!C3HFT:.@#(L=7QK8-
M>>_U1;'S>W<AS;'G?2_PS5@Z<:@]=\&D$7>8,AGX*M]H84\@>,ABF@:)!XWP
MQ3M]AU(S:B/5A_E=M6[VS.\.^!IL#-L]X1Q2-D>A1?L6S8U7\<_\/?I<SAF@
M]46VWH?/!%(9X'3X7$8=XE ,/8YLO"EV!SM23MEUDBABC]. ZJ3!;%1A$G8@
M#2A0MQU&"4+%[>]Y&.%+^W<ZZC"!_3E=/:_ZUX).^-N?%;)&*X2--PQ1&Q!K
MH!!M)5;8DPX W'^R]Q(Y#(PS5E)BI4:<&F&!)9H;[H>^:^1!!4XZ_M=1J"0,
M#J!1#Q".(4\G& X@4S<<MA(U>RH'9..+1Q_["3,I/J;Z_CPA.RD0Q<B_5M?E
M+BO]N;Q:7(;,='^'IJ!"8!V8;+VT%#LB!6[KN/<P:G_-:0O< J@@I_5=,]0Y
M(22QAAOLF$?:N*%OBJO]:H=TK6==;M/MKF $1$<1+PVFY]<M@:ZCZ->-LMUT
MC&/L2V&_Q-K>,DV N?UCJ')6G$X,?E>M6G/N9K&IPI=ZOBFO]K:]](@'TP@0
M+!P2@ IW&(01%#5AFF91<FN5\$02YBAA5DG,(0U-$T-(2-H[ICT9'3S]Z=!.
M?BI:;XO&W7X ZBM[$LA'5+P[V"<L=B?ZCRAZ_]Z@I_BI7<1I;5[O,C)I.ZDN
M)%=,SW<I617KWL6$+Y\SSSA66(;1A61.<A;LNW;A1TB!HNZR3S:JM5+6,"5H
M_98=( )@9X"T0"%@L"#GZVCJ;P?B7]<"Z-K?C*!]MBYG@K+W[7E&D#][Y].E
M&'IT0,]+E-0']51YJMU0W[!>[8FRZ!;9&>T?:WDPL(+<."((X%X0;Z'$!)BV
M^?G(RX%/?#SFQGNK(!&*4,2DQM9#+PT#UF,AAKY+JWU4J-^,22?=HGJ+H25+
M[1?.IE82Y(=6K2O.4]6+)?8S\;[,YC[B3(+"O0*HLE64=+(>47UOBW!-'6HN
M=994.RNTL6VUQY#'KWR^:($1J@5BP7DDPDC%*(N0<E(*&,P@._QL_J[./TA?
MNE.C@X+QF!U6O&ZD/9]NZ< =5K]^S$W3,8F[3\)^!;W=99H.?7O$\ R ^RK2
M_4C#S[?+[>)F6=IRN?A1KNL-?VJ]#A6HN1A[\_9P322#D&E%$*8086T(4*I=
M_!(.29MV%JRS&\!"XRA3CA%)$;'2.5M?AX(9(%H0/##-GSGX<%&TSO]T=>]]
M<>Q^C[MIARRQTQW#Q HKK?<8LIQ&.K 2J_(SL!VQZ*:QA7J,0%\]VC*0ME'Y
M]=Z;+W<W]=:<RWIKSGPSORE#ZP@)P[>R^KJMMO/EJMSN;Z#=7T [PX9)8Y4B
MUB+HJ? AOV\A 3F-NH.WGP>*8"M"6H$TT]1PJSQCV'%(A9)*F*'?*&A)\>6N
M:#PO&M?K:_J:._7VWM?'+AK_BU776WP'+J>(+'\21=2-X[_WTDD82TRBE+J-
M-88LK;@125?Q7AJQ#%X8$QC1#!]C-6;UCNLUK\K%S%2AF[X_?LJT%(37UT37
MYTX9P9SCT#$KI00$XK7--$\_T"#'&-(.<.HI4E!);YPDD$B,F> #9K^-'Z$)
M?BNC[X.MS6_:-'937O[Y6_7CWT),=08KZR^:QG:4N#Z)]YDFU%V3\S:+'GY7
M?6M#?/6U>T9_#G]C9@3&S@LI !,">$IA2"2;VJN!\1+'Y'%//I1BX3!UQ@E*
MJ35<2V:<M5HX@+D60]\FV/I2U,[$=>/INKS>J@>3)*U1QZF1HUD?!_Q"J^ZD
MR?D;=3>WJYYU(;U)_\?M?!T:S/+N8WE3K;<S[ID51-87/'/N+2'*VGTMAD""
MJ/VUISZ?:,0D#UR2&E#HD):0-?^%C@@@AWZG]E"U#WX5.\?2&WVR<O'M?TC1
M.J(@6J^<6'BDPRN$Z*K:=&#1.8)GN-%/C12$?&C> W"K*SO?EC.$,?)><&$U
M5!1X! ELFP&'Z>G!PT\G2&DJ!#,U#S&#VGLO'<2,"H;<X(=,#\UAYU7AZIN(
M@E_I]$@4+9X=P^G5D1RQ4N4$QP,17L%&-\&F XV._C^#C#Y*) TCZDO6FHGL
M/9LT<\YZPXB@5B-L,(>\K?[,NZBIX9,&"+0N,$Z$=E9?\^2U)II;HXVV1E@K
M1QM>'!SKG':DBY<P[AA2MZYCD&C)L@Y('BGQVN"DJW#3P4CW$)X;M/33(P8F
M;K5=;._\8EF^N]WMTJ68 ^ ,@BYTH)X3X]F^'2#(XB'RY(,A0-)I#Q%6A%(B
ME&020.T (@9H.C0\=OX4M4/%SJ-X:*2+]#HL!M4G#1()TN2 P^/(7X!"9X'.
M#X/NKE<9*DAJX_]8?EO4<YZK[;OY=3E3@F(EI?1(6.8$!/6.E'W==EBP-  \
M^G#IE="><6RYHDZ&3!T@H!%P''B"QH+ O5-%[54J"%(%BX7!@%IU D*L3/F@
M\%"!DV#H*-94X-#5_2> Z*5#/"3J9YO6(0=IUI<_;</(QE2WJ^WZSE17Y4P8
MB(PQ8< M@VW+I=&X;0):RJ@G/F)M<2$(K8?SRMB0 D$%.-!0AA&^MZ$?'GI#
MX;YM//#QHFB\K-^"W'M:U*ZF<J6GQK&8&4_>3M3II6P^%)U4Z229\N@[%5!E
MBN8)MW*J%(^QS_/?WER%D=7BZ^*RL;S/K5R]R@@%"SF],IK75P6"MG$9AJ,V
M2[]NA4DA)9:>(APL *(1X@PC!1CPGJ.AGR+:-[#@7?'0O8X#HLYBQI)J#!T[
M,2I=PGQ@>D&4DTCJ*^148-0[CB<8RJ-,/(#4U=6Z?E5H]Z^WBU4)9\HKYG@8
M/7CJ%+!>.Z':]H*,]&GP><X"PAIBPB .+9+2D#LP'@(T(2[."$(C#;OV+M5]
M^KHLNXV].ND7RYNAI>O$FH-J^R^*VJ_B_6J,).@904YRIH^ 4V%,KQB>\*6_
M(GW8@F;:,$-9Z(H=ETAJQH1JMU,A2K3NRQ8T\QXC"!UESB.*N=5 66P) @Q[
MAZ48FRVWBY2%Y![*=:=*7M$R4N7SK]59J((2J1(OX'2IDA!#!%52%4FFB@E?
MOE]_KGY=S4)&1(TGAM>/W6-**$%RWS*P0"#J?I53GP\P()9!ZPT']=A! .<Y
ME8YRS"5U8Q.E]JPC4%)$2\3)0'KU@TGM5#U74[LU'DCNI8C!2 ?A)@:1+A&\
MA)#.:B0#I)GC>;_^L*Y^+$*\,P*1$CRP20AN! U9$&W[5PRLC;H<\%4CU@!-
MB*?*$D.M"O]XXS3FPM>'K?W0=XD\'?@D[7+KIU\B4(:4KA]5#E/ K6_CH>61
M*#%\Z:KCQ"#3.8R72--/EV3<?*@VV_GR_UW<[!=/0&@94FJ#G286:L-]VU@4
MLE$/([]B@E-  /648@:HA/5M(-122%1 )Y/0C(R:G7-%\*[36E0W%1.1,YR
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M.'KZ_W3BHI<24===[#:<W:<\[<MV#'G,G(& 226HI=2Z=K=3&%3QZ)VH+QI
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M+^$BP#V69MU62G) NY>""<@>2\FLP'Y6Z+ZX/J'$2[#.(=X$4)TEC"ISI4K
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MFY6*FXZ*%FD:7.CD^<L34(G11S^.4UU?+[;UK6[U^1M3K>I<J%Q=UA;KUS^
MEA1;8;'B5GC0/L?CL*)I3^+TL#/TZMN]:[N)CV/G_N__2R"(_OU=M2T+EH:,
M7M+&(60L5=.0<E+0D5\7>EF@$]#)(>LT()0EDL?O!V53)_[)WL?' M^L]A<T
M?=C->:CM=KWX<KNM=])_KNI\*;A5;_$.O_)F%:!0;NY/\$ J*9*,>P9DR*&<
M1(<Y?*\12WIG:&37!D;A+H+$ X!CETX<&B=<,&DT/0[D?^U/2E\4AV"*?33%
M<3C%MBH>!E2T$9WQ4>><!7*"WF<J^6D _US!/WE2^HQED/#4T^[^K<;;YMF[
M][?;S3;D+,&)F6.(<*4(IC0,K2$ ^K"ZX2FR*O'-ISZF!L;^P;MB4[MW4?P+
M^#, L+B9KXL?M:\7!;T  -3_*S;?Y^OZVH;;[?=JO?AG>?7OQ:I:E<5BLZGW
MUU?KHKJ/+/D9J5X%$M<SC%@6::2_+X9/NV+X^T[[]Q%Z#O7&U FE3B XD\33
M0&JN8)X^/Y5/HY3A?K5ZWB)$E'K(A=2.<TD<I;0]+^&A\TGW^_2Q,\)P/Z1+
M+Y*.@5.HP^R"2GF!.&Z&MN%;1-$%$H=?WF'PWW<_#3\AX2]PNOL67DB.+RB@
M[2]W)F6O<HR?6QBC"-/G%D+I3020)S1Z97JAK[+30&.62)Z97LBC3O1ATJNK
M19V2SI<?YHNK-ZO]=I<C1V;"Z)!Y*F08%YAHHCTX)* *<)QTJK2_N8$1>>]A
M4;^0^--B55SNG$P\:)I!V#A8C:QI&K..Y*R]*X*<>_\NBF.>C7P,]57)3B L
MH][3(%G.@!Z?4,VM52S7/J_+^>9V?7?/TEE()#W"A$FB*!/02R/:$Q#>2J1F
MJ_);<Y _JM5U,!#5RN2NE1W[$K_.N_>I3?#FV^*RVFP+<H%#HL:D:%(Q$C(X
M<<'Y?2;V-?S:?6*8QKDN0L=Q;2B%.W'L(.UQ]C4NM)[J<0)2/<2;!I3Z!%!E
MJTC)-W.TK]<TVU@"YF[6Y?=RM5G\*-\T+SZ\K3;U3??OOWZ>_S;S4""E,&+&
M>R,U4%KM'Q*SP D'$^_KR&I[Z#3KZ*&?:O=>\K'#^_<QDN_VR"M_9/YU1N43
MD[$CT7=[Z![X6NR<+?Y4N_NOAY<V@L^C7Q*2(NBI5&V@HID&(@>+[NDU(P.J
M& O7C^5VOEB55VZ^7H7Q\.;(*UM^75PNMC/+%>04(1<<"'!'3&'0&O9 )O$T
M@[F!$=IZ6)1[%]-HF4//.$".+&4:$P\JMMX5?SK&Y-[!D5]!>UVQ$]#+*/<T
M.)<SH&JPJMEW6\\,,X&0UU@X)HS5%DGG6T., )^R^;C#QX^R!UE=EU>+S=VF
MV<3QY]UX<^]FL]N0_WOSF/7VKN\VG-?5[+J5)JN0_;?#/-G[\F$^_BF(IRHE
M[5&)EG0:/.H3P*M[11*UB.7-SXM5M6ZVHNRVE\RHP(QZA;AG$$-"A8>X-8,T
M25KQ3/[P@3.C1]N_%GNW$A.D=,GBD#*H6@, Y87-=.,2YK%H)_C26=]IT*6[
M^U6F>G:.#<HS1P#TSCH,@.+$ 2F /& /:M@O^QG$I5$RICSIT#!%TC6%.GMI
M]*=DCUW(YT[-NJ@_^);CZ.*=!J3'#GJ0+<:)FN=Z5&^FI%36.XPD4CI8-5;8
MUJQTRG8\9=O-V"@0/SIZNWMWH0/4^\L:A^M1%4T#\?-/YTWKO;P3I,RF[#08
MF"^<Q'?Q$G6*3F0OOY=7M\OR_==/Y;?ZB-_'LKE5J ;FUVI]W5S0H>_V/_Q<
M_K;5RWH#B[8"*%!?BZ<,$$X#YK$E*J38'ECJ=-*1NHX^8*&IU!Q8+QQU5BC"
M%3 28(>$MF3H8\2MV_5RX?U]0OOEQ/!GNRB:O&CO>N)8?+"RB4QA)U LB3GK
M48GLW2H.3A='7E\47^X.O_'+YZ:,Z@"*)H*QS\EUT_E4=CIPR4T#Q8-'^3C_
M'$756'#KV\UB56XVIKK^LE@UMNUB<[FL-K?K\MZXY))8P!WF%E,++>$8-2P(
M_0C4-NGFO$B3B!L)B86*,48=]-)[C)@F5 KCH!UZ'E29__C;FT]O/K]Y_^Y3
M&F]S21J'US.HF4;3UL'BR,/BWL7 S7,1,TZZ$X#,K/TT>)@[J&K0^IIXC.UV
MLPUIU=K44H0Q?6/^XV+SCY_+ZR_E>H:<,X!**B0#WE( 2"!MTR89A$'+I*-L
MK]F2$"%+D?904""5X,!K# WG+/R9'/PXV]Z]XH%_1>U@XI&ROIK&<6Y,.=,
M=T+)XI>==R.#[16M3A ME\K30%FV:!X?-<NJ4NI3SQ_+RW+QHQYL[,U1;8C@
M5#&+%)<<"H[HH8418KH\]OS$B' 2A4Q%0*\HE0I)KU7]%202,9)X#5^/YY[O
M'>OVXG.Z>G%\&D6X-# ]H]F9@/22.*>W'_?3<QH(ZA_&"\\_]]3E->ALUMO9
MS_/_KM8MZS;JM\5F!B%2E&@>V@QVA B+PO!EWUA$(%X,:E[Z:,8LQ<YC!@ E
M!$I*$1204HX@$7#XM[3VO?@OM3<OMX\L*IU&R@@"=<QP7M$FAATAN"-NA.\>
M,^/YZ)\A14^9SLN'OLY76:I*/ O>S:_+]U\?F++5]7RQFG'H.1<AMU$60<XY
MAE2TE=U1%)5]G+80#)@ZC[)<8RHQ$1A[;911SACC/1B-##M_$MC00[77$3&.
M8%U)\9I6V5CQH@PO(*._;.<G1X88JIP5*8XCP<S5CE:?%JMOR_+#_.[>XCZ+
M,8*Y8(!B!3RTO/X.'[I.C:(2C!@[E"'#0F+DF.)4.*@ H@1BCC#"#CDY]*)?
MXUC1>!:'DRSBG8;*V+JEH:5QK#@6KKBGS6NCFOQ27E67M_4"33/VGXRD#[P:
M1]I'(*\CKC$M@<2@@72$!L^@.J=RYP5VUDBJ_/4J]2:X1W->;Q>K\LVVO Y9
M)\ (.FXX(-X[#!1@JFTSP+ND^Y%/F.%$(*V<Q9Y32H 5&'#' ,90 V/<T.]J
M/3?+6SM7--Z-/=/[HDRG)GG[:SN-R94<@3RY12R3-IW;TX=R7?_!_%L)9\+6
M8P%H!8-<*JF XN@P2C ,S'Z4ZR]5YS9U;,H9K36#D!(;:"&AXEPRJ2$7  (@
M4$JK.O:J8[M:U^WJ3S<[!T<^07Q*IY1FU47>B3:L3J&\UK2ZZQ,UTKC_^/=?
M/P2CS5:;=M)T<WP]H'5>2D"10A1KCGUHYX=D#U,6=?=!HDFE,0%A0&6YHQ1H
M*T.JZ1"10GA% !UZ3N/>T7J3V\W.U6)][VOZ%:.Y-8\8JYQ'[K1ARY'2[[\6
M>R^/5F0V4;>0#JITPE#F/(IW&]4DU?$_]QS?1 OSTE GO[(3&/4,$%0U:&U,
MZ%Z>+L3MCP_9<KWX45[Y(,7/Y=7B<KXN9T*(T)DQK*'SQBNN,0-M&PP#-!#=
MPR1998 YK:S0&E&J0W<*)-"",H+#,!"@H7>V']:?[]M<<;5SLZ@K2M$ZFH"]
MO*I']#%G$[SW6O_%X7#EWM7"3T+TA.[F;.)WZW$R%D)<KY.BSTL=SR :3Z#O
M&2:N:NC:F= #_76Q">J&CU^::KDL+YMQU7Q;/K#K'5>AV@"I0F,TDEC,[6%2
MSG$6W?-$67,.A.9/-8)24>F5P%A+AP"6G$G+AIZ;N_>QN#PX68019]FYP\DC
M<D1',[J^:1W,D;3W_A6U@YV[E3S2)G0GHTO<K1N)K<5]QRPQ<KS4:V25<@*]
M1=YXJJ$J74+O\+'\4:YN2W7UW[>;YM7-SU5K;O^C&4)&>1#,.DVU5IYK<MBG
MIIB*7VR/L$65".,M R4CC'I -+#<&\BYE)A00@;N&?9N%/.#B_4M(ZV38832
M_#@!7CGDC>@51E8VK4]H1;WWKOA\).K'LXB:T!^,+&ZWWL"6F\OUXJ;I ZJO
MQ?9[6=RLJQ^+3?B#3?AV7L]I7=U>ELV/YM=U2EK_XN.Z78_"JV^K^CFJ^MAR
M_<O!E\7VKF\W\KJ*+W4B&?6?0!>2,YIJF%J:TGV$+NK]UX_E_]R6FZVOUBK4
ME<O%37V[ZX?Y7>W&I]LOUXMM^#[\],UJL5W,E^YFL:FNPM\S3:=&@%<.,F*)
M0\(*@NZ;JH=2QG<O_7WQ8<QE*"6HWIH-)-0 $NL@91QRI)49NONID[?0*->[
M&(JOU;J8WT=1W.S"*#9M',UOU&UTL8NF*'?A- ^.I*798Y1D3$\VK4),[.GJ
M\GM?7\:Q*[_@87$40+&/H#B$T/S&/HAB'T7] 69Z99?284ZK#/MWJ/7-7O-%
M?7WUKF-]L&048EQ</VB>36^[V+3-./QDOFW^XF8[7V_;MKEOW2\UW=[];>]"
M>+$_'J]XI]!?CQAM=9Y&-%A_'[[>U+^ZVNX=V^P]J_<H,8V8 TA(QXC"Z'[?
M+(I[\#"G/XPY;*BUUF%+.<;2$H:U )1I):T:>@FL6[^_.433LF,S>+_?O42S
M]_VC%.88_?]](&T*L!D\!^A>CH/E :.4Y[1S@;M3;7K<A."ETLB3%/0NZ]]=
M8M _XN[)02:U(P]N_;:XOKVV\[O-YVKGA%^LYDN]6"[KN>Q/=;5__W7OR$PI
MI##GUFJ.C0%<4&!:W!A'HFX,ZV*70!<:![&TWM?C+%> &T68L(1  LW0#TOM
MO2VN@KOU#/.N8R^^UAX77X++NR6<!YS8\R#I\%+>LHCHPL]8#&E==5L"M:?U
M=/3.UZ)QMJB]W:U7-O[6O;$[N_I)1\G.5@K9.]C5;7U,J6X 36-YVBZ:*>K]
MV'FQ*G[]OKC\WOSA46NZO@W9V)?R*($^6M;IV[&FJ?U2!SI0F4V@HQPJLFKX
M&I^QX[.A<S[58?_G?%,_X#V#2@H24F^IG$8>>6^Y/QSF04IDZQ%C'6*<,^QA
MT$L9"C26W&,L;&@$GA(SI:[RJAY^U5^\-H[^=;X)7R^N,M(\6_%FZ&3/4;*#
M]+YU(*\.ID,TQ8>)%F;&/OL<A3I:9Y[4<G?[Q,,?3K*WCRRGKFE [FKP.\@/
MLH><DC@,HW?T@PF/[OY^[@Y<9@-L%-708A4&\9PY;?87\ M*/$EZ'"'"'I&2
M"NV%51Q1IJ0R'#LK"0*.U+OZ!\X'/KF__.S>?2[>O//O/_ZLZINW$Q\ZR*'I
MZ5[Z7'*F=<)/'RV8Q'W;$:(] \\A))_&*>NL$3U^92"[6@,]!5,?FY@A2XW&
M",N0;QFJ%63>.2^]#.,V8W#2#;9#V!^:?#T>'(F\\VC0THEDYID+)I&A@Y3)
M%%Y^J3T\Q=D!BVDBW!TRPGZOO710,_KZ\.7R?1A.K=M'I.ZOYT<<4\>--<HA
M@K4!>V/,8)7TLDM'$P/3M7$I\;+PCEK%@7 $F=)8UWAS>%WL7'>$/ZO*"5#U
ME'$:+.H;Q./;P7-HTG4,>T2TMX=;LPB@5G!GN%'&,26HP[HU+86S?0:QG0P.
MG<N=RA7B;HH;4.QNH]O!=>X[O$V6>)3Q[7.R)0QP>ZD^#;KE#>F5(6X&O6+)
M]]=ROMQ^KW?:O%]_FZ\6_]S=:;8[C?.NW!ZNH_E4KG\L+MMS.A\.Y[9FBGM.
MM<,<*\TYLTYYV?H%#70I6!S>FX&9&7PL-CO?TDYBCE@><>2<5E&D877G>[,[
MM3CV_J(]R%G4Y53=7V*VC^'PX_LHQN5N;]%/0'F\ IT&L4>,MSI7TTF]H'43
M;/^EJJZ:%[5WQC>?JN75S(6QN5;!AC'$.,LY!H>TVG*?]EQ@=S,#T[GVK&[V
M>T)?%.5OE\O;^EJUXJJ\69>7BUWB5;\J/[^N^^)=T24^(]A#YC@VCZ1P&G1;
M<1NW&@E;QXK:L[$OOGU)H1.$S"#K--"7(Y G5]YFTB865G\I5^5ZO@S&U-7U
M8K78--?M_BC=;S?E:E/.*% 2.>BM,8YZZSD4K56.*(BZ#2J7K8&QM7=OAZ4'
M#@: -1Z^G*8,HVT<IL:4-8U5QXH^]*W8.S<NKEY1Z@2S<FD\#7!EBZ8:IB:F
M(<P>Y12UZ:.,8D8U14QCI)GRW,/P+]):%,ZII!TQ?>P,C"Z;+ZWJI68<L,82
M,@U6QUY=%.&[97F0\]C%B^)=M;I95U>WER?5'81@)Z0[0:\<@D^#7%DBJ?)7
MQX33 9_*R]OU(@Q,-V8YWVQ44XO>SG_=W"ZVFW*[79;U).7,"4L@E1!H*+1A
MT&,)]Y:EUC2*7#GM#;X*TGI9-&X6.S^+O:/%O:<7Q:K<)NSPSJ7W:;:=2^K4
MA9!8E<\@<,(.^3,(W6T#O/D^7W^KYZB7\_WF\PQ%$+<[/4ZC9WJ-(12>P-[R
MW!%5P]7']/G&>K9@GV5O9HPQY"R0D!*GK=54 -R:\9Y$W=+9^<.'WIMS4]9C
MBM6WCF/R=+'BYPH'TRE]AG W,^A>DVBP2<%C*5Z9"NRDVC2RT>[N/S/MUT.'
M6%(<&L^;U65U7;ZM-IN9Y0H9Q+PD7ACJ-'1*M):4TG2VK;;S91PLNGQ^$B\.
MKG3@Q:+Q*8T6G02+ \;06J4QXUZFG3O%GVJ'1GY&[QE)3K"CCX#3P$>O"*I\
MU2D-(F_+S:8LWY;S37ETO'.W$=D3()C%$G/CB-!"(8T!\1!#+*V->SLBAYV!
MDY"=:Q=%XUP]5W1_RK73&8M>DL;A9BPUT[#30\A!"'1"I1,DRJ'M-(B4)9(J
M?\U+)52PI=;K4-.:<=?G\+?5;XN054F(&!&PWMD,/0 TX#&80QX!Z0Q*VEK<
MV<C@; I^%4>.712U:\4OM7/)7.HJ9"R41M PE4B=Y!N(1L_+<Q)%/16="H?Z
MAO$$0EETZ4,@6UW/%ZL9IT11;JP4E&!"J.><!H,A-0N#/>625B1[F#D7A7;N
M9>!0K)S=232 DIE8])J(H]%HYT@BCQ)UG2Z14@.)8%(G;:*6'?VR++>-R?:,
MEPP?ARAA@DE,,2+861&,8$TM!6&L&+W"F/[1 ].G<6@WJ(@XG)A%JXC5P6%E
M2D/+&11*6-X;5JEN*WEIBL4MT3V)\Z75N.Z"3&#AK8?S599*$4?)S7K;7@%U
M^'Q@,/7"(&89%F%T:NU^=*J(-U'W+Z9_ZL!L;._;2VOT'<0Y3<1A=4F#8;0D
M,7E5".PHIPK?/<ZGGD3^3*/OKLYYVWL/OZN^]2+'+/;;PS%0@95T3"+.56 +
M%0P2O;>JK;9)%PSUM77&V>RW74^?]]:WS[3V,-+FF]J.477$^>VW$6?-<PD]
ME=%<IFBBYKJ[JI3&LL,*8&/^<[F^?O_55*OM>GZYG052 J:,HAAK**$+]:.%
MJ,:41[VLF-'<2$2[7]7>M\+:S?KP7.MH%Z;UTSD%:Z-)W(ULW=4=D&VG-'L5
M;UD$GQ+A\@3T+.0R:I7&N?I.WB#!,V;A3'MND0..,&,LY\ )"5J[%/JH$5L^
M:R-1;N]B3L;UTC@%<6/)VXUP794=D&\G!'L5;SG$GA+=LL3S+-SR*=4GA_M8
MKLI?Y\O:@9G&F$NFB-52<N6U !*U5@F%'<:CW6V=*WO;^]BTP_Z96Y*ZW=.V
MH83-E+-%:3I:OG8D5F*RUD7F*;$L0S01:5IWE?IP[/UNQU=5FPU@W98SQX57
M5%A /<5$,DXQW-LV*/&A@CP6S\6TG:?UP;"#K_W1UD'P[H ;5NM,F$N1>33:
M/5$ND7G=E9\N^7K$%,&_OHK%4E#/-XO-^Z_J\K*Z7=76/U3+Q>7=[O_OWU.P
MP&NIB%2>.>4=M\X2)!5%GG!L1-*=CI$FD= <* ,5X8AJ+R5SV$G@,80.*.L'
MYF#C97,E8/BE=@T^#7BYM(TCWAED34/>0=%[%R^*G7O%+_M_G^T!ESCU3F O
ML_S3X%[NH*I!JVP:^=Z5OQX97E>K\.5EL[UM\[P;P".H#1$86VF=, I!LV^G
M0GM$4QB8;-Q2Q:%FAC'#J4-&^5"1H?;.6,R$&/JA@8]E_6#\4<LM'CJ=!L;\
MTL<A\JRJI\$RN/JRVM/!9JJB)P Z6.%, Z7#A5>-5,G3\/JWD,-^=9OMXCHD
MKYN9\)XAS)5@QA@1*$XI;ELP 2SIIH?''VT\,QA[QBVC7N/PV9@S214(_T-V
MZ"7<X$V=U!S\24-AJDQQH!M0H32,/19G.N1Z*-$)+G74<AK4Z>I\E:4^I=X.
ML]J$2G'5C+0>0XI2Q004D 0X<0XL< BT#0-H'W4$(,H04IQ8AAFT/@3#E5)4
M,LRIM31 48*!:?)AO5A=+FZ6Y6:_?G?O:>KU,7W4C,/,:$*F0>>!6],ASBFU
M3O GB\C3H%&>4)[<2)--GUA2N?^Y76SOU.JJO@WGYW+[O;IZL_I1;K9'6=;,
M8&*T)Y+:D%YY"(P_3.L(1RQ,(5:4062@8489ZK$*/*8:(B*!)H(:23@;>I/'
MD4-II,JC9ARQ1A<RC5P[]YH;L9K;\W<>%D<N3@=G,5*>P%K6DI@&WO*&5 U8
M<]-PMW^.Y&-Y67U;+9[#K""*4D0X"H8";$48JQSR"4=%TG45KULCUCBKJ-$4
M,XJ $  +!)PR!F*.Z?!S8;LW@8X\3 ->!CWC:#>NE&FH>T;%Z;#M5>%.@"V?
MZ-.@6L9XJJ&J9QK//J_G5V4@:?.<Z'ZN;%//<"]^U'?]M!F'H0AZ1"44U#$"
M&*&V;8-($9#"M#B+VB"I@:!:0$8#OJ4#U!N A(>:"CGTSH_V[;/6O^+>P32^
M9=(WCG'C2YO&N<:_)J/;/47\C+K3X5Z4F"?8E[<PIL&_S#%50U;?A%LV;/EE
M^V:SN:UW#S>7NCZ_.*"9E( ")U!HK!(:AQ';MU*) ([:^)%BCS+I"%5( ,FH
MP$+5:Q!$2Z*%A'SP.\EJ+XO6S68,%CF8S:KI:?*=2\XT[CVC9!?,#2=RPBT?
M9Q"[V]4?=K&Y7%:;VW6SZC*_7S^^V2G^M5H75W7!+-J"N:S#^7//VT'B]'FF
MWQA"W0G<(Y([HFJXNIB6.?OY8OWW^?*V?/]U=_!D,5^^66VVZ]OC60BNH046
M$PRE151QCK%KFQ[V/NENW3B+P19AF&A$G*<VQ.Z-#:-F!(V2A)*AGQ&MG2P:
M+^MF=_"S.'(T+8/.I'-<!CV^Q&D]282ZT\F@H\0\D4'G+8QI9-"98ZJ&K+Z)
M"T'S]2ITKYL/Y?K3]_FZ?$QA[%6@<'UU<) -22N%;>?Q9!CD)LV+OF8K-'F-
M!40>&4^14Q(1PXQ60'%A[.#[I?^S7'S[O@WI@?I1KN??RJ)Q<E.\O]UNMF'X
M&UQ/7!;JJVWDBM"(LB8N!NT]*X)K.S6G@[E75#NU[I-)[VF@+5LTCU=[LJH4
M?1CD=K-8E9N-J:Z_U(=.ZJ?G]_Q4#EIF:!A-.<$,J?\1=6L+J:1R(&TV](09
MC;R@6GHA/*7>:L&9-EPXZ#2R0 R]EZ_UK#AV+?'01P\-XX@UDGQIL'I6N<G@
MZF7)3I J@\[3@%2.0!Z?W,BE32R:/BV^K19?%Y?SU?;1<9%%N3G:RPQ!LR\$
M:\*-UCQD>\P2!3$6M-Z<F(*I2)/(6\:T1U@02EE(*AE!"E!KG BQ(S<PLC[]
M[>>?U<?_*M[[XM.;O[Q[X]\8]>YSH8QY_[=WG]^\^TOQX?W;-^:-^Y3&L5R"
MQS'M#%JG\>W(P0?G,O8N%K^<C6UQTIW@7&;MI\&\W$%5@];7Q%FXQ6JQ+=\N
M?I17;U9A;/5M\659JLVFW&[TW<_S_Z[6N[<]ZU<C*";(>XL504 @)S7V#F#B
M@:+0")>4M^6T._2,7./J3XVOQ;VSQ<[;XLM=T?B[?]BVRXLS60LA<J+N3/HG
M3M?EE'Z8.;IX'4_-U U0&M-@YR"1/9ZU&TR]#!2]M_]N?MV^=$&QLM("!!#1
M2 6$0VY;+Y!+&P'GMGU6FEX\:-"UUQT?S\E>(KVQ.GAAY$1KEW(8FZ_/"=J-
ML;V*9O*<[1==/&LSJ)BTZ[*VTCZ*854-<^Z14$(*J)A%=&\&,95V)#CYPP<F
MYF[77^-0XOL5W>6*H]V@2J7A+$FDX?8['HGQVM;&+KI-@S7=W7]NPV)W':)O
M9ZGJUZ%ORFVIOJW+W?4%>X. *:2Y9M0Q(;GQ6!E[,,AD$C=ZF!F8(/>>%?>N
M=61)'S'CJ#*2CFE\Z2CA,!>EO"C0">9D4'4:],D1R.-K3G)I$_/:UJ?M?-N8
M^$M9?5O/;[XO+N?+9FR*.,&..J\-@M!9C2GTK2T;8!C[\E9W"P-SZ-B?I(FR
MGKJ=YLYXDJ4A)T6M;&]TO2C$,VC)(]SYW^[*$$.5LRHEL*3\]MC2?MSE#" T
M_,<Z[0&4MGXVK+6%5-S-Z?TLC,J2I#FBGLI%T&04T?K0),=<3AQ/7I+B)9[T
MEFX"/.D?0Y6S,D7R9'NSGGU^-^,"&@^D9( 8P2P+'Z3:3P5<\"AR1'[6T#,G
MY6K5W(><^NYGK!2OH&  %1)G1=R[=^[3)^=2&OJF;>F;\O+/WZH?_U;'L6OI
M]5=/6ODNRN?:<V+\9VZYJ=Y6W4HYX5RE^;Y>;+:+^<K,U^5\^]?JNMP/2ZBR
M&#@ PGB$$(L-<X3MC1''B8X^2MG=Q,!M]^!847M6S+=%[5O"V;X>XIUNUB/J
MEM;:GY>LRT/G/;1+. HYCH;=3C]VU3+ND..+D3]#T4Q23> H8X8@JJS5)P'%
M;K[9'M*)#P%GU6J^K U_*M<_%I?W,]B6&\ ="=#'G DEF,>M:8MMU%M\60T.
MC.G:S>(^SVH=W;6:UM4$\F33.8+AYY XC>A1ZG8!?#:9$W!_#KF[P3^3['%]
M0:0L+_4,N56=0#^1/:1JP%J8T(=\K#;EQ^KR'W\MY\OM]\M@<V_+84BM]TR&
MCLIYI032[<0@,99%#;G[61BXEVC]*NX=ZT*M[@)&] :C:)>&_[/+ED#W4>3K
MAO-.,L;!^Z6H7Z)U;Y4F@.?^,50YZTW:7I /\[MF>?=SI2[_YW:Q+MO39^7F
M+^MJLYEQR)AF%D'K- %>6.I;LU0+F73JJ[>Q@;'<^E>_$#C?>5A\V;N8MBND
MOZRG"7T61=-@?2SFWKGBWKN+HO%OW(TBKZEU8KM(-J&GL6DD7SC50!4R\7V+
M^>;[WN"5#]$V7V^:>T]G%&-+,*"2 <8,9(+8@T6/TMY7[&-GZ GBX%K;T*Z*
MNLB+(^\2'[CH(V<<N<92,G'*N)N(P[QI\;)")T"50]=I,"I+)(\?M,BF3O1F
MV]LZ>WO_]9Z#K?T9XX@!I"FS0A,FA;.J72&C0"N<M-FVNYF!N70D\46Q:MRL
M[QIK1AWUPX?A$]MDZRIQZVT/:>,@-9*J:8QZ=]#PWJT#LT;>>?NB/B<(E4'4
M:0 J1R"/=][FTB863P<8OGR.J;U];'_YV-\VY=?;Y=O%UW(F&?-86HN4U0@3
M83%NB<F@,TD &]21@1%WN)]MOK^?;7Y=K;>+?S;3,L5-N5Y4B6@;MECBX#>9
M$DG#XR%[VY_H7+YTHK-UOFAOU=NY7]3^CXO1/DJ? .TH!3@-%(\3:G6&!I*P
MGM*.O=?E<AYL;JOM_+=Y[<9\=?5KM?['8O7M<GZSV,Z7,X'K]1LOE'88::R4
M.ZSF,$4-B5YAR6ASK,F]O:OUO%1PMFB\;1Z1V/M;[!U.6%'(J7S$TLR91.\X
M_S=QO1/6=,ZD>[=5GGSZQRW]Q(OSTF+0 /).8'EHB*BJ82ME[YM-0S=8?ELW
M7W[<N=5<IS\35# +K !<&J.XA(ZTIP<98BII,2FCV8%[GN?N[[PHCIPM]MZF
M/(HRA/IQXX(S"9_6^^32?*PK4U]0\$1V/T Q3".7'R*PUZ]8S:-=+#/?WY2U
MK=6W-_5)Z_)MO3)&/;*N?J_-.4 D1IP)<#\B@%&[GOI\_L 4/+A4+!J?BC\M
M@U?_.F[+>T:7$TVLCXK3:$N](JCRU:G>&<7^(<M_AB'V5<AV%E\7\\,@NQV'
MJ]75V_#'B^5BNR@WX6<A:[XRM^MU^ N[W[Q__&TS<\K5V]^9T592[XTF!K6N
M<\5ISUQD?(?/DL7<AUD<Q]G>2'F8C*O'&T>Q%OM@+XI]N(=9N:.(>R="9Z@T
MG5.H:=>7',G76:K*6/E;]N)+R_S.5WNFT<]-2Y+7L\USEU?4?')'O^>O^OUA
M7=[,%U?NMYMRM2EG2@I  ,82.,((0I8==K9RY%'4K,"D'/YC],3[H(M]U G3
MLU,IAYBY]*GX^KOOC?\ U25A*6 J/@^_CJ"NZR<8FC=OFY6#H^6$T#EO%E?E
M?D*M*?W%JIA?_6B>OZT?Q&V>P"VVW^?;XF9=_0B_7 255M7UXK+X4J[*KXOP
MX_!WOMYNZX=U=ULE0F6:'ZK?-OSM<O?];A-9<17,]WU5=Z3B>VFE8VJU9P++
M)).3I)IP:Q\^B7LV^7P?FN+ZV/^9 Y1@RBV1VAO%0CO#Y. PTG+HU"V3FV=(
MV*([8/5\!UPT43[LA8?O<W-5B^$2LS/4B/[IV/^_*\/P:=<9*L7 R=;\\(M5
M4_3S745I,JUZ9WT9>I3+_=_\4H;/F2^;VM7D9*M=I?EUL?T><J]J519WY7Q=
M_ZS.M5;5^GJ^+*K#>LWEW>6RO"@67XMEM?I6KB>;GL45<^:D+'/=^OVF8KF%
MR)" #5(VYUC%^K"NF^/V[L.R?A5O=>7"[][4>)EY(;B6A#$,&>;(!G]%ZSOG
MIN_CP6?P^/<Y>];&&[ZJ([YH?O,0]/F6LGK4G/'7LL:I-).8/NM87R:_GO5B
M$8ZTH-6_"OWQ5K0R:#+@DE:N$CM'O_SXO$>36WS^/E_]I:JN?ETLES.IG<3*
M>F2YI102)43[P"*'G$<]8C%-SP?NIQ^<&]X-<A8'G^M=[9=U&TP\5S<M!<_0
MPXY;[)/H:9\Y^K>;+@F#Y571QOW[[7%?+=*1>MY\5>N/UP-GU&; GCAW"8Z^
MR^2P1759SC?ENCY[67V]W92[V;&9,LYI:9AFD$""-?&ZO0>9$T2B7K>;FL^_
MS]'R_6;P)NJB";N>S0R![^<RS[2!H&\5&GG+R8BU9Q*=^1^WXIQI\\F(%:C;
MDL@$*]+X>TQ.E](8VTPRU9/?[_+&H*H,M=DD:ZF=8X)E]RLSZ947SA,NL+54
M6"H];QW5P?%SS:)$NO?[3-)40G=ZSK(??Q9E@&*?1';U2HE/?BI$O=0=3J 2
M_/$F-5(%&'#FHE-9G/$XZO$/+B_KK3R;#_.[^C-F1 )!E0%4($N8\Y1SO8]!
M.(SY;%5^J_<$C=_9]?<]"HAR!\3C,,_-Q79CW=$/ RSWP1?[Z,]^7+5/I1J_
M#QVI-DVI>^U7C2;?^[Y:HN.>:<U0L_YX?79&;88_Y9JM!,]UW/7H!\'Q4.:!
M,E?N^F99W96EWI]_F@E/"/2>*.$EP) HQMLK9H0AA,3U^-..X0_5\^]UV&W9
MVBM1M%*<]^!CIAHW\BK&^%5M\FG!'[^.G?>T[?AU;5++'QGKW-E.W$85X8A'
M</-6J3_82LDP&@U\2'>($IU +AJ2Z?5MV9XZWLR( -I0QHTQ4E-KJ ;MW3&"
M4,$FDX"F.OZ'RCKWP;<7;$PG"4BN3F?/+@>I1Y-/*?\X%6@RJ>.0%6GZ^6)T
MA9I"BOBHJ,Z3%W:M+W_X9+"S,.-E@/W*[AR+C;;\6H8HKC[/?SOZX8Q"!;#$
M5DNCM:/8*=*^)"8 (.A\*XP='3Y+FM>?J6VT10CW^#?.MY#8M<*,OWHX9$V9
M4B*77$<FOTKX?,F-M#38L]K\\=8#^PHRX")@EK(ZWQ&DM_6.VX>.0T8\91@;
M82S72$C3.JXYA&>:9>GN\.]U=N5^ZW\3<GK7.Z$R.-MYHV%JRY2ZWC]4-3GW
MZ:)!J\ND9DJZ5)LS'BAZ7#"CGB7J7"O^8/,A&009_ 11S[(ZQ_S'NU",3Z9Q
MWE:K;Y_+];4MOVQG3#D+N06(2(L@Y9YRVL:@-,/GFPKI[_OO-3U[=JJYCORG
M;0B]J&,_WPQ)ABHU_F3)2'5I2LG;?<B=ZM'D9U%>+=*1)E3R5:T_WMQ*1FT&
MG&;)78+GZ.B/TQ(,K<'..6]\2$X,IT+Z@[<AAO-UZ2E>_EX[[TDL8R15A_&[
MX^SU8$H=[Q]BC6+\A8DN=>*/UV-V4F' OK%[J9QEN%MN9QPY[YR " )!%"=>
M'6[TD%PX>*Z+,F)\^WW>DO$N]JF-LQ7Y&0:<F4M[$CW;J8*>?(_V[MEW+\Y=
M]G^\'BPI^B%'=<FE$-MCM7>!MN;M[7JQ^O:A>;EO)K6U3%G-E&'.(6"%;/?$
M26DX3NE^>AD:N"]I?3M<0UU<-=[M7S!,ZQ#Z*1I']]'$3$-UZ];%/7]WGA4?
M3@LY"'!/B72"GEFTG08*\X12#5#WTB"E+B]OKV^;M[-L>1,:Z:+!:?AZ6=9?
M!&:JZVJ]7?RS^?.7GR!P''DB-#<6:.L(, AB2Q3$V. P"DBZ>"Z;4T 1PX%F
MC %.-:?20DD9D(PS!0@=^D[@UK$F52I;K^I7P0[Q%5=' :;1<+RBBR/G)$LM
MC;)'(13',=3;2_=1-&5Y',>T7JC)50@G*#YZ.4^#^..'79VY?:7U)'ZQ6FS+
MMXL?3Z_'/_+\V,.9U98))33""G"K WJT:L$C&4AZ\J6#>8 $H)!2[WF(/\ /
M(0,95HA@@8UQ _<.1\]MS!L_'W8,\R-7TSJ&(4HBK@LX<R&DP7[G[$^-M\^]
M?7+<&:B8PA@$Z.F2GD#W@.4S#4@/&6 U6EU/ ^^']7[__Z=M=?F/#_/U^_6G
M;6W[[_/E;1E&#Y^^S]?EC *H+%;2,&$<@E!+1=LFCASA*;"--!DH0I T@"IB
M*2.P'K'4\RN2$PHH%H.GW^V9H$WMYD5Q,U\7/VH/BS_=;J[J*8AB4SOZKVE\
MS25X'%//H'4:1^]E_K23^</NB>2=ET7C9CU+432.CDO/./%.$#.S^M.@9.Z@
MJD%K;!\:-I8VZG;[O5K7D\,SK"%S#+DPSD4(:RL81H>QKG:R.P6?F&+>286E
MQL2!T/"!XA8#!Y!S@?70#_U\[Q/ZS0^N%7]JL+?IQ;UT:;OP;E!5>W)NYUMQ
M[]PYV?98J&BF=59XBBSK'LQ)AO74J ^[WFPVM\$@Y<P+ 8W'G&MF! ;6MHU+
M.$[Z<FMOQE).K?;>4A'R5&P5AQ89R@URNIXF')M9B\:MC+R*E;,[JP90,@^G
M=HZ=GU$[/Q+YE*CJ=-F4&D@$ESIITX=)[V^WFS#BO5JLOLT\ DP@ JQP 8".
M$>\.BP<*>= 73,>VG,8""("(9Y1JZ+51 EO,, O\17KTC*JZ]RTCHI+4[<ZI
MH83- ZLC[\Y/K"-G$K'51>3ILJM3-!$ ZZY2+,5,=7U=K4Z/1SF#D! *J97$
M*$*8X.8P?O$Z:8(LQAX#*+1@KR7'@EJ')#= .F&Y),R&!C\PS78N9IX:RZ)S
M'-/&ECB-:WMUIS<C%B';"<;E%'T:G,L:435<%>W,NR=C5T"A-) A%X8_2&K+
MM#S,2V/+DW;JG+)3YR>0*2FMY)0A)I$74'H)$=&  3HJWWI/?O52-)EH@XK9
MAV1GGO,Z(5$<M3H+.SE:=8_D94KU5*<SG?8C6$@5YZ'!>&4MY/4&%>C:=N2=
M-[W(M+>AL'*:.U)O@J% >,6!,8R$H)QC&LM1J=1K>JNSBAUI-(" _4ET<99I
MK1>T24%0HIH3Q4]J%*^AIY,JG;%S/.[D6@B*/"<8,^.QUP"QMM40B9(6!D\:
M<@!3+!3D' $:["AB@U'-B,;.(#KT$]@/ =1_!JN?J!U1-)2>.7ATMIFK4RJE
MD*F+N!/%4Z=07F-4=WUB0?5Y7<XWM^N[(Z,S#1$%4G@1/M4@HZ!&9->4;+UF
ME31J>^[SN8 &<0^9DY2&A$&I@%]"A. :$D:'/B?6NK0#4S'?%I?59MN129WT
MBT/1T-*E$>B@V@,&C8N=9Q0Y09L^^DT#,KTBJ/+5IAY(^5S^MM4AIG_,A-"8
M8<ZHA\IZKJ73NFD5T/C0=R<=0WW!A . .:0Q\<%['\A(O"7U'ECL@9)FZ,L,
M/OU5?73%1_?A;Q_-7]4GUX,D";)U@,DPBO7A2?%+[5/1./5_S@B5@S*Q7$F7
M<H)HZ1#$*;ITU206,&_+S:8LF[M/-Q^JY>+R[MXB$0@YPS5B!AM"L?,>[OI>
M2)152;G+*3L,8<FM95(P1Y'U AMH8<C1L.$P#"D'1LU;%_CR*0TPO62+H\Q8
MBJ6A9N?5Q>[NYTWQR\ZSXFS$.:'2">SDT'8:[,D2296_YJ51Z.$ES!\7W[YO
MWW_]VV9W+F<6&I/53@G"I0#$"J:PV#4H@!7A8/:C7'^I8DETVA;40$'K*;7"
M4<*DL@8@AC@E1#'&;$K+.G8KNH'=7Z^^;*Y7__C^;_MSAN,VK),RG6A:>>2=
M1N/*%$LU1 7LT\#:ZW3N]E=1SZA3CBJHG.)6ABX**^';%F85]WU:V!-CSE,(
M!. 2($H)AI((R>L\!B,!($NZ)Z!3$VLOX+ZIS_A5JZ+Z6E2/6MWR7+<\GM8N
MNMUU%GV*#:][,"=;7D^->C:]F?0$H)"WAR&HU91[( QNVYQC1&1I<S.#/ ^1
M(,B H.&3)0WC!H)\&$AXB5G2H+138_M<;>?+R;>O](85K>RD6U1\%'%-*5&5
MV#;4[,"J+\%X_[49%7^OED&O37TWQO9.?=ELU_/+[0QIR^O9?*M"]^5%:%F2
MAM$Q=(AZ06SLP"N/L>&&8 ?_ZH[KV,/_5>Q\+'YIO1QY,!:EW(FFEE?Y:32\
MS#%50];5CHWR<WUGX\PIH#FTVF*B2.@N@5:Z-4(Q2]J'G?C10\]%'QK<+XT_
M+[>J+#HE4BJ_1%UQ])HZPS*G,1X#ES3!)D:11.=?PD47#9*YL*.0J:YOJE7X
M=J-^6VQFA )KG%>"(6\0LTQ@V]I$B*).F.AD:6!J[/OB>Z="MQS<Z@J/;F(F
MLF1P'=/0DBSAL(1Y3IT8X/12=6+\Z1?+2SC*H% LG1Z9LM7U?+&J-TQ#*HS!
M!F*+'<=4\)TM!@PP25N8NUD8F4;%+SN_$G'44;TX# TO7#_\O*[9(/QY5I83
MW.DGXS1XTS.&*F?%ZKQ;^>?R^DNYGF&@+!><8\<LMYXSP45K1P*5=-0^_=,'
MYLKQ9MK..Y!CA8K#R+ :I2'D6)[BEYT[(^/CB1PGT-%=NFE@HX?_+V\?[J1$
M]$7N5U>+>A%JOOPP7UR]69GYS6([7^YM:LJAM-"ZYC)"!J6P!YL"TR1T]+,T
M,$;NG2MJ[WY:K(J]?XF7J_>3,PXPXRF9!IN713P3>DX*=0)#>02>!I(RQ?+X
M4O&,"G7:B[RWQ)%U"B@G  >6*0"D JTEQ+SKO!$Y\O,'QM+#C;4]]B#'RA4'
MH*&52L/.X]W'9T'-,Y*< $P? :>!E5X1G-IPW$F-#L_6O-]^+]?UD&Q=?B]7
MF\6/\LWJLKHN]_:-$DX;;K  5 'L/,&HM8^A_?_:^[+F.'8KS??Y%?GFZPC9
MG=B!?N@(K&U-ZTH*B;9CV@\5)3(EUIBLI&O1O>Q?/\BLRN(B5A'(!+)2$>,(
M7XF+"M_Y#O ='"P'4>\\IFLU]RSH4>GZ%FGQ!&JQP]K[N9FAE ?.CL["=N1,
MZ8-^6\C-9K7XLMVTKR1NZJ;:3[O(<YZI4BAKIZ9-R9F?AM9EL.OX&RU)F0O5
MQ4_59KY85E=VOEHNEM_6^\8PE$@"A8SU_X&62HCW^_9^3B=E5/78GDUD5KP.
M5='!BA.WOKR%*=D(E,7)U@]LG4FL7B;FA#(-9'(:,C34B#II[XH3F/?>Q'JY
M\>;Z7_KV=NF':K7>[)ND0%G!J' 2<$:I=(BZKDE+8=1[3H,:RBPV3[$5';A(
MS1E&99CRC,9BG/X<(?!,*G2*I!-:E(3;:2A2&E/J#'VOYXFA=UX0W_J_KF>8
M(UDV%1:EDH9CI0G'74/4JV*O8T+A'S_>B<(&4]&"ZGLR*(*T,/7)S%><YD12
ME?<$T(&0D&,_\>Q-0U6&&'#L@$]?+L(5Y/GA9Y^UW6R;8C\?=[>\'F?[%_7+
M(C<KE1-&&&*8XTIH7&HG.W#*$#';/7_NS5IM0K5G%& QX^^Y#<%#4<W]EY?5
MFR>7#O9W#L8>D"E8/3F(1W7;5 ;^N$;_(!9GX#Q88'ZH(8: 0-P!*5#)D'.E
M 4AT[1A4FAY:$=W&F,.^^&6Q+'K5]>K!7>!$)2MAD?.4<]<1C"D>V)^XB2A5
M?_S/16<@$U$3E%V95+-=-9+6#L>VJ+R]O;NI[ZMJ5W'>]Z_K^;IJWO^>.:"I
MU(A29KC34BD(NETX"!2(JFZ:!T'F1*G!VXI/_75?8O!/1;4'N__&W1YN<>?_
M96P*E<4IH5G6N?T1FX@U;.\ %SO$Q0[RF]W3&&^*#O;^)$ 'O/AXRC/Y)HBQ
MY+XV'\SFK(F(:EX;7YKM969TH#CO8L-1,.N9D8Y92@21O"2J)$B0;C4,$D%=
M GD>C&%B MVS-&PV#PW2ZE&=DTZMNZGJ*;D>N2Q'3X+C%3N9RR:MV>FL#%/M
MQ*R^IMOSV^KJ9 !Q?EC\=[6J/RRK_]JC6OTZWUQ>SX3Q[5F)?)O8PV >ECP$
M$"V"KA]G;/X,:HU+\,L__Q@Q>\[)_FDYG@CQJ91X_Z)< [IH4!<>=O%?G2RO
MBA;Y^7UR55]NFS7\>;,$-W7?/ $;[*.=(PZ#8O^^S]7.69OKJM@MGC6G!+O)
MS;J8K[LO5G]8%[>-*<VOMVN2S2IE4UK._X/FGU_6MW?SY;W_M6:T_=<KH^U9
MA&V8;>*F* 4JVZC9G^L7 N8(CCMOK!S#P'JT03 \0NZ"]7$D&!N,,>&N>0S/
M2A^HM>F0*,?XT! YM/WSQLC(!":K(_I'RS%]D"Q<[A\QS!TO![ME>, <TSW]
M(N;[;7,>J!TC.Z_\S#'S%;HC@V8JYTTW:B:S,"!LIF4SQ7;-IVKM.^OE9O\6
MNOQMOKIZ7VT^?'7UZFNUV&R;YV  P%P@7&J&D6A27BG4(9P3%W6F-CN8D2+J
MO_URV?QQ<]-*S1\;\5C6RS]]]R9XY5C'7[',[Z7A6SFC.RCYKLZ#!?N%PM:&
M-X6WHG'A(SLFL688S'K/[9ZD#IWT*F(&<R,V@3+PG&0_* @7QP1R8[E!0#!;
MEA*1[A8'+)V*JB>6'\UT]#_']E :AR78*!K=5^FWC'ZR6!#.>]^=I*0^G70T
MR&%OS.Y2!J939 /MSS[<-8JVMK]7J\O%VB<S'",+N-5:&B0$)U8?K@DC 7!D
ME=O4K6?6^P[(PPI:O4.8;G;?D_7AT_G\A">?O^]^98^Y.(">A$ ?Y[3G['R8
M?R8MP"GLBYA_IV RR83[92 6,%5B+7A)C;2(:D /0#BV4;41,C1_+HD=<$H_
M@P\23)KSTQ\IN VJ/WV9>Q1M=9YJN6[3F4*N5O[W=E<5O]P7CW_OX_R^_?9^
MLKRWYLU!B]>%=]K.Z$FH\@GF^\Z3A[EQTKJ<Q,"8F7 *+L/KD_[?[7K3]-[U
M17VDZF"+JNWICP?$I^I?V\5ZL:D^5ZOOB\MJ9\&GZK+^MFP_I8TR,P69!0AA
M#)O2A!908[J38:@D,.JB]]G!9E;]]_7R3Y?S]76[-]9!CRV0>FY_AL6$L^/,
M%T$>F=;L=3ZKVEH\5&U]4QP+-LU"S-[*8F]FMTG^R-"QB[WF]=B)R#.9SC*-
M.#4=.GZH6CL58!&'J-K'0;W'JGWTG2&+ "Z1ME9):S57Q**N$5(*.%M6WYI*
M<B$GI*(_/$B6Q$Z6'N,(G]\^0-JO^L:<J(DG*^0,4QZ6^DW_1Z8GYBQ15IKZ
M'1/:']GR6>KE[B6$7;*Z?L2BSY4NJU53"^W1.2$?%YN!O_YZ7]1?;A;?YKOD
MUO^.U\!E==EF7+\M-M?M4:%F!ZE9^.J2X3]W1\6NJYLVH#XK43S?^(]9;_X\
M]#31<\*/'A3J[9DIG 'J#[Y.TCL'5"EOHX*\]+%CU<23IHS5YKJ^FD$'J<(^
M3X((6$<=,::[1HBP@"A,PI,VF5_8=T-B577W\8ZO-60D-FSV/QZC"2J>'Q;:
M.XQOB@9EL8-YQC+H1X@[,9%.ROLT)L-I33I5.3T-7Z$Z]^MB6:_:&CF[NC>F
MNFS 5,XS8!;KPW':];%".7_95=J9E=9@+@7A5BNMG)%"'^ 1(UB<%HX&*[M>
M/BMVN>B*75X]LB).0<=S69C*3LM7*2N2OBDZ6XI&$8HGUC23RV.53/<6C2O:
MJ?QP0MA'=_4TQ']\L^LS#[&(E8U]C;7;N_GEIO[ZZ3 OK+\>J:QFH-$EE<#A
M$BMG%6",'O9^A<,1"Q_)V\X>#AXP[L\MOA0<(M8"TK,?L))R'MJ'/+ZZP]I0
M_M0!1P3\K Z(6*LYJR/Z+>4D=DC8$DLL3\=68++Q/8$%FGRVU6/TV+,4^A4"
M6L6QML PB*621'?G1+'"MBO>:9>!:<](L&)&^5,+@H?Y_R_RF\MITY@2CVUT
MGB*_<9SW+_+K2BX99M9)(X$U2BC9W2[%M/0Q/U8GHEL8;\@''1V<8.G:4 8G
M,O[ZXW^U=&T<$Z&CXN_5XMNUSY?D]VHU_U;M;OY_^/I#\VJ^7ES.I,]4!<88
M0"<E-1))I$K)A(>&G+%XYC_E2QUZHBNN;>J4$H[84F- A,62 *<XX-Q8JD#<
M*Q6/80:/I YN,=_A+9;/RR34#YB+/Q5?&M@][[PE=DO8DN'Y_!&7/1X<L0=:
M/-2KV.^#/0+[IFCACJMY44R>T,,\'IF&5F:RK1ZC3R?06+.XV6ZZ[?)'0!Z.
M4<DOZ\W*)V0S;@5UUB.2V@!.M!=]N1_>6!L:5+,I&19&D02\A$(@HDKDPQ"G
M6#!J(4(49+]]]O5KM5N@N&HP-^_FKJO+[6JQ653K?T^@L2G=,D!US^21.!WV
MD_M5>R5B?E/\H,E[)7[^#J_IW+;WY#\Z.T9^]6D@Z[&:G<&?$U;Q'-:&Z'HV
MED.5_M&(T.V1N!V4IUEO^SW5G-'97QUZ=+EH/9-4<<2(I<(JP8!2A)9[5:&E
M55&UA1+ @1H@0($!QB""")%6,D.$0QI"PJ7*K/>?GUY_ZS67'L,I85(_,7_T
M5_L=^E"-[^;ESR_,/;)K7/$?[H<3^C^BDZ<1 L8TN#[;@(K8>W]?+__6EKW9
MU;)8[O[\ZW+AFU- 8T$8+@D Q"EJ_/\Z)7%>5H+KKYYJQ!*(%>,66%D2PIPH
M&7#82J& *?V?F47[_?.Z/SX*[_^V;?#UJ;(ZB-. S?.QZ(P^ 57L8'45>9;=
MWUIH8Q$8L?D]%I$]*YMZ0D]US:&W!DY8?VSW.@5A$]BH3F)&G;@C)5D+/Y95
MS 276H-2:^HS"2@-*\UA5@B)5;--[0/3H+7PHVT;90UBRC!C)&&$*B&:O_K4
MQ4BC (F2^ /,;&OA5SL[TJZ&]W?,H/7P47R2=45\;\$$5ER.LQF_*C[8+].8
M3F>S+FQE/!&+P24HEIM%MY3[^;"2:W]OC@U45\U)VN:F\'87YC]\M?/5TH-9
M?ZQ6+4)Y6V^7FYEVU-)FV9Z7"%DBV$-^SC@F42OD:1#Q4A*C$23*2<(Y%'Y:
M!9A /KW0D"*;>0K>&/&G%Y;(>PKP2%X*D^7I.2A.K!_C+QX,*#H+=K<:'MG0
MR'AG15,)8J?I;XJ=)2,7@DA!_@EM']>YTU#\D6U^7K?A#(R'1H=WU7I=51_N
M?(1J[H"_:VY7O%O,ORQN%IO[_6K.VFRK]]7OFXO?JIOOU:_U<G.]GE'GIWE:
M&P&%)IR44%MFL 0(^L26.AL3$'J#@,1 JZ#4SC "(!6:&H8D4=AG*93G?E[Y
M@+AH(?M9>).O%K_,(\4_GQ/"]'X2_,=)_ YR4PSNB0O>% ?<;[IE\+6?CF_]
MA-V#+W;HBQW\<76]+\DGI#R[WZ:AWOG-K$<>#WDT^O]4\]7%;_5,$\4=1MHX
M)J!V$$! .E40,NP%LKYM2VV%@TR TOKYI_\+$7XZRIP3BFFG<K\^]I(BPS*/
M&@?3G5:$<S"=6WL;S%Y[ZVDJ[I[1!$(;ZYN?2U^CK>LIJ_U8S**FOCM6,]=H
M.A/<6J,H,E8S(+L!CK6*JI4<W[I0E/%FV]0XXQ, +$J%@#'2<%9"Q'._4/^B
MHH*,BAI&>09-3<[V.*K:P)ZPKC;P4BEKE(=^0FV-LV^(NO9@,H>^-N\2S@R@
M6FAGD0 *:> ,5ZH;ZY8XETM>V\8) D@I)Z4#?A[GYVL4< V!PHAJA'7NM_U>
M5%>83UW#"$\OKLFY'D5;&]33E=8&72)EC7+/SR>L<>8-T-4>/&:1U<7W:H8
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MSU?PN=1ZO5G[-O>MK&>H9*610#.N$<5"<NIPUXQR ,XVS9,\8?(5_>%14G7
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MDE X 4E/:,P/.R().0HM%[Y=M3=P]8UO7%XVO>[=_+?U=K'9MZHT(P8032S
MB% (I%;[H:0A%U'UPE]K2_K1JA'0G"E.4&E\ADJI0D:76C(&<J]</" L6HC%
M#F.Q!]E'JE(0'*#_(W,;%P F2FM<H? QZ>T7 P;3'%SH^Q4NCD6!A"Q.( RD
MM*;.T]=B L'\:_5M.U]=_7>]K#ZNZF^K^>W;Y:;ZYJ'<-\?F5_-+3_4> (/:
M2.M! *I)*86%M#NTK#DWX:_PQ35K(9=68"B$<00*+"R%""!*N26RY#!W>.C
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MOQ;E336XOTTWIK:H8SO+1S.48$>=UP9!Z*S&4>5=C2D9I^=%HM85KR;!;I5
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MNM^4"1+%J06-5II'*R'=.'+"0ZF$%Y"YK"2U/3Q@:GWIR06X$W+L?"OW6:E
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M^W#W8:7ZO9C52O);NXT@@??66^&0AQ0#+03G6#(&#,( @IRD83WT,':^:N6
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M2W=\ RAWQ:Z+V6U1_1IMXFHP5I,K=74WFHS2LU?IK3?WY;Z8[/2[UZD>M*0
M64(!TXPR1Z0C'#(.(*0L#CW'ZPD/]K''S>MC^?H8U@+01V^R:CA+'OZ%YKD,
M=MBV5VXH&H 6B ).&),I%H((%U$@1#./TWL]6>K8>7O!&X+T^-LH5556[^)N
M>EE4PP3_S::U85O1$&U6EJZA2\/C7X1J;Z45CA#FE ,B*U'#=^#0SH<TXT;M
M57$W&5V/AH_ +S2I;:+?6#AH#3WP7D,+(B4%D4P;A73LON>>Y67I^ [<UTV
M>K3XE^FF_O-^-'Q7?"HF\^)=<35?'*AL(\&.*G&;8MQK+Y6DA"J!I4=<>H4X
M]@0SGN.>AM^!?[HY:+M2,M5PN#"]GNC%Q6S_<?JN:L%'34<91HQ!<07D0B!L
M")<2$4BBYI/U;-%Y>Z!;@/?HE>4Q3\V;U:.+[XI9_/+%N]5WHZT;S,Y*041C
M2@EI.;5Q\$CKM"Y*X%(Z"TQ)CK6!O@/'<I/@'DV+/\M%]N'TE$4T;!9B.) C
M]5L(VGBM*(&22T"=8YHK;Z,FQ0R5A&0]:X2^ _=P:T@?S9[+JKPN'E_C&K\=
M#3Z.QJ/9PX'\.:2-8!@0W$(&XBBHADYJJ1%*^;J,1]#G6+3H.W#BMHCU5P[]
M^R\O8([=_FOQJXV_6;;S KG!\MV_GX?EW2/B$8MI.8XJ63J &XQ3I]_?%L77
M:Q>/?2F^Q(%<%5<_=IA[]>+:CR:Q0Z/!^+)<YO59OFJ_0_&J4SUPX+PGQ"C&
MF;.$&@^-T]HK;)1V]1+VMJ1N3J<1_!KC_+9@<(X8@+CF5BO+H.&2H=6($'9G
M<I>V'2$_URUSD.W,+%ET<JGQUJ;+L_(AVMJ0QMW+"T\@M4((RE=CH]Z>V7VY
M8P6[D1]Y4'9%$S.8WJK)5?K+_?<\6DKC=+>K_I686O4#$DAR@$AZ5=ZAJ%D#
MK5=C%]#E7.KN+8V.EG_9/L*OV3=BA-44^3@5&:;8<T2Y7XY40V1S$C_UT*!I
MEDL- MO9'?"JN!^,KI:G@/NYL[%\-.T]@QQ*SX@GTA/-$%V-C9BL=(0]M&&:
M)4T3B'9ZXO_-\/>=[W]3.$1T)!!&2&2%(H(;95?+J*:8Y>3C[F&P2+,\R8;S
M)*IQ794X:"ZT,BF%:SJ%]A@C+E=C =QV^]9S.1N,7Q$U<I#L;J,I[XMJ]G Y
M'L013ZZ2LG6?3,BX1>[<;[97"YR3:%0J@["-&VC4PT!ZKN)QI"+NL^>HJV2;
M3PTBVMFV$SL\2"[#M^GN[[O1S>WLXOJ/:;% 9-<.M*M>L((JSS%F6F (J+32
MV+5"9K/8TUNE)9L]34+:%7U^+<NKSZ/Q> =35D6"9!A@'0T]H23G!@'"P7($
M<9^U9ZFA9)/B2/2ZDO^;*(O)S2B:8X_CC0N=^[*\;%"#&W6J!VX!$E$OEY8"
MY](3V4BM1DZY[E9]>2V\:0'9KCAEEP+Y,/BR[OL.#FTJ'B#5&$,7=7CEJ1=0
M$;MRD!MHR9DE\6^(,PT@>0)KN=9]BXWE@\2:(XJTPYAZ1!V'8F7D&:G%F65R
M:$I-:0#*;NWEO89RB%:^3O&Y,J40%YH:3]"Z]WDI^0\/@NW(0F[HL.A [#J[
MGK4,6!@5TVB(O9^5P[]NRW&4R#099;.'&N>*=9L(P@ML(8/8<64CBA#X]3:*
MHG)^7K9RJP?4+6%^ M;5/[_>7BE$"+VSC&*7<L1Y;31:K:HV;K\Y:DP/3Q^;
M%_YV=N4AW?4IY.7@H5ZJL\T5 L:&(PMY')FRT%B'+%F-CGMX)L\/-"GF+<>/
M6;AVQ1IW=S\N'XIB><7Z)1P["+2W;C ZHD:!!U*":!@X\O5DQ&*+SNTIF^:Y
MU#3$'2Y&U?Q .FVM$Y2/JS=7A#@,XPINN,(K?Z:U4IW9N78[2U(CT':7,&%R
MDS(LV^+C;!$5=#]*AD[R=5]\'(]N%E*L0:F#V@E,,TZ44,1!F'(*,JM6A_V6
M*GYF3N<6:-8FW*<YY%K'LM>(L]A9,0!++?6*0\^HQDYZ*N5Z^]=97L8>>J9;
M(%>C^)[.R#O(N N((T*4 C0=YSF"&5C[6YQV(N=P]'#?=.O.IC:6I%Q,^[7E
M9>]U06(#!/-:*H\D]#;^O +21>TQQ[SKMTK>DIN@#=1/O-?5.R795S=02K1T
M4D!B@5*.4[1V]CK$30[3^JVUM\.TI@'O]/CM"3KUS^ V5@I"$@.\)DH+:[FW
M6)L5?DXZ<KY:>DNT:@KI$ZA4]72IJ#L8SSU"$&*<TL)+!>!J')"3'"6JAS&M
M77K&#X2VL^M>Y=W=:+9XKBWMR4_O.>^@S(Y:(=TY EI2;(7%BEOAP2HDV.%H
MMIY7C$CK%&H.ZJXH]1*$=5;OR[):B'0VJT8?Y[/D\_]0IF4T#BN"/GZ2^+O6
MQ>TFORA *BE*&848D'$-=Q*MC1VO$<N)5NAAV$KKQ#VI=#J\C/8HU<5H%S<O
M+^:SZ6PP2>/<>4M@5\7@&")<*8(IC?H#!$"OC2!/D<U*&M8_+IZ**B_OM34G
MDRXW\')R*/UVU H04>HA%U([SB5QE-+5.8>'SI]=W$TON-><0#H[M[RZ6@0G
M#<:7@]'5F\G2G_-D(+L.,/=6#L+H"*%"AG&!B2;:@S62"O"<3!,]](GTA(:-
MRZ4K-GY(CRS.JX>O,V@'^UX6#G$]]P@3)HFB3$ OC5B=B7@K4<Z&6]]5(A_9
M-BEN%A$,WP'?LB71893&_&Z^B"Q9N(%2 KBJN"TFT]&G(D)7WA4I4=COQ>SB
M^L/@R^[8C4-:"AX*I!1&S'AOI 9*J^4%1PN<<#FIA'MX&MH37K8KI*Y(^ZZ8
M#4:3XLH-JDE$9_ID5';Q+. NZWI_Y6"Y@IPBY.+HXXQ%3&&P&K4',H>:/73U
M](2:C<OE='ZA@WP[ 3.!D-=8.":,U19)YU>C8@3DG&8<[I]IW3?=$[9ERZ$K
M=OTVFI35 J6M#T%N*QJHP(RFO.&>00P)%1[BU8B0)CD6;P^3]?>$69E2>%W>
M[-:]V,$1 +VS#@.@.'% "B#7LQ+JG+WX\%<&OM_5L0/9]>6N7[TCY8U5@Y)2
M6>\PB@:=C@,V5MC5B*53W:ZX9W7.W 3>7QEVBCS2EPM,;XO9:#@8?]NQ,TLJ
MC8&4&*JXZBA)#6 :<".0%1X)AXFL]7A#Z^X.6T09Q^ZGGL=_CXO%$"97ZBZM
M</]<?+XU0U,]/TC65P2@B.% ,\8 IYI3::&D<2%GG"E :$XBDUZ>E35)K.UN
MCRYETM6.%@$;S8JWHT_%U?-$+D]&_G2$._A[>&,!( $HI-1['M&P(*7RAPPK
M1+"(*WQ.:$PO3]9:9&KKZ)\F@B#N?1?5 KBKA3?\LJC>WT:T:T<2;&L@$* )
MD@9012QE! J) (G:IN2$ HK/[&)@J]QK!?'3\&W1TZF:SVZC+?[/8M/+]/4J
M!A:M)H6EQM%^H99$0\9BX !R+F4T\CG/2?0PUKA#?F4B?4I>O9E.YP=SZK%2
ML)13J[U/.3TIQ59Q:)&AW$3#W'&4X^WMY;%7QWPZ"N53<NF8L+H7-8/36  !
M$/&,4@V]-BI:W)AA%F<1TCFK5"]/K#IFU?%0GR!<[@A=JT;MP !"'G@M.1;4
M.B2Y =()RR5AUHH<);^'8<2M4JQYN$] LP-4K!VU@HJCA$Q):26G##&)O(#2
M2XB(!@QTFTOO;&B5"?/)Z+17L]I2(RBLG.:.) <-!<(K#HR)QHGTZ85*G).;
MLX>/47=+HZ,@/AF%#@X4W[#% QSM6 4Y1]&@]3H:NIQ@S8C&SB"J<SRO/7R5
MNELV'0_T26)N'SM=-^CVL73@ AK$/61.4@J=52I.&T*$X!H21K->$_S>?/?Y
M^'9^[+?&8WIQG9ZS\^/R<R^>D5UWYK"3OA?5 I7(,,.AD40PD.X,4>5<U"Y(
M_ 3)6F=3[8PVO?,6NWM9E9]&$5_]\,<TN=+7J1/4<#;Z]'BBO!^#PQL+EB^>
M@/+&"^X8<9 ZO4*&2YGCW^GWS,\@2=DQZMWY>\KKT2P%5.]T[:P*!005%<@@
MQB6(:Z3& */E*#2,GYX7=]H4\\N7EH[#N+M+9_\UGS[>AO]0OBN&9=Q#%V]6
M?HW)_U VMZZU\74!T90C1%/FL.7&,2@P6R$;]_R<>(4>G@)WR-X>2*NK>5 G
M.F,'K^M4#Q99S*W@C#GK)5/28[$<N4&6Y^2"Z>$J>UKRO'@RIG'Y=!8OG2P/
M/8C0I#M3Q62ZCXN;*P0@.=+&<0B!U=QQ9]A**3*&9EU[Z^$JV2OV-2*1SG3'
M=">OG"P?(]ZE/WY3,$"(I=9*"\P)4((3H_QJ-)YDO1K>PWB87O$K2Q+[>95\
M#HDM46_%8,&5]$EXNG8.)E=O[NX'HRHA4EX?^EIG5GM!*62U8I0B@9VB!A@C
MU_/(9EF^/8R4Z07SNA185PO?KX/1)*%W,7D_&!<7U]\$X]8)P*[70$!1JQ (
M PGBV)60BND5UH9KEO,P1?U G XS(_2"L*W*J#LCY5&TC\!]&'Q9KOBZF!37
M.^^>[ZD9%*(:8</BCB$U0!#ZE!QX,=XX4V5.MHX>AO'TBI'-BJ8K*GY%RD=X
M'R]%_5;,;LLXCD_%$MP=A*Q5/RC"O.06"AE59:^<LG*ER5CN?8Y?LG[HS_>Z
M5+8AHL[<FD]4D_79X.3&E--%UD\[FCZ^D[7+55FSB4"BELT$UD())P5"%M"5
M=\TRDW7FVL- HEY1M"49=<72/ZO1+.H@UQ?7JTT@I?)/42_I\F8:Q0Y^[J\<
M@!92>.,(]=IY+0!V<#UJAW(<CCV,3>H5,QN73E><W+S.VU%";'(UO:CBI'J\
M@;_G39##&@HBW=:'DACB(4.41OMPO8](B;.<XST,?>H565L558<::0K8*6SQ
M^/<3J)9)%VN<3]9O)'C#XSREW'(L@ =<46E7*#B?%V_QK^.<O:II.V(Z'5E7
M+[=&:(O1IY3=Y"":OJP>>-Q$" 2:89<28&!O#5F.W%&INSEN[-!X:H,4>WF7
MC?OI&'=9%?>#T=5*/UFZ':+:O$C0^'CU^R .UFDP0$XY18RYB(2CUB*NU5=T
M4,XQ4?UCR'-G90N2..$VGOK\=1<YG)>;&@@1:6Z0I)9I&BU"0CA;@>T4R+K^
M4_^X\MQYV #RI]^1EV^I'[4=+^L&Y A$B$*'%?*0>V"06XV9 )83HM;#(\J3
M[L3'07Y2FCU['_M0ICVK'K3U'$GA" ?,I5@ YLUZY$+G'.;T\*;_J<B6A_J)
MM].O+^T=R[OMS03JG8' *F>!%$Q@JI5>+_#8Y&RM/3Q,/-W&V@3Z1T?_[!CV
MMX^$;@OWJ=U $,PG18$;P CW"%I*^7)$'GJ4DVFIAPD 6N13J[BWQJ2:X6,'
M-A.B<F"4Y.D%9&"YL%X8MQX=D3EA.#T\MCLUJ_+0[VJWK'^W8L=>6;^10!7V
M#D(FG8A+MHC_1JL[0=[$7W4:,]MZUMX.;ZZT)H,3,_'Q=*:AVZ0[&@LNCISJ
M:*<#KX7G%'J/5ZA0EV6P]O"V0)>W29M#O</;I,.BN%J$ 3U&3;XKTGG@<%;4
MC/:JV4(@F%MOO6,0,)!>Q&!6K>>BS6)=#X_4VB3(RWNH+0C@= 0\)C_V :U$
M]00:(Z*&(CD2$GN;K*<%#A9PG/5<; ^7OY,2L2DA=$;&P</R%%P-8U>KHN82
MN*-:B,J'Q$)%**5BDBF_MK0LH,[DY/WIY6%$EX1K#O>3,>RHU:YV(R'B:=(=
M1.(0(A(ZX1%>H:")SPE@[>53G:=D7U-2.!D7]7PZFA31AG]\JS$!N?S-SKS$
M!S03A-#02J 4$I01Q9BB8(4$Q+B;\XOOA(_-R:%_EG$C%G&0$BF?<NPZ$G41
M;K%6=KU'$)%S!^7PTXQ3^6C:X&)K,C@Q$]?7$)KPT>QH+!B?(G6LPYKB."$1
MEV0]/X50.1D=>GCCODL?37.HG\1$3@D++^X7P=KN2U$-1],]CP;LJ1NH( ZX
M]-B&H5A$?#%866+0(YUS5O)Z_#*-D&*7.=P ]">C6])G:WL UQ4"4A$N!..V
M883S+LYAA5:C0^SYV_1GZF?IA%C'X-VUD?&N6#PR]:'\,/CRYVAVFYY<C+#X
MLCHX"=*Q308'!. F'6\KIA>!%'2-D%<Z)Y_W:W+%M,+);F1R="!"PN'I3:<#
MWAX^J'X@GF$IG%-24,BP4<*N (0$D9R;&:_)X=(DQ]H4P-&$>KH(Z[*JRL^Q
M$],_)E%2'XKJ[FTYV+2$U:T:/")Q6J!H#Z5'%1#4B*]'P6%6THX>QGEV1:+F
MD3^)4G9;5K/4WW3MN*Y>]K1.B-H <<(SKQGFE .EL5N-T2F<8UWV,(KS5*I9
M!N1=T>I=<;_<N"^NZ])J:YV H&-",Z ,E\A9+A!?N7(0XSCGH?)>IG3ID%A-
M@7X*8KTM)S<'\NIIE:"\,A@(PA3!S@HD%66K$7H+<_;"^M&<YT^K#,R[-B:?
MYX.I82P^KQ*((2+.%&2D,H1(R[5=C] J6.L]^>P$*N?)JH8P[YI5T4B-\V%>
M#6^CE7IQ_>21H1K\VEXY$,:](3P9M)A@+U.RM]6H.<59V23JIS\Y;ZHU!O_Q
M!N'FGASF9CBHD4"Q%@YJJ:$4$AK.#%3KK=^BG =:#TA3<E[$:ET,_3O!;.3D
M,DBHH4@9 PF-$PQ1;RE9H> 8R%KE#O?WG^HPO8TUKC4A=$7%1>3)Y"K]E6*B
M/@W&:7)=%M4HY:3Z]G+1#C(>TDS@4C)".$\/*"MGC)9LM>ICKT&.+7KXK?S6
MV=C* 7J+>)^6>2K.IZIZB%-G\3SRP91[5C] @1A$V$0KR0!.&(9V%=Z''9 Y
M/O^#G;7W"_%$/E2S<V%<'MSG134F/'<0Q.7<:&T4$1K2U=B9L3FW"@_VW#Y2
MS4W:U?E.2+3#P.Z*:._G]_?C!2*#\0J1-Y/KLKH;/'T;=0?5:K80M!(> Q?-
M=,2\!< 1LC+7L=!9:1![>#F_%:*U W5W&48>39S+P>CJ]XW7\[>4#$ J'151
MQ; $/LXCJB!WSF'B. <$9SU6W$/J-"WE%TE"<M#M,!_-XRL'Q;0.89X7#@H;
MZ-/9!3<R6D?*:; R7H@D/$=E[V' 6/N<R02X*]JL\]U$$+X&B$^NUO;MF[@L
MUPFS/JRAH)C60%C!-$?40B0 %RLT@-4YJ6=ZF"2DE=VM5<2[4]P7.5(6J4PN
M/HY'-PMI3M\\)F#:%5R]IV8 1#,#!+,4(@,HU-"MXGL)I>[,KKRW1887JGN3
MH'\EV;__\@+OM_&#Q:\V_F;9S@L,DP=Y-'V8_AS7WT?L3>Q?.1Y=)?_X>AY.
M+U8OJ3W)M?_8J>++K)A<1>IUM6>O.U4OC?JF&D$ SP4A5..TC@C)*(4@:B3*
M:\4YJK5[MS/&OQ>#\>PVFG;%174SF"S?%'E7?"HF\V)Q->XR?A+'\KZH/HV&
MQ?(W"W_K=,]+"-EM!ZB<X(!'K!"2<38(S^@2-X>I/[.7@[/94YX6_\XVI7(:
M^_YK65ZEQVZ6G9^^+\<[]Z.ME8(P &(:5U80M3XDF!)</HXRKI56Y9CR/=2M
MFV998\!V19]?BTG<6L;I%>RKN]$DQ4U'L7TJ5MG"]R_S-5L(F"G&#?,JJHH4
M&H$8AZOQ4R;.[&G@IHG5#LI=L2Q"75:Q[\M+'_N?E=Y<(4!LJ-8$0^LY@!I@
M)NUR=%!P>V;.HL9E7K8 <F?.[$,O?VVY1L2$T0I@'R'3 #EG 0.KT1D.<K2H
M'NYO;5.H$9 []1_M062?UVA/]8")\EY8:K5#EDOGG6:KD2,"<^C5PUVN;7JU
M 'E79+-%%-9P]"C$V/4GCU3NX-B.6L%3!@4ECD#%#;:66<57XR3>GMD+]TTK
M4,TAVZ5EEZR()<]W.1>>%PT8<)#BI+DPF!&I!/-D-2+M88Y#\?!;@:T'-;5A
MQ67 V=E^MDID_/7UO5W;U\O2P7JBK0!&:H60(!"GS!*K<6&=<Y#6P[1&3=,D
M']'.0GS+2?EM9^O;]WOK!DOB@DF!,NF^HM!*8+B:'0@0>&;1'TVSJ&E\NSO$
M7Z70?.SU*O1@\>3VXZ.Q.P\']M8.E@*F%,)&0*6C^FB\$JMQ*T%SLG#TT-IO
MD <O#OB;QKKKL*+]QMFSDL%#PB 3UE+,-5:*42'76 G3C9G?Y867%MF3@VRW
M(45I"TXWZC>_9;WG;:O]]8.(8T:"4\(1,U)B!/%J=T<"LIR=KH?6?9N<:A[M
MKJ.0-D-3(^IH<\6@H7. :$(%8LHX)"%=CY9Q>F;F?7O<:A3FDROHQRCF(0Y'
M$JL9XD;'L5%I"5J.$2N?E5"OA]9_>U1J"N'3;(*FG,2.SV/?OX8/Z>*Z3-GO
MUQ&?[DN$*,IV-!E4#XNXJ]KWD#OXUB!@BE*.=K1G226ERHG5610F2.?<8CD\
M]/+5.2CZ(YG.(\N7$U47D^)Z5"N\_-L:06F%*8/08T6ED5@1 -<SG-H< Z*7
M63_:X5XNKAUF38N=V^-!_5HH<$RQ<59H;#&R&@!OUNRGG.8$LQR0J>/5+DQ'
M(]EA3H2OBZ>:/2:33"^*'Y .].BV0M1*L& > AZ!Q-&JCCK%"A-F4%:8R['I
M.CZ\/L=JR[B?A(MU>1:DQMIA:U+NFM@PA?&GY5CB'UE9JX[(LO&ZR7,@F%T1
MPPVJ24I+>EFL<R:/AC5.=';6"\@X 33%GBM)I4Z'X7 ]5I.7YK^'3JZFB=,D
MN"<ETJ$$"@8#I24'D@*$K-(0K^+CX]B\S5IQ^L>;AN1<AST'(ML5:_XLTG/>
MQ97Z%*W)F^+W^=W'HDI)1V._IQ?SV70VF*24[OO8=% [P3B.I-4:>4ZTD9+B
MKTNQ-B1'\^[AMM8.R]I$_%1KEAV-YVE(AV]_SVH&2227 @'%B?"",F#H*AJ,
MR&B^YJQC/?3$M[T!YL%[8CH=3J. G8DZHM' Q#GCG)4$K(P(ZI')2F_7/_8T
M)NUZ+#H0W1-OA<M.OUA7#]\,M[44*,?$"F,]QXQXC[1:1]I32K)27K^"[; I
MMK6+^DFOCB]2VZ;'=:)P'@_:U[_]MI<=WB5_DF+B9??JI*6J4S\@;5/67FV5
M$MX+J+6D'GOH$/6"V%KO:;<\_@_)'55GH(N"P2F@.;3:8I+<Y@QHI5<CHICE
MO$+:PZVE82D_O[F4 VUGE]Y6G7P<=+IC54X6">B^C':Y G?6"X0":YQ7@J$4
M]&"9P'8U5H3HF64;.5;0V_C2 *2=*;7?=M66=X/1KMM'&\L'A3RDPAAL(+;8
M<4P%?QQ;W%^!.3._3D-R?J[.-H!L=_>.UBGQ?RN2(K2#,2_*!@R4Y8)S[)CE
M44%B@HO5F"106:GF^\>63+F^N'>4AV97#%%75Z,DF\$X)8Q[,UEF6MK+EIWU
M@J8<2@NM,TP8QZ 4=CU6@6D.<_IHRC3*G":1[8I%'U(^\'GU4&^EV5 Z<&3C
M=JZ<2-?SF ) *K :%V(^)SJLAR=5S3(F'\_.5IOA<'XW7Z2H6,3V)@2JXK:8
M3$>?EJ%K^U>>NFT$HX33AALL %4 .T\P6F& H<UY\;"'SM^&5Z&64.Z*:>^*
M61Q^<;5R,^VEU>8*@2"%%=38NO@'<DPALK1)X]JK5,X1>@_?9&V60XU VF'8
M_H8XHKVTV54M,*B=Y$QZ!05G3'G,_&JDCJ&<P-,>/KG:+'D:!+9S%\_;R/I%
MP'4=O\ZZ<" "*X \\$HK*X@V5)#5J%B<)^>E-3?MS#D6Q^[8\=SQ&;?1\3P=
M0ERF!"917GG!J<U\00#:2RLMM=P++0T!QJL5>MIV>U6[\X=MCB#1"SZ>0 J=
M<?B X\^71VT82BP\5!(#CKT'%F*Y&I/%6<]S';R^O49F90+:Z4+W9CJ=%U=V
M7B7>+[!>/*_C[N['Y4-1+,I<+A]9O!P/=F;_.Z:]X*%ARF#&N!7>**T17!G
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MS%$+D)!,8&VPLP@JQW-6#72F#L9&D&P]Q*$R@UEQ4U8/>Z,<UB4#=2EKLY+
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M7X:WZ;E!7U:'ZPP9K0:$.$(V);Y7E$J&E!-:&BPXC9LCUCF^]5>@CAY)O>X
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MS MPZRM:DXV9WV9HPCSDX_\]6_S^ARMAN#!6" TZ FH]G2B((%ENF<!\+-$
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M,(/D-$6G%-@2)3- MZE;WIP5ZK>;20TZNA M1]P$))(L: M6"&6M9*&H\>@
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M_M0*X"EI CS:R CB$X(NJ=LTH /P;AG1.:Q]%_Y*\\5/'*YN_?S^?CY;\_J
M7CD^N!)4@C0DI& ,R$AL6G="# BF\  C:;]T'O72.;RMM4RN#Y$MKOHFEXE
M-B_S;_^VF%[O#9T>&%(ICGXF(0JD<* T,5IXXKS42@7\,DIR 0=TW'T&#=,=
MJ)UL.(W)<'!011P#NRXB!C37)K"$:"#.&)J(#[(DH#Z@=DAGWG!*8;W$L=6K
M/[ZY4RN4$'.Y\UU(J&N==P&$U590*CVPV,AV[L%/:'(DO7M %0F1D3DNDI"0
M4+,(W%L 4)TD8HT?]UE78_$><@O:8MG/]_CP>5G_^P$'Q^_/TB#[3R1Y.8\F
M=1#W#:F,,MJ(Y#WZ[>"BU-$+D(Y()WE "5PPD>35E!NEBNP;4R5(%H(D"3B
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MIX]5ZZ*BJ6]!;;4FP*E]L4[#N>>#NUP1#%>PCJC]<[KZ>K2UR4GCJZ2]0ZM
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MO;'ZZVWUUR(MLK$":FP%U"(IM''T]DKXK\G7C:-7#T?O_3-_&R-@WW</FWV
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MSQI6,WT)1;W0KO^=#^\C?^!=GS_S>/I2\_3WQ^E?^8\^;R4SG?M=+YCYT0M
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MX-T)".0PR@#0$L0%76,>/?LP+R$09DEW3((P\<=!(@B_%<9)6I84WIG"W \
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MPA]X%AQHIXZZL%%&]L$P=GLN"6520G/M$9&-A!,,%SY,OCB/VZ:WL0@C.PK
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MMB?<[/PU\)/7IAKCP:_O:'!Y)(>';J+AQ8-Q$K:^GTI_D\]E&4E]+Y*>O>Z
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M\B-L]0@P[1,8'8EW!J@1SB1(V:Y;*AB(W5--[BD_7C-QIPK9=+\=[Q-2YZ#
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MC/;CB=F*A#:HOM('F72 W&ZS.WA4/'^ZGXCH1'2VPPHI5J79E8HTE$,T&#@
M+HR3TD5J? 22__(->H<MR[&CIXE\/S:^HS5"="(Z$9V(3D0GHA/1V4YTONAX
M[L9*$G_Y;EC^9S(9E('"]V6%(@<.KWXM%LMBM"E6=+!.ME^$J;>:X3D-(E(5
MB386C&%.4&==&7>2E/_LSF[\1I#Y/B_N?#S,"[Q^E_UM,!^]*99O/Z79_%,Q
M7J[6J<@:JQ'_SA'M:+"XV"(D-F$=@5'H*J^VFN(U5YI0'KT% 401(U)R07LB
M03GP^S9(;DH(SR)6*ZH)5$,?:AU5@/QL@=-VQ%R%*LMJ3 +A6;+24B<"#R:2
MZ'P"0T6RBA[,!K9@MF>=NT.1HDC1YPQ6TUL;#A@WT9"D?;8D()S642GOJ8Q4
MA_SLHS9M'I*CM=1%]IFO5B=Q=['^'-"\W(PTY/FQIDG0=""D$%((*8040@HA
MU:HRP'%O68B_%_/A>+&U96%V57K+]QQ9V<WRU7XI$J/8;?@5@XZ:F4!,R"^F
M:(RV+AGJM =!I7M,^+5^[>UFU6]NQZC)70J\S[7&WK&.5IA/CI:FJMY9B$H8
MHHWVMIPW[PAC/EG@01L7B'U4E>%QO&Q%64&3OF!([:Y2NYO6MTO-(XC.KJ%S
M+R,D":O&K=K(@ :7LF600*-QEG,=?0 (G(IP]Z#^6GS#ENU10#\3Z7YL=$=C
MA.A$="(Z$9V(3D0GHK.=Z.S0X/XWL^FKX6!QD5%W>55,%^O]"1TL@>T71^9_
M;"4SE8@R@&+2@4Y&Y[<H#\9+GHR#G3C2COYGM5B64=_BP^R>V&Z=V?PXR$&D
MWUKN]T4.$Q?C97%>S'\=#XM- /J^&,Y^F:Y_RSH6;;(D075?U'H21VL-1P?L
MP]%Q[PC+SR< HZ.6<X040NIE/ 1599JU5C9Y*I/C"91,%H3DCH&)FG)A=S95
MO9B'T++$-'H;R&DT$P@IA!1""B&%D$)((:3V3:H>=[OW^6H^+Z:C8EX.?5FW
M&9Y2"6"_?;:2;35Z!^:BEXI280((QYTSP5D:!3%""9^^G#A:K>[Y=0]G<RE3
MT^>ZS@$2#][)8]_]VN6277<XVJ4RW2DCLIL6!-&)Z$1T(CH1G8UYWUQ4!0Y"
M2 +'8V)@ +32UAONB6*.4<H\>Z+W_<ARQ(=Y,5BLYI_KG2R%_CLRON.,1WN$
MZ$1T(CH1G:>-SFZU*Y=.Y7PVF>3/[8VS?YD]S65O-"YG*'Y<=;I[^4'?76R=
MU16U9DX#(T)JH$'I_)BQ0#0(YKG;F<7P>CR=Y8_^?':]I*$8EGYWD>:SR["U
MNHL/LR]OPLT/_'4VR<Y_LSEW2G"L9!=KK4='R".LKYX C(Y:XQ%2""F$%$(*
M(8600D@AI!!2""F$5&L@M6<*!J JGRK'3!)1VV@4)&M,])'+P(" %>#2P5,P
MCRR\WOTA]55@3S*;<PIMSF^*96^<L7-9/+=D,)MG0-]<"[WZO;>83<:CWA_)
M^L]QE13VVV *2E8Y7*J9XM)+PP1$4"9:!U%K&207PH6O!>3=?/9IO/QYMF@V
M"VOZAM<Z6/"I=[FUQKK+];[3(>PS:H"(Z"-"]&F:(T0WHAO1C>A&=".Z$=V(
M;D0WHAO1W98TD-2JVH83P"L(@6H6P4BBP2D!.@I)J .CGI &>F0F^'VQ'(RG
MQ2@.YM.\7(OZ<L"F3Q7FDE !4 &^5@!%JD0PE0:4MU))88!%;C@W*G$9#!%.
MIIUFWOH5H.%:D))UUH*.3P0ZU*+O!I/!=%CT>^?%U7*-CQXG_5X)O&??2IYO
MY6BV^C@I;N_E4];D^I>6[]@%1\/+\Z<F%Z'V:SZLXO'J*$FEA1;2^9"<!<*I
M3C9ZKH-SSM) =V:KKC<'7VSJWQLA.YL.)ZMR%=[-YN7'V>6F@#[("W=? ?TK
MM3S;J&4-^B8)[PM9ZW[CAS!1"\BQS:71 MF+ZMEAN;TU5D Q$J--F=KY14FE
MEMHE83/!(TO9H]GA]GJ<P-O5<K$<3,MKOYNFK3@"ELL^Y*"&*8Y<1ZZWANOH
MNS2M;[+:>NF42RQX3B/SP+(70ZD@1EIK+)<<[CX&NR'?I491?/(YI JE\"6D
ML $J/#6%A4)X.D*H>=6_*"S+4NBE$Q0\E<Z 4/FQ2$H:Y=LLA';4[!D8DHN^
M!H'*B$XB:F-7M/'!W2&:;(^V3MXY&[76 FC*@L@\BTJ!3EY$O1L%MT<<GS&1
M;Y$7/3_W36UD0/M$-5<0^ :^'K5[Y"59AH-"4$J[+*4/*NGV2:W*9O7D1CA0
M((1QU@JJE7+:D.#H3G]$BY34#H>KR]4DOW7T=IG7HWS;O+@HIHOQK\79>@M5
M?<>N8?D!)1(E\G0D4E0226)V/:U6^=MQ ,V-%Y0;(ZWB-AG39F>SL=XS1G5?
ML>::SU 44111%-LFBK+J,:$$-##.E 8 9Y4AG@L7G/-4YU#<M%@4FQ[-0.H\
MGO=(9?'AGKP#ZN-%L7ZCSF\\5$\N;V!*2WLO^X0NM=$Y/.V][!.Z5.1PUR\5
M[W#7+Q7O<-<O%>]PUR\5[W#7+_44[W"K N.#W5_RS"VJ3UF,>W,?PZ),^3PW
M:;9^]-L&-!]GDU'^#6DV[RTOBMZ;\;1X]3J_?K'HQ>FH&.UNY],(C5OJSV>_
M[1=2-X&21S0"-X:;#[/E8'+W.NV]-EW"A#P)M=AL%^BM$^,M=050! X'!SNZ
M:9K^<K$._#7*CNU7X^F+?H?K?G%41"3(MI6\;IQ]46A^0ZT1F"<*S*T^Q!?%
MYKH)\F6%>[L#LW?VC2GV2)83)<M-1]J+XO2F':Z'X$1P;N'BR\Z@%X7H35O2
M A-%IXW)S0 73!"<Y,VWE[/5='F"-_\43GJZ'?87BN%U<8"NBP/J0#?\WN4[
MNO[KAW!PU'W7"G@U%L(ZG0)/*CC#@5MA0S N$!J-A\ H/UC?M?J[J*%9&JCL
M"R;K;)AN%-0XP?A@&TOJO/!C(+FHAI9#T-)(3HV,%&B,-C(>+/&*^B2IV)W]
MLL>0O\S7=@SY@[X2JD]YK?-;D/2=(#UZ,1WV8F0UD]V'F'1@-B9/P7'A? @T
M&$JYHTEK>D@OI@U3_FJ=+H!:B%J(6MAN+=1;YU,X2:4D5.18#AP)-CDMB*=9
M%ID/TK58"ZN>E68&_8'4?:5K'6:%XHCBB.+8ZDE_2I)JWKU4G !Q)GN/J4QP
M9:\1@DJ6EF?Y9'ULL3HV/.D/>%_16B?E/P2K3@_X0RE%*3TZ*7U02=F6DGJA
MO00NI300-'4TRJRLTFOOJ#.DQ4IZO)/^T-U$C42-;+=&;IVNY'Q@@7-O2/#9
MS13&0?0Z>A$3),7:G)=L;M0?P4H-*B(JX@DIXM9Y3)8Y4QX?*9)1P)TS)G')
M&9/9<53R@'/^'J^(#<_YHWU*3MA7[-"INV>+Q:KLQ.O-/N4?R_CM_<<?-:/T
MIUYQ>369?2Z*ZZ>O5O/AQ6!1]*XF@^G=M[C1^7 MD0=EJJ!2*$4,#9%% *69
M(\SI*'5RP49E_)WR4*YW,0JK>2D*^8O,1O\UF*R*>+W8Z_>\NU[J=WFE[SB'
M6Z_/X:Z%Q4K7><9::ST5=$A:RR>C;_G$D] A:N>)"R 9-SX_ 2$PYVB0]NXD
MS2Z?-@UA]Q+JKI/M]5-.MF^H18SU#3%(RJ,@Y5$;O+6=9T^1&X040NH9FJ]X
M=;Y$5,S3"-P&J4%QKWTTWF@N&8'@V-TA5FT^5,M:/M ?0YZB]".D$%((*804
M0@HAA9 ZB=W@]R>A!:'?_>O[.G+.M:Y0.P(IS:ID=# ZD62=X$*#(,I))WST
M.C!JDTBW!_7EOT;?C*+2;#7_[V(^>SLM_G8=4<U?#Y;#BR8ST:I/]4'J2:VU
M#"=;3.\B+T65U+867.+&1Z(IJ.B=%DQH(:QU*D5!]^'E)J/]>&*V(J%-*>\3
MS9#<'25W-PWPTQU%1">BLR5F2%=Y=JJ4" Z,%,X .-#.>24UDXSHR/E>9NB)
M[F'+DNSH:B+?CXWO:(T0G8A.1">B$]&)Z$1TMA.='>R*_\MWP_(_D\F@C!*^
M+^L3.6IX]6NQ6!:C3:FB@U6R_<)+L]4*#X3KY*U.1 -$)C5QVH80(N'>)?.H
M-J[W>7'GXV%>X/6[[&^#^>A-L7S[*<WFGXKQ<K5.1-98B_AW#F='@\7%%ANQ
M!>L(+$)7>;75$B\$<.9U"I90D"PZZS577D4/UJ0D']42_RQBM:.6($U?4XK\
M/ I^=M\&:D*K%"L'&8R-F:'4 2>@&1BRWL8"RC-^]_[Y)FQ@"X9Z(D61H@>B
MZ$,3U339VFZ@% @I/?74>@#J' %N@E;4$.N#A[9RM):BR#Z#U>HD[B[6GP.:
MEYN.ACP_UAP)F@Z$%$(*(8600D@AI-I3 SCNW0KQ]V(^'"^V=BO,KDI7^9Z#
M*KM9N-HO/T(YJ78H.&F4-"[&9,IY.8YZ;Y@--B@"2L;'Q%[KU]YN5OWF=HR:
MW*# ^DK4.96C?=6[4ZXMGQPM156Z2SH1SIWV1FF(VEL18V2,,Z-I].+N(?/W
ME1@>Q\M6U!3TP4;)([7;[  >%<V[U#:"Z.P:.O<T0KHZV5<:FHT.E2(P!UQ(
M'4/(#SF-(0434W.^8<MV)Z"?B70_-KJC,4)T(CH1G8A.1">B$]'93G1V:'?"
MF]GTU7"PN,BHN[PJIHOUYH0.UK_VBR.9KFH,+(A$A$J2!P%$<*TUMSQZRZR,
M3.[T=]G1_ZP6RS+J6WR8W1/;K3.;'P<YB/1;R_V^R&'B8KPLSHOYK^-AL0E
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M&U)[>IH2X-;3C%(&*XBWP4N0@;E@O*8A1AVM59S7ZFFV(E.,OBK2MYWT18N
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MC%S'GJ/BX[(W7BQ6Y4&X&6&+Y>(OZ^=&X\6PG.Z%WN\NU6$K :N$"S(H!IJ
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ML6)^V9M]S+]^O6\"RYQWDG,[ 92(TB'&\C0]H-Y:05.DTGANN??VKHW9=R6
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MM6K0XWEVW:,/][(_CYOM:*S5W'R2C;4[;;H8!IW5@9+'!#OU>2?H7!N-K&2
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MJ'^3+K(]]>^I_S51/[%MIV.]>RI0H>"Q&[)0AER$L1\%+(P(J !RF\+_(<;
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M?G]@$@,BP5U.$^-5KY,_D-MG8Y.^<O.8/(<[\R\ZJ2E81H3?S,:ZXL'$K_J
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MH1,53.)[Q3AAS3_PX54K#.Q5\-6PU3H2/>]724>#M&@%3O7NSY:\Q%]/ZXV
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MV+*;Z<5[MK 3;&%G*)^VB1=QY(5N&-&0!!$+0A#V#+L..JZ0BKED.S)_DZ5
MPMUH2&@O\_?$_;J)NQLRPN'I(951'&,>I!\ D0N',F['(B(NVXI8WV11$&?O
M7*%_4X5!<CS-#E;4!&WC*%\U";-6/K-8A=3QN&]SPAP%)"R]2-FV&S,:Q61I
MA#C"N ;Q:0/AZ"=.Q4@'<9%?A6W/WI.+Q=;C4O?)W;*E3ISM.>A6H,+.2N9W
M+X!?-9'ZK9RE2H4\"E7@>: ^2SM@U"4A]<!V=GV/+*5$;HM(-YK _*P&]9Y&
M]S2Z!1KE;2*'P[E/>2A<RGQ&?8^'H1,YRK7CV/%CMC2E>8N"=&,:,F'/:OON
MB71/I)LG4K<3@0I=.XRY"UJN%S,21T)&C!.I8L]7ON/[SRA(-T:D_D9;U>PL
MC6YQ,OK\J+NU)KL$LS(;IV4)Z'">C?632C-F:=7XEC#DL1,%*O0%8Y'O"^I(
M8A,6$4(!;>/.^!9%A21!&,E8>HR14-C<%K%O.])S') _=XYON?<]KW6Z4@UN
MJPOON^<IK9QI^*"M/GC"TOT#71YR($\Y3_J@53Q@TMB3!I7Q]1(QZJF8>D90
MTO^?659F^F M/&TSD:GS=37N"3,UJAOQ(CV&' >!)N-^:EUGTZ$EVU]/T;.8
M% -$G(&>Q:J?]%&/JK6_R--0_T6^?+*XS7K-6,PGX_!]*+N$G,O?/)[;;0 ?
M-X10@!&'< Z=(]5#P,S!I -SXJ4UF17]85*F93.UU8Q;[0Z$PGJ14L^"'>OH
MIYX'U@YK+4$6FU(AZP+$,R)-5E@@6R>IF4[?Q2"\N82%54-D\1<]'W9^1CT.
MF04N@H/% -7&-SV]LFIT[.*XV6KDV.);NBB,0UDG18;?XCU)!YD/K7_D^> Z
M&XVLRW2<FBG<>A]S])#I:;+YY1A.>]",U$I_]A&_JCE9-2S-F' +U4T+L/\R
M0VF..\RP\ 9HH)INW/ZFH;%BZ-F]8V/O8J@[-D!RF8EO<%J%_B?1=%+:BE%)
M@Q#T3H=QRF0,9,&$ MW4M]W(@5?^+7GRXI\B:^<EJW.XYFR[%1J0RLK^*$<J
MN7.8G0H%E;XO(U^%++!9X H9"Q:[BG"A).]H0X&O1"#B,/3#D$7<E=RFG*,>
MQ.$G&=\IM^Y]SY(V),/__GYT>G1V=')\^M19;@]Y^U,63Q^AO&UO9N3OJ9[9
M-TJGZ3S+,LPXN](3]?1_D:.CL8%? +,J9V8T7SE%KG=Y@WPLPWK11'-._*D:
MK#X!;IZB=#^_P6'856JFOC<M?B"SP^F/9I+V>(ARH?IYDE<<&5[=!_,G@?]>
MIOEED4R&. X0WX5B".>#)_JAP*E_X-!P7,P09P,.TV2$8PR'>3G!-^%+)FE1
MYF.0/7T]Y=VL <3*V3(7GB398%F] 78^3B_S::;9_718Y+-+G%YXI0?1^U]*
M6,_X$C09 ,VX-#8>CO]&Y:8>:V[0KAE[B=M-8$TW9882H8<CP1$*>K3Y=(A&
M:D^?5%)H_C^W'@VYGR@PTVJR.3HJRAV6X+LB-:WSM)_,X/;J<2T4@5!TC;->
M2?7KW.J "O3P>0R-PT9 A9WDN).&( XM(*[IS02-]A%@_O@2TY4Q.QG6I+6*
M)"L!?A=9<:4?!TO*RJD92=F=_VX-@#J+JXI):SJ[>U,(JA(8A5:8]4C[=MT5
MFA?I*,,G%C>+((3%YI6:#0>0#)#9H"Z5(-(CZ.&>GC6;: ",4^LF30"3<'K[
MDB*%P@2I4BM4H(M= 8:;NG K/T=J+JVK7*.<<9?@/45Z"?H^WJ4WTVI<Y6UJ
MWN'#%8HN3R7>UICJR=B*T_-BAM E/0M%,%!_VBJLZ(3"TP8N!) )D>Q^J1C4
MQP]A^,N'3P!ORYPW8$C-O#2_:E@<L+;!_\ [ /*&6G'JYO\%WI;>F+&MR1)U
M7*QK(-6^NS_?ZKQS7-]W4\<CG9JMD+/0"P2VAH_B /2GD'B*NS220> NM92N
MN@>49[DT<*HUE+3\1Y&7"U4B1K$A &>;_+MZQ+_K.SI\3_[,RG]C <J_YX".
M,*] _IL>U=8\X[1F9_7#3M-+O:[V27,W=IR"LW(PYQ%DC4?0NR=KS3]<+I*V
MX$!&\,>"<_#1)]?3LW+A[+5D:'#P.9"!M?V<B.WY@;(=Y85,<B;=B.) D$#8
MPN7+:84AK+5" ^VV[9SHV\4#[]#?&A8<+NF_3QF'O0+ 97#3^72G 1%%KH@B
MZ8:><%CDNJ@;^V E4%\$1 1AQX"(?,>+;"X\J1Q&0H_C&&P_#FQ"E<_CNZ=A
MW_N>]=VIV]/(43QK%!W?H "NM '@^K7:@YK7*/M?[3P#8=^Z)&HMY6'>D4-+
MM8/3IWK *ZB<H*&:2=^@KRR-LFPE&>IE!?Y>>56T3*]N-"J#40@;_1;$T/@R
MU6I.JP7\M03P@VV!.J'1/W%IIG\EO,*,CD?SXS&["KJ3Y"M PHNZ&D\#LI[9
M?#X%(5NO9+"@HC\#G_3=O=#<,:%I@=H$QD$ZKO5A@XD/Q$)4EI=M!J,')ZB?
MC] ^FYM"7ZU;#Z%_=%BD=JRUWJQG=^T1NK!N_>^PJ!\R 9H_. >+_8\#;2Q\
M3D;7R4V)[K1A\5*+7M\?N:DUK/#HR=\B=73ZK].>=70<@@U_K*S3[\'ID3J2
MWXZBTUU;[O')671JG9U89[]$5GARK*+CTTCA7Z<GOQXI>08?XJ-C>1P>R5^M
MTS/XXK?H^&SG]O'Q^SB9#3(@]$^OUDO^YM?0X7 =CK<!9RY]FC/7>5#8[0'Z
MZ-H:Z*U@[SQO+BO(KN^O.KKAY^X+QRAZ1_,N$]ND">FD#JN?CD;5K__UP?Z@
M/_]_]MZ\N6TDOQ]^*R@GFWBJ9*7O8^:IJ>H+.TK9DM?29&M__VQ!)&0Q0Y%<
M@K1&>?5/=P,@P$,W*5$44\G$(@F@T?V]C\_7GU6G_GO%49_UKKR2#'&*;T-O
M!BZN]BH;?^\-RN5ET\FP_J LR8J?7/>ZD\N?!3N$5 I" "54>/?@+W4A3,>K
MUFQ4Y#_7_VCO42QY^3#KGYCAWY,/MW=7E _D_"^_U#]:_ [>_A6ZX[O65Z^*
M\O=:0P?P5LSCO;4\:F,C=\L:L^=@/;YU"(^O7C[F,2S=*<U?[TWFO1]!J+Q0
MK>>6MFO_^R:Z.=\L+$'I'!/4<HX- U1!1%)"_?^'FECN*"$86 ,P>4B*^]LL
MH734RJ&4!25UO%$-NI\;GTZ5+IV9CL<!VS;^\MN,8!<<[*.6@QW^^=:=;,0.
M7P0+>SMA$K8*?7<=@G><QX1VR'(.BMOZ+#<Z%FA;I J638TY@Y0@Q9"QC'*>
M2DV!U0@P"2EBPLRAF#U1I&3WBI3J;%QY-+LM5<"A6*-0V7[Q\-8-MI-8A=(I
MR;6*@3Y3=NP6U$(E5&@C5 B#B'&#E!"4@A1K[44)8J%E6Z92TG4(E95V2CRK
MMF39=5&RVQ.P=L\$&8[\^F_*FC5/:J- (._8$.&-S& *88J=HIR" .BOF 06
M0)8Z0&P+T'\3[DU]+E_[F9<;@ZZKCV8O/O:6R/:(CZ/%6L>]&;(L4F0C4A"7
M%&F5&J EU9R'] -WSDB2&ND=GTV*E.:LRA]'R^3L,AO4Q;^[+5H0.=S/)GI+
MILG)*);\#+Z';H(B3^*C0QE'J ]?C[3915SX4NA0V @=*[GB3+L (NG25&K%
ML7,:0:Q"6(5M+* R.\%X@'$#AA?^],K#VVUQ@]<K;=XNR/WC-#O84G&T(G%X
M%LL4%RK0-BR1WA$*=B7'6H%AP"!S A.L *.4:AE&72B'N91.<+ $@KU.XTF]
M Y%%Z7J32T^EY7WRZ47 /NML_RB[N3W5OQ,QGX_W"9E6H!@98A"P)N7<4LJH
ML@)!XYTUY.4,)?H%<MKM+ZI#^EJ>T6[+'TA7%) _7?XL\]1S2')=;/?3>PX7
M>3(>#_O],MA\->H/;_(\.<\'^<6MHV5W.W1TKV023>L55D0R#;G!'%#)@#0<
M XN1A12E5,%-Y\5;7U3GZ'_MJE/4U2'NN(2":\V4WTNR.R2ZWHB$\@IW/,W?
M14G.?;*'@:9W',A4*:NE)BF@PCD-O?.EG$7,8J:$>D'94YU059BS^P('[$VB
M73:);'Z1CT/KXB3[<]:Z>+.WA5;((X2;U'R QG-"IX!9RJQ53D%!12HT99*)
MC:;FZQ,[R_YL?;G;<@B\3.YL!^73&Q%#B\FV5A/U>S:!2-/LX.4,H8P2R2F!
M"FK)&?*&$*5 4TP4WGP6[7,XF7<C<M:;0-M!R;*K&;4Y_(9]6FU#DJV%!249
M10@[0$U 2 =2$<>P=$0A12SF&VWC>C?BC*!#N@W)M2<)PM?-R.V^_;5"%A[G
MDWE8R?46&FRS57:?Z&H-#;(2"Z*I!(8PFG*M(*"$&R0@QL;9)7BF=8JNXUWO
MY8!HWQ?VIF))=2'O>XP>W2,T.&B$!L6*<8( ,492PIQ4!B 7T N%)#A=FC16
M;VLM#4J<OJ\176^'\=P@/5SKB,%]P?3K^%.W "ENRYBS-PCQ\=!MV'8G\3Z9
MB??@T>O"P=SD4/3M+9=\B7%S#\5GVR"^_%(77 -(6DUO2+[DW5Z$B^][6@MY
MZX,X0:,<H95'=-)!'F#])^/,_SPP4PG!ZXGH4Y@S$0>"?!_GY62'<FK PWZ;
MQ,$.YWD88>&?&&8WQ+$,65)JB[S[*0M#$[[G-6+P\R%V%_"L%P4+:3)Y!!OM
MSXIHJ0"UU"ID#;%A&*P 3*#EB9(U"'G/,VK^N?=CN;'M[]5KJ?*M?B_RBVG_
M<^\BOW7:ZUIESATKTS=?LO\=CDW?WR;>M[[F+)SD<3C(9PNPEFCZ5.2=G[O3
M<1@)\>%7U)02+,W@>>)A1ZK;,*GP!GL\-8!P"*4G%HJTDT(C#ATQTN 44OD^
M2.5X.*AX7,U8?)-$@]=.-.'.7OXU$VGZ-]LW,\28WYJA,P%!.DR=^S,:TOV;
M32.0<]I$YS7%,H4\9=A J@#6J;.2("$LMA8L>ZN_Q0E+@>9.QM^S0>__JBC7
MCWPPS8_SR<E%A?=W6@Y:JK[Y&L:8!((M5I/^W]9,^J\1@J>'RZ-^UP90WAO$
MN1[U"*UQN:U10@YGR?5>X-WG#7[Y=W H%Q?]^-5^C(9)$<9!Q?F?#2AZ'-+D
MS_][A;??&1:3HL3D#V^P:<IG+=, "F!2EW*N-358">S_93  WA71<)GR5P1W
MCYH7^5;.+S#A=7:6Q%<ES==%X3\EW2<-J%B'D7 _V31F J L=9S#T!=(A=,*
M>8))D84L%89J]T("<]VVPJLD / K24Q_JT9H]H?EH)6GBTQRB'989/(FM,V@
ML)(I2JC#E#BK):.68TF"Y+0.K%MD[@*1OYC,' 13]D$B\W!A,/"S!LJVSL/+
MK#3LQ%$SX._NR;(<4(4914103TY4>L^="2$=AY8315N#H3!*N2<]RK3F- 5
MH=1!(Z6R1&AGZ),G.VW0Q@\QE'+V2SRB$D7?_RA.0IS6XR?"K*>2@&Z;O3F;
MN!D$0R6WXL#,UAS%>EQF5)QEM&:1'(J[5:C_AR@'VI0$E4W*D4K>45D<\E@.
M7/KO;- :>2A6CK<YB/,[1W%85%)<A@B5?Z=L<>K-<V=-[(<>W#OT +(/M^>E
MRB=2]*2I!_))5SWMJZ<]:U?>ZUT.CN#;A+*TL3$1:26_SZ+C$S,37Z+L+NL
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MN1,2$_,U#[W93JYY>CMYB&J^D>#ER4++PON%FX&@U9) +6-$"VU"123&3!J
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M0,K^\DO]H\7OX!U?R2==AC;YL/MA2'<0:QC?-Q>HI)[J3>#H3^]]]WO=Y-]
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MX.AJE/7&,4,[ESDNS8-O)[]7@)#/G"IUGPN]8Q.B2U:F3;X6,( I4 (#IVB
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MGL)+"<W[HD,OZB\L;](C^BGWH:.7#QV]V7#1@HVVY#"V@D44*L<E5819117
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MY8".2+BS6P;C.=C.X=9G-Z,\WK3Y,AL47[.;P +E=>MHIN%HK<!?VU=9N$\
M[F7;&Y9MM*E$<,IA:T/0 CC*E%%40VLX-(Q;B]3*B-(C9)OX&WGCLFW?QKML
M?.Z2C4DI:-F8W_(?P_Z/$$DRGAY[DZ0FO);-.1ST;V9-2ANU1>DZ;-&=*#^]
M3Z*UVATM55@J+7@*E)=H4E%K4\ZY9EA2JY?:+S9@K04!5HFTM'?AI59)73/B
M*FGK*3+MSENL8Y "7VL?]-8::#M@A[T+OA;MMBHAO /&;)K2 # @C'98"&H
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M-XVM%7P%5Y9;7@433-CJXWQSRO%E'=.W VRT]V3?":^2E@9E/.5*.IHZ1-.
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MYZ:ZW5[)1;-/SH<_\K1\M]2_6MBUA6!),]I@?7K-[WC\H%%M1\?I3+=]0O=
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MB@363!"NO%].E$(":>. _[%1#KY](MN4F?LX$ML@+&.[Z^T-]:^M&5/EHA>
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MV-[\0 H(6@U.#FE-G9&"6(D%=PYSZ0Q,M?&6)8?+K0KK((V'U'^^<=*0&TQ
ME^-_ J$L^:M%Y;!NT?P=3Q*C>B;E8;+52E4T2'0&2ZFM$*EDBFKD72UG+:&$
M>L[0S"SUO:]9J:Z[=*/Y,AL47\L"R/7IT0W//%V1-7L)!2I:_@MC "/"E*&0
MAKFXFC 'O9WE_RF@W(R4?(@"?14Z>9<Z4\A&9UKK**-46<@E3E.86J]"$:06
M$PL87RLU5,00<VY0?O+R&?L/=I P-JXQ5P5VMT9/1AI>J#!;JM)]S@#P#2OV
MASOK<X.%6#V,:.W>^];-(5R*#RXD(U] I4'0"#$+L5/$$<RM-W"$TS3E0%*
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M/?"_ONR-FM*8Y455J]=M3R)P\:RX]J(W*-M& S-OF%U)TXL,G*4HY0*FJ:$
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M0MU&S)EVI[%K-0[-BOLZN:G"=&5Q32##C5-"XRI0:AFSA *.A7<5 FPW!2+
M=7.1"KZ$L[K0SOYMMO+C67_9"@TA'JTA7H$DR(IQFNML7=_TJ8HF9* (4!BF
MG%J(:>J,8I(PH?UY.D885<\^U3W#SS-\B')O_'R;'+U3GD.UT4JFSC.PT,IY
MIB:,.,,AYV;Q?&/W<-5OJ0;=^=R.*WND5PQ4%G\C8:#R&SA;N#G.K7KJK\N:
MS1)ZQ'-S!3I3>E;SR9P:F^*@*H8)IG-O14M^4>_48@-^*W%WZQ1>ZWFT1*N
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MPBEVJI1^E_EN8#$?TX!:(&B>;OC(P=0 L\4-M@(TQ616<UE,I;/JNW,#0[5
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MO%<"8K0Y-" =YR!G8YB@/;&C9K_,.)!-U^R7XBLP[N+Y0CCSI4.5Z-(N.!7
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M_"7)S3P:K=C>:_H  K',I9")]+5:N\MLR2W**GU(WWZ$8;J#"[(5#W_\4\Q
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M9O8.=]T3J'Q]RM>G?'U=V\%V<\&R!S;J53*'LH&Z+E+FP#)[Q<W00:NF'WO
MGGDR$!K0O22S>W%PRM Z/?&T #<;=;9U'%![@IO?:_4_QM']@%?S400XKPWE
M% _-?0X*.XO8)P#,2OZ/)_^&,;3V\35V?$WHNY&]D81?+AI'TI?7LP3V"OY]
M:JY?UQJSAW0?!>N>-7;.>P6E8EU6,5C#3B-G\J0V/"M'49*/KJ,,_IK&LRM1
MYPB>\]!BUG.GI;W/SKNSD'X"R-US>4)Z_ZSSLG[V1C6M\@6O6)E)59A_=%;?
MH7Y4F!=I5;E(JTJJ @]:QNNKYJ*H:%'EG9?8J!7:YF7%-G,O!MKV":V69EJT
MXY@#9CVK%9!?*S9>UA\\Z/G%,^;P]*RL4J\%J_*#_UC"I4@6%1QH>6T4<FT<
M3Q)>QQ#:5*NY610RO(NU:WAA0:X!5_&.P/?3.()])G_E5/QQ%T_A*E'44%9<
MA'4Z6RSGQ6/X<V&JXI\P87E18S&JMZ/VYN%3Z*!T\7%=Q/W011G,E,QXD6->
MIG/T[R4O?BO$G$L0+/'I;;I9GG);'!YK^=I*_"J56%<,"]]E%<*NU5/\.M/"
M^#);1ED-(.YB.1T9*+SG_3XHJAJG=P(G1&GA @XH695;K(/'4(/G.H!&T]T/
M_9[F\?=T]*?VNRA@RF]]Y"7I+-[UEJ'FK,F, '4A3>,2LWG=:9ZW+*%K5=P'
MP&DA"BCGLEHJX%C""[OG\P(O:\*H\9MYT?.J8NQ@9YG)BG^H+#C)L7)5QI77
M5A)MG*4+;;+D=9='Z<T\RK@4[UE<N$6QN!4ELF5/TPV:D%IYWE\0657D%;6Q
M?Z&VM)_*;^LU>6?;G,>R"O;NL>/+R[]!,GD)Z+L8AFZ>\CFYY96 $QBZ$9_5
MRWMQG1CG:L'.XN3F<IGE8I9+T5JK'OUDR\2L7=4X\L2B]4!UZ %O!T@;]&$9
MC\MBWZ+T\+T8PSJ\R3ZO 1Z_-4LNEXOMDL<&TZJQ7&M<K1HR;]WF+/&:O]MR
M^I_YUAB_J(#W?I+Z*N#+*;8OBDG]OBMAM@-Z5IN@<FIKVK6A3(-'9 .$4THY
MF'310@J3,)0*,:A#6L11+EG<#S5>3C>+;Z)DQ@7G%X2T;;V51G%5+#O2Z-LU
MY1&/WV&50G,U-#37+U[3S%J%;"Z,A0;F&J]PGW )%/#\=;1(N1#*I8055;%A
M'5F.%J7P+[/5^,&RPQ>*= 9/$E9S-RM<;U)3BG]5A>O&4: \$2N08* %/[F1
MP.7=Y_L^L BD4H!4.3<I&,=_K97]ZR)4;)9WKT$&08]#!K:;A0R\$S% !WE)
M;GCA>"F>MP4:.[>Q? XXV,C5G3=P/HUFW""\BZZJ;A:[RLMXQ'>0%8:,EQEO
MTRFO:9+KLMI6!#NY+CL@K0]P<J[9CG1-5#]NBBK"=5$5<E$3L2R>"K/^)<)*
M=@IK(:*5=/$%1;2_MMM8O:_LR: FY'DTA3]B*<"7\2R>)(O5<WG#^9@OBH[
M2@H-YLL<_)@OYW/ G%(!:H;C.4J^^%A/A7I,%;[!1C.=P7;.X[-T(<W;KND!
M%\!).IVF=V)^!+SFRQLN-W_!;'+)G9?]$-)6;B=+(QT$IM BL&0^/+][Q_.-
MO\QT6G-R<<_:]B#7'KAUM7A@ E(PDY_K;YQQA^YT;6)1X;MKS&>XT5JY,Y3-
MBY:+M/Q"GF&);Z03D=&A32SZMF3)&H%,1/,\_E#^\7'SL*7R1JY.HMB;AYV/
M\C46>EMS5:[_]MA/>+_;VGS9&9:<MUZA[OB#_6ZMRGA8N!V>\=\/L99]%FO9
M-[&6Y9K8> 3;*]I>41$G)T)G7+I^GUH/IQ2G<,93ORMVYMG*WWNV@'!UL/&I
M.M0N1^1 6=NG=>+R#\D"1GFTJ[WO8']5[,-R166@J S4[)]X0.?C-:F/%UQW
M]ED[_\]_,(SP/FBC(DU[E".@%."$%. \\M:^I+/WCR\3YUI<$^L-U&7I0W%-
M9?">GW C>Z^"BOT3[GWL>=9=M-X.ESO)))H]L;>S$'I.2-E-B=H3\#J.6WVW
M/C=8$]0:O2:RM($"8WU8HY4!>H;";0SW(N3KG7"?E$/YMUI:QDF:"72H.'%[
M"I#=%*C]8*[C:-5WL_.A(.GSHATE0T5S=3;HJ&2SPWC:%]C<R'0]V'Y7Y<^?
M&H8.ES\_I^KG9V!G*[4]"[5%>VUP>ZJV'=S-'-Q;\?$E5<N0"O55H;YJ]D_<
M-G>3Z53D6EZGR^PT*Y8Q; SP7M3<RF[L@ >BHT*%](&!>Q5LTD&KIHW0@&DB
MB.)X:$ \/B_O%\(#D^T5?-HY!Y@RL4Y2/ G;*WRT<^)Y4C;@Q74RV60Z/9%E
MFEBP3"O;KZ\ UU&AHA8 V3Z%2#J.5WVW_>J5%_E^5I7XZ5V)'TR'Z#1*_)RS
M!:M4K,LJ1H:&LL([O7CEW")7R>>O'=1+AW:ODG_.8.N@Q/]XXD^&NMDG\3^/
M3<[O_*#NJ57B5%V(>*@V!WV'\-.5S;TB&SLGFTV5=ER;)8//09T,^KT@)6^G
M&T>O.%<(V)$KSK'Y:5=_?*3B7&-5YD39OJ>$UVQ"4E^O[%SS?1%UZ#;*_*Q7
MC!-%%/(\EHSXKJAV('C_?^>EKF09DR)[7UXL:KSQ:S_#;='H>@GW+O)7KAFW
M3O7?G8IQK<SH9CVRC8(=N\L>5.5!-HN!;-29VU5W9G<=MW0R@;GGA=BB^F/J
MMVW4T_E8E/_84;Y$%A/AD@&=Z61A*;+I8ABKPE+-13D_7FDJF_/O6ZLR]_*J
M'<7"]W01DE'9]B<*C[S@W:IBB*H8HBJ&J(HAKUTQ1!4,.2CMXG2K1JB"(6<[
M]:I@B"H8<H*N\+/MN)K]DXI=>1DQDCK#/QZ-F*Z(Z;JD]4KZCQJHC_8ZDE4!
M+*WVWH_G60S6K"S]/1MKT4T*G?QKS:H]EY"!??:TW0L94*;L*<JF"A+O'';*
MD(A&#&W%S74JW%P&49QZY[-%4'I[*GI+SDIO]PHK?4ZH7@-M7D6"5(%#/*PL
MD5%&/-HHE^%0(AY#QD/%/^/14D22W42SZ$K$FHGM3!6:(38WXYMD!@_B"_8M
M#^.8PX\\/FPV$I$: VV>)3RR8WJO)95WOPQM@M^CT0CL*?[J01'?%@^T2^Y>
MA\;(%TZG<?FT:7P530<B\FR:R&NS)/^SUDC^QG2TS(H/\.X_8_GT$3Q2, '6
M&YW.!AK\ 9_Y)==+>!"/.8$A&/&@S(TNIK.AME\X38O3ZR]%_"$_DEZ(\^8;
M<=X\%^?-6KQ]U"R"^@:UF=P1659%OOV"]/*XX^-F&)Q9A<%-BK#'!$9ML<B2
MRZ6,60%YXBWSO-_K,8D?ZB%S,A0OYY?RRUXJ8;4HNHTG);-%-+M*H!GYVC9<
M/GB]*^2AA]0C*?E]\-#X2@J#U)VA%OSD09OE)"0W\V@D5&M'QP</!_/5AMQ8
M-48.:L:="KD(]Z1O12P4J.@OEK4S?+"(-!QJ/-"J^B'7QDLQ'>57_(U:'DU!
M.PM1OXQG\22!EQ1M&JSI["(>7<]@UW-U7_XN;LHX,I1?R.;>Q5FLS2,8[XC'
MB=9#'L=QU5 8_TF<YXF(NYS$/$:UK5BU!N'^M1OUK#/*+[QE];@338:<M'DN
MNL(8:?R50-/F*S5/A"#+,%ZN;=WI-VNUW]T2R<?#4*L ]FZU^IF1J+7X^YW!
MJ-H[6%J6')H?B0O8/[WDY5&V346Z;@^P"FQ5@:UG&9:H ENW_MM::1_.ZCI&
MVU5$K0JK5!&U:NH/BJ@]A?B#+]LYAZ_-8M9#]_L!%&>O7<IF8%"CV<"+;GK<
MSSDJ0^GNB>HNQJQ9#J!NZNY)1:W4RW\/M'AU%C!N,1*PFT%5IJ[O);V=74-.
M8*GHN4@9MC4\7YH^UE'0VSZD>/-W<2[YZ([C-&-)=XV%L5]H_I/]KB;X]3,G
M=LJ LM//5>+U(542?X+6[<N2'_MN;5"TE^M$&; =P-!NBA0Q[;U2390!JPS8
MUUO."1KN4U;L))=S9<">A<3KS68$]EGB3\J ;34A^YAQ/PU6*MV+-N.ISBHC
MN LXW$N)M/<[L.ZJ0)Y'I,DFI7;+DMLK"P- EM!6A+I[% 3*/CY#Z49L:)V%
M=)^4+5P0; B7[KO"D_MK =\#7J[@)%UP[_:+A^OB#N[-WU]4W.8,#>!NBB#9
M"RT[#GI]-V _R4HPB^AG>:IU3DXPP,5S\/+NAYC*9NVC.)^!"W>W.)^0D;K+
M1QU,)D59LZ2"[.W21F?A+-LU/G@_\^*YW>^2_#=U:'=6.'XJ8F[L%V-VPF)^
M'H8ZSVE4/N8=QR;MG)MTSPFGS/4S%.YV3JF[)]PG9+S7H7J+!G"6PO>S199*
M;D?.HY?%^68UZ!-Q^+W3]S+)NVB+*)]S;T5P'W.Y/R)X;L;O%J(Z-_$XR>_S
M@?9I-AH>O%@VQ;;=S5ST5FBX>TPV )N'O9@&]AZ2;E(1G//60F&#PH;=V+!?
M&MRI84.72?V_PA1$T^E L-2F&Z&8:_3MEH2 %5/[3(O*-*>*'CR=:+]@O"(4
M'VI?X;$EW^VD((:<\;X^BUV>/WBZ',?BMAK]N>#.%93HL['V/<WC[^GHS^'6
M-YK8*')3)]XB:D?8KM&>KWHB(OMGM9&8<E86>-N#/.\KOGK1UIP?+_%10*3^
M^"?9W\6WOZS=\Q#M_(:%)OZ1DE=]?DRRGD/1^_+(E,T( /'O=58^9!Y=Q>\O
M04C^?!]-X)T?HNE==)_#J_YVG3VCT2VIYT,C^-IJZ<!;%H+1?GK_@&[>1;DV
MBZ]$/0->%D.4"P Y%_SXOU2<_M%HE"VC:5&/0%"<Y_%B,96U.,#P'RT%>7ZN
MW26@D5S3_CF\&&I^S*GWQ44@S__@?1O%VKL\CK4OZ2+63.T]YTV_2<0U4H"]
M5)3@B&>C1%8^*+BOQSPJ9KS.@CU9U>O.___VOK6[;1Q9\//NK\#Q)CO.'EDA
MJ7=RI\^19;G;W>DX8SMW[GR$2,CBA"+5?-C1_/JM DB*>OE!219(8LZ9M"61
M *I0;Q2J0OA"#((B@J:P9_L&?%@G^V-O$LJV.:.H;\X0)I1F?+TN+YHXQGXC
M 0%%]0AX1?1D]G *TN1!; &*!\<133=@:^X%)N+N#-BIQ)QGZH0+D7J?*1;%
M*6'FH719HP0N1,T)R!'1I\%G]G04^8&8.<0\3ES..[VU$-G_!"GH!!X7GK8K
MFCWX;$KA];$'Q (C+Z26*&^^M1D%_$X1+2AH0 )DKL9F=(OGPJKUNOZ>-V1)
MZO#/0#,(_'X&W-C!4@^*)5F[*MF;KY*\JWTWGGVAEAMD@46D?6#%+< 2BP4S
M&XG)H2X^^XB#+)IMX)+X,F,N$>,GG6:0N>/6)H+N)&PTL[D9A@PZ;-61+:D.
M.U@[D6S]W*>:.?R&^NLW1AV0B[="X!6PI\,$H9@(*&*QO;FU@VKBH)HXB$6K
M)@[%KX2OFCB\I(D#JB+53$%5U%?-%-36[]1,X1CG)_NWAD&@IN&.JT50(V=S
MMU5:VSDK=,-Z3[-MR':9:'G83[OR1V7/T4H,N-K]4B7O_<DL6+C_5@UCI#S6
ME2)UJ]UL%JMH9 4L047^;T?^>B]7_73)4[B+G8GX1.+\5\\]>UIW5/42@]%K
M[R'+K@BW&)097$'J;ND5H>X\9KZLM:]?T2.RX#<@>DW5CZJPLE).DNIV\MVJ
MD5QRE=8T'7@!3X.+Q9W2W]DW6NVJW+%5UFD%J;MAJ!JEQ0M"9]NIEM*$:'0Z
M]4U'JM*:$,HJE9ZD&@4CJ8I;I0=JJE<P!6T8^4ZYY%/ RKPL(75J^3I/RT>=
MI3(/7]9U9.\ZO'CWTP\&U/Z:2+0:N:P6.2^+5\!*5EQ5!*YJY#OTD).K)'04
M#N<8\.>6TVYOZ921V]#S&?E5W$<^U3^H7%R5BZMVO]QV;I)/5>H#^CR'3^M[
M(4.NI:I!7T3Z*T^)U@H7A\\DG^Y)6!8L4K7Q@E[)NM[DD:^E-704+9>.EDME
MNXHVH]2:VJ) F;(="F<[*-M5=OHKM^]4#=M5",H'SXFFC)P:6_HLE%77[_5T
MM3BDK<S6\I%RKCS3XI-R":W6X<P./,LV,^8K.6WL*IGEI-H\ K@XQ*E,6-GI
M+\\=_^+0GYPEL@XO.!-SMEDQ<S;73:KBVP!24;>L\K=@I%Q1S^QXYNS. &U(
M'?J#S<EM2$,[X!"0"QI2<D:$M#YM[9Q%5 +^+3M\E=E+"<.%AV#IY)Q;)0"J
M!$"U^Q+I[P,8*/UR'Y_JS4ZMV2U4*94J&0Q%)2JCUNWF<<35!8>#0G_#3 1J
M#&"%>Q!I):M4TC5JK=9J'\9REBI1!EH%R;M9,_+E]16.O$ME@6:S4TII+A@-
MK:8U\@0[I96?51*3DA*5T:GI6J'*CE;DI/+),I'3F<.P]R[CQY@5+,53:S?R
M>./RZ6"IB%A6V5DX^M1J'4.5XY%,HI[\\M_8<;N<$<I&K==HU?1NH52YL@^+
M0%:-FM$K5'^G:D0I^P 3O4]O$9,9\X':5BQ#<MK>DMBV=V(\GN[*4QKIV=T_
MK@51ZQFYRB))9S]4V;Y5+"8UBW6;N4XQI&.Q$IKHVY19IYQ76_1.KLX6T@KU
M$LCNXE-4H;)5)#39=X:6?UQ.B<R6_U%ID2HM4NU^N:V9LJ=%:EI-+U8&FS)=
M9">J;K=HJ;82&B\J*_*M[].V:KUFKB/IPJ6-*?NL@N2MU;IMU3V[< 9HZ;,B
M]6:[IAN](ID+R@25GJB,7JW1S%,F2V*I5?:LR+TD]Q1,+1NUAM:HM3KER#63
MBG1EE9B%HU"MV:NU\]F.TE%HN6JNJ.(J%;3(RKZ7U0C&<6,'YB0#QW9MTX;7
M!UX0\KP)_IO*2"I<1E+7J!MYBDS*IR:K;,@I%I.9Q?2Z5@Y?J5112J'$P!;]
MD[KT'E382W39WD+Q<CI.G7KO$$4VI-4))1#]Y:?(0]3%D%R$%MM3>$)Q">]?
M+J^A>"W6=[%WCMQ[O:?5];V6 9>S*;MR1I0S(J<STJMK>^4_R35I(11FJ8L$
MM&M&HUOKM/*8<=+*[Q*(Z8*35:O6ZQJU7JM0M2>XS/H8TI'#TN_YOYGE.+;+
MSB;BS$PWM/>?,^O[=Q2$]GB>G=!X]1*-K:3!%T9,YCCQEO[]1#OAG^$I,_F\
M898[>\H"\I4]DAMO2MW/9!TCRY+ZT;;"R:>F)D@EWK37"/:3IW&V,O\2">MM
M,>NK=_54?U59 U0_SRSSZ:W-2WVW=,K@!<]GQ';'GC_EN=/$9S.?!<P- Q).
M>.D&$SX0<T+=>WR2>)%/DHMB-9*]-E:+>V)0UUIT,8IK0-2R?> \/VEN!/,F
MT]B>16A :#JE-^8_[6VN>+P9S.3'$];)<#QF9F@_,/)[Y,R)7B.&IO=J),A@
M)R 6&\.F\/7AY 37QWS$$ W)(R,3"@-X,";%.\$(%'SO, H.+$[I\#\>F0-/
M36$?)@%?=Q!2/XQF\3 X+FPA^PD;B4O']=+L.C(SUY^3&HI'G^;1;2UB)>/1
MI;ZVMFLZD06[0YUL4W!.2O[*#0A%(#L2R+9.E5(2R*9>FPMJ67R'@BD1H)QL
MLA*5S.C<2V3:R 8: QE$25L[L^@\K7, 0HD_/**!K:AL5RK;UMI/;BI;DT=/
MRR)%=K*17:M(9+<@,_.OB.<6)80&[J_WX#U/#OQKX6LE;M2+P1'VUCZ@::PF
MT/!_)WXRR(S>L[.1S^B/,SJ&.3]1YY'. R2KB?^"11_((5U@+(-!Q6!/,]CK
M*ML=C<&2.GVI+'ZZ8)\M7$*Z[2U&?3=V?Q@U)XL'UH>*Y;F2Y#L2VK:J4Y(1
M6DH)#T_5T,('D, F'E@7$T:=,$-#\9M@'*R]"/ZY_6!;\,5HOGV ].'%^U;D
M8Z+J(@#Q$E6R%75+ <\F[.@A<,G'M)CI^=RX^A2Y%O-Q*3#6-0] ($0W+(B<
MU9."EZZ]>Z"EPP)1<CA.C<>0O'2UH.$]84^"]@M@7]X930(C.3P*@M;@NXZ6
M?I$\AK$HEX4D8/Z#;:92J$ZN8?![WPL",J7^/3R5C2JAX +ADXBL1_AMYJ%1
M\<"<.;&G(%7"!2%A+"@.?:%'!:_9TU'D!VP*0]5PED<@,?A!F,1!30A(,[+#
M.7%@#@<G0VAG "H/JJ'A M/XW@-,$X6V8_^'[V2=W,&K8@%)J"HS_=KL?.GT
M673P^9:P@6&E&<S_TY[2$(%^UTMP6R?Y*.8HU/X5@+V-@;T1P$I'[[#QR3YD
MJ#M#S*?=]Q]BA^?]TE:&V<@/[B$EC>4G-BKM6,@)8HK?CJD4Z<7R@<Y=I&Y*
M.LO#+9RXF!)?.%5B%?A<Y(B@I5XWE@=?H5P;EB/>F5(;MQ0D,8A^;Y6>GV.F
M.NG#-B)E@%29"['B9GW+4UPHUQP<ARSV8#\0#-0&F3U9Y@C ]./$!@O&1LD!
MPFEDNR(ZCJ(#GDG?C/DY_?2B1:^B-\%J$@QWD5IYG#B)BS,7M=LMFX5L.@*0
M&IJ(4PLAX 3>-B%&87 K,D,A./DZTCWTD7-,SS59O.\%8GZ>&P:(C05 C0Q_
MHI>(VN0"#S!,6^P7[DY_ZH$5)*2LC!+"C&%))#=L26 ':.N,^6^PPT'@(42P
MIYQW+!L@#(F97K#AQ![3'AH_P;K:"<@CP[BQX-9D3C-);YZ*]&9X:N(1Y,J0
MQN-Y0FF#M^T ??GSU'8GFQ:_8"D0:%RP-3<*-F[-B2'$-V:2[2?8=1MKZN\1
MA%B!3CEH,.@"$QF-RC??FX7V-/D"UFG9@6G/<+=!!O\$_ !IH/" W\8!:)29
M0UUT8A[I?8;+5P5-QB1 +&?MS<PI#1[PC,=(DT(X,HL+6A),[+% FL>/I<:(
M./XL&?O>= VG(!@]V(FLR<1^SIB+ H<C#[]9T>F-5*<7B*NO.90+,W880RD=
MUV[;C6U4^TYOIRH?Y"Y88C#^%J474 =^CC7+B+ELC'Y//(6P91>ZEBN;F#2%
M71L 09J<,$@0S68@^I;M@-H6$N?3K3I/*0%SD@U@^#'S&6@, ' $#+A.7#($
MVE8SUPH<:#LZN_*/V;O93_'O;UXP0X%UR^Y1-,O&MFAWC3W'\1ZYU\]#2T$T
M16[\#ZI,+LD%!(& (.8TH4X%NX-R_O1RP-XN*V=7-LN\OQ2;TI+M0$/=%9^S
M$[B8.>(L[: >!]'V%KQ;6:UP9,7R:!1ZR1<B98Y_(Z)YW5:]U^BTWB?IWR9L
M/IT%[%/RQ^?5K*Y%6#!-?.N>;(\"BFDZ^OM,S'#YMZ=^,O*]=LC)7ERKYVTS
M9KNO993NRQ,;.S+=B%ICSUR0KPGMDU\N8]_R9?_[B@S^)_= OW$/-"!<*PW7
M_=!="CZ5AXB>K8E] ")Z!28.1E88A*AX8G2%MWY3LKZ<U=[V;P>#2+5=ZIHV
M=<C5(G\VP<B.M)9G=?SQ3S;& \Q-ZST%YS)V0H.=ZRI5]FI:F0%7NU^JZV+)
M,<@;*6@I[UE*<0NIV=#JA6I36@'[39'_VQ7:[+;K):M87/SR&\L=OU1+@26"
M->JY2G$5KJ& ,G:K1]QZ*U='S^(1=QY;OBNOM%[/[2OEC?UF*Y_PE5:&5DE4
MRDE2#<VHYRE8*+GD*KK].5A.<U):>LD$;;;J>4Y6BJ>FE0U:/>K66ZVZ:ME6
MN(#RKYE[)*6T% RM8)$J97S*3E)ZLYU+D4LNL8IN?&Y+X:Y6"RQ=T_)9F=+I
M665%EH\ZVT8]5]MJZ8BS5$;@]<J][9W-^ :8\9878:[X+CEQ!2S0_E(TR%NH
M7==:]=T[+VP O9@%VTN@3!3C5H)QN\T]G (6AF\E]&EVAI9_7,[PY25];WFQ
MV%]%T8=37?9,WPS!;" GB45A%1P*E0=<!HM]M7Q+*>-L>7(&UO="ACS/]]4T
M/ M.?WJ>#(/B$*"$%M0!($\*&"R*854KXK;7<%MQB%O9>N4CY3S'N"4@Y5(9
MKDE]8HMBN223N4%4TNYGI;8=E/$J._WI>9*QBD. $AJOAPC__<'FY#:DH1UP
MT,@%#2DYBQMEG1JR1P)5K$_%^E2L3S8/5DZ%U=!J6BN/MZJ.CI41M#7YM]9L
MYCD45<>:1?,""Q;+T+5:K[?7@(:T8K"T5D:)R;-3:^FYDDFDH\Y2F8(WF68=
M%IW7L#V,JH5S;%'>TNH==<5(+L&LZ/\-KT-UZD:>C&')=4+1C>R5R_B)TG@C
M?CF>)9 K_?>YO3XJAW7U>B_7W6KIK+$J^PJ*Q21FL4ZKWE8WTZ3386F@R [,
M"?7A+X>Y]^&$Z[5PFS(K>-2R5RACJ@+.A**GMY9?27/FE49:R01';,JDVI<_
MN:NG>C':E_-[50&_5V4O6CT0'SN-!KP'9=Q"')MM9!HV8T>QU<L7-;)^1$L\
MG] -IQQI1]BX#6RVD772_6^G\>,Q9C"ZG[1 )\/QF)G82Y;\'F''3=%JMD:"
M#!8"8K&QC5T$84V9EI>("1J21T8F,&%<7P.>0D#@>X=1<#-Q2H?_\<@<>(JW
MNA4-"$%-^V$TBX?!<6&KV$_8L"#N<$BSZ\C,_&SK=L6+3_.B40Q>%-E,MHOM
M?K%KI?E7A UC.9DC!8&&]QZ\U6;&Z^3PU,J7%/%1&J&F-19N1 -"V5HI]I?;
MD**@X_VHL]M1V]A1<5%R)^FMB+)!O S;AUV%.-^[7DC&$7;F-;WIC/JX:SE[
MV1ZP$>P#[XTL(/56"F-D6[X;>MK_E3=%?J>W-&$P)%]G6\"ZZ[5^1:ODM2FP
M_[?+[NG&UM_O.NFDBR[@H9=V $=\WV=*NL$/#I?6V#N6A:$CVK6C.Q7%BB1M
MW?Z]?EO'5ML@KJ>Q-OH=\0HK/@T8(U^]D)$V.2,#;SJU0]&I&2<<  X! .::
MMNA2Z_$NTMA<$C&%S:_QSKC0&FF')= +8=SNF:L2*^G&G%7('U:1E*6PUS96
M9T"#6YJJXU#\H86F7VIP7XN[QR]U?7YVA]>W [7=<AOAM(MP#==A<E1&S(I;
M^XJ.P7..T26Y*):#C_OV* HWM"<VNF1!B$LK>J<O_;1&@?$.KK#YWX(=D%\G
M^?C\**(:ZW+'7>C)S:;[M1)(J<S^)%N;D4VKHNCS4]0!-"FH"4Q &@IZXH95
M3 <9NH._@7G@3^R?CKUW?8:-Y9%VWAD&61=\PHQ>:!6*/>2S7,,GV&3'(J%2
MHM=7GE_B2L)2NQ9),N:^@& G>1L)D?=>OS9##VE16+W=VGJ'>!2M[MJR$KR"
M*0U8!E:#H0.A!6-\"8ME1['\C.B%'<.^\Z [Y>[0O1H\Y?^J#MU[%T[)J5XL
MH&ID^!.I$%GP IU7T*V"4X'D^E,/*/T_2UT,991@YLI)94:2]?0E059;%61=
M;1<Y-E^38KJ^48J!#,">XC"C%?$!UP395B$V<ZB+7O4CO5] %HO/[ "K2(B/
M:_&K[GONGOL@Z-R-U@ 5K<ZS;O26T1:H=4":H4_N$OU]G?R3\7J99K@V^-^V
MCH5H6.P&?]$!P]6<DRD#])NXK$<6F_PV2)I[C!R@P)L"&GW$MZ$96DX7X#A>
M'*\QNO#EAAMKC$K 75MJH699J]%]VD9H++%6N$2N05:#O9BYNAMY*^:HE#6X
M_N7KS\2"TOD22&H9G@RH W\PP6\CYK*Q':;CXL(3YP(! 6,$%FP*3R6(9C.0
MD0F_9HSNS6S+?PI]8'8G^5/ %B]+-EKF'[-7RIXB[F_,#[@#-D"\WPJS7S;*
M1I(:>X[C/2+:A8 /HBE2PG^8$(.S! Y./TF4(G%>,+8A^ *$VZ>7@_=V1PR[
M&F^9]Y<"B5JR*3:ZYN)S=@(7O6YG:1_U..*YMTCKRFJ%.2R61Z/02[X0!W_\
M&Q%Z[;;JO4:G]3XI+F8""=!9P#XE?WQ>/:):Q'#3X[ONR?:0K9BFH[_/!'B7
M?WOJ)R/?:X><[,5=N]\V%2!7K_(7'L]VCM"W?2O<!^O2?AE'7U[VOZ_(X'_R
M&,TW'J,)"/=UANN1FES))*4CHF<OS1Z B%Z!B8.1%8;I*I[>4>&MWY0B\F+F
M+WR9A<OT5.)J<?:08&1'6LNS.O[X)SL$+)N;UGL*+E+L2@6J!H2J :%VO^1Y
ML$\W]7Z[G,3*7W;ZO_^G:^A&'FFC$G0+=+5",4")&* :U_V^>N[9TVJBJJU)
MV_EZ11>O,ZDR>*M'W*U6/4^IT>(1=QY[OBNOM%[/%BSEW:.<LE=:$5HE22DG
M1>44>)++K:);GRO%)I2.SK[1;.^A,UL1=+0R0"M(W$8]5QW#PA%WJ0+*OV:R
MT4MI)NBM7&0IK>BLDH24E**,>IX$"<GE5=$-SVV9SM6JU]JKEZ-XD3(@RTB;
MY:AS72K[[WKETN_.%KSJ'/\<&N3M'-^NYZHN6<S&\14PM!7;5H)M&U5B6PF]
MF9VAY1]?T_!-5\F^*ME7[7[);?-SVW'X?<N)%_GE;/9FU%I:NZ;KC2(%U"I@
M.1:>K!JM3JVM%:_@K5R6S2$2!!R;UWK#! %F52L"IH.H:Y2CG98RLTI(GJU:
MIY$K0UHZ\BR5'7@[L<>K=6)+HJCUFFYT:SU#*Y*B5O:?_&2EM8U:T\@3%Y-<
M9A7=_LNVKD2_5O5(*ER/)*.9K\^E?&9"E:U8Q6(RLUBCWBH'BY7*$L\JKP"M
M<G4-_?BW@#3E/)1<LRCRWTK^1KU1*/*OAI/S&Q[8/:<ERAI&-/*EHTAGN539
M.5"T*3=M[JLYYM(N-7$/LH6ASW@]\L. \>8]^V(">^.>?=U9N?MG/M&S;V]]
M^GCCP^>(M[T/2CU>X[[]P[*>V[_:JV%S??QL9XB5SG:=#7T;MK2T&VQMY;+2
M7:*9C/DY;O:PH5F%:!T![W( 1->V,?S%&TL$+"WI3WD75R#% %M!Q<TJEAJD
MP'=#;$]ZQUR7!=C-;K790=PZ"F#\DR8=4KN\Q\,Y[U3"'_L-L0F/K+24JI-,
M\\3:!ASOMT.B#.V>5DMP6*K=T_[2@)_N_^3/\/N#M:1[?2>+6",\WYC#3-;^
M3#..5\RMNFC,5!>- TY6P08(JHO&2[IHJ"8:.UU$*&\G!=5$H[);KYIHJ"8:
M)0P*5Q9PM?NERN)X7:D@=9K]AI6UC'JA3K,K8,\I\G^[ DF&JF@LG[:X8#.?
M@3DK6EJ[%J%3#X#\SY)96XW3\TZNPH?RG9XK6[9\M-DN2>5#28.$.R8([,78
M5A6KRE*Q2C=Z^51),6M65=U-4(Q;%L;M]?;00JTP?)LKR_(EF6O[<$LBGHZ$
M1Y<N+F'*#R5G_%"2L/7S2)YE5,ND7FS(L\JF?NF+O*R5C"U#7Z2%C<GCQ#8G
MQ X(#4/?'D4BMR'T^,H&@]^R^5>?R+M6^JY(1@OP47QLL3#N8UE3V[6#T.?I
M7B2(9O CYD2Y)D\1J663TU9&LMV0NO<V+"-8\M7$P,NPZ%M'R2R;OPBCLGN1
MH )K#<*@3H8_,>LQV05[.J-FF&2=K0Q1VY[<ED&ZKJ6K$6CUT?<,>+V<YGN>
M)!/YL '&YD2\-/D.4W!$SER<_!<_$I"9;V,B#H!N17R7DA]Q'22@#OR(: .
M1\QE8QMFCE<:8R$]T2$A,R<N&,WW\_01L>I'YC,RHX!XBBELWG@<L)",8$Z6
MF0SV8<R"P.;9<6/&8$^M55?['D#@N7B(4E@=3^H;.PR&>V P%VQQG>1*]]DC
M)VZ0'F^]B VG6E]L(#[+#N<<D0,ZPP,P3%T%$C)7S>_]98WML/[GSND&-)B0
M2S!I)%O\RU+></%HCXF43Z1G(:N1%[!9*^;EGH*XBI#9GSB1S$]:KT_HVU=2
MW5K>W#K.59:=RK*3-OBALNR.GF6W3?J\Q>)5=I]*\5+9?6KK=\KN*\-1*+?
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MZ%@HDJT589D]>T4L>V]>J,BEBN22O]VAHI<JT@LV2"2*8!3!O$TWQ4)$-#=
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MOEVM1(,2#9(2AQ(-^XA5*=&@1(,2#247#5WC0)TUY=S^2MQ/.W1GS;++PQ+
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M';W=[FB-CQ;[V=#KDW":!\EX;NX%=LA[?PX0HV/ J?AXY0)DLZ07;=P_"%_
M5KJ\MU<@6GCR7KQTREQ+Q-3#B>]%]Q/R>^3&9=?U)EZ1U1;YFE0ZV50VV7N
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M0%6@*E 5J)4%52H-JWSL7<ZH]6KDN:\?2NOYL];31/4X,_T;C1QR7B=_1$'
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MP7H_BV>O_WJP/BK&R>O_!U!+ P04    "  .0UY/+-)>:],'   H(   &
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M1XBC5@)W*([9CHLC&1NSC/.VR>V\ON@2/)<"K0V\AOV=E(3.B:!M)J)T!QA
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MPN=@<S?W>SC!P.U/'G\KZ:GN47<4.29"C$?6ETV+@^JV@Q.A6#0DZ%<ZAU$
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ML3._K)*BX0AKMD!:.6E2AG9BL&?0:#EZBF<D4.L3?FL P+84CWF 6PI25GT
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M>JX_3=3M4RRTIW.3@!K"O=@@"E?8H22VMD@^98MVH1=61SSQ*<FE)#!:TV;
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M.CX?PNG];]\_F93IZH=___[)O%GD/_Q_4$L#!!0    (  Y#7D_A%_Z8KP0
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MW_7XOM.QS5\6W3>=XK^4[C]02P,$%     @ #D->3\<E?5.?!   @1$  !@
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M,"0A1A8>\7'X'"%F5L5?^LS[^+&J]*>>S'>:IGX;T=IM9J])6O\"4$L#!!0
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MU0T8AMYFW[U35)E2E3W?%#=SL#6'&F7LN@_=M>XW'F?J6X/V+\'O,]:ID,]
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M&KW2^HK=8AQ''@K09\(""T!3;KN.%KAGNU&4B5>X?/#G/?9?:^N.M7/?MSY
M8;\=B?;=EG9(?S"*63?$.1L<U0KHGM3O<J'I+HGW:FQG0;[US"*1UE#.+44!
M+L?92+,2F**L%@L\Y+D&D,70*%9MU/T/FX-G)9DLD<:=_5W7+NF54A[Z1^$F
MX'"$W#2/ZJ%R@ZJU=:/=8>I\F%A2AU" QU9][^?B\L>/NZ0Y3K[F\I,3 =PP
M-[?;.R;[8^?UOV8VUW*?,/8@;"XACQTM=UG=KL<][A:\XZ4+3+H]D'453]HX
M@LA7:S^:\9--4Q(O> ^3-EW&%2Y4" [8^$W8!"MOBBX2H%+:PI&5/,710P'3
M8)K2^ 2HHK4>U>$7\J-"\O=[!/6YMK8UK<&B6U]NS$0IQ5GPLGFD&VX]:'P3
MKJ+L:>*ASB5:6=3^=G1L$ 8O3F#<UJ[<XC8<E>6=#Y!:4O2\\&;B/'^WD!5^
M(,IM5/Z=Y$>DMGT:Y\K%#,X5CP#0JL-"G*Y<J818+R5NJG92?:V*)V6<\Y)%
M9S(VV+N("(1-E>)R*^-]$'H=]"D5WRZY,^OQ"U?V:.7SQ,;>VYMFK)D^.AQ@
MU>U^]FZEW4.Z<2@^D6Y3Z+._,W44:WS2N'1BTBI?,L%E67B[T<6.?G>-D9.:
M__W:>7=UMZ0+V!@V13;79N#+*67E=3[LT7(&I7I&<SL*1.>=NVZ>@EJ_\]L$
M8!'V*X]0**.7\$<SW<]-^YJ.E//:U"H60J9L^;D=/)W>E[VR6FOVA1(*WUZJ
MG_=V/4%B46([B@(R!5T36RM,FEN29N)%/HJ(E*(,^9N#0:HAPA1_RR3^Y@S'
M3W">XZ<D8\3.(_@W(H<@EMJ&AN<(.!!X"=]45F:7H2R=WDJG>+:1*U!6)3<C
MF3PS=TE55<-8B<*R;0/%12A/+XW(T]5*U!!NN3RFS+*3#9H5["D2[\]=<:V]
M4*(*VJDP#MUZ>"XB7(9!=@H:[<GJ'A;MZ8S7[E^A]U#) 3LDRL[&[4XX=5=N
M=%?9#*XF0SZ/^:$X\M'OO@>:344[PCU<(-[["Q%(ID/#2VH/*)? V&UVPC/+
M4/?NL435T>JT;Y()K V;(G(/S].Y?!E[VM3IM*].![&JPUT=$ H(_G0HKB_>
MX.GI*]CM:,EAN67! J]CI"+TC""S.&F>$-:@!\OABT?+W527./I8U._# M1I
M@4=!!9^SZ *D :ZG3\C3Q*KEG?N$C#UO^OD5D@Q6_/T5/ "=LRA<\=5?>YQ-
M:I;>Y=X2I FK*&S#KA+7/KTNX_Y8Q& P/,_+Q:'VXDZR9#P-^A)A:ZRT6=89
M.N%P,"#,'/?*(V9A/N]LOK%'HU;/NG%/R6G>"1%WW9M[6'#05 X,X>C:.S6X
M(*Z'X2W/DK'Y<B@(>_($%Q$#[=G(]T4-;Y0&N52;,#L0PJ]TW-K=.4)^QHQG
M\0EK%,5FY4T0@=.A]WF3LS)P'-#*$"+0>F_)IS;!\R[S9U1$IOJ/]GG^VD!U
M6O43 *6\]LYBSR,-V>33'-]W#T+N?I^!IXA+?&.3HUF=-V/05<&XY"-;[4XH
M2%-$6SH.C3H5S]([NZQ8#2]'[C]-.YMWU0ZM/SY<UN;S: .I"VXO+Z#N1;>5
MR8"2OU[#BK>GEGV([%\2G;0IE/GT*JQ!S1G^UIYQ,@.1CDX?&6O<,_UE<$>B
M:<+RJR.2DN\A[ES,U_YAE2L+HR3&,Z"%J&+]2MVA<FD.92!-K?Z*&J8YSMF/
M+' 690MYZL"^-@E>920"3^:WTMA2\AN&Y5=FJMRF!%SLA]7C"7-L^,,3>X-(
MRDXD-,WA56J,H6:DW!?V:E8/@?BW^1W"*HYN!GK(@"J:X<BTM4RZ.ZHMLEUI
MC#7U!SWBH,F([%&?B@,!B[,&C\)8[3; \]6>YK2T]!0+R3*$G="%[MIJYCM>
M[C:/-6U2'J!A ?=ICZ?^PX@M\)::C)=P/:YW'RXO*=?KM".94IJ9QI$%N248
M5R0.?=2S)MBZR,-WV;@@T><TEK%/N]JL<1RL9Z7 ?S=I,6:B^+Z+PQB2<1P[
M,R8V$*N15!0=+IDJRA#*<U8S]GX?NB*<5:!4C7P=XT#P&BCX).ZFL=EQ@CQ,
M^ESN'7\$"/%B8UU#8+ U7=ZQGV1$Y-KEYB/*[;SW?=P'6FEGAK:*BG];[!$H
M&4-(7):+69,J#VRE0WJ$2^&1%)NM\6_L>%,_E#MN-9,PUDF//5S(R2<O_L'(
MS6'O#PS?]L,G25ZH736,%4TS*12!*,=IK(!,Z^JF5:H4=$3:(LLG/+V2I-3[
MM$:YCK<U <<B%3T' L3%XQCCZ-1/K3T^EX?_MBO;<]"KDKZDT!SG/#JX3NFN
MW7/WF22-5:&D1]#B2HU?&4=*M4BCM!:CGSQ7,VFT)?\@'1HU/:LN$*.3.V<$
MS8HN)$[L"IFB;H_>%L<T$*CB[QLY6%58,?MN+H,+B #=7,[83"A;,#KZ'CJ$
M_WTS<U5&XSB]&,-^Y.AE,U$V 7S]F*('-G/KL&MP*D<A=ESGJDVVKB2JPBBA
M\\:XI5GV6ZKP#-%L-9AN7JG3V'N,\4;3$0J'Q#N IEW^N,92L5%[6>PF$;@L
M] .P[Y*Z_AP1N(AL+L\D$;+B)-P9# W&8I/\Z$5<.-Y+CL2EXC8M)QJ]'TPW
MV/I57YDL._);ARZ_)Z7?5NTY7;[7D,V\VX1*2ORIHGHB0$5U;_J./,D2 E7?
M <<ZDALF'F:?F1:\<[Q*;&MQW2ZC/';]ZW6G_;<#A59M\/J*8,3IDBCPWA<,
M*)]>M8\EZB+V 21]0^997&EFSQC;LI7NI0QTP8)D A'@TYZSZJEA2*$\W]RZ
M%S=9YJN@V8EZA>5'@SB77)QATIZ![W[LM=H/E W7Z9HM?2S>>?ON_+ZF\Q$.
M'LY:U?W0(.PJXR_V,+6HI#2O/"'F,)YQ;2Y;T3LR_#Y6B7D@V.CG--;;3E^X
MCZ[E(QZ_8 M0WGQXUVA#G!"]P$C=9;O#(ZQ@]04=ZQS?*_N65Y:%?5&G6#5#
MYJ;;O0".3V,GJ6$Z<0$>>PUZ$),&NK<*6\WB6?;0(&=H+#C \SRLW[FOK]CK
MQ>UEYJ.,KD F@DN"IM,GM%C$7&@X=4K"#1M2AH12[XPVD0A*'XCTR,AVOZ)V
MB SL/W.-?QC,/;,%WU>>;9K4X_& ^I4HKWR[^#G, 32PEK3DNWA$!!(\&SV=
MV;]2WNM$\YJ37.[W&>RK-==[2:F^,R3^G0.3'LG!JMS!TXB;2DK*;)7(H.&D
M-VZGXJ\>&#(:OR9L+D#YYG6E/3X$;RN-A5%L5>4-0E(VE&+QZ"G:&9<VX=IJ
MN\Q#]/;\1KYKM<Y'''P7&=BM=>6RGB^V=HQ =>"TW]L9*-@H(]XM)D;J^WN=
M%-]?BKV=.JHUF#6IUE;?&_7T*'P>\10!GY[CF2H_ME# !(Y!YCE-,62]AKL^
M_:HZ&3R?<#W838[EI#K#%Y'C;W0DJ>XC:33/B-G=\+D;"=6%)X \;CA(ZZ5Z
M^@:BZU,L'(;KCGF;PIN^V<X5FZ=4/XO4D$V/E/\^ZHPHML+IS'-2K:0G]$H'
MF)J?7* F I=(&?OG:D1<E\Q*[D)NZY[<599%+?7T;)G/+DSIN>Z-B0'9^A/#
M@TI+GL)M?'/N^>AZ D7?2HF.U6*J'R5K/?58>=":R'1$1'_U*52[B'GCV)O/
MSU0_?'_SV?E?;SWI$!:?;M/%V6;X)[[M_&V/;J*W7/$9'Q-7<GZ9KK(CLAGD
M@GK# /I([N'";J2;3FAM7-(&1@3#7U$BXX&-3J^K+I))6A4#A31%[BXH#YA_
M=4_PHGR6A'RV0HD78-FZH?$:OBZ((*5.C;^E3E-Q_S ;AK%";H%[H<MSROC3
M?72;:97B&1_@.?OL"G1N@481L9?&?+';BT<L6_.;&+Z"LMN> =4?B$!,=[:O
M&6B-*J7QTF=_"A0UY2^0G+/7RE@R*!ET&$C)E,?@;R]#PU5+=,:XYH8^WX_@
M)XA,Y<'DEG*O)9Z3(B?WE];I0V^YQ \VW?\0(3OQ.1L>LN,JGH&FP.J?L/"K
MK\\2X&6KD#0R=OWA/ .OM3[:8MZ5(0J;,Z&747NGT9H&#Z("I"DD_2HV"BH=
MQ>PW*ZU]OK?R\=]79-5NERZ[&4E4AN061$.#LC+?49Z.H..DNTUKPJK<JVI)
MJ 1'3YV7$COFQ 9=1ZM!/ENV-[W:<;T#?=X#ZN.=[&C9>-[T@>7(JBNGY>@D
MIS+H/CHUX@,T!IGFF>8I8N9IYD*^1NI(O5.3"+WIL0?C^T]&6$PATH/D-DTQ
MT&9?T&)/6^GNEN+U.IFTP<-C<1LCP>-S2UHSL[..JUAVH2^HZ)04)T-6$T.Q
M@HPAN<REB]I2>W/V[W">2?5Y\#P2U;'4H%/*W8L+=BCE+PA0'$W,V.J8UX7)
M?6%SE&9;Z5 M+'JA7/"\?\RUB2) ?Q/7BVTC G7(9"+@BSS<,2<"SXC /0)I
MZ.\M#&2M<N9G)*]>'UW,S#<C7,93'I)&WC>T[!$[#KPW3P1J9<*M+DSOOEQS
M[H4+$($SA$#\ 1%8[T+_H6Q)H/W_F0)],S6"W9_?3(EZES3 3[0K6V/!B<A;
M>AF_/TPYYNKR,*+<RMI:^YXXK^^6T2Q+4B]%754RAWF;E?REL) 9*Z.ZV'GE
M3:'4-W4/"*KX:^&=$P10N'RNNC_G)W*FL+[Z*V9.H7?N)&Y*2YDX[%:>]7I*
M!'A2M$3VKF8M#TD\RAZ.GEK$F32.;%T/*97P.:F5KS]U\MO0T>V9'(-\UK/A
MCT2AS6I*N@76;VHT2SV>10H6"D;>,G/4"EY3%$9!FL6+LC<N1/*5H-VXYB!2
M'SRO2$!YE2<@/<L)&T)!11L-O'!*^\\:.&?PNWQ4M?RM63\).MCL$Q(0%&3^
M<;^ ^GD[A7#-;M.BE^?>M]PBT#"<UT^)DLNY)>1BZOZP0%Q 7"4++L/5XD75
MJPI!;_8%#AXIW@BZ&<O%"D8$8J\>6;W%,,-FHV3?L+:L_-?;(^!*5Z9,]_^X
MZG8*&02=T>U%+@\KX\D&7L"+]_T)TE]E"=6II&"MZ%YB;UASPV'JMA2);(T0
MI-R2L(/(!:%Y]87:\[4S5SR(@%X@P5]KD@@$!25O)J11PQ!OQK^/<XW>=[>U
MU<<JMDP".GVYI-U]O+YZ4+X0C.GVEA(+:!"XS"U+_Q@+?CJ]E2^NYJPBZD#5
M)7"I,BE0+%N6]?,;R.-F[\'J]IOU6P#AU =+;Y4O9%^X>;\P7_S^^BDV7]YI
M)O;6US..+?.5,%W3I],C7D'=YXT/+H>)3TC*XG#@GD6]$)4F<:L;O(4LYY[?
M>XFDPUX7^:K'&&*:FA](LKO)G[&746_Z*V1%;'X8K2OM>GM##+J)#)_6K?;<
M>U&,6=6G?!A4'D<UU]3DT.O+PESUO*IE8S8I:[X_G#N +.?XA=,S5(B.=Y9&
M\"Z>M>WMPBEE4WJZ3<_5&@;+1+T9G'7H5IMX\S9^LM=7ET"]L3V;4!GV+ _B
M)G$!Q8%YL/XC-37N8:VZI/AC28W]/35NUAN9A0^_2Y,Y&+E:2@0^DK/C*#^G
M.\Z^,&[1+2B?UT[87M).:)QYT]:N0_Y^!7KLJ;IY2I7KVII'?)S8A=<N/I;C
MG2<*XOFIAF39JA/4F ,> 2> "WV-WF+=1SFB6,XK<Z\/'&:0IY>0EX]R2C&R
ME!<T]<O'[@J''I*(@![;),)H\])HTQ3';%.K((73VAGP)")!%Q->'%/3I;$&
M&N-YP_W+6N"ZKR;YAE"H^[;4&XW0"8\ [1X[':4^GK5.XWHF;\^0+2A7CK2'
MQ=#H]JY$]_ 4I%)SC6=07"73Q&"4+J8JJ5Z2.^FN';.)P-"M+^'BR5C]#8Q<
MCU U%!XB%-IRQXB-WWX9RV#5FZ$A@#!+5DJ)V^;K^O-H^5T=:B";28,,*X(Q
MY^U%(FU3H 9+R-BMX*]2>E&<'#E%R7TNJU"9<)>=2=V07(76LDF\,NBS)9AJ
M+=6PPB;7/F-O]N U@8%\6=>Z\(MX'G=[]X,F[G9'.5P/Q,\]N-7F B<\:N2>
MQGK#\-<U;_Q=:\:<:];@R*DBA!:K:,10QZ&L8(NCS)8PBXS1 EK(WV;-<,0K
M-(TL+! L_[["9AO?"GF.N]^$4RF-S>2:S;7]!7NS;!]F2F/$7%WQ;.[:&S1T
MY8&T?MFF4IE-.)_*VVF"IS 1P)\5BEG8++VAH;I03SU,G5IJ-&=EE%NR'YQ=
M_]0)5/UQ33[::#\,*C]6N!^:T79W?$31&EF5X1D^@Y3?MH1H#F16Q''UZ"D1
M@2:ZDN<9DZU.!F[T^^4JZLIMI_J7Q% 3'"DIJ:-C0Y>CXBLIL+5D1* YP8@(
MV$!WC."1\+Q]%L+]9;Y#"R* IBNK.[+K'*#<C.\E,65R^_\>6R@OGQB\3^ I
M)#/F-#MZE32/J$3 )U@[4%.2$>5X2!^D]OP&PP?D$X[OO^7QQYU?E%<V@:8@
M[#ED1WU2?U&.0@-TB]\2C-T@ NU%5DVQ#1V\.D5F=3?/AM-HHAU/Q!*!&K6D
M1<0GA/*$0=(5[21I)R(01H=%K=4=G5NI/[I.8AVPSC]N1')?1_68H3 ?UWF1
MM[1 15/K!W3KM=\(?@4Y34D-'?S(R[>/+CI,GX7N@PE/^I;59Q+/D""TKI5
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M&$G7U1A#EZEWL=E.^*/]1AVA=GF)64-?%_"6)C6UO*J\6MW7>.J-8=DK= /
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M"P-?/V1XE8[64AM>8]7*%*XK/F-$70A9;__9-Y7B.WQGA86V\H6->U!HQ<F
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MS#4O46;Y:A9X=R)D09*(-U93S3SA_/SARQ%.53^I,H'IWOM'1J\@\[7/-S@
MD/Z^;E32'F0QYU"4FC;0LP0M"K$ZW%%OPI5V;$\($^+]NGR^9S-_8#*,]?/#
M5-S+CX:L1PB9>B;JXF%-76HB$7IJS*K_[6_.^F\=>1UG%I"#\J?:.F6CG9LH
M@%%%QC62D'14]3D/F&WB3H<!N7N-*85#W)0\?\5G*IM$ <2Z;QZ49O%M2<5.
MM>CJE'E'^;7/C "A3C!8>3%T]P$%(+X)3R<;+NNI1WR*5)=.%30\\IZYP4^N
MFU#.GIB+W]8[-]\7O@[$>"+F+"=:.;85!-6[ZA[^NR#W_XZ_&1O8YU69&'\&
M#,?]NQS3P&7NY @R8NX\3'QP2-M=_+,KCX?R1]@+^$@STA_<.Q9@*^I?/%3I
M*EGB[9NX-?-@X&GR43%75\XK!?-\=U%*FK),+8O*P'D+AWZ3'VI?/=) D7T=
MT-;H7=A)WC:^,-G&>",EQIN%.I(WG[:+1E[0]X>Z[_;E"&+-#^)O/51&)_3X
M?X D[?_D<:B1I-JGW/%.(Q,W$#6]XN>A0A;8A27 7"<M3CE4M5<KM9BF/+.\
M^#5W6V-J,7JG'T:Z$+]-VM.@ )!Q)(?V7+9VIX&)K$PA>*,<O'Y"1VP/U-!Y
MO?6%-;=CW>UA BLPR)4(>8+@[UL>TP]B&>1P)Q.D78>/]-=>*FWH<7765X\1
M*LVEKIMJAK>I_W5A^_\=__DX0AG\-U!+ 0(4 Q0    (  Y#7D_UH;*(E18
M +GL   1              "  0    !A;65D+3(P,3DP.3,P+GAS9%!+ 0(4
M Q0    (  Y#7D^9USY%>1H  #$/ 0 5              "  <06  !A;65D
M+3(P,3DP.3,P7V-A;"YX;6Q02P$"% ,4    "  .0UY/'V=73*I9  !^]0,
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M9"TR,#$Y,S P.7AE>'@S,3$N:'1M4$L! A0#%     @ #D->3UY;Z,6Q!P
M]Q\  !@              ( !BC@$ &%M960M,C Q.3,P,#EX97AX,S$R+FAT
M;5!+ 0(4 Q0    (  Y#7D]^?1+*-U   $9A @ 7              "  7%
M! !A;65D+3(P,3DS,# Y>&5X>#,R+FAT;5!+ 0(4 Q0    (  Y#7D_A%_Z8
MKP0  *81   8              "  =V0! !A;65D+3(P,3DS,# Y>&5X>#,R
M,2YH=&U02P$"% ,4    "  .0UY/QR5]4Y\$  "!$0  &
M@ '"E00 86UE9"TR,#$Y,S P.7AE>'@S,C(N:'1M4$L! A0#%     @ #D->
M3WEH _CH90  6:<   H              ( !EYH$ &EM86=E,"YJ<&=02P4&
2      T #0!J P  IP %

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790052160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-Month Periods Ended September 30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-Month </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Periods Ended September 30</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Home Health:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hospice (1):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Personal Care</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Acquired Compassionate Care Hospice on February 1, 2019 and RoseRock Healthcare on April 1, 2019.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.07602339181285%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Financial Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value as of<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in&#160;Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Markets for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.20272904483431%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:52%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Month Periods</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested stock and stock units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average number of shares outstanding - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802240816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,757<span></span>
</td>
<td class="nump">$ 20,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">254,703<span></span>
</td>
<td class="nump">188,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,601<span></span>
</td>
<td class="nump">7,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,458<span></span>
</td>
<td class="nump">7,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">299,519<span></span>
</td>
<td class="nump">224,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $101,446 and $95,472</a></td>
<td class="nump">29,969<span></span>
</td>
<td class="nump">29,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">84,124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">660,472<span></span>
</td>
<td class="nump">329,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $36,799 and $33,050</a></td>
<td class="nump">66,468<span></span>
</td>
<td class="nump">44,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">17,568<span></span>
</td>
<td class="nump">35,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">54,260<span></span>
</td>
<td class="nump">54,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,212,380<span></span>
</td>
<td class="nump">717,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">35,901<span></span>
</td>
<td class="nump">28,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">115,899<span></span>
</td>
<td class="nump">92,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">127,111<span></span>
</td>
<td class="nump">99,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">8,959<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">26,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">314,653<span></span>
</td>
<td class="nump">222,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">231,641<span></span>
</td>
<td class="nump">5,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">56,619<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">6,002<span></span>
</td>
<td class="nump">6,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">608,915<span></span>
</td>
<td class="nump">234,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 36,599,273 and 36,252,280 shares issued; and 32,246,575 and 31,973,505 shares outstanding</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">634,854<span></span>
</td>
<td class="nump">603,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost 4,352,698 and 4,278,775 shares of common stock</a></td>
<td class="num">(251,070)<span></span>
</td>
<td class="num">(241,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">218,728<span></span>
</td>
<td class="nump">119,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">602,564<span></span>
</td>
<td class="nump">481,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">603,465<span></span>
</td>
<td class="nump">482,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,212,380<span></span>
</td>
<td class="nump">$ 717,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804690336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 244.3<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">240.6<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">231.6<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">67.0<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802544656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 99,938<span></span>
</td>
<td class="nump">$ 92,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">12,440<span></span>
</td>
<td class="nump">9,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">18,451<span></span>
</td>
<td class="nump">12,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">401(k) employer match</a></td>
<td class="nump">7,545<span></span>
</td>
<td class="nump">6,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">27,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">17,798<span></span>
</td>
<td class="nump">14,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(4,120)<span></span>
</td>
<td class="num">(6,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity investment</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(39,469)<span></span>
</td>
<td class="nump">6,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(10,194)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,145)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">27,903<span></span>
</td>
<td class="nump">14,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(231)<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(24,116)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(2,622)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">126,780<span></span>
</td>
<td class="nump">159,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in equity method investees</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(3,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,337)<span></span>
</td>
<td class="num">(5,684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(345,460)<span></span>
</td>
<td class="num">(4,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(351,562)<span></span>
</td>
<td class="num">(12,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld upon stock vesting</a></td>
<td class="num">(9,385)<span></span>
</td>
<td class="num">(5,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distribution</a></td>
<td class="num">(910)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsFromBorrowingsUnderTermLoan', window );">Proceeds from borrowings under term loan</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">192,500<span></span>
</td>
<td class="nump">127,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(133,000)<span></span>
</td>
<td class="num">(70,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(3,820)<span></span>
</td>
<td class="num">(91,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="num">(847)<span></span>
</td>
<td class="num">(2,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(181,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentsForRepurchaseOfNoncontrollingInterest', window );">Repurchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">225,310<span></span>
</td>
<td class="num">(219,182)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">528<span></span>
</td>
<td class="num">(72,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">20,229<span></span>
</td>
<td class="nump">86,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">20,757<span></span>
</td>
<td class="nump">14,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">7,756<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 11,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentsForRepurchaseOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentsForRepurchaseOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsFromBorrowingsUnderTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings under the term loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsFromBorrowingsUnderTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6782339856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES Finance lease (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets</a></td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeFinanceleasesAccumulatedAmortization', window );">Finance leases accumulated amortization</a></td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinanceleaseRightofUseAssetNet', window );">Finance lease ROU assets, net</a></td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current installments of obligations under finance leases</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of obligations under finance leases</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceleaseRightofUseAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease, net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceleaseRightofUseAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeFinanceleasesAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization of finance leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeFinanceleasesAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795883808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Pro Forma (Details) - Hospice - Compassionate Care Hospice [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 494.6<span></span>
</td>
<td class="nump">$ 467.3<span></span>
</td>
<td class="nump">$ 1,471.0<span></span>
</td>
<td class="nump">$ 1,373.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Businessacquisitionproformaoperatingincomeloss', window );">Operating income (loss)</a></td>
<td class="nump">46.8<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">142.2<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="nump">$ 97.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic earnings (loss) per share</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted earnings (loss) per share</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Businessacquisitionproformaoperatingincomeloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Businessacquisitionproformaoperatingincomeloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
